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IMMUNOGENETIC ANALYSIS OF HLA CLASS II IN PREMALIGNANT 
DISEASE OF THE CERVIX AND CORRELATION WITH HPV STATUS 
The human papilloma virus (HPY) infection has a causal association with cervical intra-
epithelial neoplasia (CIN) and cervical cancer. However, pre-malignant or malignant 
transformation is not always observed with HPY infection. lILA molecules are important 
in the regulation of the immune response to foreign antigens. The role of genetic variation 
at the lILA class II loci (DR and DQ) in CIN was investigated in 176 British Caucasian 
patients and 420 controls (normal cervical cytology and negative for HPY 16, 18, 31 and 
33). lILA DQB 1 *03 typing was performed by a novel polymerase chain reaction-
restriction fragment length polymorphism method (A-RFLP). The technique uses PCR to 
mutate the first base of codon 40 (DQ alleles) from T to G to create an artificial restriction 
site for an enzyme, MluI, which distinguishes DQB 1 *03 from other alleles and is 
confirmed by digestion of amplified DNA with Mlul. Further lILA DR-DQ typing was 
performed by PCR DNA amplification and oligonucleotide probe typing. HPY types (16, 
18, 31 & 33) were detected by using type-specific oligonucleotide primers and PCR. The 
alleles of the DQB 1 *03, DRB 1 *04 and DRB 1 * 11 groups were strongly associated with 
susceptibility to CIN. Specifically the haplotypes DRB 1 *040 I-DQB 1 *0301 and 
DRBl*1101-DQB1*0301 were significant and indicated susceptibility. The DQBl*03 
locus was more contributory to this association than the DRB 1 loci. A weak protective 
effect was shown for the haplotype DRB 1 *0 10 I-DQB 1 *0501. Positive correlation was 
also observed for HPY-positive CIN, suggesting that specific HLA alleles may be 
important in determining the immune response to HPY antigens and the risk for CIN after 
HPY infection. Immunoaffinity purification of the susceptibility and protective lILA ~ 
molecules was performed and the naturally processed peptides were eluted and sequenced 
by Edman degradation. The data obtained was used for motif prediction of HPY 16 E6, 
E7, Ll and L2 sequences that may be capable of binding to these HLA molecules. Motif 
II 
prediction as well as the binding affinity of predicted peptide motifs for HLA D RB 1 *0401 
and DRB 1 *0 10 1 was accomplished using the published data' on the naturally bound 
peptide sequences bound to these HLA molecules. The results revealed significant 
differences in both the number and binding affinity of the HPV 16 derived peptides to the 
protective and susceptibility Ill.A molecules. These results should help in the rational 
design of vaccines against HPV. 
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2 
1.1 CERVICAL CANCER 
1.1.1 GENERAL INTRODUCTION 
Cervical cancer constitutes a major health problem worldwide. Each year, there are 
approximately 465,000 new cases and in excess of 200,000 deaths from the disease l . The 
areas with the maximum incidence are in Southern and Eastern Africa and Central and 
tropical South America. The risk in Western European and North American countries is 
considered relatively low at less than 10 new cases per 100,000 women annually. The rates 
are 10 to 20 times higher in some parts of Northeastern Brazil where lifetime cumulative 
risks can approach 10%2. In the United Kingdom, there are approximately 3,000 new 
cases each year and over 2,000 deaths from the disease. Likewise, in the United States, 
each year there are approximately 16,000 new cases of invasive cervical cancer with 4800 
deaths due to the disease3• For each new case of cervical cancer found by cytology 
screening, there are approximately 50 other cases of abnormal cervical smears that merit 
careful monitoring by colposcopic follow-up and eventually, biopsy. To this triage burden 
must be added an equal number of cases of borderline atypias (the so-called "ASCUS" 
smears) that are found concurrently and need to be confirmed by repeat cytology (MMWR, 
1994). Although much effort has been applied to the early detection of cervical cancer by 
exfoliative cytology and the provision of conservative modalities of treatment for pre-
invasive lesions, study of the molecular mechanisms of cervical carcinogenesis has only 
recently become an intense field of research. 
1.1.2 PATHOGENESIS 
The uterine cervix consists of the ectocervix, which is covered by glycogen rich squamous 
epithelium, and endocervix, lined with a single layer of columnar epithelial cells. 
Colposcopic and histologic examination of the cervix from perinatal to adult life discloses 
three epochs when columnar epithelium on the endocervix is activated by contact with the 
vaginal environment. These epochs, which correspond with periods of maximal estrogen 
3 
stimulation are perinatal, at the menarche, and during the first pregnancy4. As a result of 
contact with the lower pH of the vaginal environment, the columnar epithelium is induced 
to transform into stratified squamous epithelium. The new squamous epithelium soon 
becomes an undifferentiated 8 to 10 cell-thick structure composed of rounded cells. Later 
differentiation occurs into basal, intermediate and superficial cells. Finally, the mature 
epithelium comes to mimic closely the squamous epithelium of the vaginal portion of the 
cervix and of the vagina which it adjoins abruptly at a line running concentrically around 
the os. Within this line, the squamous epithelium is new and distinct from the original or 
native squamous epithelium outside its limits. Thus, the limits of the transformation zone 
lies between the original squamo-columnar junction (now squamo-squamous) and the new 
squamo-columnar junction. This site is thought to be where premalignant lesions of the 
cervix develop. 
Cytologic examination of cervical smears is used to detect cervical abnormalities. Women 
with abnormal cervical (papanicolaou) smears are subsequently examined by colposcopy. 
The lesions in the transformation zone that appear atypical by colposcopy are diagnosed by 
histological examination. Cervical lesions with the potential to progress to invasive cancer 
were originally histologically diagnosed as dysplasia. Cervical dysplasia is characterized by 
a disturbed epithelial architecture and cellular atypia. Depending on the proportion of the 
epithelial layer that shows dysplastic changes, lesions are classified as mild, moderate or 
severe dysplasia. In 1968, the concept of cervical intraepithelial neoplasia (CIN) was 
introduced5. In this scheme, CIN is a continuous spectrum of intraepithelial changes, that 
starts with minor atypia, progressing through increasing degrees of intra-epithelial 
abnormalities to invasive squamous cell carcinoma. CIN lesions are classified according to 
the thickness of the epithelial layer involved in neoplastic change. Involvement of the lower 
one third of the epithelial layer represents CIN grade 1, one third to two thirds involvement 
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CIN grade II, and two thirds to full thickness CIN grade III, which is equivalent to 
carcinoma in situ (CIS)6. 
This classification scheme led to two major problems. Firstly, the relative high inter- and 
intra-observer variation in interpretation by pathologists 7 and the attitude of the clinician 
toward treatment of CIN II lesions, with a choice between treatment and watchful 
expectancy. By 1988, several classifications and many modifications were in use 
throughout the world resulting in confusion in communications among clinicians, 
pathologists and researchers. The result of a workshop by the National Cancer Institute 
was the Bethesda System8 to replace the various Papanicolaou designations and to 
standardize cytologic tenninology to correlate with histologic reports. A comparison 
between the Bethesda System and earlier ones is summarized in Table 1.1. The term CIN 
was replaced by Squamous Intraepithelial Neoplasia (SIL), with CIN II and III replaced by 
high grade SIL (HGSIL) while CIN I was replaced by low grade SIL (LGSIL). This 
suggests that eIN grade I lesions constitute a different entity from CIN II or III lesions, 
lacking the ability to progress to cervical cancer. In reality, about 20 - 30% of cervical 
lesions with mild dysplasia will progress to carcinoma in situ9-1O• In another study, 50% of 
patients with CIN I progressed to CIN III, while 25% either progressed to CIN II or 
remained at grade I for nine years 11. In the United Kingdom, approximately 250,000 
women are diagnosed annually with CIN. The much lower frequency of cervical cancer per 
year suggests that only a proportion of lesions diagnosed as CIN will progress to 
carcinoma. 
The mean age for cervical cancer is 52.2 years, and the distribution is bimodal, with peaks 
at 35-39 years and 60-64 years12. The incidence of adenocarcinoma appears to be 
increasing relative to that of squamous cancers. Older reports indicate that 5% of all cervical 
cancers were adenocarcinomas13, whereas newer reports suggest an incidence as high as 
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18.5-27% 14-15. There is evidence to suggest a poorer prognosis for adenocarcinoma than 
for squamous cell carcinoma in every stage. Hopkins & Morley15 performed a Cox 
proportional hazard analysis of 203 women with adenocarcinoma and 756 women with 
squamous carcinoma and reported 5-year survival rates of 90% versus 60%, 62% versus 
47%, and 36% versus 8% for stages I, II, and III, respectively. Although this has been 
attributed to a relative resistance to radiation, it is more likely a reflection of the tendency of 
adenocarcinomas to grow endophytically and to be undetected until a larger volume of 
tumour is present. It is also unclear whether or not patients with adenosquamous carcinoma 
of the cervix have a poorer prognosis than those with pure adenocarcinoma or squamous 
carcinoma 16-17. 
1.1.3 ETIOLOGY 
The epidemiological pattern of cervical cancer strongly points to a sexually transmitted 
infectious agent as being etiologically important. As early as 1842, Rigoni Stern 18 found 
that compared with breast cancer, cervical cancer was eighteen times more common 
amongst married than unmarried women in Verona. Modern epidemiological studies have 
shown low cervical cancer rates among catholic nuns19 while higher rates are found in 
women marrying at younger ages20-21 • The latter is related more specifically with two 
aspects of sexual behaviour namely number of sexual partners and age at initiation of 
intercourse22-23• The risk associated with ten or more partners is nearly three times higher 
than that associated with one or fewer partners24-25• Women with first sexual experiences 
before age 16 have about twice the risk compared with women who initiate sexual 
intercourse after the age of 20 years and this may reflect the increased susceptibility of the 
"younger" cervix to carcinogenic insult26• Other risk factors include cigarette smoking and 
the use of the oral contraceptive pill. 
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Different candidates for a sexually transmitted agent have been proposed including syphilis, 
gonorrhea, Trichomonas vaginalis and Herpes simplex virus type 2 (HSV -2). In particular, 
HSV-2 appeared a plausible candidate, because of the high frequency of HSV-2 specific 
antibodies in cervical cancer patients compared with healthy controls. Although HSV was 
proven to be carcinogenic, in vitro and in vivo clinical studies eventually demonstrated that 
only a fraction of cervical carcinomas contained traces of HSV viral DNA, and 
epidemiological studies failed to demonstrate an association between HSV and cervical 
cancer27-28. 
In 1976, zur Hausen hypothesized that cervical cancer shows a similar epidemiological 
pattern as genital warts29• The formation of genital w~rts (condylomata acuminita) was 
considered to be associated with infection with the human papillomavirus (HPV). 
Subsequently, zur Hausen and Gissman using recombinant DNA technology were able to 
clone and characterize isolated HPV DNA from genital warts and papilIomas30-32• Novel 
HPV types in cervical cancer were identified that differed from those associated with genital 
warts. Since then, there have been several compelling epidemiological, clinical, and 
molecular biologic data indicating that the infectious agent with a causal relationship to CIN 
and cancer is the human papillomavirus (discussed below). 
1.2 HUMAN PAPILLOMA VIRUS (HPV) 
1.2.1 GENERAL PROPERTIES 
Papillomavirus belong to the family Papovaviridae. They possess a closed, circular, double 
stranded genome and are encapsulated in an icosahedral capsid of about 55nm in diameter, 
consisting only of protein. Their genome is approximately 7.9kB in size and more than 70 
different types of papillomaviruses have been identified, many of which infect the ana-
genital epithelium. By definition, the different types share less than 50% homology under 
stringent conditions33-34• Since the number of complete sequences of different HPV types 
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is rapidly increasing, and many more HPVs are being identified, a modified definition of a 
new HPV type has been proposed35• Here, a new type is defined when less than 90% 
sequence homology in E6, E7 and Ll region is found with any other known HPV type. 
Two major groups are defined according to their epithelial affinity - types infecting the dry 
skin and those infecting the moist mucosal areas of the body (fab!e 1.2). The genital HPV 
types are placed into three broad categories based on the frequency of association with 
malignant tumors and thus the presumed oncogenic potential. The low risk groups includes 
types 6, 11, 42 and 44, which are common in LGSIL and less so in HGSIL and practically 
non existent in cancer specimens. The intermediate risk group is comprised of types 31, 
33, 35, 51 and 52 whose combined frequency of as~ociation increase within the SIL 
spectrum but decrease in carcinomas. The high risk group includes HPV 16, 18, 45 and 
56, which are strongly associated with carcinomas and exhibit diverse behaviour with 
respect to HGSIL36. 
HPVs infect the basal cells of the epithelium and rather than proceeding to a lytic infection 
in which viral replication kills the cell, viral DNA transcription and replication are 
maintained at very low levels (20-100 copies per cell) until more superficial epithelium is 
infected. At this level, viral transcription accelerates, DNA synthesis begins and virions 
assemble37. In addition, the activation of late gene expression and capsid assembly occurs 
concurrently with the amplification of viral DNA. In benign or pre-malignant lesions, the 
HPV DNA exists extra-chromosomally as a plasmid. By contrast, all cervical cancer 
derived cell lines that contain HPV DNA and the majority of primary tumours reveal 
integrated viral DNA38. 
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1.2.2 HPV GENOME ORGANIZATION 
The HPV genome consists of 3 regions: one regulatory non coding region, termed the long 
control region ( LCR ), and two coding regions (Fig 1.1). The ' early , region consists of 
six to eight open reading frames , whereas the ' late ' region encodes two genes. By 
definition, early genes are expressed shortly after viral infection and prior to viral 
replication. The late genes code for the structural proteins forming the viral particle, and are 
expressed in the late phase of infection. The functions of the different reading frames are 
summarized in table 1.3. 
El: HPV El is homologous with polyoma large T domains39 and BPV-E140. The viral 
ring molecule is usually opened within the 3' end of th~ El or the 5' end of the E2 open 
reading frames and mutations in the E 1 or E2 gene increases HPV 16 immortalisation 
efficiency in keratinocytes41 . In monolayer cultures, both El and E2 gene products are 
required for the transient replication of viral genomes42-43 and the origin of replication 
(ori) maps to a region adjacent to the E6 open reading frame (ORF), which binds the El 
protein. The El ORF also encodes a nuclear phosphoprotein that can bind the E2 
molecule44• While the El protein may bind DNA by itself45, the presence of E2 increases 
its affinity for binding46. 
E2: The E2 protein acts as a transcriptional trans-activator, via the E2 responsive elements 
(E2-RE),located in the LCR47. E2 disruption is thought to alter regulation of expression of 
E6 and E7 genes48• In high risk HPVs, the primary transcriptional activity ofE2 appears to 
be as a repressor E6 and E7 transcription49-50. Two E2 sites are located 2 to 4 bp upstream 
from the putative TATA box and this close proximity may result in steric hinderance by 
bound E2 proteins. 
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E4: The E4 gene product is expressed as an EI-E4 fusion protein in the "late" phase of the 
viral life cycle. In this form, it disrupts keratin assembly in stratified suprabasal cells, 
allowing for viral egress51-52• 
E5: The HPV ES encodes a membrane protein with weak transforming activity53. Part of 
its transforming function may reside in its ability to complex with epidermal growth factor 
(EGF) receptor, resulting in an enhanced EGF-mediated signal transduction to the nucleus, 
as shown by increased c-fos expression levels54• 
E6 and E7: Analysis of the transcription of HPV 16 in cervical cancer derived cell lines 
and in fresh premalignant and malignant cervical biopsies have shown that transcription of 
the E6 - E7 region of the HPV 16 genome is selectively retained in the neoplastic tissue 55-
56. E6 and E7 have been identified as the transforming genes of HPV16 and it appears that 
both are necessary for full transformation of cervical epithelial cells57-58• 
The E6 and E7 gene products of HPV 16 & 18 can each transform immortalized rodent 
cells such as NIH 3T3 and Rat-l cells to an anchorage dependent state59• The E7 proteins 
can also transform primary rodent cells, but require the additional presence of an activated 
ras gene for full activity60. In the human keratinocyte, the HPV E6 and E7 act in a co-
operative fashion to efficiently immortalize cells61 -62. The E7 gene by itself can immortalize 
keratinocytes at low frequency, whereas the E6 protein does not exhibit any such 
properties. Furthermore, keratinocytes immortalized by HPV 16 and 18 E61E7 only 
become tumourigenic by the addition of activated ras gene or following prolonged passage 
in culture63• 
Ll and L2: The Ll and L2 open reading frames encode the major and minor capsid 
proteins respectively. 
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LCR: The LCR is located between the early and late genes (also tenned upstream 
regulatory region, URR), and contains viral gene promoter and enhancer sequences which 
are dependent solely on cellular factors for function64• These enhancers are called 
constitutive or "C" enhancers for HPV 11, 16 and 18 and are located in the URR 200 to 
300bp upstream of the E6 ORF. C enhancers direct expression of heterologous promoters 
preferentially in cell lines derived from squamous cell carcinomas, as well as in primary 
human keratinocytes. Transcripts controlled by these enhancers initiate upstream of the E6 
gene at a promoter referred to by nucleotide number p97 in HPV 16 and HPV 31 and pI 0 1 
in HPV 31. These enhancers include AP-l, keratinocyte specific factor, KRF_16S and 
steroid receptors11,66. 
1.2.3 HPV DETECTION METHODS 
Classical viral cultivation techniques are not applicable in HPY because the virus cannot be 
propagated in culture. Consequently, in order to assess the presence of HPY in clinical 
samples, HPY DNA detection methods using hybridization based techniques have been 
developed. Southern blot analysis allows highly specific HPY genotype detection with a 
sensitivity range between 0.1 and 0.01 HPV genome copies per cell. However, the 
methodology is too time-consurning and labour intensive making it unsuitable for mass 
screening purposes. Other methods like dot blot analysis, in situ hybridization and filter in 
situ hybridization, are less labour intensive, but suffer from other drawbacks such as 
reduced specificity and sensitivity. 
The advent of the polymerase chain reaction (PCR) has considerably increased the 
possibility of screening a large number of samples67-68• The method is superior in 
sensitivity as compared to other HPV detection techniques, with a sensitivity of 1 copy per 
106 cells in a clinical sample being detectable69, and it requires low amounts of target 
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DNA. Furthermore, it can be applied directly to crude cell extracts without the need of 
DNA isolation from every clinical sample70 and can also be applied on fixed tissue71-72. 
Many alternative sets of primers are used for detecting HPV by peR. Two commonly used 
sets are the consensus primer pair MY09 and MY1173 and the general primers GP5 and 
GP669• In both systems, the primers used are homologous with sequences in the Ll ORF 
of HPV s, since this region is highly conserved. Several other sets of primers have been 
reported in the literature, such as consensus E 1 primers, but their use is not widespread 
enough. In the MY 09111 system, a peR amplicon of about 450 nucleotides is produced 
and this can be subsequently typed by dot blotting of peR products using radioactive or 
biotin labeled oligomers73• In the GP 516 system, an amplicon of about 140 nucleotides is 
produced from a region of Ll that overlaps with MY and subsequently separated by gel 
electrophoresis, blotted onto filters and hybridized with radioactively labeled probes. Both 
methods are fairly equivalent for in-vitro use, but the GP primers are better for 
amplification of targets from paraffin-embedded sections, because the longer MY 
amplicons are not synthesized as efficiently because of formalin cross-linking in the tissue. 
The use of type-specific primer systems is an alternative approach for the detection of 
HPV. This system is of particular use when the determination of a single genotype of HPV 
is of interest. Additionally, these systems provide an excellent means of confirming results 
generated by consensus peR or other methods of HPV DNA detection. 
1.2.4 PAPILLOMA VIRUSES AS CAUSATIVE AGENTS IN CERVICAL 
NEOPLASIA 
Genital HPV infections are highly prevalent (20 - 80%) in sexually active age groups 74-75. 
The causative role of HPV in the induction of condylomata has been proven by 
experimental transmission from person-to-person and in animal model systems. The 
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etiologic role of HPV in intraepithelial neoplasias was demonstrated by observations of 
naturally occurring transmission between sexual partners in whom histologically similar 
lesions developed harbouring the same HPV type76• Transfection of human keratinocytes 
with HPV 16 induces histologic features of intraepithelial neoplasia when cells are grown 
in organotypic cultures allowing the formation of stratified epithelium 77. The histology 
resembles CIN I at the beginning and corresponds to carcinoma in situ after several in vitro 
passages. 
Using PCR-based and other HPV detection techniques, many cross sectional studies have 
been performed to study the prevalence of HPV in women with normal and abnormal 
cervical smears. In women with normal cervical smears, HPV prevalence rates varying 
from 1.5% to over 30% have been reported74,78. Some studies may have suffered from 
insensitive HPV detection and PCR contamination making comparisons of the different 
studies difficult. However, prospective studies of women with initially negative cytologic 
tests showed that the cumulative incidence of CIN II at 2 years was 28% among HPV 
positi~e women compared with 3% among HPV negative women 79. Infection with either 
HPV 16 or 18 is associated with a relative risk of 11 for development of CIN. 
The magnitude of the association between HPV infection and the risk of cervical neoplasia 
have been examined by different groups. Pooling of data based on Woolfs technique80 
leads to a combined RR for CIN from all non-PCR studies of 10.3 (95% CI, 6.9 - 15.3 ), 
whereas the RR from PCR studies was 19.8 ( 95% CI, 15.2 - 25.8 ). The difference 
between pooled estimates is more pronounced for studies of invasive carcinomas with RR 
of 3.7 ( 95% CI, 3.1 - 4.6 ) and 34.5 ( 95% CI, 21.5 - 55.4 ) for non-PCR and PCR 
studies, respectively. These data place HPV infection as the strongest risk factor for 
cervical cancer with a magnitude of association that is greater than that for the association 
between smoking and lung cancer and is second only to the association between the chronic 
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carrier state of hepatitis B infection and liver cancer, causal relations in cancer that are no 
longer challenged81 , In addition, recent evidence from a large international study indicates 
that meticulous testing by PCR of nonfixed specimens of cervical carcinomas results in 
positivity rates of 95%82, A consensus panel of the World Health Organization's 
International Agency for Research on Cancer (IARC) has concluded that there is now 
compelling evidence both from biologic and from epidemiologic standpoints to consider 
that HPY infection leads to cervical cancer83-85, 
Cervical HPY infection detected by DNA hybridization techniques is found in 15 - 40% of 
sexually active women 74,85-86, Most of these infections are transient, and only a small 
proportion of women tend to harbor the same HPy'type on a persistent basis87-89, 
Prospective epidemiologic studies have indicated that the risk of subsequent cervical 
neoplasia seems to be proportional to the number of specimens testing positive for HPy79, 
Little is known about risk determinants for persistent HPY infection, The risk of HPY 
infection seems to be independently influenced by other variables such as parity, oral 
contraceptive use, and smoking90, 
1.2.5 MOLECULAR MECHANISMS OF HPV IN CERVICAL 
ONCOGENESIS 
HPV E6 and E7 are small proteins that show some similarities to each other, It has been 
proposed that they arise following amplification and divergence of a 33 amino acid peptide, 
The main feature that the two share is a series of Cys-X-X-Cys motifs, which occur four 
times in E6 and twice in E7, and are thought to play a role in zinc binding by both 
proteins91-92, 
1.2.5.1 The E7 Gene 
The E7 oncoprotein is a 98 amino-acid phosphoprotein localized to the cell nucleus within 
the nuclear matrix93, It possesses transforming, immortalizing and trans activating 
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properties and is phosphorylated on serine residues94. The amino-terminal 37 amino-acids 
bear significant sequence homology to conserved domains I and 2 (CD I and C02) of the 
Adenovirus 5 E I a oncoprotein as well as to a region of the SV 40 large T oncoprotein. CD I 
and CO2 have been shown to have several important biological functions such as 
cooperation with the ras oncogene in transformation assays, stimulation of DNA synthesis, 
as well as possessing binding sites for cellular proteins which may be important for Ela 
mediated transformation. Recent experimental evidence has shown that like Ela and SV40 
large T antigen, HPV 16 and 18 E7 proteins bind to the retinoblastoma gene product, Rb95-
96. The Rb binding domain has been localized to the region of homology with CD2 of the 
adenovirus Ela protein96 and mutations in this domain eliminated Rb binding96-98. This 
region consists of a stretch of 17 amino acids99• 
The Rb gene consists of 27 exons spanning 200 kilobases of chromosomal DNA (band 
13qI4). The associated mRNA encodes a nuclear phosphoprotein with M.W. of 105-
11OKda. It is expressed throughout the cell cycle, and it is found in the non-
phosphosphorylated and phosphorylated forms that are specific for certain phases of the 
cell cycleHX>. In the non-phosphorylated state, it acts to restrict cell proliferation, partly by 
binding to the transcription factor E2FIOl. E2F is capable of transactivating several genes 
expressed during the S phase of the cell cycle. E2F-pRb complexes can be identified 
primarily in extracts of cells at the 01 phase of the cell cycle 10 1. In this complex, pRb is 
unable to activate promoters which are important positive signals for growth such as c-myc 
and n-myc. In the phosphorylated state (02/S), the control of Rb on cell growth is 
released 100. Regulation of the phosphorylation is mediated in part through TGF-BI 
probably by blocking phosphorylation of Rb protein 102. 
HPVl6 E7 binds preferentially to the under-phosphorylated form of Rb and releases E2F 
from the Rb complex 98. Furthermore, the HPV E7 gene product associates with the E2F-
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cyclin A complex103• The complex consists of cellular proteins E2F, p107, cyclin A and 
cdk 2, all of which are important in the regulation of cell growth at different stages of the 
cell cycle. The released E2F will activate the expression of cell-cycle regulated genes such 
as c-myc, thymidine kinase, and DNA polymerase alpha, required for entry into the S-
phase of the cell cycle. The functional significance of the E7 -pRB interaction is underlined 
by the fact that the E7 proteins of low risk genital HPV types 6 and 11 bind with much 
lower affinity than the E7 proteins of HPV 16 and 1896.104-105. 
The E7 oncoprotein also has another biochemical function which it shares with an area of 
structural homology to Ela in the carboxy terminal region of C02. Aminoacids 31 to 37 
represent a substrate for casein kinase II (CKlI), which phosphorylates serine 31 and 3297• 
Replacement of the 2 serines by non-phosphorylatable amino acids lead to a reduction in 
transforming activity and abolished phosphorylation, but not Rb binding. CKlI has been 
implicated in the regulation of RNA and protein sy'nthesis as well as DNA metabolism by 
phosphorylating the enzymes and proteins mediating these processes. It also mediates the 
phosphorylation of c-myc encoded proteins suggesting that it may be involved in cell cycle 
regulation. 
1.2.5.2 The E6 Gene 
The E6 protein of HPV has been shown to possess various transforming and immortalizing 
activities, the most important of which seems to be the ability to co-operate with HPV 16 
E7 in the efficient immortalization of primary human epithelial cells58•106• The protein 
consists of approximately 150 amino acids which are believed to form 2 zinc binding 
fingers. The base of each finger contains four cysteines (Cys) in two pairs of the motif 
Cys-X-X-Cys, where X varies among the viruses. These E6 fingers comprise 29-30 amino 
acids and have been shown to specifically bind zinc in an in vitro binding assayl07. 
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The oncogenic activity of the E6 proteins of the high risk HPVs has recently been 
correlated with their ability to interact and inactivate the cellular p53 protein 108-1 09. The 
documented effects of wild type p53 on cell proliferation include regulation of the transition 
from 01 to S phase of the cell cyclellO- 1l2 and a role in determining cell death through 
apoptosis. p53 also appears to function normally as a 01-S checkpoint control for DNA 
damage113-114• Thus normal p53 may function as a 'molecular policeman' monitoring the 
integrity of the genome 11 4. Removal of policing activities of p53 allows for continuous 
cycling of cells and the more rapid appearance of chromosomal abnormalities. 
E6 binding of p53 leads to an increased rate of p53 degradation by a ubiquitin-directed 
system109• The enhancement of p53 degradation has reen shown to be mediated only by 
E6 proteins of 'high risk' HPV types. Crook et allIS have shown that a C-terminal region 
of E6 is involved in the binding of p53 while a region in the N-terminus is involved in 
degradation. It would appear that all genital HPV E6 proteins bind p53 but only high risk 
viruses have the ability to bind with high affinity. The E6 protein targets all quaternary 
forms of wild-type p53, while mutant p53 proteins are variably resistant to E6 mediated 
regulation and this correlates with PAb 1620 reactivity1l6. It appears that the PAb 1620+ 
conformation is important for recognition of p53 by E6 but is not the actual target for 
degradation. The function of p53 seems to be dependent on a conformationally flexible 
domain encompassing about 150 residues in the central portion of the protein. 
The enzymatic reactions involved in the ubiquitination of proteins are well characterized. 
Ubiquitin is a 76 amino acid protein which is found in all eukaryotic organisms. The El 
ubiquitin-activating enzyme stimulates the ATP-dependent formation of a high energy 
thioester between the carboxyl group of the last amino acid of ubiquitin and a thiol group of 
a cysteine residue of the E 1 protein. The E 1 protein then transfers the activated ubiquitin to 
a cysteine of an E2 ubiquitin conjugating enzyme, with retention of a high energy thioester 
17 
bond. The E2 proteins usually require an E3 ubiquitin ligase protein to specify proteins that 
are to be multiubiquinated. In the case of HPV 16 and 18 E6 interaction with p53, this 
ligase is a l00KDa cellular protein, called E6 associated protein (E6-AP). Neither E6 nor 
E6-AP alone can stably associate with p53. The 3 functional domains of E6-AP which are 
important for the association has been characterized to an 18 amino acid region from amino 
acid 391 to 408 for binding, a 502 amino acid region from 280 to 781 for the E6 
dependent association of E6-AP with p53, and the C terminal 84 amino acids for the E6 
and E6-AP dependent ubiquitination of p53 117. 
Several studies of p53 sequences in tumours and tumour cell lines have shown that while 
HPV - negative tumours express mutant p53 sequences, only wild type p53 is detected in 
HPV- positive cancers1l5-118• However, Kessis et al1l9 provided recent evidence that 
HPV infection and p53 mutations are not mutually exclusive and that some HPV negative 
carcinomas may arise from a pathway independent of p53 inactivation. Indeed, an 
overview of data from several studies suggested that overall, the rate of p53 mutations in 
HPV positive carcinoma is only 3%; whereas in HPV negative tumours, it is 15%120. 
1.2.S.3 The ES and E2 Genes 
Both HPV 6 and HPV 16-E5 proteins form complexes with the p 16 component of the 
vacoular ATPase, which serves the acidification of intracellular compartments 121, E5 of 
HPV 6 also associates with the receptors for platelet-derived growth factor (PDGFR) and 
epidermal growth factor (EGFR)122, The HPV 16 E5 stimulates the transforming activity 
of EGFR by enhancing growth factor mediated signal transduction to the nucleus54.123, 
The lack of immortalizing activity of a HPV 16 variant from normal human cervical 
keratinocytes with a mutation in the E2 gene may point to a fourth viral oncogene124. It is 
unlikely that E2 and E5 have a major role in the maintenance of the malignant phenotype of 
18 
cancer cells because they are frequently destroyed by integration of the viral genome into 
cellular DNA. 
1.2.5.4 Physical State of Viral DNA 
The integration of HPV 16 or 18 DNA into the genome of cancer cells appear to be a 
potentially important step in tumour progression. Opening of the viral genome at the time of 
integration frequently disrupts the regulator genes Eland E2 and engineered mutants in 
these genes revealed increased transformation efficiency in vitr041 • HPV 18 DNA is 
integrated in most cancers. However, a substantial proportion of HPV 16-positive tumours 
and one cancer derived cell line revealed only episomal viral DNA 122,125. This 
demonstrates that integration is not a necessary prerequisite for tumour progression. 
A specific mechanism for upregulation of E6/E7 expression has recently been shown to 
operate in carcinomas containing only episomal HPV 16 DNA. The promoter of E6/E7 of 
the wild type HPV 16 genome is downregulated by a silencer element in the viral control 
region, which depends on interactions with cellular transcriptional regulator yin-yang 1 
(YYI) with four binding sites l26• Analysis of six cancers carrying exclusively 
extrachromosomal HPV 16 DNA revealed deletions affecting one to four YYI-binding 
sitesI26-127. All of these mutations resulted in a four to six fold increased activity of the 
E61E7 promoter suggesting that deletion or mutation in the target sequences for the cellular 
repressor represents a repeatedly used strategy of HPV 16 to escape from cellular control. 
A deletion of 38bp from integrated HPV 16 DNA in the cervical carcinoma cell line 
SiHa128 removes one YY-I binding site indicating that inactivation of YYI target 
sequences is not restricted to episomal HPV DNA in cancers. 
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1.2.6 Summary of evidence for the role of HPV in cervical oncogenesis 
I. The incidence of HPV -16 DNA in CIN lesions increases proportionately with their 
severity. 
2. PCR-detectable HPV -16 DNA occurs in more than 50-90% of cervical cancer biopsies. 
3. HPV -16 DNA in cervical cancers is often integrated into host DNA. 
4. HPV -16 DNA is retained in continuous cell lines from cervical cancers. 
5. HPV-16 DNA can transfonn and immortalize human keratinocytes in vitro, whereas 
non-cancer associated HPV s do not. 
6. HPV -16 E6 and E7 proteins inactivate endogenous tumour suppresor proteins p53 and 
pRb, respectively. 
1.3 THE HUMAN IMMUNE SYSTEM 
The human immune system is equipped with several different functional cell types which 
are involved in the identification and subsequent destruction of infectious agents. A 
division can be made between the specific and the non-specific immune response. The latter 
is represented by natural killer cells (NKs) and macrophages, which do not require specific 
priming for lytic functions and lack immunological memory. Macrophages can be enhanced 
in their lytic activity by cytokines such as g-IFN, IL-2 and M-CSF. Activated macrophages 
can kill target cells by production of cytotoxic products, including TNF-a., or by mediating 
antibody-dependent cell-mediated cytotoxicity (ADCC), using their Fe-receptor. NK cells 
may recognize and kill target cells which lack MHC class I molecules on their cell surface, 
according to the hypothesis of 'missing self recognition129• In addition, NK cells can also 
engage via ADCC using their Fe receptor. 
The two main categories of specific immune response are the humoral immune response, 
making use of antibodies, and the cellular immune response, mediated directly by T cells. 
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1.3.1 ACTIVATION OF THE IMMUNE RESPONSE 
Upon invasion of a host, a pathogen may reside either in the extracellular space or within a 
cell's interior. Cell associated receptors can readily detect extracellular material but cannot 
directly recognize ligand separated from the receptor by a lipid bilayer. The detection task is 
further complicated by the existence of two distinct subcompartments for intracellular 
pathogen residence within a cell: the cytoplasm and membrane-bound endocytic organelles. 
A central role is played by the 'professional' antigen presenting cell (APe) in the onset of 
both the cellular and humoral immune response (Fig 1.2). These cells, including the 
Langerhans' cells and interdigitating cells 130, retain the ability to take up antigenic proteins, 
degrade these in the endocytic route and present small protein fragments or peptides at their 
cell surface to lymphocytes. Also B cells and monocyteslmacrophages can process and 
present antigens in a similar fashion. The peptides are presented at the cell surface by major 
histocompatibility complex class II (HLA class II) molecules, after which the specific 
HLNpeptide interaction can be recognized by the T cell receptor (TcR) of CD4+ helper 
cells (Th). Recognition of the antigen as non-self leads to the activation of the specific Th 
cell, which then proliferates and starts producing different Iymphokines, that stimulate 
various other immune cells. Activated Th cells have occasionally been found to exert 
cytolytic functions as we1l 131. 
Two subsets of CD4+ cells, designated Th I and Th2 have been recognized based on the 
cytokines they express as well as functional properties132-133. Thl clones produce IL-2, y-
IFN and TNF-B, thereby providing help to cell mediated effector responses. Th2 clones 
secrete IL-3, IL-4, IL-5, IL-6 and IL-lO, which stimulates B cells to produce 
antibodies 133. The conditions that dictate which Th clone develops after antigenic 
stimulation are not fully understood and may be determined, at least in part by the invading 
virus. The cytokines produced by one Th clone can inhibit cytokine production by the other 
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Th clone134• Also transforming growth factor-B ( TGF-B ) inhibits IL-4 and -5 production 
by Th, while g-IFN and ll...-2 production remain unaffected, suggesting that in particular, 
Thl stimulation is promoted135• Furthermore, co-stimulatory signals from the APC may 
dictate which Th clone develops, since the requirements of costimulatory signals is 
different for Th 1 and Th2 ce1l136• 
1.3.2 HUMORAL IMMUNE RESPONSE 
Generally, B-cell responses require help from T cells. A B-cell recognizes a determinant on 
a native antigen via its membrane bound immunoglobulin (ig). The antigen is internalized, 
processed and the resulting peptides are presented on the cell surface by HLA class II. The 
subsequent recognition by the TcR of a CD4+ Th cell leads to activation of the B cell, either 
as a result of direct contact with the TcR (cognate interaction) or by lymphokine production 
by the activated Th cell. Activation of B cells leads to clonal expansion and differentiation 
into antibody producing plasma cells137• Antibodies recognize intact protein structures. 
which allows them to bind and recognize free viral particles. In addition, by binding to 
structures present at the cell surface of host cells, antibodies can effect complement fixation 
('classical' complement fixation pathway), promoting phagocytosis and damage to plasma 
membranes via the membrane attack complex (MAC). Furthermore, antibodies can enhance 
the effector functions of the non-specific cellular response via antibody-dependent cell-
mediated cytotoxicity ( ADCC ). 
1.3.3 CELLULAR IMMUNE RESPONSE 
Cellular immune response involves two types of reactions mediated by different T cell 
subsets: delayed type hypersensitivity (DTH), initiated by CD4+ T cells and T cell mediated 
cytotoxicity mediated by CD8+ T cells (cytotoxic T-Iymphocytes, CfL). Both require 
antigen specific priming and retain immunological memory. 
22 
In DTH, sensitized Th cells are activated by antigen, presented by APC and the resulting 
cytokine production recruits and activates lymphocytes and macrophages capable of 
inflicting local tissue damage. In T cell mediated cytotoxicity, CTLs constitute the main 
effector targeted towards endogenous antigens such as viral proteins. Also the CIL 
response is dependent on cytokine production by the Th cells, mainly IL-2 produced by 
Th I. Since the present work concerns immune response to the human papillomavirus, the 
CTL-mediated cytolytic pathway is discussed in more depth below. 
1.3.3.1 T cell mediated cytotoxicity 
CTLs are CD8+ T cells that recognize antigenic peptides presented by lILA class 1138. 
Interaction of the TcR with MHC-I1peptide leads to the activation of CTL and expression of 
its IL-2 receptor. Subsequent clonal expansion is mostly dependent on IL-2 production by 
the activated ThlI39-140. This results in an increased number of antigen specific CTL that 
express cytolytic agents, packaged in cytosolic granules. The contents of such granules 
include serine proteases or granzymes141 , the pore-forming macromolecular complex 
perforin or cytolysin 142 and the calcium-binding protein cal-reticulin143. 
When the activated granzyme expressing CIL engages with its target cell, the TcR is 
trigerred by the appropriate MHC-I1peptide combination. This activates protein kinase-C 
(PKC), resulting in phosphorylation of lymphocyte function-associated antigen-l (LFA-
1)144. As a consequence, the affinity of LFA-l for its ligand intercellular adhesion 
molecule-l (ICAM -1), present on the target cell is increased 145. Furthermore, 
phosphorylated LFA-I associates with the cytoskeletaI protein talin146, which stabilizes 
LFA-I expression at the cell surface. The enhanced LFA-lIICAM-1 interaction further 
consolidates the CTL-target cell contact. 
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In addition, engagement of the TcR results in a rapid reorientation of granules in the CfL 
towards the target ceU147. This probably involves reorganization of the microtubuli 
organization centre (MTOC) and the golgi apparatus l46, which promotes the intracellular 
flow of vesicles towards the CTL-target cell contact site. Furthermore, the association of 
LFA-l with talin stabilizes talin clusters under the CfL membrane in the proximity of the 
CTL-target cell contact area, which promotes fusion of secretory vesicles with the CIL 
membrane. The combined action of the MTOC/Golgi reorientation, and the talinlLFA-l 
association results in exocytosis of the cytolytic granules into the luminal cleft between the 
CTL and the target cell 147. Either through the pore-forming function of perforin 148, or by 
specific adherence and subsequent endocytosis of the granule149, the cytolytic components 
are delivered to the target cell. A number of other cytotoxicity pathways involving CTLs 
have been described. These include secretion of lymphokines such as TNF-a and TNF-B 
by CTL which are cytotoxic to some cells 150. 
1.4 THE HLA COMPLEX 
The lILA gene complex is found on the short arm of chromosome 6 in the 6p21.31 to 
6p.33 region where it encompasses approximately 3,500 to 4,000 Kilobases of DNA (Fig 
1.3). The lILA class I region spans approximately 1600 to 2000 Kb and contains genes 
encoding the classic class I antigens: lILA-A, HLA-B, and HLA-C as well as the three 
non-HLA-A, B, C class I genes: lILA-E, HLA-F, and lILA-G. The lILA D region 
contains the genes for lILA-DR, DQ, DP, DN, and DO and spans 1000 to 1200 Kb of 
DNA. Between the class I and class II regions lies the class III region, which contains at 
least 35 genes including complement factors (C2, C4 and BO, steroid 21-hydroxylase 
(CYP21), heat shock protein 70, opposite strand gene (OSO), and tumor necrosis factor 
alpha and beta. Recently, genes encoding molecules involved in antigen processing and 
assembly of class I molecules as subunits of a large multifunctional protease (LMP) and as 
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a membrane transporter associated with antigen processing (TAP) were mapped to the class 
II region 151. 
The HLA complex covers a relatively small segment of the chromosome corresponding to 
approximately 2 centimorgans. This means that genetic recombination occurs very 
infrequently and the complex can be considered as a single genetic unit. The genetic unit 
composed of HLA alleles present on the HLA-A, HLA- B, HLA-C, and HLA-D loci on 
each of the two homologous chromosome 6 is called an HLA haplotype. The two 
haplotypes present in each individual constitute the HLA genotype. The gene products of 
each of the class I and class II loci are co-dominantly expressed as cell surface antigens. 
This means that each individual expresses two HLA-A antigens, two HLA-B antigens, two 
HLA-C antigens, and two sets of HLA-D gene products. These HLA antigens constitute an 
individual's phenotype. An important characteristic of the HLA gene complex is the 
existence of linkage disequilibrium between the alleles of the loci. In a random mating 
population at Hardy-Weinberg eqUilibrium, the joint frequency of 2 alleles from 2 different 
loci will be the product of their individual gene frequencies. If the observed value of the 
joint frequency is significantly different from the expected frequency, the 2 alleles are said 
to be in linkage diseqUilibrium. 
Most expressed HLA genes exhibit a remarkable degree of allelic polymorphism. This is 
the occurrence in the population of two or more genetically determined forms in such 
frequencies that the rarest forms could not be maintained by mutation alone. The molecular 
genetic basis for polymorphisms of HLA class I and class II alleles is due to differences in 
nucleotide sequences within the coding regions of the individual HLA genes. HLA 
polymorphism has several unique features: most have many alleles, no allele dominates in 
frequency, and alleles differ by many amino acid substitutions. Although the reasons for 
this extensive genetic polymorphism are currently unknown, there are two dominant 
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theories, namely, retention of ancestral polymorphisms and hypennutational 
diversification152-153. It is evident that most major MHC allelic types diverged prior to the 
origin of the species in which they are found based on sequence data from rodent and 
primate MHC genes152,154-155. The rate of amino acid altering substitutions exceeds that of 
silent substitutions in codons of contact amino acids in the antigen binding site of MHC 
class I and Class IT molecules, indicating that selection operates directly on the antigen 
binding site156. The high degree of polymorphism, long persistence of alleles, low 
frequency of homozygotes, and high rate of replacement substitutions is probably best 
explained by overdominant selection. 
1.4.1 CLASS I AND CLASS II HLA MOLECULES 
The main biological function of HLA molecules is to bind peptide fragments of processed 
protein antigens and present them to T cells. Class I molecules consist of two common 
subunits; a polymorphic 45-kDa heavy chain glycoprotein that is non-covalently associated 
with a conserved 12 k-Da B2-microglobulin (B2M) light chain157-158. Class I molecules are 
expressed on virtually all nucleated cells1S9. The class I heterodimer is expressed as a 
transmembrane complex at the cell surface with three N-terminal heavy chain domains 
called a-I, a-2, and a-3, extending outward from the membrane. The heavy chain-B2M 
complex bound with its antigenic peptide is anchored by a single transmembrane segment 
on the heavy chain that is followed by a short intracytoplasmic sequence of variable length. 
The membrane proximal external domain, a-3, folds in a manner similar to that of an 
immunoglobulin domain and has several extensive contact with the B2M light chain. The 
structure of several class I molecules as determined by X-ray crystallography (Fig 1.4) 
reveal that the two most N-terminal domains fold as a unit to form a prominent groove on 
the top face of the molecule138,160-161. Two parallel a helices and eight antiparallel B 
sheets comprise the walls and base of the groove, respectively. The groove was found to 
be of dimensions appropriate to accommodate short peptides (8 - 10 residues). 
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Class IT MHC proteins consist of a 33 KDa alpha chain that is noncovalently associated 
with a 28 KDa beta chainI62-163. Both chains are glycosylated transmembrane proteins, 
and each consists of two extracellular domains (al and a2 ; and BI and B2), a hydrophobic 
domain, and a short cytoplasmic segment. Class IT molecules are found on B cells, 
activated T cells, macrophages, monocytes, dendritic cells and endothelium, except under 
the influence of the cytokine gamma interferon, which induces class II expression on 
diverse cell types. As determined by X-ray crystallography, the N-terminal a-I and B-1 
domains of the class IT subunits fold in a manner analogous to that observed on class I (Fig 
1.4) and form a groove similar in overall structure to that observed on class I, with the 
notable exception that unlike class I, the ends of the class II groove are open 164. 
One of the most important features of HLA molecules is their ability to form stable 
complexes with several different peptide sequences. This enormous binding capacity arises 
from hydrogen bond interaction between conserved HLA residues and the peptide main 
chain, thus providing sequence-independent affinity for peptide ligandsI61 ,165-166. HLA-
peptide interaction also involves polymorphic residues in the HLA molecule and specific 
side chains of the peptide. Some of the peptide side chains contact residues within the HLA 
cleft and increase the overall binding affinity and specificity of the associated peptides 
(anchor residues)167-170; others interfere with residues of the HLA cleft and reduce binding 
(inhibitory residues) 171-173. These sequence-dependent interactions are due to "pockets" 
which stud the grooves of both HLA classes164 and the side chains of polymorphic 
res~dues contribute to the walls and floors of these pockets. Thus, the distinct chemical and 
size characteristics of these pockets in different MHC molecules result in strong preferences 
for interacting with certain amino acids side chains. For example, a negatively charged side 
chain in one HLA molecule may preferentially interact with positively charged peptide 
residues, whereas a positively charged side chain in another HLA molecule may only bind 
to negatively charged peptide residues. The residues that fit optimally (anchor residues) into 
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these pockets occur with high frequency in specific positions in peptides associating tightly 
with particular HLA class I or class II molecules 169-17~ and most HLA molecules require 
two to three anchors in a peptide for optimal binding. For any given HLA allele, the anchor 
positions are at fixed distances from one another and involve only a few specific amino 
acids. They can therefore be described by simple motifs, which is proving to be a useful 
way of predicting which segments of a protein may be efficiently presented by a given 
HLA allele. Once they have been produced and transported to the plasma membrane, . 
peptide-MHC molecule complexes function by interacting with clonally distributed 
receptors of T lymphocytes. 
In contrast to peptides associated with HLA class I, those associated with HLA class II are 
commonly presented as nested sets and are typically 10-34 residues in lengthI74-175. The 
term 'nested' set refers to a family of peptides sharing a common core sequence with 
extensions/truncations at either the N- or C- terminal ends. The ability of peptides to vary 
considerably in length is consistent with the open ended structure of the HLA class II 
binding groove 164. Most peptides bound to HLA class II have either an aliphatic or 
aromatic residue near the N-terminus, which presumably fits into the 'hydrophobic' pocket 
formed by a22, a26, a31, a54, 885 and 886 residues of the HLA class II molecule. This 
pocket seems to be capable of accommodating many different hydrophobic residues (e.g 
lIe, Leu, Met, Val, Phe, Tyr or Trp) 170,172. The fact that many different hydrophobic 
residues are accepted in this position, combined with the occurrence of substantial 
variations in peptide length, has hindered the identification of other anchor positions by 
simple sequence alignment. 
1.4.1.1 Viral Antigen Processing and Presentation: Class I Pathway 
Both infectious and noninfectious forms of viral antigen can enter the endocytic pathway of 
a professional APC to be processed and presented, in the context of HLA class II 
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molecules, to CD4+ cells. However, infection with live virus is a requirement for induction 
of class I-restricted CD8+ T cell responses I76,177. This difference results from the distinct 
intracellular location of processing activities for HLA class I and class II antigen' 
presentation. Viral epitopes presented by class I molecules are derived from viral proteins 
synthesized de novo in an infected cell, whereas viral antigens that enter the 
endosomalllysosomal compartments have been specifically routed to these compartments, 
usually after capture from an extracellular location. 
The cytosolic proteolytic processing enzymes required for the generation of class 1-
presented viral peptide fragment have not been positively identified. However, proteasomes 
and a larger ubiquitin-dependent complex are attractive candidates for generating peptides 
from larger proteins because of their broad specificity, ability to cleave on the carboxyl side 
of hydrophobic, basic, or acidic residues, and the demonstration that proteasomes can 
process proteins into oligomers within an appropriate length ·range for class I binding 
without further degradation to single amino acids l78. The finding that two proteasome 
subunits, LMP-2 and LMP-7 (for low molecular mass polypeptide), are encoded in the 
HLA class II region further implicated the involvement of proteasomes in antigenic 
processing179. Recently, it was demonstrated that the MHC encoded LMP gene products 
specifically alter the peptidase activity of the proteasome to favor cleavages that result in 
peptides possessing basic residues on their C-termini 180-181 which is necessary to anchor 
peptide binding in class I grooves. 
The intracellular association of appropriate octamer or nonamer peptides with class I heavy 
chains is essential for stable assembly and transport of peptide-loaded class I complexes to 
the cell surfaceI82-183. Peptides bind newly synthesized and translocated class I molecules 
in the endoplasmic reticulum (ER)184-185. The empty class I molecule may temporarily be 
stabilized in ER by complexing with pS8 (also termed calnexin), a chaperone-like 
29 
molecule 186-187. Binding of peptide results in the release of p88 187. The genes responsible 
for peptide translocation over the ER membrane have been identifiedl88-189, and are now 
designated the transporter for antigen presentation (TAP) 1 and 2 genes, previously known 
as peptide supply factor (PSF) or Really Interesting New Gene (RING-4 and -11). They 
belong to the superfamily of ABC transporters, displaying properties like an ATP-binding 
cassette. 
1.4.1.2 Viral Antigen Processing and Presentation: Class II Pathway 
HLA class II molecules present peptide fragments derived from exogenous protein 
antigens, including structural components of virus particles or secreted viral proteins, to 
CD4+ cells. Exogenous viral antigens are taken up into endosomal compartments, cleaved 
into short peptides that associate with class II molecules targeted to this compartment, and 
then the peptide-MHC II complexes are routed to the cell surface for T cell 
recognition 137, 190-191. 
On translocation to the ER, HLA class II a. and B chains rapidly associate with one another 
together with a third, nonpolymorphic or invariant (li) chain192. The Ii chain is a type II 
transmembrane protein, with the amino terminus extending into the cytosol and the C 
terminus residing in the lumen of the ER193. The Ii chain has been demonstrated to prevent 
exogenous peptides from binding the associated HLA class 11194-195. The alB-Ii trimeric 
complex is transported through the Golgi to the trans-Golgi reticulum (TG ), where the 
cytoplasmic domain of the Ii chain targets the class II molecule into the endocytic 
compartments 196. Subsequently, the Ii chain is degraded by proteases in the acidic 
environment of the endosomes, which renders the class II molecule free for peptide 
bindingl97. 
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Proteolytic cleavage of the Ii chain yields large fragments termed LIP and SLIp198-199 as 
well as a set of nested invariant chain fragments termed.CLIP200. The CLIP epitope resides 
in the class II binding groove potentially to prevent peptide loading in early biosynthetic 
compartments. Release of these invariant chain fragments allows antigenic peptides to bind 
to class II proteins. Although the spontaneous dissociation of CLIP from class II molecules 
is observed at low pH201-202. a novel MHC heterodimer DM has been identified that 
enzymatically catalyzes rapid CLIP dissociation203-204. The ability of IllA-DM to release 
invariant chain fragments has led to the proposal that DM functions as a peptide editor and 
triggers the dissociation of unstable peptides from class II proteins205. In this way. Il\1 
may catalyze the release of suboptimal peptides from class II proteins and directly influence 
epitope selection. However. alternate mechanisms within APC may also control peptide 
loading. including antigen trafficking. sites of processing. and the protease content of the 
APe. 
Where in the endocytic route the class II molecule picks up peptide is not clear. and may 
differ per cell type and per antigen. Endocytosis of soluble antigens can be accomplished 
by internalization of surface Ig plus bound antigen (B cells). by absorption of soluble 
antibody-antigen complexes by Fe-receptors (NK cells and macrophages). or by fluid 
phase endocytosis. The endocytosed antigen proceeds through the early and late 
endosomes to lysosomes. The proteolytic enzymes involved in antigen breakdown. such as 
cathepsin D and E206-207. are probably of sufficent concentration in the late 
endosomaIllysosomal stage 197. Here these peptides may be protected from further 
breakdown into single amino acids by binding to class II. which makes the late 
endosomaIllysosomal compartments the most likely site where the class II molecule meets 
its antigenic peptide. Similar to class I. the stable cell surface expression of lILA class II is 
enhanced by binding of peptide. 
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1.4.2 HLA DNA TYPING STRATEGIES 
Until recently, lILA typing was dominated by serological and cellular techniques. Within 
the last 10 years, more powerful DNA-based typing methods have evolved, and these have 
proven considerably more accurate and reproducible than conventional serological or 
cellular typing. 
Prior to the advent of the polymerase chain reaction, the most widely used DNA-based 
lILA class IT typing method was restriction fragment length polymorphism (RFLP) 
analysis208. RFLP entails the restriction endonuclease digestion of genomic DNA fo))owed 
by electrophoretic resolution of the endonucleotic fragments which are denatured in situ and 
hybridized to a nylon membrane. The membrane is then probed with a homologous labeled 
cDNA or genomic probes which yield hybridization signals characteristic of various HLA 
alleles. Although RFLP is considerably more accurate than DR and DQ serotyping, it has 
certain disadvantages. The technique is technically demanding, takes around 7 days to 
complete, relies heavily upon linkage disequilibrium between DR and DQ loci for 
identification of certain alleles, and it does not define allelic variation at the level of the 
second exon of the gene. 
The development of the polymerase chain reaction (PCR)209 allowed the evolution of 
improved molecular HLA-typing techniques. PCR is used to generate specific amplified 
stretches of DNA sequences in vitro through repeated cycles of DNA denaturation, 
annealing of specific primer to a single strand, and nucleotide extension from primer pairs 
using a DNA polymerase. Currently, most HLA class IT typing methods rely on the 
amplification of the second exon of the polymorphic DRB, DQA, DQB and DPB genes 
followed by a simplified analysis of allele-specific nucleotide sequences within the 
hypervariable regions of the exon. The techniques for analyzing polymorphisms in 
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amplified DNA can be divided into two basic groups: probe hybridization and direct 
amplicon analysis. 
Probe hybridization techniques rely on amplification of a target DNA sequence which is 
generally immobilized onto a support membrane (known as dot blotting). The initial 
amplification is normally generic but may be a mosaic of amplifications which when used 
together amplify all possible alleles of a given locus. The polymorphisms in the 
immobilized DNA are subsequently detected by using specific single-stranded DNA probes 
in combination with highly stringent washes to remove non-specifically bound probe21O. In 
addition to the use of radioactive isotopes, hybridized probes can be detected by a variety of 
non-radioactive methods, such as horseradish peroxidase211 and digoxigenin labelling212. 
The technique became known as PCR-SSOP (PCR followed by sequence specific 
oligonucleotide probing, also discussed in chapter 2). PCR-SSOP was first applied to 
histocompatibility testing in HLA DQAl by Saiki et al (1986). Subsequently, the method 
was applied to HLA DRB1213-214, HLA DQB1215 and a combination of DR, DQBl, 
DPA1, and DPB1216. 
The method is useful for analyzing a large number of samples at once. However, it is a 
time consuming and expensive method to use to define HLA types in a small number of 
samples. This led to the development of an alternative strategy, the reverse PCR-SSOP 
method217, where a panel of SSO probes are immobilized on a single membrane by means 
ofpoly-T tails,leaving the detection end of the probe free to interact with target DNA211. 
Biotin-labeled PCR-amplified target DNA is hybridized with the membrane bound SSO 
probes. Following stringent washing, the specificity of hybridization is revealed using 
streptavidin-horse radish peroxidase as the conjugate. This converts a chromogenic 
substrate into a coloured precipitate218. Another modification. of PCR-SSOP is PCR-HPA 
(hybridization protection assay), and is based on nucleotide hybridization utilizing 
33 
acridium ester labeled SSO in the liquid phase. As in the case of the PCR-SSO method, the 
design of the SSO is critical for the accuracy of this technique. 
Current PCR-SSOP approaches require lengthy post-PCR steps. This has led to the 
development of direct amplicon analysis techniques, These methods, while not so efficient 
for large numbers of samples, are more suitable for rapid limited sample number 
throughput. These include PCR-RFLP, PCR-SSP, nested PCR-SSP, heteroduplex 
analysis, and other confonnational assays. 
The first of these methods, the PCR-RFLP depends on sequence recognition by restriction 
enzymes. The main advantages of this technique are that sequence variations at different 
positions can be recognized at once if there are several restriction sites in the region 
analyzed, it may be perfonned in less than 5 hours, and it eliminates the requirements for 
radioisotopes, probes or reporter molecules. However, some of the currently known alleles 
cannot be easily distinguished because of the unavailability of restriction enzymes 
recognizing their sequence variations. Furthennore, the identification of some allelic 
combinations in heterozygous individuals is not possible219 or is complicated by 
incomplete digestion of PCR products. 
Another method, allele specific amplification of an allele or group of alleles is based on the 
fact that peR cannot be accomplished if the 3' end of primer has a mismatch(es) with a 
given allele. Newton et al220 described the detection of a single point mutation using one 
generic sense primer and two antisense primers: one antisense primer was specific for the 
"nonnal" fonn and was refractory to peR on "mutant" DNA, and the other antisense 
primer for the "mutant" was refractory to peR on "nonnal" DNA. This was tenned the 
amplification refractory mutation system (ARMS). The technique works because Taq 
polymerase lacks 3' to 5' exonucleotic proof-reading activity. For efficient ARMS 
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amplification without false priming, the conditions need to be highly stringent. The first 
comprehensive ARMS lILA typing system was described in 1992 by Olerup and 
Zetterquist221 for low resolution HLA DRB 1 typing, including group specific detection of 
DRB3 and DRB4 by ARMS using 19 PCR reactions. Olerup and Zetterquist221 renamed 
the assay PCR-SSP (PCR using sequence-specific primers). Modem PCR-SSP features 
multiple PCR reactions where each reaction is specific for an allele, or group of alleles. The 
method requires a large number of primers to detect a specific allele and is therefore used 
more often to detect groups of alleles. For example, PCR primers, complimentary to 
conserved flanking sequences of second exons from a group of DRB 1 loci, will generate a 
mixture of peR products, depending on the DR haplotype. This is useful since it permits 
dot-blot, reverse dot-blot PCR-SSO and PCR-RFLP typing of the individual alleles 
simultaneously. 
A modification of the PCR-SSP method is the nested PCR-SSP technique first described 
by Bein et al222. In this method, the region of interest is amplified in the first step and this 
amplicon is used instead of genomic DNA for the second sequence-specific amplifications 
using primers which are internal to the first set of amplification primers. The results 
obtained by this method are similar to one-step PCR-SSP. The advantages of the nested 
PCR-SSP over conventional PCR-SSP include the very small amount of DNA required for 
the former, and the possibility of subtyping highly polymorphic alleles. 
PCR-heteroduplex formation or 'DNA crossmatching' is another direct amplicon analysis 
method. At the end of any PCR cycle, the individual strands may re-anneal with each other 
to form homoduplexes, or they may re-anneal with an unrelated DNA strand to form a 
heteroduplex, or they may remain as single stranded structu~es223. These different forms of 
PCR products have unique conformational structures which may be differentiated by their 
electrophoretic mobilities in a temperature or denaturing gradient gel. PCR heteroduplex 
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analysis has never gained popularity for identifying HLA polymorphisms due to the 
complexity of the gel analysis and the technically challenging conditions. However, it has 
been used to match individuals for HLA DR and HLA DP by "DNA crossmatching,,224. 
The single-stranded confonnation polymorphism (SSCP) analysis depends on the fact that 
single-stranded DNA molecules of differing sequences exhibit confonnational changes as a 
result of intra-strand complementary base pairing22S. The single-stranded products exhibit 
different mobilities in nondenaturing polyacrylamide gel electrophoresis that can be used to 
ascertain the genotype of an individual. So far SSCP has been successfully applied to HLA 
A, DRBI, DQBI, DQAI, DPAI and DPBI typing, and HLA-DR4 sUbtyping. However, 
like heteroduplex analysis, the complexity of both the technique and the interpretation has 
prevented the widespread application of this technique. 
Finally, HLA typing by direct amplicon analysis can be accomplished by directly 
sequencing the PCR products (sequence-based typing, SBT). The principles of SBT are 
that the polymorphic regions of any given allele are amplified by flanking PCR primers. 
The resulting peR products are sequenced by one of a variety of methods and are analyzed 
by computer to ascertain the type. Computer analysis is required because the sequenced 
product from a heterozygous individual will contain two superimposed sequences that need 
to be aligned with all previously known sequences in order to be identified and separated. 
SBT was initially described for HLA DRB 1, DQB I and DQAl by Santamaria et al226 and 
for HLA DPB 1 by Rozemuller et a1227. The main drawbacks of SBT are the equipment 
costs and the time required to fully sequence one individual. Offset against this is the 
tremendous advantage of having high resolution typing. However, sequencing is not 
infalliable and some sequenced alleles have had to be retracted due to errors, most 
commonly GC inversions. 
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1.5 IMMUNE RESPONSE TO HUMAN PAPILLOMAVIRUS 
Advances in the understanding of the nature of immune responses to HPV infection has 
been hampered by three major technological problems. Firstly, there exists no useful 
animal model of the disease (with the exception of the analogous bovine papillomavirus that 
is associated with malignancies of the gastrointestinal tract). Secondly, until recentIy228, 
there was no permissive system for propagating the virus in culture in vitro and thirdly, it is 
difficult to isolate intact genital HPVs from lesions or tumours. Nevertheless, there is now 
a substantial body of evidence which indicate that humans can mount immunological 
responses to the genital HPVs. However, the different steps of onset and the efficacy of the 
immune response is little understood. It is noteworthy that there is no viremia associated 
with viral replication in lesions and the infected cells are relatively inaccessible to the 
elements of the immune system that are not associated with the skin. Thus, the principal 
mediators of the immune reactions to papillomavirus infection are the keratinocytes, 
intraepitheliallymphocytes, and the dendritic Langerhans cells229-231. 
A significant higher prevalence of sera with antibodies to HPV 16-E6 and E-7 have been 
observed in cervical cancer patients (33% and 23% respectively) compared with healthy 
controls232, Antibodies to recombinant proteins and to synthetic peptides corresponding to 
HPV 16 early and late proteins have been detected in sera from patients with CIN, but the 
concentrations of these antibodies are generally low233, In the case of the rabbit 
papillomavirus model, carcinogenic progression seems to be accompanied by variable 
levels of antibody response to the viral proteins, but the antibodies have little or no ability 
to induce regression234. Overall, whilst antibodies to early proteins may represent 
predictive markers of disease progression235 t they are unlikely to confer any protection 
against subsequent HPV 16 infections. However, neutralizing antibodies to HPV 16 in 
cervical secretions may prevent reinfections and effective cell mediated immune responses 
probably explain why the majority of untreated CIN lesions do not progress to malignancy. 
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There are several lines of evidence indicating that cell mediated immune response is 
important in the control of papillomavirus infection. There is increased frequency of HPV 
infection in therapeutically immunosuppressed patients or in immunodeficiencies 
specifically involving cell mediated immunity236-237 as well as in patients with HN 
infection238• HPV infections are also found up to 9 times more often in renal transplant 
recipients compared to the general population239 and these patients have an increased 
incidence of CIN lesions240• The presence of HPV 16 or 18 in CIN correlates with a 
decreased number of Langerhans cells241 and decreased numbers of CD4+ cells are 
observed in CIN lesions242• Furthermore, patients with HPV positive eIN or cancer 
exhibit decreased natural killer cell activity243. Regression of warts shows many 
characteristics of a cell mediated immune response. Histological examination reveals 
intense mononuclear cell infiltrate in the dermis, and the majority of the infiltrating cells in 
regressing warts and CIN are CD4+ T cells244• Finally, patients with common variable 
immunodeficiency (characterized by failure to produce antibodies) appear not to be unduly 
susceptible to the development of HPV lesions245• 
Although antibodies may play a direct role in the clearance of some viruses246, cellular 
mechanisms are probably the most important tools for the defense against HPV infection. 
Thus, the mechanisms underlying the impaired production of JgG antibodies may be 
important in increasing the risk for persistent HPV infection and cancer. Because a class 
switch from JgM to JgG antibody production in response to a certain antigen is induced by 
CD4+ regulatory lymphocytes, HLA class IT antigens are likely to be involved in the 
recognition of foreign peptides by these lymphocytes247• CD4+ T lymphocytes are also 
involved in the function of class J restricted cytotoxic T cells, which are thought to be 
responsible for lysis of virally infected cells and malignant transformed cells. 
38 
The ability to respond to HPV antigens therefore revolves around the capacity of infected 
cells to effectively present viral epitopes to T cells, and the host immunogenetic 
background such as the lILA class I or II type is an important parameter in the overall 
cellular immune response. 
1.6 liLA ASSOCIATIONS WITH HUMAN PAPILLOMAVIRUS AND 
CERVICAL CANCER 
The early population studies on HLA association with cervical cancer were from the United 
States. In the largest of these studies248 in which 253 patients were HLA typed, lILA A-
All was significantly decreased in the patients. However, in another report249, deviations 
in the frequencies of AI, A9 and B 12 were noted. The frequency of HLA B5 was 
increased in the data of Tarpley et al250 on 67 patients while the frequency of lILA B8 was 
increased in 33 patients studied by Twomey et a1251 • In the combined analysis of data on 
Caucasian patients from these early studies (391 from the United states and 64 from 
Germany), HLA B8 was not significantly increased. There are two early reports from 
South Africa on Indian252 and Black253 populations. There was no indication of any lILA 
associations in these studies. Koenig et al254 examined the sera of 89 German patients for 
antibodies against Herpes Simplex type 1 and type 2 viruses. The titre for type 2 virus was 
significantly higher in patients positive for HLA B 12. Furthermore, in their study of 120 
patients, a small but non-significant association between HLA B 12 and increased risk of 
cervical carcinoma was found. 
More recently, there have been a renewed interest in HLA association with cervical cancer 
(Table 1.4). The results have not been consistent probably because of differences in the 
size and type of population examined and techniques used for the HLA and HPV typing. 
Wank & Thomssen25S reported on the frequencies of the HLA class II phenotypes in a 
German population of 66 patients with squamous cell carcinoma of the cervix and 
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compared with two control groups. The first control group was a local panel of 109 
individuals, and the other control group was a caucasian panel of 2,019 individuals from 
the Ninth International Histocompatibility Workshop. Using serological typing, the 
frequency of Ill.A DQW3 antigen in the local panel was 50.4% (Ninth workshop panel, 
41.2%), whereas the frequency in the patient group was 87.8%, suggesting that a 
caucasian female with the HLA DQW3 antigen has a 7.1 times greater chance of developing 
squamous cell carcinoma compared with females without this antigen (p = 0.0009). In 
addition, there was a weaker association with HLA DR5 which is in linkage disequilibrium 
with HLA DQW3, but a 12.7 fold decreased relative risk with HLA DR6. 
The limitations of this initial report was that serological typing methods were used, the local 
control panel were not very well defined, and there was no information on the HPV status 
of patients or controls. Two subsequent reports by the authors256-257 using sequence-
specific oligonucleotides to define DQ alleles in the same group of patients showed a 
preferential increase in the frequency of DQB 1 *030 1 (40 of 57 patients; relative risk 8.71, 
P = 0.00(1) and *0303 alleles (9 of 57 patients, relative risk 4.5, p = 0.0012) in patients 
with squamous cell carcinoma of the cervix. However, these findings were not correlated 
with the HPV status of the patients or controls. In addition, these authors also found that 
11 of 22 patients with sec from Tanzania had the HLA DQB 1 *0602 aIIele2S7. The latter 
study utilized data from South African donors as controls (22.7% frequency of 
DQB 1 *0602) and suggested that this antigen may be important (p = 0.0041). A full 
discussion of the limitations of studies by other groups is found in chapter 6. 
1.7 SIGNIFICANCE OF HLA ASSOCIATIONS WITH DISEASE: 
REVERSE IMMUNOGENETICS 
The discoveries of HLA associations with certain diseases represent a significant break 
through in the understanding of the genetics of these diseases. The primary data showing 
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the associations are increased frequencies of certain lILA antigens in groups of patients as 
compared with a sample of normal individuals, and usually none of the observed 
associations are absolute. 
The association of lILA with some autoimmune and infectious diseases are well 
established. These include rheumatoid arthritis, ankylosing spondylithis, Behcet's disease, 
insulin dependent diabetes mellitus, malaria, schistosomiasis, tuberculosis and hepatitis B. 
In addition, previous studies have revealed several associations between the lILA system 
and malignant disease. For instance, Hodgkin's disease-associated with Epstein-Barr virus 
(EBV)258, thyroid carcinomas259, non-melanoma skin carcinomas associated with 
HPV260, cutaneous melanoma261and nasopharyngeal c~cinoma262. 
The process of identifying an lILA association with an infectious disease and then using 
this information to identify candidate antigens involved in immunity has been termed 
"reverse immunogenetics". Classical immunogenetics for infectious disease uses an 
approach in which antigens are identified (often by relatively unrelated criteria such as 
reactivity with murine monoclonal antibodies) and then immune responses to these are 
studied. It is then possible to analyze the MHC restriction of the response to these antigens 
and to map T-cell epitopes. The difficulty with this approach is that there will be immune 
responses to many antigens of a pathogen, and only some of these may mediate protection. 
Therefore, it is necessary to assess whether responsiveness to a particular antigen correlates 
with protection, which is often a difficult task in clinical practice. 
"Reverse immunogenetics" has the advantage that its starting point is an observed 
resistance or susceptibility to a disease in a subset of a population bearing a particular lll.A 
type. The mechanisms of this resistance or susceptibility can then be analyzed by the 
identification of antigens derived from the pathogen and recognized in the context of the 
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significant lILA molecules. This approach has been applied to the investigation of lILA 
B53 mediated resistance to severe malaria and has been used in this thesis. 
1.S APPROACHES TO DEFINING HLA CLASS II BINDING MOTIFS 
The characterization of naturally processed peptides bound to lILA class II molecules 
associated with susceptibility and protection to HPV infection provides an approach 
towards understanding both antigen processing and peptide binding events in vivo. 
Crystallographic analysis of lILA class II /peptide complexes have shown that class II 
molecules bind peptides by forming hydrogen bonds to the peptide backbone and by the 
sequestration of the side chains of the peptide anchor amino acids inside the pockets of the 
groove of the class II molecule 165. Different class II moiecules have different pockets and 
bind different sets of peptides263-264. The positions and type of residues which anchor a 
peptide to a particular class II groove determine the peptide binding "motir' for that class II 
molecule264. 
The binding specificity of lILA class II molecules has been analyzed by a variety of 
methods. Direct binding to class II molecules has been measured using synthetic variants of 
high affinity binding peptidesl72,265-266. More recently, in vitro binding studies have been 
employed using libraries of random peptides encoded in the coat protein of M13 
bacteriophage 170, or by studying binding of peptide librariesl73. Another approach is the 
sequencing of individual peptides and pools of peptides eluted from affinity-purified class 
II molecules267. 
1.S.1 The Use of Large Peptide Repertoires to Identify General HLA Class 
II motifs 
Of all class II isotypes, lILA-DR is the best characterized structurally and functionally. 
Thus, for class II HLA-DR molecules, motifs have been identified by the analysis of large 
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peptide pools selected from MI3 bacteriophage peptide display libraries 170,173,268. This 
technique is based on the ability of filamentous bacteriophage to display peptides on their 
outside surface and involves the screening and enrichment of bacteriophage-displaying 
peptides that bind to a particular protein. By inserting oligonucleotide-encoding peptides 
known to bind to HLA-DRB I *0101 into the protein-ill encoding gene of bacteriophage 
M 13, Hammer et al268 demonstrated that the bacteriophage displaying the appropriate class 
II ligand can bind specifically to the DR groove. Based on this observation, a large 
DRB 1 *0 10 I binding peptide repertoire was selected from a M 13 peptide display library 
consisting of millions of random peptides. Sequence analysis of the DNA encoding the 
DRBI *0101-selected peptides led to the identification of peptide positions in which amino 
acids with similar side chains occurred with increased frequency (anchor residues), thus 
resulting in a DRBI *0101 peptide-binding motif 268. The motif consists of four anchors at 
relative positions 1,4,6 and 9 that are fixed at distances from one another, thus reflecting 
the architecture of the DRB 1*010 I groove in that both the spacing and chemical 
characteristics of anchor residues correspond to the major pockets I, 4, 6, and 9 of the 
HLA-DR cleft. 
The screening of bacteriophage libraries has also been applied to other lILA-DR alleles 
such as DRBI*0401 and DRBI*IIOI17o. The results show the presence of conserved 
anchor residues, i.e., anchors found in each of the HLA-DR selected peptide pools, as well 
as allele specific anchor residues. For example, most of the HLA DRB I *010 I, 
DRB I *040 I, and DRB I * 11 0 I selected peptide pools were found to have aromatic and 
aliphatic amino acids at positions 1 and 4 respectively, whereas strong allele-specific amino 
acid preferences were identified at position 6: Ala and Gly for DRB I *0 I 01, Ser and Thr 
for DRBI *0401, and Arg and Lys for DRBI *1101. These results provided the molecular 
basis for both the promiscuity and specificity of peptide recognition by HLA-DR 
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molecules. Further, by varying the conditions used to elute bacteriophage from the class II 
cleft, it is possible to identify secondary anchors at positions 2, 3, and 7173. 
General lILA class IT motifs can also be identified by the characterizing large endogenous 
bound peptide pools. The technique was originally developed for the definition of class I 
motifs169. In this approach, endogenous class II-bound peptide pools are eluted and 
subsequently analyzed by Edman sequencing267,269. Because the class II-binding cleft is 
open at both ends and endogenous peptides are not aligned due to the variable length of 
class II ligands, pool sequencing approaches with class II-eluted peptides failed to reveal 
patterns as clear as those of class I ligands. However, pool sequencing combined with the 
alignment of natural ligands and the consideration of predicted pocket structure resulted in 
class II motifs similar to the ones obtained by the bacteriophage technology270. 
1.8.2 The Use of Single-Substitution Experiments on Naturally Processed 
Peptides to Identify Specific HLA Class II-Binding Motifs 
The effects of single residue substitutions in naturally HLA-bound peptides have been 
studied to identify residues critical to the interaction of these peptides with HLA class II 
molecules. For example, in the case of lILA DRB 1 *0101, the importance of an aromatic 
residue at relative position 1 was initially found by Ala substitutions of the influenza 
hemagglutinin (HA) epitope 307-319168• More extensive truncation and single-residue 
substitution studies on HA 307-319 or tetanus toxoid 830-843 revealed specific class II 
binding motifs for DRB 1 *0401, DRB 1 * 11 01, and DRB 1 *070 1172,265,271. Substitution 
experiments on myelin basic protein peptide 84-102 also revealed differential binding for 
DRBI *1501 and DRB5*0101272-273. 
Comparison of the results from single-substitution studies with other methods, such as 
M13-displayed peptide repertoires have confirmed the generality of motifs derived from 
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single-substitution experiments. Furthermore, only this approach is able to reveal the 
presence of side chains that interfere with peptide binding. These inhibitory residues are of 
similar importance for binding with class II molecules as the presence of anchor 
residues171-173. 
1.8.3 The Use of Quantitative Matrices to Identify HLA Class II motifs 
Data from X-ray crystallographic studies, large peptide repertoires and single substitution 
experiments indicate that peptide side chain effects (anchor, inhibitory, or neutral) seem to 
depend on the position within a particular peptide frame rather than on neighbouring amino 
acids. These observations led to the approximation that each amino acid in a peptide 
sequence contributes to the affinity of the peptide independently of the neighbouring amino 
acids173.274-275. The determination of the effects of each amino acid at all peptide positions 
resulted in matrices that define quantitatively HLA class II ligand specificity. DRB 1 *0401 
and DRBI *0101 matrices have been determined using 9- and 13-residue-Iong275 designer 
peptides (see also chapter 5). More recently, this approach has been extended to the use of 
"pocket-specificity" profiles to generate quantitative matrices for many HLA class II 
alleles276. 
1.8 AIMS OF THIS THESIS 
Despite the compelling evidence implicating HPV in cervical oncogenesis, the majority of 
women infected with 'high risk' HPV do not develop cervical intra-epithelial neoplasia 
(eIN) or cancer. It is clear that competent cell-mediated immune response is required to 
control HPV infection and prevent the development of CIN or cancer, and this in turn is 
dependent on proper HLA-mediated antigen presentation. The aims of this thesis are: 
1. To examine in detail, the association between HLA-DQ and -DR alleles, the human 
papillomavirus and premalignant disease of the uterine cervix. 
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2. To identify susceptibility and protective HLA DQ-DR haplotypes in relation to human 
papillomavirus and premalignant disease of the cervix. 
3. To identify naturally processed peptide sequences bound to susceptibility and protective 
HLA molecules and use this for motif prediction of HPV 16 Ll, L2, E6 and E7 sequences 
that will bind with high affinity to these Ill..A molecules. This should lay the basis for 
future work in evaluating HLA DQ and DR restricted immune responses to HPV infection 
as well as peptide based vaccine approaches for the prevention and treatment of eIN and 
cervical cancer. 
46 




E uivalent Terminolo 
Squamous atypia, Pap class II 
Mild dysplasia, eIN 1, Koilocytotic atypia, condylomatous 
atypia, HPV related changes 
Moderate dysplasia, eIN 2, severe dysplasia, carcinoma 
in-situ, eIN 3 
Table 1.1: The Bethesda system of classification of squamous abnormalities compared 










Cutaneous warts, flat warts, plantar warts, 
butcher's warts. Cutaneous plaques and 
papillomas in patients with Epidenno-
dysplasia Verruciformis (EV). Skin 
carcinomas" in renal allograft patients and 
EV patients. 
Laryngeal papillomas, condylomata 
acuminatum, eIN; vulvar, penile and 
perianal intraepithelial neoplasia; cervical 
42,43,44,45,51,52,53,54,55,56,57,58,59, cancer; vulva, penile, perianal and anal 
61,62,64,66,67,68 cancer, verrucous carcinoma of vulva and 
penis, Buschke -Lowenstein tumor. 
Table 1.2: HPV genotypes from cutaneous and mucosal lesions ( Walboomers et al., 
1994 ). 
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Reading Frame Function 
El DNA replication 
E2 Transcription, DNA replication 




Ll Viral capsid 
L2 Viral capsid 
Table 1.3: Function of HPV gene products 
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Table 1.4: Summary of Studies on HLA Associations with HPV, CIN and Cervical Cancer 
Reference 
Yandenvelde et al. 
(1993) 
David et aI. (1993) 
MehaI et aI. (1994) 
Apple et aI. (1995) 
Pa tien ts Controls 
71 323 
(24 CIN I. 21 (CINO, not 
CINII, 26 CIN typed for 
III) HPY) 
SO 99 
(5 CIN I, 15 (CINO, blood 
CIN II, 30 CIN donors) 
III) 
66 160 
(27 CIN I, 15 
CIN II, 24 CIN 
III) 
128 1220 






Sanjeevi et 01.174 1164 (1996) (10 CIN I, 41 

























1. DQB 1 *03: RR = 2.647 for HPY 
associated CIN 
1. DQB 1 *03 : RR = 2.5 for CIN ill 





3. DRBI *1501: OR=4.75 
4. DRB1*1102-DQA1*0501: 
OR=O.19 for HPV positive severe 
dysplasia/CIS. 
t. DQB 1 *0602: OR=5.67 for HPV 16 
seropositive cases/controls. 
2. DQB1*0303: OR=2.98 for all 
cases/control. 
3. DQA1*0102-DQBl*0602: 
OR=6.00 for all cases/controls. 
4.DQAl *0501-DQBl *0301: 
OR=3.00 for seronegative 
cases/controls. 
5. DRI5-DQAl *0102-DQBl *0602: 
OR=6.8 
Reference Patients Controls Population HLA Typing HPV Main Results 
Method Detection 
Helland et al. (1998) 92 225 Norweigian PCR-SSO PCR 1. DQBl*0602: OR=3.2 for HPV 
(10 CIN n, 82 (CIN 0) positive cases. 
CIN nl) 2. DQB 1 *0604: OR=O.1 
3. DQAl*0102-DQB1*0601: 
OR=3.2 for HPV positive cases. 
Wank & Thomssen 66 109 German PCR-SSO Not done Increased risk of sec for 
(1992) (SCC) (local panel) DQB1*0301 & 0302 
Helland et aI. 213 181 Norwegian PCR-SSO Not done 1. DQW3: RR=2.0 
(1992) (SCC) 
Amar et aI 30 400 Jewish PCR-SSO Not done No HLA associations 
(1993) (SCC) (local panel) 
Glew et aI. 65 857 British PCR-SSO & PCR No HLA associations 
(1993) (SCC) (organ Serology 
donors) 
Nawa et aI' 23 Int. Japanese PCR-RFLP PCR Increased risk of SCC for DQB 1 *03: 
(1994) (SCC) workshop p=0.0003 
Apple et aL 98 220 Hispanic PCR-SSO PCR I.DRB 1 *1501-DQBI *0602: 
(1994) (SCC) (CINO) OR=2.87 
OR=4.78 for HPV 16 +ve cases 
2.DRB 1 *0407-DQB 1 *0302: 
OR=2.19 
3.DR13: OR = 0.29 (-ve) 
4.DQB 1 *03: No association. 
Gregoire et al. 66 214 African- PCR-SSO PCR 1. DQB 1 *03; RR=2.3 
(1994) (SCC) American 2. DQBl *0303 ; RR=5.2 
3. DOB 1 *0(i04~ RR=5.2 _ 
----
~-L I; L I ORF from 5516 to 71 54; map capsid protein; 
g<!M-L1; L1 ORF from 4 133 to 5656;minor c."sld protein; 
pph 16.gb_ vi 
7904 bp 
~6; E6 ORF from 65 to 559; tnnsforming protein; 
gene-E7; E7 ORF from 544 to 858; putmlve;transfcnning prot";"; 
E2 orf272r>-3852 recu1a\ory proIein 
~-E4; £4 ow: from 3331 to 36' 9 
. 
Fig 1.1: Schematic presentation of the HPV 16 genome. The numbers indicate the first and last 
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Fig 1.2: Antigen presentation by HLA class II molecules on professional APCs leads to T-helper activation. Subsequently different Th subsets 
stimulate different effector function: Thl cells stimulate NK cells and macrophage activity by Iymphokine production (g-IFN, IL-2 and M-CSF). In 
addition, Thl stimulate clonal expansion of primed CTLs by IL-2 and g-IFN production. Th2 cells stimulate primed B-cells to proliferate and produce 
antibodies by the secretion of IL-4,S,6 and 10. Alternatively, the interaction between the T-cell receptor ofTh2 and HLA class II on the activated B-cell 
leads to antibody production (cognate interaction pathway). Arrows indicated A-D represent different effector pathways: A, viral particle neutralization by 
antibodies; B, antibody-directed complement fixation,resulting in membrane damage by MAC; C, antibody dependent cell-mediated cytotoxicity 
(ADCC), in which NKs and macrophages bind via their Fe-receptor to antibodies adhered to the target cell; D, MHC-I restricted CfL mediated killing. 
HLA Cllu II 
• Clln III ------,.1--- K.A clu.' ----, 
8 A 8 A A 8 8 A 8 A B 8 8 B BAG CY' C2 
2 2 I I 2 2 I I I 2 J .. 5 I 18 21 
8 c EAr G 
-------1000 kb 8 1100 kb --------i 
~------------------------------------- 3S00-4000kb 
Fig 1.3: The HLA gene complex showing the 3500-4000kb of DNA with the locations and distances of Class II, Class I, 
complement (C2,C4, Bf, hydoxylase genes 21 Band 21 A), the heat shock protein genes 70 (HSP70), tumour necrosis factor, 
and HLA-B-associated transcripts (BATS). 
T cell 
Receptor 
Fig 1.4: A representation of the trimolecular relationship between the MHC molecule, 
peptide, and T cell receptor. The class I molecule is shown. Class II molecules have a 
similar structure but different domain organization. On the right side, a top view of the 
peptide-binding site which consists of a B-pleated sheet formed by eight anti-parallel B 
strands, and the sides are fonned by two alpha helical segments. Polymorphic residues in 
both Class I and Class II proteins are clustered in this peptide-binding region and are 
responsible for the different peptide specificities observed for different HLA proteins. 
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2.1 SAMPLE COLLECTION AND GENOMIC DNA EXTRACTION 
2.1.1 SAMPLE COLLECTION 
Cervical smears were taken from healthy women and those with CIN attending the outpatient 
clinics at City Hospital, Nottingham; Whittington Hospital, London, and the Margaret Pyke 
Center, London. In most cases, the referral for colposcopy was based on current British 
guidelines, i.e. a single moderate or severely dyskaryotic smear or a persistent mild abnormality. 
At the time of colposcopy, another smear was taken with an Ayre spatula and sent for routine 
cytological examination. The same spatula was used to collect additional cells, which were then 
agitated in phosphate buffered saline, and stored at -200C. Any areas of abnormal epithelium found 
on colposcopy were biopsied (punch biopsy, loop diathermy, or laser cone as appropriate), and 
sent for routine histological assessment. Women with no visible colposcopic abnormality were not 
biopsied and were assumed to be histologically normal. Patients with colposcopic and histologic 
diagnosis of CIN formed the test population. Patients with normal cervical cytology who tested 
negative for HPV infection formed the control population. Histological classification into normal, 
CINI, and CIN III were carried out according to established criteria6,277. 
2.1.2 GENOMIC DNA PREPARATION 
Mter thawing, exfoliated cells were pelleted and washed twice in PBS. Cell pellets were digested 
with SDS (0.5%) and proteinase K (500llglml) for 6 hours or overnight at 370C. An equal volume 
of equilibrated phenol was added and the solution was mixed with gentle rocking for 30 min at 
room temperature. The aqueous layer was removed by suction using a wide-bore pipette and re-
extracted with phenol two to three times until the interface was clear. The aqueous layer was 
extracted once with an equal volume of phenoVchloroform and once more with chloroform. DNA 
was· precipitated from the aqueous phase by the addition of two volumes of absolute alcohol, 
washed once with 70% ethanol and resuspended in 10mM Tris (pH 8) and ImM EDTA (TE) and 
digested with lOOIlg/ml of RNAse for 1 hour at 370C. Mter re-extraction (once with phenol, once 
with phenoVchloroform and once with chloroform), the DNA was precipitated, washed with 70% 
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ethanol and dissolved in 50J,l1 of TE. The amount of DNA recovered from each specimen was 
determined by spotting IJ,l1 of serial dilutions on a commercially available dipstick (Invitrogen). 
2.2 HPV TYPING 
2.2.1 POLYMERASE CHAIN REACTION WITH TYPE SPECIFIC PRIMERS 
Separate PCR reaction were run for each of the HPV types 16, 18, 31, 33 using the primers 
shown in table 2.1. The PCR primers were chosen from the literature to be type specific. This was 
confirmed using cloned HPV plasmids and by the results obtained on some clinical specimens 
using alternative type specific primer pairs which gave entirely consistent results. 
2.2.1.1 PCR AMPLIFICATION CONDITIONS 
PCR amplifications were performed in either a Techne PHC-3 or Perkin Elmer Cetus machine. The 
reactions were performed in 50JlI containing lOOng of specimen DNA, 10mM Tris-HCI pH 8.3, 
50mM potassium chloride, 1.5mM magnesium chloride, 0.01% gelatin and 5Opmol of each 
primer. The nucleotides (dATP, dCfP, dGTP, dTTP) were each at a final concentration of 
l00JlM. 1.25 units of Ampli Taq polymerase (Perkin Elmer Cetus) was added at 700C after the 
initial denaturation. 
2.1.1.2 PCR TEMPERATURE CONDITIONS 
HPV 16: Sense and antisense primers for HPV 16 were used with the conditions described by 
Seedorf et a1278• Initial denaturation was for 8 minutes followed by 35 cycles of 940C for 15 
seconds, 540C for 15 seconds and 72°C for 30 seconds, with a final extension at 720C for 8 
minutes. 
HPV 18: The primers for HPV 18 were used with the conditions described by Coles and 
Danos279• Initial denaturation was for 8 minutes followed by 35 cycles of 940C for 15 seconds, 
700C for 15 seconds and 720 C for 30 seconds, with a final extension at 720C for 8 minutes. 
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HPV 31: Sense and antisense primers for HPV 31 were used with the conditions described by 
Goldsborough et a1280. Initial denaturation was for 8 minutes followed by 35 cycles of 940C for 
15 seconds, 540C for 15 seconds and 72°C for 30 seconds, with a final extension at 720C for 8 
minutes. 
HPV 33: Sense and antisense primers for HPV 33 were used with the conditions described by 
Cole and Streeck281 . Initial denaturation was for 8 minutes followed by 35 cycles of 940C for 15 
seconds, 650C for 15 seconds and 72°C for 30 seconds, with a final extension at 720C for 8 
minutes. 
2.2.1.3 AGAROSE GEL ELECTROPHORESIS 
Agarose (Sigma) gels of 2% concentration (wtlvol) were made with and run in IX Tris-acetate-
EDTA (rAE) buffer pH 8.0282. The PCR product were mixed with 2J.lI of loading dye282 and 
loaded into the wells of the gel. The gels were run at room temperature at a constant voltage of 70v 
for approximately three hours. Variations of both voltage and run times were used for convenience 
and for better resolution of the DNA fragments. Once the DNA had run for sufficient size 
fractionation, the gel was removed and placed in O.5J.lglml of ethidium bromide (Sigma). After 10 
minutes, the DNA fragments were visualized on a UV light transilluminator, wavelength 254nm. 
The gels were photographed. As an aid to fragment size identification, 123 bp marker from 
EcoRIIBam HI fragments of adenovirus type 2 was included. 
2.3 HLA DQBl*03 TYPING: ARTIFICIAL RESTRICTION FRAGMENT 
LENGTH POLYMORPHISM (A-RFLP) 
2.3.1 PRINCIPLES OF A·RFLP 
Restriction analysis of PCR products is one of the earliest techniques used for analyzing amplified 
products209. This approach is applicable for distinguishing alleles in which the polymorphic 
residue results in the creation or removal of a restriction enzyme site. Unfortunately, many 
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polymorphisms are not associated with restriction enzyme site change and thus are not amenable to 
this analysis. However, by using site directed mutagenesis using primers with mismatches near the 
3' ends, it is possible to create an artificial RFLP (A-RFLP) for almost all naturally occurring DNA 
polymorphisms283• Fig 2.1 illustrates the principles of this approach. 
2.3.2 DESIGN OF PRIMERS FOR A·RFLP 
An A-RFLP primer can be designed using a semi-automatic approach by using a computer 
programme which will search for restriction enzyme sites for a given sequence, e.g DNA Strider. 
The process is illustrated in Fig 2.2. If it is assumed that the polymorphic residue is P and 
restriction enzymes with recognition sites of up to 6 bases are needed. The five bases on either side 
ofP are entered into the computer programme from -5 to +5 and the programme is used to search 
for a restriction enzyme site encompassing P. If a restriction enzyme site is found which is only 
present in one allele but not in the other one, then no further searching is required. If no restriction 
site polymorphism is found, then the nucleotides from -2 to -5 and +2 to +5 are changed one at a 
time with a computer search being carried out after each alteration. For each position, the 
nucleotide A, T, C and 0 is substituted in tum. The -lor +1 position is avoided as this may reduce 
amplification efficiency and is used as the last base of the PCR primer. All possibilities are 
investigated as more than one solution may be possible for a given polymorphism and some 
restriction enzymes work better than others. 
For lILA DQB 1 *03 primer design, all DQB 1 *03 alleles possess an A at the last base of codon 38 
followed by COC (Codon 39) and TIC (codon 40). Thus if the first base of codon 40 can be 
mutated from "T" to "0", then a Mlu I site (ACOCOT) will be created for the DQB 1 *03 alleles. 
The non DQB 1 *03 alleles, on the other hand, possess a "0" in the last base of codon 38. No Mlu I 
site will therefore be created by mutating the first base of codon 40 (Fig. 2.3). Following 
endonuclease restriction, the PCR product from the allele with the restriction site will have the 
portion containing the ARFLP primer cleaved off, thus resulting in smaller size fragment on gel 
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electrophoresis. The forward primer "A" is used in conjunction with the reverse mutagenesis 
primer "B". 
A: 5' AGG GAT CCC CGC AGA GGA TIT CGT GTACC 3' (forward) 
B: 5' CCG GTA CAC CCC CAC GTC GCT GTC GA,C GCG 3' (reverse) 
(The mutating base is underlined) 
2.3.3 PCR AMPLIFICATION CONDITIONS 
PCR amplifications were performed in 50JlI volume containing lOpmol of each primer, lOOng of 
specimen DNA, lOmM Tris-HCI pH 8.3, 50mM potassium chloride, 1.5mM magnesium chloride, 
and IU of Taq DNA polymerase. The nuc1eotides (dATP, dCTP, dGTP, dTTP) were each at a 
final concentration of lOOJlM. The initial denaturation was at 940C for 8 minutes followed by 30 
cycles each at 940C for 1 minute, 600C for 1 minute and 720C for 1 minute. There was a final 
extension step at 720C for 15 minutes. All PCR reactions were performed with both negative and 
positive controls. 
2.3.4 RESTRICTION ANALYSIS 
Following amplification 10JlI of the PCR prod\lct was restricted with 50 units of Mlu I (Boehringer 
Mannheim) in a volume of 20JlI at 370C overnight using manufacturer's buffer. The products 
were analyzed by electrophoresis on 4% agarose gels (Metaphor, Flowgen). The agarose gels 
were made with and run in IX T AE buffer, pH 8.0. The genomic digests were mixed with 2JlI of 
loading dye and loaded into wells of the gel. For fragment size identification, 123 bp marker from 
EcoRI/Bam HI fragments of adenovirus type 2 was included. Once the DNA had run for sufficient 
size fractionation, the gel was removed and placed in O.SJlglml of ethidium broinide (Sigma). After 
10 minutes, the DNA fragments were visualized on a UV light transilluminator, wavelength 2S4nm 
and the gels photographed. 
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2.4 POLYMERASE CHAIN REACTION WIrH SEQUENCE SPECIFIC PRIMERS 
(PCR.SSP) FOR HLA DQBl *03 SUBTYPING 
2.4.1 PRINCIPLES OF PCR·SSP 
PCR amplification of the HLA DQ locus with sequence specific primers is a powerful method for 
detecting genetic variability, including single base pair mismatches. The technique is based on the 
principle that a completely matched primer will be more efficiently utilized in the PCR reaction than 
a primer with one or several mismatches in the 3' end. The resolution of the method is high, 
especially in heterozygotes, as each primer pair identifies two sequence motifs located on the same 
chromosome, i.e. in cis. The post amplification processing of samples consists of determining 
whether amplification has occurred or not, since the discrimination between alleles takes place 
during the enzymatic in vitro DNA amplification. The PCR-SSP technique for HLA DQ typing 
was introduced by Olerup et al284 with good reproducibility, and the results were 100% 
concordant with allelic assignment by Taq I DRB-DQA-DQB haplotype analysis. 
2.4.2 PRIMERS FOR AMPLIFICATION OF DQB1*03 ALLELES 
Eight primer pairs (Table 2.2) were used to identify the DQB 1 *03 alleles. The primers were 
defined by Olerup et al284 based on the nucleotide sequences of the first 92 amino acids of the 
DQB 1 alleles. 
2.4.3 PCR AMPLIFICATION CONDITIONS 
PCR amplifications were performed in 50J.11 volume containing lOpmol of each primer, 100ng of 
specimen DNA, lOmM Tris-HCI pH 8.3, 50mM potassium chloride, 1.5mM magnesium chloride, 
and lU ofTaq DNA polymerase. The nuc1eotides ( dATP, dCTP. dGTP. dTTP) were each at a 
final concentration of l00J.1M. The initial denaturation was at 940C for 8 minutes followed by 30 
cycles each at 940C for 1 minute, 600C for 1 minute and 720C for 1 minute. There was a final 
extension step at 720C for 15 minutes. All PCR reactions were performed with both negative and 
positive controls obtained from the British Society for Histocompatibility and Immunology 
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(BISHI). Agarose gel electrophoresis was perfonned as described above. Once the DNA had run 
for sufficient size fractionation, the gel was removed and placed in 0.5Jlglml of ethidium bromide 
(Sigma). After 10 minutes, the DNA fragments were visualized on a UV light transilluminator, 
wavelength 254nm. The gels were photographed. 123 bp marker from EcoRIlBam HI fragments 
of adenovirus type 2 was included. 
2.S POLYMERASE CHAIN REACTION DIGOXIGENIN LABELED 
OLIGONUCLEOTIDE HYBRIDIZATION FOR HLA DQ-DR TYPING 
2.5.1 INTRODUCTION AND PRINCIPLES 
The amplification of specific DNA sequences by polymerase chain reaction followed by 
hybridization with sequence-specific oligonucleotide probes (SSO) has become a powerful 
technique for detailed analysis of genetic variations209,285. Each probe is constructed so as to be 
exactly complementary to an allele specific motif within one of the hypervariable regions of the 
exon. When hybridized under the appropriate conditions, these synthetic DNA probes (usually 15-
20 bases in length) will anneal to their complementary target sequences in the sample DNA only if 
they are completely matched. The peR product is denatured, spotted onto a charged nylon 
membrane, hybridized with a labeled SSO probe, washed at a stringent temperature and examined 
by an. autoradiographic, colourimetric or chemiluminescence assay. In the case of an absolute 
nucleotide sequence match between the SSO probe and the membrane bound target DNA, washing 
at a stringent temperature fails to denature the probe-target hybrid and this is shown by a positive 
signal from the probe. A mismatch of one or more nucleotides results in denaturation of the probe-
target hybrid and elution of the labeled probe, and consequently, no signal is generated. With an 
appropriate selection of oligonucleotide probes, the relevant genetic content of a DNA sample can 
be completely described. 
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The temperature and salt concentration at which the membrane is washed are influenced by the 
nucleotide composition and length of individual SSO probes, and therefore a variety of probe 
specific washing temperatures are used. The allele specificity of the target DNA may thus be 
determined using a series of SSO probes. This requires the preparation of replicate membranes, 
one for each probe to be tested. Alternatively, a single or small number of membranes may be 
used, necessitating the removal of each probe after signal development, before reprobing with 
another SSO. 
Traditionally, the PCR-SSO technique has relied on 5'- end labeling (usually 32P-Iabeled) of the 
SSO. Radioactive labeling is associated with several disadvantages and a number of non-
radioactive alternatives have become available. In these systems (see section 1.4.1), probe target 
hybridization is revealed by the use of reporter molecules such as streptavidin-enzyme or specific 
antibody-enzyme conjugates, in colourimetric or chemiluminescence assays. The complexity of the 
dot-blot PCR-SSO typing system is proportional to the number of SSO probes required to 
discriminate between each allele at a given locus. 
The 11 th Histocompatibility Protocol for PCR-SS0216 with some modifications have been used in 
this work. A complete listing of probes and reagents are at the end of this chapter. 
2.5.2 DIGOXIGENIN LABELING OF SSO PROBES 
Digoxigenin is a steroid hapten (Fig 2.4). DNA probes may be labeled with DIG-ll-dUTP via 
random primed labeling, nick translation, cDNA synthesis or Taq DNA polymerase. 
Oligonucleotide probes can be 3'-end labeled with DIG-ll-ddUTP, tailed with DIG-ll-dUTP by 
terminal transferase. In this study, probes were labeled at the 5' end with Digoxigenin-NHS Ester 
(Digoxigenin-3-0-methylcarbonyl-E aminocaproic acid-N-hydroxysuccinimide Ester). 
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The synthesis and labeling of these probes was done by Dr. Ian Goldsmith at the Clare Hall 
Laboratories of the Imperial Cancer Research Fund. The oligonucleotide was synthesized and 
deprotected according to standard protocol by treatment with 25% aqueous ammonia which was 
subsequently removed by lyophilization. Ethanol precipitation was performed by dissolving the 
oligomer in a mixture of 300JlI of distilled water and 30JlI of sodium acetate buffer, 3molll; pH 
8.5, and transferred to a microfuge tube. 9ml of ice cold ethanol was added, mixed and kept at -
200C for 2 hours. The solution was centrifuged for 15 minutes at lO,OOOg and the supernatant 
decanted. The pellet was washed with l00JlI of ice-cold ethanol, centrifuged for 5 min and the 
supernatant was removed. The pellet was dissolved in 200JlI of sodium borate buffer, O.lmolll; 
pH 8.5. Img of Digoxigenin-NHS Ester was dissolved in 600JlI of ethanol, and 200JlI of this 
solution was added to the solution of oligonucleotide and kept overnight at ambient temperature in 
a shaker. Separation of labeled oligonucleotide from the unlabeled compound was achieved by 
using reversed phase HPLC. 
2.5.3 lILA DQB GENERIC AMPLIFICATION 
Generic lILA DQB 1 amplification was performed using primers: 
DQBAMP-A S'CATGTGCT ACTTCACCAACGG-3' and 
DQBAMP-B 5'CTGGTAGTTGTGTCTGCACAC-3' 
PCR amplifications were performed in 96 well microtitre plates in SOJlI volume containing 1 Opmol 
of each primer, l00ng of specimen DNA, 10mM Tris-HCI pH 8.3, 50mM potassium chloride, 
2.0mM magnesium chloride, and lU of Taq DNA polymerase. The nucleotides (dATP, dCTP, 
dGTP, dTTP) were each at a final concentration of 100JlM. Each final reaction mixture was 
overlaid with several drops (about 30Jll) of mineral oil. The initial denaturation was at 950C for 5 
minutes followed by 35 cycles each at 950C for 45 seconds, 600C for 1 minute and 720C for 1 
minute. There was a final extension step at 720C for 15 minutes. All PCR reactions were 
performed with both negative and positive controls obtained from the British Society for 
Histocompatibility and Immunology ( BISHI ). 
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2.5.4 HLA DRB GENERIC AMPLIFICATION 
Generic HLA DRB amplification was perfonned using primers: 
DRBAMP-A 5'CCCCACAGCACGTITCITG-3' and 
DRBAMP-B 5'CCGCfGCACfGTGAAGCfcr -3' 
PCR amplifications were perfonned in 96 well microtitre plates in 50Jll volume containing 1 Opmol 
of each primer, l00ng of specimen DNA, 10mM Tris-HCI pH 8.3, 50mM potassium chloride, 
2.0mM magnesium chloride, and lU of Taq DNA polymerase. The nucleotides (dATP, dCTP, 
dGTP, dTTP) were each at a final concentration of lOOJlM. Each final reaction mixture was 
overlaid with several drops ( about 30JlI ) of mineral oil. The initial denaturation was at 950C for 5 
minutes followed by 35 cycles each at 950C for 45 seconds, 600C for 1 minute and 720C for 1 
minute. There was a final extension step at 720C for 15 minutes. All PCR reactions were 
perfonned with both negative and positive controls obtained from the British Society for 
Histocompatibility and Immunology (BISHI). 
After completion of thennal cycles, an aliquot (3JlI) of each reaction sample was subject to agarose 
gel electrophoresis. Once the DNA had run for sufficient size fractionation, the gel was removed 
and placed in O.5Jlglml of ethidium bromide (Sigma). After lO minutes, the DNA fragments were 
visualized on a UV light transilluminator, wavelength 254nm. The gels were photographed. 123 
bp marker from EcoRIlBam HI fragments of adenovirus type 2 was included. Generic DQBI 
amplification generated a 214bp fragment while DRB1 generated a 274bp fragment. 
2.5.5 PREPARATION OF DOT BLOTS 
Hybond-N positively charged nylon membranes (Amersham International pIc, Aylesbury, Bucks, 
UK) were used. The membranes were cut to appropriate size allowing lcm2 per dot, 
corresponding to the size of a 96 well microtitre plate. The membranes were not pre wetted. 
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PCR products were heated to 95 degrees for 10 minutes and placed on ice. Spotting was 
performed using the Biomek 1000 Laboratory Automation Workstation. The equipment was 
programmed to perform multi-tip pipetting of 2J.lI PCR products from microtitre plates and dotted 
on the nylon membranes. Using its 8 channel pipetting tool, the Biomek spots samples on to the 
membrane held on a purpose made vacuum blotter. Spots are placed in an 8x 12 array for 
compatibility with a standard 96-well microtitre plate. The membranes were allowed to air dry for 
at least 10 minutes before being placed in a UV cross linker. DNA cross linking was performed 
using the auto power setting. This provides 254nm UV lamp of 0.12J/cm2• The membranes are 
stored at 40C until required. 
2.5.6 PREHYBRIDIZATION/HYBRIDIZATION' AND TMACI WASHES 
The baked membranes were placed in 50ml Falcon tube with no overlap. The membrane was 
blocked in Sml blocking solution (Boehringer Mannheim) at room temperature on rotisserie for at 
least 30 mins. The blocking solution was poured off and to the tube was added 5m1 
prehybridization solution {4X SSPE, 0.1 % laurylsarcosine, 1 % blocking reagent}, 50111 
(lOmglrnl) sonicatedlboiled salmon sperm DNA, which has been preheated to appropriate 
temperature (520C for DQB and 540C for ORB). Prehybridization was performed for lhour. The 
solution was poured off and 2pM SSO ( listed below) per m1 of hybridization solution was added 
to the tube and incubated at appropriate temperature for 1 hour 30 minutes ( S20C for DQB and 
540C for DRB ). 
The hybridized membranes were removed from the tubes and washed twice in lL 2X SSPFJO.l % 
SDS for 10 minutes at room temperature, in trays on an orbital shaker. The membranes were then 
washed twice in SOmM Tris (pH 8), 0.1 % SDS, 2mM EDTA (pHS), 3M TMAQ 
(fetramethylammonium chloride, Sigma) solution at 5S0C. This allows A-T rich probe to remain 
annealed at 100C higher than the predicted temperature of dissociation. Also, as a means of 
standardizing posthybridization washing temperatures, TMACI was used in the washing solutions. 
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It allows a common washing temperature for each probe used, provided that they contain the same 
number of nucleotides. The membranes were gently blotted and stored moist in polythene at SOC. 
Once washed, the membranes were stored for up to 24 hours before the detection procedure. 
2.5.7 CHEMILUMINESCENT DETECTION OF DIGOXIGENIN LABELED 
PROBES WITH CSPD 
Disodium3-( 4-methoxyspiro ( 1 ,2-dioxetane3,2'(S'chloro )tricyclo 
[3.3. 1. 13,7]decan}-4-yl) phenyl phosphate (CSPD, Boerhinger Mannheim), is a 
chemiluminescent substrate for alkaline phosphatase that enables sensitive and fast detection of 
biomolecules by producing visible light which is recorded on film. Enzymatic dephosphorylation 
of CSPD by alkaline phosphatase leads to the metastable phenolate anion which decomposes and 
emits light at a wavelength of 477nm. 
All steps were carried out at room temperature. The membranes were washed in IL of buffer 1 in 
a tray on an orbital shaker for at least S minutes. The membranes were blotted dry and placed in 
clean plastic tubes dot side up. S ml of buffer 2 was added to each tube and placed on rotisserie for 
at least 30 minutes. IJ.11 of Anti-digoxigenin-Alkaline Phosphatase, Fab fragments (Boehringer 
Mannheim) was added to the solution (1:10,000 dilution). The tubes were placed on rotisserie for 
40 minutes. The membranes were then washed thrice in buffer 1 to remove any excess Anti-DIG 
fragments. The membranes were blotted dry, placed in plastic tubes and equilibrated in buffer 3 for 
S minutes. For membranes that required to be reprobed, buffer 3 was used without magnesium. 
CSPPD was prepared by diluting the 10mglml solution in buffer 3, 1:100 and placed in a container 
with a large surface area to volume ratio. The membranes were placed face down in solution, for S 
minutes, ensuring there were no air bubbles at the interface. The membranes were removed and 
gently blotted dry. For the briefest exposure to X-ray film, the alkaline phosphatase 
chemiluminescent reaction must be at a steady state. This was brought about by a 15 minute 
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incubation at +370C. DRB probes were exposed at 45 minutes and DQB at 1 hour 30 minutes. 
Because not all ofthe SSO may be labeled to the same extent, long exposure (12 hours) was also 
performed. 
2.5.8 STRIPPING OF MEMBRANES 
Membranes were stripped to enable reprobing. The membranes were incubated twice for 10 
minutes in 0.2N NaOH, 0.1 % SDS solution at 370C. This incubation removed the DIG-labeled 
probe. The membranes were then rinsed thoroughly in 2X SSPE for 15minutes. They were either 
stored moist at 40C or reprobing was commenced with the prehybridization step of the desired 
hybridization procedure. 
2.5.9 HLA DRB GROUP SPECIFIC AMPLIFICATION 
From the hybridization patterns in response to the SSO, individuals were assigned as belonging to 
one or more of the following groups. 
A. DRl group 
B. DR2 group 
C. DR4 group 
D. DR52 associated group ( OR3, DR5, DR6, DR8 ). 
E. DR 52 group 
The ORB 1 genes that can be typed directly by the generic amplification procedure are ORB 1 *07 
(corresponding to DRB 1 *0701 or DRB 1 *0702), ORB 1 *0901, and ORB 1 * 1001. The 
DRB3*0101 and DRB4*0101 can also be assigned for the DRB3 and DRB4 genes respectively. 
Further subtyping utilizes group specific amplification followed by SSO hybridization. 
For group specific amplification, samples from the different groups were amplified as follows. 
A. DRl group with ORI-DRB 1 specific primer pair 
DRBAMP-l 5'TICTTGTGGCAGCIT AAGIT -3' 
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DRBAMP-B 5'CCGCfGCACfGTGAAGCfCT-3' 
B. DR2 group with DR2-DRB 1 specific primer pair 
DRBAMP-2 
ORBAMP-B 
5 TICCTGTGG CAGCCTAAGAGG-3 , 
5'CCGCTGCACTGTGAAGCTCT -3' 
C. DR4 group with DR4-DRB 1 specific primer pair 
ORBAMP-4 5'G1TICTTGGAGCAGGTTAAAC-3' 
DRBAMP-B 5 'CCGCfGCACTGTGAAGCfCf-3 , 
O. DR52-associated group with DR52-associated group-DRB 1 specific primer 
DRBAMP-3 5' CACGTTTCTTGGAGTACTCT AC-3' 
DRBAMP-B 5'CCGCfGCACfGTGAAGCfCf-3' 
E. DR52 group with DR52-DRB3 specific primer 
DRBAMP-52 5' CCCAGCACGTTTCTTGGAGCT 
DRBAMP-B 5'CCGCTGCACfGTGAAGCfCT-3' 
PCR amplifications were performed in 96 well microtitre plates in 50J.l1 volume containing 1 Opmol 
of each primer, l00ng of specimen DNA, 10mM Tris-HCI pH 8.3, 50mM potassium chloride, 
2.0mM magnesium chloride, and lU of Taq DNA polymerase. The nucleotides (dATP, dCTP, 
dGTP, dTTP) were each at a final concentration of lOOJ.lM. Each final reaction mixture was 
overlaid with several drops ( about 30J.ll ) of mineral oil. The initial denaturation was at 950C for 5 
minutes followed by 35 cycles each at 950C for 45 seconds, 600C for 1 minute and 720C for 1 
minute. There was a final extension step at 720C for 15 minutes. All PCR reactions were 
performed with both negative and positive controls obtained from the British Society for 
Histocompatibility and Immunology (BISHI). 
Each reaction sample was subject to agarose gel electrophoresis. The product sizes were 261, 261, 
263,266 and 271 for ORI-DRBl, OR2-0RBl, DR4-0RBl, DR52 associated-ORB I, and 0R52-
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DRB3 respectively. Oligonucleotide hybridization of the amplified products were performed as 
described above using the SSO probes in section 2.5.12. 
2.S.10 SEQUENCE SPECIFIC OLIGONUCLEOTIDES FOR HLA DQB TYPING 
DQB2301 GAC CGA GCT CGT GCG GGG 
DQB2302N AAC GGG ACC GAG CGC GTG 
DQB2601 CGG GGT GTG ACC AGA CAC 
DQB2602 CGTTATGTGACCAGATAC 
DQB2603 CGT CIT GTG ACC AGA TAC 
DQB2604 CGT CIT GTA ACC AGA CAC 
DQB2605 CGT CIT GTG AGC AGA AGC 
DQB2606 CGT CIT GTA ACC AGA TAC 
DQB3701 AGG AGT ACG TGC GCT TCG 
DQB3702N AGG AGG ACG TGC GCT TCG 
DQB3703 T AA CCG AGA AGA GTA CGT 
DQB4501N GAC GTG GAG GTG TAC CGG 
DQB4901 GGT GTA CCG GGC AGT GAC 
DQB4902N GGT GTA TCG GGC GGT GAC 
DQB5701 GCG GCC TGT TGC CGA GTA 
DQB5702 GCG GCC TAG CGC CGA GTA 
DQB5703 GGC GGC CTG ACG CCG AGT 
DQB5704 GCG GCC TGA TGC CGA GTA 
DQB5705 GGC TGC CTG CCG CCG AGT 
DQB5706 GGC CGC CTG ACG CCG AGT 
DQB5707 GGC CGC CTG CCG CCG AGT 
DQB5708 GCG GCT TGA CGC CGA GrA 


















GAG GGG ACC CGG GCG GAG 
GAA ACG GGC GGC GGT GGA 

























GAG GAG GTT AAG TTT GAG 
GGT TAC TGG AGA GAC ACT 
GCG GTA CCT GGA CAG ATA 
GCG AGT GTG GAA CCT GAT 
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DRB3701 CCA AGA GGA GTC CGT GCG 
DRB3707 AACCAAGAGGAGAACGTG 
DRB3712 CAG GAG GAG TIC GTG CGC 
DRB3713 GCG CAC GTA erc erc TIG 
DRB5701 GCC TGA TGC CGA GT A erG 
DRB5702 GCC TAG CGC CGA GTA CTG 
DRB5703 GCC TGA TGA GGA GTA erG 
. DRB5704 GCC TGC TGC GGA GCA CTG 
DRB5705 GCC TGT CGC CGA GTC CTG 
DRB5708 GCC TGA TGC TGA GTA CTG 
DRB7001 TCC TGG AGC AGA GGC GGG 
DRB7002 GAC TIC CTG GAA GAC AGG 
DRB7003 GAC CTC CTG GAA GAC AGG 
DRB7004 GGC CGG GTG GAC AAC TAC 
DRB7005 ACC GCG GCC CGC TIC TGC 
DRB7006 GCA GAG GCG GGC CGA GGT 
DRB7007 ACA TCC TGG AAG ACG AGC 
DRB7008 Aer TCC TGG AAG ACG AGC 
DRB7009 AGC GGA GGC GGG CCG AGG 
DRB7011 GAC ATC erG GAG CAG GCG 
DRB8601 AAC TAC GGG GTT GGT GAG 
DRB8602 AAC TAC GGG GCT GTG GAG 
DRB8603 AAC T AC GGG GTT GTG GAG 









3. DRBl004 DR4 
4. DRBlOlON DRB3*0101 
S. DRBl006 DR7 
6. DRBl007 DR9 
7. DRBl008 DR 10 
8. DRB2802 DRI2 
9. DRB3709 DRBS*OlOl 
10. DRBS703 DR 11 
11. DRB2810 DR53 
12. DRB1003 DRS2 Associated group (DR3, DR11, 
DR13,DRI4) 
13. DRBlOOS DR52 Associated group (DR12, . DRS, 
DR14) 
14. DRB 1011 DRB3*0201+ DRB3*0202 
IS. DRB1002 DRB3*0301 
B. GROUP SPECIFIC 
(i) HLA DRBl*04 PROBES 
Probe Probe Probe Probe Probe Probe Probe Probe 
3701 5701 5702 7001 7005 7006 7007 8601 
DRB 1 *0401 
- + - - + - - + 
DRBl*0402 
- + - - - - + -
DRBl*0403 
- + - + - + - -
DRB 1 *0404 






DRB1*0406 + + - + - + - -
DRB1*0407 
- + - + - + - + 
DRB 1 *0408 
- + - + - - - + 
ORB 1 *0409 
- -
+ - + - - + 
ORB 1 *0410 
- -
+ + - - - -
ORB 1 *0411 
- - + + - + - -
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(ii) HLA DR2IDRB5 PROBES 
Probe Probe Probe Probe Probe Probe 
2813 3707 7002 7003 8601 8603 
DRB1*1501 + - - - - + 
DRB1*1502 + - - - + -
DRB1*1601 + - + - + -
DRB1*1602 + - - + + -
DRB1*1503 - - - - - + 
DRB5*0101 
- - - - + -
DRB5 *0 102 - + - - + -
DRB5*0201 - + - - - -
DRB5*0202 
- + - - - -
(iii) HLA DRl PROBES 
Probe 7001 Probe 7007 Probe 8602 
+ - -
DRBl*OlOl 
+ . + 




(ivJ DR52-ASSOCIA TED DRS1 PROSES 








- - - - - - - -
+ 
- - - - -
- + 
DRBl·0302 + 





+ - - - - - - - - + - - - - + - -
DRBl·1l01 + 






- - - -
+ 
- - - - - -
+ - -
DRBI·1102 + 






- - - - - - -
+ - - c - - + 
DRBl·1103 + 
- - - - -
+ - - + - - + - - - - - - - - + - - - - + 
DRBI·II04 + 
- - - - -
+ - - + - - + - - - - + - - - - - - - - + 
DRBI·1201 - + 
-
+ 
- - - - - - - - - -
+ 





DRBl·1202 - + 
-
+ 




























DRBl·1303 + - - - - - + - - + - + - - - - - - - - - - - c + - -
DRBl·1304 + 
- - - - -
+ - - + - + - - - - - - - - + - - c - - + 
DRBI·1305 + 




- - - - - -
+ 








- - - -
+ 
- - -
- - - - -
+ - - - + 
DRBl·1402 + - - - - + - + - - + - - - - - + - - - - - - - + - -
DRBI·1403 + 






- - - - - - -
+ 
- - - - -
+ 
- -
DRBI·1404 - + 




- - - -
+ 
- - - - - - - -








- - - - - -
+ 











- - - - -
+ 
- - - - - - - - -
+ 
DRBI·1407 + 




- - - - + - - - - - - - - + - + - -
DRBl·1408 + 




- - - - - - - - - - - - -
+ - - - + 
DRBI·0801 - + 
- - - -
+ 
- - + - + - - - - - + - - - - - - + - -
DRBl·0802 - + 




- - - - - -
+ 
- - - - - -
+ - -
DRBI·0803 - + 
- - - -
+ 
- - - - + - - - - - - - - - - - + + - -
DRBI·0803 - + 




- + - - - - - - - - - - - + + - -
DRBI·0804 - + 




- - - - - -
+ 





c = Cross hybridized. 
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2.6 HAPLOTYPIC ASSIGNMENT 
HLA DRB 1, DRB3, DRB4, DRB5 and DQB 1 haplotypes were inferred based on known patterns 
of linkage disequilibrium in Caucasians for these loci286-287. If a sample contained DRB 1 *0401, 
DRBI *0101 at the DRBllocus and DQBI *0301, DQBl *0501 at the DQBllocus, then the correct 
inferred haplotypes would be DRBI*0401-DQB1*0301 and DRB1*0101-DQB1*0501 which is 
known to occur naturally. For supertypic antigens HLA DRB3, DRB4 and DRB5, the 3-locus 
haplotypes were inferred287. 
2.7 STATISTICAL ANALYSIS 
Odds ratios and their approximate 95% confidence intervals were calculated for all variables by the 
X2 test for 2 x 2 tables without a continuity correction288. For small samples, exact 'p' values were 
calculated. For 2 x k tables, the X2 test for trend was calculated289. The unit of sampling was the 
allele in all analysis except when studying the effect of homozygosity versus heterozygosity. For 
other analysis, each allele or haplotype was taken as an independent observation so that the sample 
size was twice as large for these comparisons. No formal adjustments of 'p' values for multiple 
comparisons were made. 
2.8 CELL LINES AND CULTURE CONDITIONS 
In the present study, the haplotype HLADRB 1 *0401-DQB 1 *0301 was shown to correlate 
with susceptibility to HPV and CIN while DRB 1 *OIOl-DQB 1 *0501 indicated protection 
(Details of results in chapters 3 and 4). Although the binding motifs of several lllA-DR 
molecules have been defined, studies on the binding motifs of HLA-DQ molecules are 
few269,290-297.Therefore, the peptide pools eluted from HLA {DQAl *03011DQB 1 *0301} 
and {DQAI *01011DQB 1 *0501} were sequenced. Amino acid preferences based on 
peptide sequence alignment with HPV 16 and polymorphic residue substitutions in the 
binding cleft of HLA DQ are discussed in chapters 5 and 6. 
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2.8.1 JHF CELL LINE 
The JHF cell line, Xth International Histocompatibility Workshop No. 9030, is a B 
lymphoblastoid cell line obtained from the ECACC. The cell line is homozygous for the 
following HLA alleles: 
HLA-A*31011; HLA-C*lS; HLA-DRBl*0407; HLA-DRB4*0101; HLA-DQAl*0301; 
HLA·DQB1*0301; HLA-DPAl*Ol; HLA-DPBl*0301. 
2.8.2 JESTHOM CELL LINE 
The Jesthom cell line, Xth International Histocompatibility Workshop No. 9004, is a B 
lymphoblastoid cell line from the ECACC. The cell line is homozygous for the following 
lILA alleles: 
lILA-C*Ol; HLA-DRA*0101; HLA-DRBl*0101; HLA-DRB6*0101; HLA-DQA1*0101; 
HLA·DQB1*OSOI; HLA-DPA1*01; HLA-DPB1*0401. 
2.8.3 CELL CULTURE CONDITIONS 
The cells were grown in RPMI 1640 supplemented with 5% fetal calf serum, 5% C02, 
2% bicarbonate, 2mM glutamine, 50U/ml penicillin 0, and 50J.1g1ml streptomycin in roller 
bottles at 370C. Cultures were split every 3-7 days to two- to fivefold volume, depending 
on the expansion rate. When the required number of cells was reached (1011), they were 
spun down at 1,000 r.p.m. The supernatant was removed and the pellet washed with 
PBSA. The wash was repeated twice and the final pellet was frozen at -80 degrees until 
used. 
2.9 IMMUNOAFFINITY PURIFICATION 
Immunoaffinity purification is a powerful technique for the isolation of proteins. Under 
proper conditions, purifications of 1,000 to ] O,OOO-fold can be achieved in a single step. 
The factors that affect the success of the technique include the starting purity of the antigen, 
80 
the affinity of the antibody for the antigen, and the ease with which the antigen-antibody 
bond can be broken. The affinity of the antibody for the antigen determines the total amount 
of antigen that can be removed. For example, antibodies of high affinity (> 108 I mol), 
quantitative removal can be achieved in less than 1 hour. Even at high antibody 
concentrations, low-affinity antibodies (106 Imol) will not bind all of the antigen in 
solution. The ideal antibody for immunoaffinity purification is one that has a high affinity 
for the antigen and whose binding can be reversed by a simple but gentle change in pH. 
Irnmunoaffinity purification was performed in three steps: preparation of the antibody 
column, the binding of antigen to the antibody-bead matrix, and the elution of the antigen 
from the column. 
2.9.1 ANTIBODY FOR IMMUNOAFFINITY PURIFICATION 
The anti-HLA-DQ IA3 (Winchester et al.) is a pan HLA-DQ monoclonal antibody and was 
kindly provided by Dr Robert Winchester (Columbia University, New York, NY). 
2.9.2 TECHNIQUE OF AFFINITY CHROMATOGRAPHY 
Crude membrane fractions of the cell lines were prepared by hypotonic lysis and 
differential centrifugation. After washing in ice-cold phosphate buffered saline (PBS) , 
109 of cell pellet were lysed in PBS with 3% nonidet-P40 (NP40), IJ.lglml leupeptin, 
IJ.lglml pepstatin and 5mM ethylenediaminetetraacetic acid (EDTA). Cell lysates were 
cleared for nuclei and debris by centrifugation at 100,000 x g for 90 minutes at 4°C. 
Immunoaffinity chromatography columns of anti-DQ JA3-Cyanogen Bromide-activated 
sepharose (Pharmacia) were prepared293• The mAb JA-3 was mixed with the CNBr-
activated sepharose beads and incubated at room temperature with gentle rocking overnight. 
The beads were washed twice with 0.5M sodium phosphate (pH 7.5) and once with 1M 
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Nac1, O.05M sodium phosphate (pH 7.5). 10 volumes of l00mM ethanolamine (pH 7.5) 
was added and incubated overnight with gentle mixing. The beads were further washed 
twice with PBS, 0.01 % merthiolate was added and they were stored at 40C until used. 
The detergent soluble membrane fractions from the cell lines were passed over a pre-
column of Sepharose CL 4B (pharmacia) followed by passage over the affinity column 
with cyanogen bromide-activated Sepharose beads linked to the anti-DQ IA-3. After the 
lysates have been passed over the columns, the columns were washed extensively and then 
eluted with O.05M diethlamine (pH = 11.5). The DQ molecules were immediately 
neutralized with 1M Tris (pH 6.8) and concentrated by ultrafiltration (Centripep; Amicon, 
Beverley, MA). SOil! aliquots of eluates were analyzed by 12% SDS-PAGE and silver 
staining to confirm protein purity (Fig 5.1). 
2.10 PEPTIDE ELUTION 
The HLA DQ eluates obtained after immunoaffinity purification were concentrated on a 
CENTRICON-1O Microconcentrator (Amicon, Beverly, MA). The centricon tube was 
washed in 0.1 % tri-fluoroacetic acid (TFA) for 1 hour. The tube was filled with 1 m1 of 
TFA, the eluate was added and centrifuged at 5000 x g for 1 hour to obtain an ultrafiltrate. 
Im1 of TFA was added and centrifugation performed for 1 hour to obtain another 
ultrafiltrate stored in a different tube. This step was repeated to obtain more ultrafiltrate. 
The ultrafiltrates containing HLA-DQ bound peptides were stored at -700C until 
characterization. 
2.11· SEPARATION OF PEPTIDES: REVERSED·PHASE HIGH 
PERFORMANCE LIQUID CHROMATOGRAPHY (r.HPLC) 
The reversed-phase (RP) HPLC separation of any peptide or protein mixture is dependent 
upon the strength of the hydrophobic interactions of each component in the mixture with 
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the hydrophobic surface of the column matrix and the elution strength of the organic 
solvent in the mobile phase. When peptides or protein mixtures are applied to a RP column, 
the adsorbed peptides or proteins are eluted in order of least to most strongly bound 
molecules by increasing the organic solvent concentration in the elution buffer, collected as 
individual chromatographic fractions, and analyzed separately. 
Organic solvent (acetonitrile) was removed from the RP column with degassed, HPLC-
grade water using a gradient from 100% organic solvent to 100% water over 15 minutes at 
I mVmin. The RP column was then equilibrated by pumping 100% trifluoroacetic acid 
(TFA)/acetonitrile buffer at ImVmin. This was gradually switched to 100% TFA buffer 
with a 10 to 15 min linear gradient and equilibrated at 100% TFA buffer for an additional 
20minutes. Equilibration was achieved when the pressure and detector absorbance were 
constant. A blank run without any injection for the equilibrated column was made. This 
was by pumping at ImVmin, a linear gradient from 0 to lOO%TFAlacetonitrile buffer over 
45 min at isocratic conditions, at 100% TF Alacetonitrile buffer for 5 min, returned to 100% 
TFA buffer for 15 min (total run time from gradient start to completion of requilibration 
was 80min). Detection settings was 0.1 absorption units full scale (AUFS) at _210 to 
220nm for 50 to 200pmol peptide. 
The DQB 1 *030 I and DQB I *050 I eluted peptides and the RP peptide standard 
(transferrin), were centrifuged at 5000xg for 5 min. An aliquot of each solution was 
withdrawn into an HPLC syringe that was rinsed with TFA buffer through a needle 
compatible with the HPLC injector. The injection loop was loaded with 1O~1 of the peptide. 
The lILA DQB I *0301 and DQB I *050 I peptides were separated by HPLC on a Vydac 
microbore CI8 reversed phase chromatography (RPC) column (250X2.lmm; 300A; 5~m). 
Chromatographic analysis was monitored at multiple UV wavelengths simultaneously. 
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2.12 PEPTIDE SEQUENCING 
Peptide sequencing was performed at the HHMI Biopolymer and W. M. Keck Foundation 
Biotechnology Resource Laboratoty at the Yale University School of Medicine, New 
Haven, Connecticut, USA. 
2.12.1 EDMAN DEGRADATION 
The chemical process employed by automated protein/peptide sequencers is derived from 
the technique originated by Edman in the 1950s for the sequential degradation of peptide 
chains298-299. The first step in this degradation is the selective coupling of a peptide's 
amino-terminal amino acid with the Edman reagent, phenylisothiocyanate (PITC), a 
reaction catalyzed by an organic base delievered with the coupling reagent. The second step 
is cleavage of this derived amino acid from the remainder of the peptide, a reaction 
accomplished by treating the peptide with a strong organic acid. Each repeated 
coupling/cleavage cycle occurs at the newly formed amino-terminal amino acid left by the 
previous cycle. These repetitive cycles provide sequential separation of the amino acids 
which form the primary structure of the peptide. 
The identity of the amino acid removed by Edman degradation is determined by converting 
the cleaved amino acid derivative (anilinothiazolinone, ATZ) to the more stable derivative 
(penylthiohydantoin, PTH) (Fig 2.5). In modern sequencers, this conversion is 
accomplished automatically, using an aqueous solution of a strong organic acid, in a 
reaction vessel separate from that in which the Edman degradation occurs. The PTHs 
produced from each degradation cycle are then transferred directly and automatically from 
the sequencer conversion vessel to an on-line analysis system. 
For pool sequencing of peptides bound to HLA DQB 1 *0301 and DQB 1 *0501, dominant 
peaks identified by HPLC were first removed, then the remaining fractions were pooled, 
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speedvaced to dryness and redissolved in 0.05% TFA and 50% acetonitrile. The sample 
was then subjected to 17 cycles of Edman degradation using an Applied Biosystems 
(Foster City, CA) 477 A pulsed liquid protein sequencer equipped with on-line HPLC. 
Cysteine was not quantitated. The pool sequence data are shown in tables 5.1 and 5.2. 
From the analysis of the pool sequence, a motif for peptide binding to HLA DQB 1 *0301 
and HLA DQB 1 *050 1 were derived. The source proteins of peptides were identified by 
searching the Protein Identification Resource (PIR), Genpept and Swiss Protein Databases. 
2.13 SOLUTIONS AND REAGENTS 
Blocking Solution: SOOml 
4X SSPE 
0.1 % Lauroylsarcosine 
1.0% Blocking Reagent 
dH20 
l00ml 20X stock 
5ml 10% stock 
Sg 
390ml 
Blocking reagent from Boerhinger Cat No 1096 176 
Lauroylsarcosine Sigma L-S125 
2X SSPE/O.l % SDS: 500ml 
2X SSPE 
0.1% SDS 
TMACI Wash Solution: 500ml 
3MTMACI 
SOmM Tris 25ml 
SOml 20X Stock 
2.5ml 20X Stock 
300ml 5M Stock 











pH solution to 7.S with conc HCl 
Dilute 1110 before use. 
Buffer 2: SOOml 
20% Stock 
O.SM (PH 8) 
O.IM Tris SOml 1 M Stock (pH 7.S) 
Buffer 3: 500ml 
O.1SM Nacl 75ml 1M Stock 
1 % Blocking reagent Sg 
dH20 370ml 
O.IM Tris SOml 1M TrislHCI (pH 9.S) 
O.1M Nacl SOml 
sOmM MgCl2 2Sml 
1M Stock 
1M Stock 
CSPPD ( Lumigen ) Solution : l00ml 
Iml of CSPPD is added IOOml of filtered buffer 3. The container is wrapped in tin foil and stored 
at40C. 
Boerhinger 
Anti-digoxigenin-AP, Fab fragments: 
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Boerhinger 
2.14 DNA CONTROL KIT 
DRB 1 and DQB DNA control kits of the British Society for Haematology and Immunology 
(BISHI) were obtained from the United Kingdom Transplant Support Service Authority, Bristol. 
2.15 CHEMICAL AND MATERIAL SUPPLIERS 
AMERSHAM INTERNATIONAL PLC 
Amersham place, Little Chalfont, Amersham, Buckinghamshire 
HP7 9NA. 
BDH 
Merck Ltd., Merck House, Poole, Dorset, BH15 lTD. 
BIO-RAD LABORATORIES LTD. 
Bio-Rad House, Maylands Avenue, Hemel Hempstead, 
Hertfordshire, HP2 7TD. 
BOEHRINGER MANNHEIM UK (DIAGNOSTICS AND BIOCHEMICALS) LTD. 
Bell Lane, Lewes, East Sussex, BNG ILG. 
DIFCO LABORATORIES LTD. 
P. O. Box 14B, Central Avenue, East Molesey, Surrey, KT8 OSE. 
DUPONT (UK) LTD. 
Diagnostics and Biotechnology Systems, Wedgwood Way, 
Stevenage, Hertfordshire, SG 1 4QN. 
GmCOBRL 
Life Technologies Limited, Unit 4, Cowley Mill Trading Estate, 
Longbridge Way, Uxbridge, UB8 2YG. 
FLUKA CHEMIKA-BIOCHEMlKA 
Fluka Chemicals Ltd., The Old Brickyard, New Road, Gillingham, 
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Dorset, SP8 4JL. 
FMC BIOPRODUcrS 
Flowgen Instruments Ltd., Broad Oak Enterprise Village, Broad Oak Road, 
Sittingbourne, Kent, ME9 8AQ. 
ill I 
International Biotechnologies Inc., 36 Clifton Road, 
Cambridge, CB 1 4ZR. 
ICN BIOCHEMICALS 
Division of ICN Biomedicals Inc., Cleveland, OH 44128. 
NBS BIOLOGICALS 
New Brunswick Scientific (UK) Ltd., Edison House, 
163 Dixons Hill Road, North Mymms, Hatfield, AL97m. 
NEW ENGLAND BIOLABS 
CP Laboratories, P. O. Box 22, Bishop's Stortford, 
Herts, CM23 3DX. 
PHARMACIA LKB 
Pharmacia Biosystems Limited, Biotechnology Division, Davy A venue, 
Knowlhill, Milton Keynes, MK5 8PH. 
STRATAGENE CLONING SYSTEMS 
Stratagene Ltd., 140 Cambridge Innovation Centre, Cambridge Science ParkIMilton Road, 
Cambridge, CB4 4GF. 
SIGMA CHEMICAL COMPANY 
Fancy Road, Poole, Dorset, BH17 7NH. 
UNITED STATES BIOCHEMICAL CORPORATION 
Cambridge Bioscience, 25 Signet Court, Newmarket Road, 
Cambridge, CB5 8LA. 
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, 
Type Primer Location (nt) and product size 
HPV16 Sense: 5'-AAGGCCAACTAAATGTCAC-3' 7763-7781 
Antisense: 5'-(GCGGATCC)TGTCTGCI I I"IATACTAA-3' 78-61 
I (Seedorf et aI, 1985 )278 (+5'BamID site) 228bp 
HPV18 Sense: 5'-CACGGCGACCCTACAAGCTACCTG-3' 127-150 
Antisense: 5'-TGCAGCACGAATGGCACTGGCCTC-3' 531-508 
( Coles & Danos, 1987 )279 405bp 
HPV31 Sense: 5'-AGAAAGACCTCGGAAATTG-3' 125-143 
Antisense: 5'-TACCTCTGTTTCTGTTAAC-3' 233-215 
( Goldsborough et aI., 1989 )280 109bp I 
HPV33 Sense: 5'-CTACAGTGCGTGGAATGCAAAAAACC-3' 190-215 
I 
Antisense: 5'-CGGGACCTCCAACACGCCGCAC-3' 536-515' 
I 
(Cole &Streeck, 1986 )281 347bp 
Table 2.1: Type Specific Primers used for HPV amplification and annealing temperatures 
HLA Allele Primer sequences F AMPIRAMP Size! peR 
product. 
DQB 1 *0201 5' GTGCGTCITGfGAGCAGAAG 3' 205bp 
5' GCAAGG TCGfGCCGAGCf 3' 
DQBl *02011 0302 5'GACGGAGCGCGTGCGTCT3' 129bp 
5'CTGTTCCAGTACTCGGCGG3' 
DQBl *03011 0304 5' GACGGAGCGCGTGCGTTA 3' 122bp 
5' AGTACTCGGCGTCAGGCG 3' 
DQB 1 *03021 0303 5' GACGGAGCGCGTGCGTTA 3' 122bp 
5'AGTACTCGGCGTCAGGCG3' 
DQB1*0303 5' GACGGAGCGCGTGCGTTA 3' 129bp 
5'CTGTTCCAGTACTCGGCGT3' 
DQB1*0601 5' GCCATGfGCTACTTCACCAAT 3' 198bp 
5'CACCGTGTCCAACTCCGCT3' 
DQBl *0601/0301 5' GACGGAGCGCGTGCGTTA 3' 129bp 
5'CTGTTCCAGTACTCGGCGT3' 
DQB1*0304 5' GACGGAGCGCGTGCGTTA 3' 129bp 
5'CTGTTCCAGTACTCGGCGG3' 
~ -
Table 2.2: Sequence specific primer pairs for typing the HLA DQB 1 *03 locus. 
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Fig 2.1: Principles of A-RFLP 
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Fig 2.2: The design of A-RFLP Primers 
CODON 38 39 40 
DQBI *03 Alleles 5'---------GCA CGC TIC 3' 
3' GCG * CAG .. 5' 
mutagenesis primer ! PCR 
Mlu I site 
5' I GCA CGC GTt 3' 
3' ---------CGT GCG CAG 5' 
CODON 38 39 40 
Non-DQBl *03 Alleles 5' GYG CGC TIC 3' 
3' GCG * CAG .. 5' 
mutagenesis primer ! PCR 
No Mlu I site 
I I 5' GYG CGC GTC------ 3' 
3' ---------fCRC GCG CAG 5' 









I II) O-A. .... O 
I 
o 




















































































/\/'\ o C CH-II, ~ ~/ 
c=o CF COOH 
""- :I ) 
NH (OAS) 











~ ~~ PROTEIN _ ______ ~P~TC~-~PR~O~TE=IN~ ___ T~F~A __________ ~·~!.~-·~·~ ______ ~ 




HZ 0 • 
ATZ-"" TFA 
Fig 2.5: Schematic illustration of the principles of Edman chemistry showing the coupling, 
cleavage and conversion steps. 




3.3 OVERALL RESULTS (APPENDIX 1) 
3.4 ASSOCIA nON BETWEEN HLA DQB 1 *03 AND CIN 
3.5 ASSOCIA nON BETWEEN HLA DQB 1 ·03 AND HPV 
3.6 SUMMARY AND DISCUSSION 
96 
3.1 INTRODUCTION 
Recently, Wank & Thomssen255 showed a significant association between lILA DQB 1 *03 
and cervical cancer. Subsequent reports have not consistently confirmed this observation 
(reviewed in chapter 1 and Odunsi & Ganesan3OO). Evidently there is heterogeneity within 
results depending on the size and type of population examined and techniques used for the 
lILA and HPV typing. This chapter reports the results of HPV and HLA DQB 1 *03 
typing conducted in a Caucasian population. 
Allelic products of the polymorphic DQAl and DQB 1 genes encode functional IX2 
molecules through cis- and trans-complementations. Cis-dimers comprise <X and B chains 
encoded by DQAl and DQBl genes of the same chromosome, and trans-dimers are 
encoded by genes on homologous chromosomes. Although it is clear that HLA-DP, -DQ 
and -DR products can all present antigen to human CD4+ T cells, HLA-DR restriction 
overwhelmingly predominates. The apparent inefficiency of HLA-DQ as an antigen 
restriction molecule presents a perplexing paradox: HLA-DQ restricted T cell clones are 
rare, reflecting the low expression of the dimer on antigen presenting cells, yet disease 
association studies relatively frequently implicate lILA-DQ, rather than -DR alleles in 
predispostion to autoimmune and some infectious diseases. Human T-cell clones so far 
characterized show a marked bias against HLA-DQ restriction, reflecting the low level of 
expression on APes in the periphery. Although this low frequency of DQ-restricted clones 
may reflect a truly marginal role in the immune response, the stimulation requirements or 
effector functions of DQ-restricted clones may differ from those in conventional studies. 
3.2 RESULTS 
The ARFLP-PCR technique on DNA from cervical smears, following Mlu I digestion, can 
lead to three possible results: negative for DQB 1 *03, heterozygous or homozygous for 
DQB1*03 (Fig 3.1 ). 
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5bp-~ ~-'45bp 
Fig 3.1: A 4% metaphor agarose gel showing amplified DNA after peR 
with primers A and B with and without digestion by Mlul 
The size of amplified DNA is 145bp and on digestion with MluI, a lIS and 30bp product is 
produced in DQB 1 *03 homozygotes. DNA for all controls were from the British Society 
for Histocompatibility and Immunogenetics. Arrows show the 145 and 11Sbp products. 
Lanes 2 and 3 show heterozygous DQB 1 *03 control with and without digestion by MluI. 
Lanes 4 and 5 show homozygous DQB 1 *03 control with and without digestion with MluI. 
Lanes 6 and 7 show non-DQB 1 *03 control with and without digestion with MluI. Lanes 1 
and 8 are 123 bp markers. 
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Fig 3.2: Example of A-RFLP on study samples.Lane 1: 123bp ladder DNA; Lane 2: JRA 
28, DQB 1 *03 heterozygous cell line after digestion; Lane 3: JRA 28, DQB 1 *03 
heterozygous cel1 line before digestion; Lane 4: Amai, Non DQB 1 *03 cell line after 
digestion; Lanes 5-8: samples from patients with CIN- 5: heterozygous DQB 1 *03; 6: 




r~- 19 bp 
Fig 3.3: PCR products obtained by liLA DQB 1 *03 sequence specific primers. (a) 122 
bp product obtained with primer pair PBS'09 and PB3'09 to identify DQB 1 *030110304. 
Lanes 1 and 12: 123 bp marker; Lanes 2 and 18: negative control; Lane 3: positive control 
DNA. An intemaJ amplification control primer pair PC'5 and PC'3 (amplifies the third 
intron of DRB 1 genes) was included in this reaction to give a 796 bp fragment; the rest 
represent study samples. (b) 198 bp product obtained on the same set of samples with 
primer pair PB5'03 and PB3'04 to identify DQB 1 *0601. Lanes 1 and 12: 123bp marker; 
Lanes 2 and 18 are negative controls; Lane 3: positive control DNA and the remaining lanes 
are study samples. Fig. for DQB I *0304 not shown since aJl were negative for this set of 
primers. Allelic assignment was by comparing and integrating positive results. 
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Fig 3.4: Type specific amplification of HPV. 
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3.3 OVERALL RESULTS 
lILA DQB 1 *03 typing was performed on DNA from cervical smears of 178 women with 
CIN (CIN 1=66; CIN ill = 112) and 420 healthy women who had a normal smear. All 
samples were successfully amplified for the locus. HPV typing was performed for types 
16, 18, 31 and 33 on all the test and control samples. The lILA DQB 1 *03 and HPV results 
on individual samples are included in the tables showing the complete lILA DQ-DR typing 
results (Refer to Appendix 1). As shown in appendix 1, the women are either homozygous 
for the lILA DQBl*03 alleles (0301, 0302, 0303 and 0304) or heterozygous (DQBl*03 
allele in combination with any other DQB allele). The analysis of lILA DQB I *03 is 
presented first. 
Table 3.1 is a summary of the distribution of lILA DQB 1 *03. Of CIN cases, 61 % were 
positive (56% of CIN 1, 64% of CIN III) for the lILA DQB 1 *03 type, compared to 34% 
of controls. The association was significant (X2 trend = 37.3, p<O.OOl), and the odds ratio 
for CIN overall was 3.03 (95% CI 2.11-4.35). The association was significant for both 
CIN III (odds ratio 3.45 vs 2.45) and CIN I, stronger for CINIII, but not significantly 
different from CINI. 
One hundred and thirty-one patients with CIN (73.5%) were positive for one or more HPV 
types 16, 18,31,33. Of HPV-positive CIN, 64% were of the type DQB1*03. There was 
a significant association between DQB 1 *03 and HPV ( X2 trend= 38.6, p<O.OOl) with a 
odds ratio of 3.43 (95% CI 2.28-5.15). 
3.4 ASSOCIATION BETWEEN liLA DQBl*03 AND CIN (Tables 3.2 and 
3.3) 
Of women with CIN, 38% were negative for DQB I *03, while 37% were heterozygous 
and 23% homozygous for the DQB1*03 locus ( X2 trend= 39.01, p<O.OOI). Compared 
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with controls, the odds ratio was greater for homozygosity (4.0, 95% CI 2.43-6.6) than 
for heterozygosity (2.63, 95% CI 1.75-3.94). Further typing of the DQBl*03 locus in 
positive samples by PCR-SSP showed that the 0301 allele that was present in 40% of CIN 
as opposed to 9% of controls (odds ratio 2.53, 95% CI 1.79-3.57; X2 trend =28.6, 
p<O.OOI). DQBl*0302 was present in 32% and 10% of CIN and controls respectively 
(odds ratio 1.84,95% CI 1.29-2.62). The association between HLA DQB 1 *03 and CIN is 
shown in table 3.2 while association between DQB 1 *03 alleles and CIN is shown in table 
3.3. 
3.5 ASSOCIATION BETWEEN liLA DQBl·03 AND HPV (Tables 3.4, 3.5 
and 3.6) 
HPV typing was performed for the major oncogenic types, HPV 16,18, 31 and 33. Of 
CIN cases, 57% were positive for HPV 16, 7% for HPV 18, 12% for HPV 31 and 7% for 
HPV 33 and 16% were positive for multiple types. All types correlated strongly with 
DQB 1 *03 but there was insufficient data to find a difference between the types. The 
highest odd ratio was found for women with HPV 18 or mUltiple types. There was a 
significant correlation with "gene dosage" at the DQB 1 *03 locus, with 39% of HPV 
positive CIN being heterozygous and 24% homozygous for DQBl*03 ( X2 trend =37.9, 
p<o.OOl). Homozygosity was significantly associated with HPV positive CIN (odds ratio 
4.47,95% CI 2.58-7.77). Further typing of the HLA DQBl*03 locus in positive samples 
showed that the 0301 allele was most strongly associated with HPV infection (odds ratio 
2.69, 95% CI 1.88-3.94; X2 trend=32.9, p<O.OOl). Table 3.4 shows the association 
between HLA DQB 1 *03 and HPV type while table 3.5 shows the effect of zygosity at the 
DQB 1 *03 locus. Table 3.6 shows the association between individual DQB 1 *03 alleles and 
HPV. 
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SUMMARY AND DISCUSSION 
Cervical cancer and CIN have been shown to be strongly associated with the oncogenic 
types of the human papillomaviruses (16,18,31,33,35,39,45,51,52,56 and 58) in several 
cross-sectional studies68,8S. However, additional factors must operate to determine the 
progression from normal epithelium to CIN and cervical cancer after HPV infection. One 
host factor is possibly immunological, as in other virus induced cancers, such as 
nasopharyngeal carcinoma due to Epstein-Barr virus301• In cervical disease this is 
supported by the fact that spontaneous regression of low grade CIN is frequently observed. 
Thus immunological mechanisms, in particular the cellular immune response, may play a 
significant role in the development of CIN and cervical cancer after HPV infection. 
To address these issues this large study, of sufficient test samples and controls evaluates 
the significance of DQBI*03 association with cervical intra-epithelial neoplasia. This study 
was performed in CIN, as it is the precursor lesion of cervical cancer, and the results of 
HLA typing may be relevant particularly when correlated with the HPV status. Further it is 
quite important to evaluate the association between CIN, HPV and DQB 1 *03 using 
controls that are negative for HPV and have a nonnal cytology. The interpretation and 
reporting of negative HPV results must be interpreted in the context of the detection system 
used. In this study, HPV 16, 18, 31 and 33 were tested for and a negative result simply 
means that the specimen does not contain any of these HPV types. 
The use of consensus primers in PCR for HPV can result in competition between non-
specifically primed human DNA with HPV DNA and between different types of HPV DNA 
in individual clinical specimens, and the apparent level of any particular type may be 
distorted after amplification. For this reason, type specific primers were used in this study. 
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Consensus primers are reserved for qualitative demonstration of the presence of HPV types 
other those specific types tested for. 
The typing for HLA DQB 1*03 was performed with a rapid technique which was 
concordant with data based on sequencing302. The advantage of this method lies in the 
need for a single mutagenic primer. which is used in a single step PCR amplification. This 
technique is also informative in assessing whether the individual sample is heterozygous or 
homozygous for the DQB 1*03 locus. Likewise, the PCR-SSP technique is an accurate and 
rapid technique for detecting genetic variability with a high degree of resolution. Each 
primer pair identifies two cis-located sequence motifs, which allows the separation of all 
homozygous and heterozygous combinations of DQB 1 *03. For instance, a 
DQB 1 *03011DQB 1 *0302 cannot be distinguished by PCR-SSO typing. However, the two 
alleles can be unequivocally assigned by the PCR-SSP technique. Since the method is ideal 
for analyzing a small number of samples, it was not used for typing the remaining DQB 
alleles. 
The results show a significant association between CIN and DQB 1*03 that is only slightly 
stronger for CIN III than CIN I. The association between CIN and DQB 1*03 that was 
found (odds ratio 3.03) was less strong than that reported by Wank and Thomssen, but a 
slightly stronger association in HPV positive CIN (odds ratio 3.43) was observed than that 
reported by Van den velde et a1303. Homozygosity at DQB 1*03, was significantly 
associated (odds ratio 4.0) with CIN and was more strongly related than heterozygosity, a 
result not reported so far in any previous studies. The 0301 allele was the most strongly 
associated with CIN (odds ratio 2.53, X2= 28.6, p<O.OOl) but 0302 was also positively 
related. This agrees with Wank and Thomssen's DNA typing data for 0301 on their 
original sample of cervical cancer patients257• 
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A significant association with HPV positive eIN and DQB 1*03 was found for all HPV 
types tested (16,18,31,33). Again homozygosity at the DQB 1 ·03 was strongly associated 
with HPV positive eIN (odds ratio 4.47) with intennediate risk found for heterozygotes. 
Typing for HPV has not been unifonnly perfonned in all the previous studies, but in 
general HPV positive eIN was significantly associated with the DQB 1*03 phenotype. In 
this study type specific primers for the major oncogenic types of HPV were used and it is 
possible that some of the HPV negative elN are positive for other types. Detailed typing 
for other HPV types is only likely to increase the strength of the association. The results 
also show that the association between DQB 1*03 and HPV positive eIN is intennediate in 
risk for eINI and greater for CINIII, in agreement with the natural history of the disease. 
These results suggest that probably the DQB 1*03 locus may be an important determinant in 
allowing the HPV infection to be tolerated and pennit the progression to eIN or cancer. 
Another disease due to HPV infection, recurrent respiratory papillomatosis, has been 
shown to be associated with the DQB 1 *03 phenotype304• In an analysis of 16 patients, 
75% were positive for DQB 1*03. Analysis of HLA class I and II using restriction fragment 
length polymorphisms, in New Zealand rabbits infected with Shope cotton-tail rabbit 
papillomavirus, showed a strong linkage between wart regressions and DR locus, and an 
increased risk of malignant transfonnation with the DQ locus305• Thus based on this study 
and others, the DQB 1*03 locus seems to be important for HPV associated disease. The 
results of the analysis of HLA DR and DQ in squamous cell carcinoma reported by Apple et 
a1306 in a Hispanic population showed no significant association with the DQB 1*03 locus, 
although the haplotype DRB 1*0407-DQB 1*0302 was associated with increased risk of 
cervical carcinoma. 
In summary, it is possible that women who are positive for the DQB 1*03 phenotype may 
be unable to mount an effective cytotoxic T cell response against HPV infection. This is 
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particularly important as it has been shown that HPV16 E7 is a target for cytotoxic T cells 
and to mediate tumour rejection307• 
Table 3.1: Summary of Distribution of liLA DQBl*03 
Patients liLA DQBl*03 Odds Ratio 
(No.) (Positive) % (95% CI) 
CIN (178) 109 (61) 3.03 (2.11 -4.35) 
CIN 1 (66) 37 (56) 2.45 (1.45-4.12) 
eIN 3 (112) 72 (64) 3.45 (2.23-5.33) 
HPV negative 25 (53) 2.18 (1.19-3.97) 
eIN (47) 
HPV positive 84 (64) 3.43 (2.28-5.15) 
CIN (13 I) 
Controls (420) 144 (34) 1* 
(HPV negative) 
X2 (trend) for (controls, eIN 1 and CIN 3) =37.3, p< 0.001. 
X2 (trend) for controls, HPV negative and HPV positive) = 38.6, p<O.OOI. 
* reference category 
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Table 3.2: Association between HLA DQBl *03 and CIN 
HLA Controls CIN Odds Ratio 
(%) (%) (95% CI) 
nonDQB1*03 276 (65) 69 (38) 1* 
Heterozygous 102 (24) 67 (37) 2.63 (1.75-3.94) 
forDQBl*03 
Homozygous for 42 (10) 42 (23) 4.0 (2.43-6.60) 
DQB1*03 
Total 420 178 
* reference category 
X2 (trend) = 39.01, p<O.OO1. 
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Table 3.3: Association between HLA DQBl*03 allele and CIN 
HLA DQB1*03 CIN 3 CINI Controls Odds Ratio Xl 
allele (2n=224) (2n=132) (2n=840) (95% CI) (trend) 
(%) (%) (%) 
0301 49 (21) 25 (19) 79 (9) 2,53 (1.79-3.57) 28,6 
(p<O.OOl) 
0302 45 (20) 16 (12) 85 (10) 1.84 (1.29-2.62) IS,S 
(p<O.OOl) 
0303 5 (2) 7 (5) 21 (2,5) 1.36 (0.67-2.76) 0.05 
p=O,82 
0304 0 0 1 (0.1) 0 
nonDQB1*03 125 84 654 1* 
Total 224 132 840 
* reference category 
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Table 3.4: Association between HLA DQBl *03 and HPV type 
HPV Type Number of DQBl *03 Odds Ratio 
present Patients (positive) (95% el) 
(%) 
16 75 45 (60) 2.88 (1.74-4.74) 
18 9 7 (77) 6.71 (1.56-oc ) 
31 16 11 (68) 4.22 (1.5-11.84) 
33 10 6 (60) 2.88 (0-.86-9.64) 
Multiple types 21 15 (71) 4.79 (1.88-12.2) 
Controls 420 144 (34) 1* 
(HPV negative) 
* reference category 
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Table 3.5: Association between HLA DQBl *03 and HPV 
HLA Controls HPV positive Odds Ratio 
(%) CIN (95% CI) 
(%) 
nonDQBI*03 276 (65%) 47 (35%) 1* 
Heterozygous 102 (24%) 52 (39%) 2.99 (1.90-4.71) 
forDQBI*03 
Homozygous for 42 (10%) 32 (24%) 4.47 (2.58-7.77) 
DQBl*03 
Total 420 131 
* reference category 
X2 (trend) =37.9, p<O.OOl. 
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Table 3.6: Association between HLA DQBl *03 allele and HPV 
HLA DQBl*03 CIN CIN Controls Odds Ratio '1..2 I 
allele HPV HPV HPV (95% CI) (trend) 
(positive) (negative) (negative) 
(2n=262) (2n=94) (2n= 840) 
(%) (%) (%) 
0301 60 (22) 14 (15) 79 (9) 2.69 (1.88-3.94) 32.9 
(p<O.OOI) 
0302 45 (17) 16 (17) 85 (10) 1.71 (1.17-2.50) 10.6 
(p<O.OO1) 
0303 9 (3) 3 (3) 21 (2.5) 1.35 (0.63-2.89) . 0.71 
(p<0.4) 
0304 0 0 1 (0.1) 0 
non DQB 1 *03 148 (56) 61 (65) 654 (78) 1* 
Total 262 94 840 
* reference category 
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CHAPTER 4: ANALYSIS OF HLA DR-DQ ASSOCIATIONS WITH HPV 
AND CERVICAL INTRA-EPITHELIAL NEOPLASIA 
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DRB4 AND DRB5 WITH CIN 
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4.6 CORRELATION BETWEEN HLA DRlDQ HAPLOTYPES AND CIN 
4.7 CORRELATION BETWEEN SIGNIFICANT HLA DRlDQ HAPLOTYPES AND 
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In the preceding chapter, it was shown that there is an increased risk for HPV positive CIN 
in women with HLA DQBI*03, specifically DQBI*0301 (O.R. 2.53) and DQBI*0302 
(O.R. 1.84) alleles. The next phase of the thesis was to perform a detailed analysis of the 
HLA DR and DQ alleles in patients with CIN and healthy controls in a British Caucasian 
population and identify haplotypes which confer both susceptibility and protection in the 
development of CIN after HPV infection. By defining susceptibility and protective alleles 
and haplotypes, these studies may help to provide a framework for understanding peptide 
binding and T cell recognition events in the immunological response to HPV infection. This 
chapter reports the detailed analysis of HLA DR-DQ in HPV associated cervical intra-
epithelial neoplasia. 
4.2: RESULTS 
lILA DR and DQ typing was performed on DNA from cervical smears of 176 women with 
CIN (CIN 1=63; CIN 111=113) and 416 healthy women who had a normal cervical smear. 
All cervical samples from patients with CIN and controls were typed for DRB 1, DRB3, 
DRB4, DRB5 and DQB 1 using the PCR/SSO technique except for DQB 1 *03 alleles which 
were individually detected by allele specific primers and peR 308. The DRIDQ haplotypes 
were inferred based on known patterns of linkage disequilibrium for these loci286-287. 
HPV typing was performed on all the test and control samples and 131 of 176 (75%) cases 
of CIN were positive for one or more of the HPV types which were examined, and all the 
controls were selected to be negative for HPV. The overall results on individual samples 
are shown in Appendix 1. Statistical analysis was performed to evaluate for correlation 
between HLA type and CIN, CIN I, CIN III and HPV positive CIN. 
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214bp 
Fig. 4.1: Generic DQB 1 amplification using the primer pair DQBAMP and DQRAMP to 
obtain a 214bp product. Lane I: 123bp marker; Lane 2: Negative control; Lane 3: positive 
control DNA from cell line BVR (DQB 1 *0501); Lane 4: Negative control; Lanes 5 to 9: 
samples from patients with eIN. 
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~-- 274bp 
Fig. 4.2: Generic DRB 1 amplification using the primer pair DRBAMP and DRRAMP to 
obtain a 274bp product. Lane 1: 123bp marker; Lanes 2 and 11: Negative controls; Lanes 3 
and 4: positive control DNA from cell line PREISS (DRB 1 *0401); Lanes 5 to 10 and 12 to 
21: samples from patients with eIN. 
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Fig 4.3: Digoxigenin labeled oligonucleotide hybridization after generic HLA ~ 
amplification. In this example, the probe DQB490 1 identifies the HLA DQB 1 *0501 allele 
in a set of control samples. The arrow shows a positive signal from the HLA DQB 1 *0501 
control cell line BVR, obtained from BISHI. Further confirmation of HLA DQB 1 *0501 in 
these individuals was by demonstrating positive signals from probes DQB2601 (0501, 
0502,05031,05032) and DQB5701 (0501,0604 and 0605). 
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, 
Fig 4.4: Digoxigenin labeled oligonucleotide hybridization after generic HLA DR 
amplification. In this example, the probe DRB 1 004 identifies the HLA DR4 group of 
alleles in a set of samples from patients with eIN. The arrow shows a positive signal from 
the HLA DRB 1 *0401 control cell line PREISS. obtained from BISHI. Further subtyping 
was by group specific amplification followed by DIG-labeled hybridization with the 
appropriate probes (section 2.5.11). 
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4.3 CORRELATION BETWEEN INDIVIDUAL ALLELES OF HLA 
DRB1, DRB3, DRB4 AND DRBS WITH CIN (Table 4.1) 
The occurrence of different DR allele groups is clearly related to CIN when analysed for 
heterogeneity (X2=28.76, d.f.=12, p=0.OO4). The DR4 group correlated significantly with 
CIN (O.R. 1.76 {1.28-2.40); X2=12, p=O.OOl).Within the DR4 group there was also 
evidence for heterogeneity (X2=22.5, d.f=8, p=0.OO4). The DR4 alleles principally 
DRBl*0401 (O.R. 1.99, p=0.002); DRBl*0403 (O.R. 3.61, p=0.02); DRBl*0406 
(O.R. 3.74-, p=0.OOO7) correlated significantly with CIN. In addition, DRBl*1101 also 
correlated with increased susceptibility for CIN (O.R. 2.35, p=O.OO4). 
There were several DR alleles which suggested a protective effect for CIN and HPV 
positive CIN. In particular, DRBI*0101 (O.R. 0.48, p=O.01); DRB1*0701l0702 (O.R. 
0.58, p=0.02) and DRB5*0101 (O.R. 0.45, p=0.03) indicated a protective effect. HLA 
DRB 1 * 1301 showed a protective effect for CIN III only (O.R. 0.32, p=O.OO4). 
4.4 . CORRELATION BETWEEN INDIVIDUAL HLA DQBl ALLELES 
AND CIN (Table 4.2) 
Different DQB 1 alleles showed a relationship with CIN when analysed for heterogeneity 
(X22=49.39, d.f=4, p<O.OOOl). HLA DQB 1 *03was the most significant, and there was no 
evidence of heterogeneity within it (X2=2.74, p=n.s.). The DQB 1 *0301 demonstrated the 
stronger association (O.R. 2.49; p<O.OOOl), but DQBl *0302 (O.R. 1.82, p=O.OOI) was 
also significantly more common. Further analysis showed that the positive association with 
DQB 1 *0301 was also significantly more common in CIN I (O.R. 2.02, P=O.OI). 
Similarly, the frequency of the DQBl alleles, DQB1*0501 (O.R. 0.48, p=O.OO4); 
DQB 1 *0402 (O.R. 0.49, p=0.06); DQB1*0603 (O.R. 0.47, p=0.03); and DQB1*0604 
(O.R. 0.6, p=0.06) showed a protective effect with either CIN. However when the data 
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was re-analysed after excluding the positively associated OQ and OR alleles, none of these 
protective associations were significant. 
The significant individual ORB 1 and DQB 1 alleles were analysed to assess whether 
homozygosity conferred an additional risk for CIN. Only at the OQBI*0301 locus could 
homozygosity be shown to increase risk (O.R., 4.39{ 1.84-10.50}; p=0.002). There were 
insufficient homozygotes of other alleles to yield clear conclusions. 
4.5 CORRELATION BETWEEN SIGNIFICANT INDIVIDUAL HLA 
DQBl AND HLA DRB ALLELES AND HPV (Table 4.3) 
The same alleles that were found to significantly correlate with CIN were found to correlate 
with HPV positive CIN. The susceptibility alleles were HLA DQBl*0301 (O.R. 2.77, 
P=O.OOOO 1); OQB 1 *0302 (O.R. 1.85, P=0.OO3); ORB 1 *0401 (O.R. 2.34, P=0.OO04); 
ORBI*0403 (O.R. 3.23, P=0.04); DRBl*0406 (O.R. 5.05-oc, P=0.OO02); and 
DRB 1 * 1101 (O.R. 2.19, P=0.02). The alleles that showed protection to HPV positive 
CIN were DQBI*0501 (O.R. 0.54, P=0.04); DQBl*0603 (O.R. 0.44, P=O.04); 
DQBI *0604 (O.R. 0.55, P=0.06); ORB 1 *0101 (O.R. 0.56, P=0.06); DRBl*1301 (O.R. 
0.52, P=0.05) and ORB5*0101 (O.R. 0.40, P=0.03). 
4.6 CORRELATION BETWEEN lILA DRlDQ HAPLOTYPES AND CIN 
(Table 4.4) 
The analysis for specific haplotypes was performed for all the possible DR-DQ 
combinations. The most common naturally occurring haplotypes (where n 10) in British 
and Caucasian populations286-287 and ones where there was a significant correlation are 
displayed in Table 4.4. The two locus haplotypes ORB 1 *0401-DQB 1 *0301 (O.R. 2.22, 
p=0.02), and ORB 1 * 11 Ol-OQB 1 *030 1 (O.R. 3.95, p=0.OO3) showed significantly strong 
associations with CIN and in particular with CIN III. Other haplotypes also demonstrated 
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nominally significant positive associations, but these were difficult to assess because of 
small numbers and multiple testing. They included haplotypes principally from the 
ORB 1 *04 group, i.e., ORB 1 *0401-DQB 1 *0302 (O.R. 1.90, p<0.05), DRB 1 *0403-
OQB 1 *0302 (O.R. 4.34, p=0.OO7) and DRB 1 *0406-0QB 1 *0302 (O.R. 2.48-oc , 
p=0.008). 
The only haplotype to confer a significant protective effect for CIN was DRBl*0101-
DQB 1 *0501 (O.R. 0.48, p=O.O 1). The haplotype was also protective for CIN III (O.R. 
0.37, p=O.OI). None of the three locus haplotypes correlated positively or negatively with 
CIN. There were insufficient cases with homozygous DR-DQ haplotypes to analyse for 
correlation with risk for CIN. 
4.7 CORRELATION BETWEEN THE SIGNIFICANT liLA 
IIAPLOTYPES AND HPV (Table 4.5) 
The haplotypes that correlated with CIN showed similar results for HPV positive CIN 
(fable 4.5). In addition, two rare haplotypes DRB 1 *0701-DQB 1 *0302 (O.R. 3.24, 
p=0.03) and ORB1*0801-DQB1*0301 (O.R. 9.63, p=0.05) also correlated significantly 
with HPV positive CIN. 
4.8 CORRELATION BETWEEN SIGNIFICANT HLA DRlDQ 
HAPLOTYPES AND IIPV TYPE (Table 4.6) 
The significant susceptible and protective haplotypes were analysed to examine for 
correlation with individual HPV types. 131 cases of eIN were positive for one of the HPV 
types either alone or in combination. HPV 16 was present in 75 (57%) cases, HPV 18 in 9 
(7%), HPV 31 in 17 (13%), HPV 33 in 9 (7%) and there were multiple HPV types 
detected in 21 (16%) cases. The relation between the most significant haplotypes and 
specific HPV types are shown in Table 4.6. No clear association with HPV type is 
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apparent, but because HPVl6 positive CIN was the most common it is not possible to 
comment on associations with other HPV types. 
4.9 DISCUSSION 
In this study the two OR-OQ haplotypes most clearly associated with CIN particularly CIN 
ITI were DRB 1*0401-DQBl *0301 and DRBl*IIOI-DQBl*0301. Two other DR4 
associated haplotypes ORB 1 *040 I-DQB 1 *0302 and DRB 1 *0403-DQB 1 *0302 also had a 
significant correlation with CIN. The major susceptibility haplotypes are different to those 
reported by Apple et a1309 and this may be partly explained by ethnic differences as they 
examined a Hispanic population. Nevertheless DR4 associated haplotypes have been 
identified in both studies as significant although the individual alleles are different. In this 
study the haplotypes ORB 1*0401-DQB 1*0301 (n=22), DRB 1 *0401-DQB 1*0302 (n=23) 
and ORB 1 *0404-0QB 1 *0302 (n=21) were the most frequent in controls, and 
representative of a Caucasian population286-287. In contrast, the haplotypes ORB 1 *0407 ~ 
OQBI*0302 (n=18) and DRB 1 *0404-DQB 1*0302 (n=14) were the most common in the 
Hispanic population309. It is probable that both studies together suggest that the DR4 
associated haplotypes confer increased risk in the development of CIN. The other major 
susceptibility haplotype DRB 1 * 11 0 I-DQB 1 *0301 in this study, was not identified as 
significant in the Hispanic study309. Instead ORB 1* 1501-DQBI*0602 was reported as a 
positively associated haplotype, despite both being observed at comparable frequencies in 
the control population. This is likely to be a genuine difference between the studies, 
particularly as a protective effect was observed with DRB 1* 110 I-DQB I *030 I in their 
study309. Two further haplotypes, less common in Caucasians, i.e. ORB I *0701-
DQB 1 *0302 and DRB 1 *080 I-OQB 1 *0301 were also found to be significant in this study 
though the observations were few. The haplotypes were all significant when found at the 
heterozygous level, but additional risk for homozygosity was not observed. On further 
analysis, the Hardy-Weinberg law was not maintained in the controls with an excess of 
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homozygotes typed for DQB 1. This is probably due to false negative scoring of some 
controls as homozygotes on PCR-SSO. However, further analyses using the individual as 
the unit and combining heterozygotes and homozygotes for each allele gave similar results. 
The linkage disequilibrium between the individual alleles of the significant haplotypes is too 
strong to determine the individual allele contributing to the overall risk286• However, in this 
study positively associated haplotypes all contained DQB 1 *03 alleles and the simplest 
explanation of the data is that the relevant factor is most closely linked to the DQB 1 *03 
locus and the resulting association with DRB 1 *0401 or DRB 1 * 1101 is due to linkage 
disequilibrium. 
The haplotype DRB1*0101-DQBl*0501 was the only one found in this study to be 
negatively associated with CIN (O.R. 0.48, p=O.OI). Other individual DQBl 
(0402,0603,0604) and DR (DRB 1 * 130 I, DRB 1 *070 I, DRB5*0 10 1) alleles that were 
more weakly negatively associated, did not reach statistical significance at haplotype level. 
The protective haplotypes identified for CIN in the Hispanic study309 are completely 
different and may be partly due to genetic differences between the populations. However, 
significant results for protective haplotypes have to be interpreted cautiously, because of the 
number of comparisons and both our observations and that found in the Hispanic study 
may still be due to chance. This is suggested by the absence of a significant protective 
effect for any of the DR or DQ alleles when the data are reanalysed excluding the positively 
associated DRB 1 *04 and DQB 1 *03 alleles. 
All the significant haplotypes correlated with HPV positive CIN. Firm conclusions could 
not be drawn, with -respect to type specific correlation due to insufficient number. The 
presence of multiple HPV types (16%) in CIN, unlike cervical cancer, also dilutes the 
ability to delineate the contribution of an individual HPV type in calculating risks310• 
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TABLE 4.1 - CORRELATION BETWEEN INDIVIDUAL DRB1, DRB3, DRB4, DRB5 ALLELES AND CIN. 
DR Controls CIN I CIN III Total Odds ratio (95 % C.I.) Trend 
'pI 
DRBI CIN p CIN III p 
0101 71 7 8 86 0.48 (0.27-0.84) 0.01 0.39 (0.19-0.82) 0.01 0.01 
0102 8 1 0 9 0.29 
0103 15 3 8 26 1.76 2.00 
0301 132 24 38 194 1.13 1.07 
0302 12 1 1 14 0.39 0.30 
0401 53 12 30 95 1.99 (1.30-3.04) 0.002 2.25 (1.40-3.60) 0.0012 0.0007 
0402 13 4 1 18 0.91 0.28 
0403 6 3 6 15 3.61 (1.33-9.82) 0.019 3.75(1.26-11.16) 0.03 0.02 
0404 30 3 9 42 0.94 1.11 ! 
0405 1 0 0 1 
- - - -
0406 0 1 5 6 (3.74-oc ) 0.0007 (4.87-oc) 0.0004 0.01 
0407 4 1 3 8 2.38 2.78 
0408 5 0 0 5 - -
0410 4 0 0 4 -
-0801 22 5 5 32 1.08 0.83 
0802 3 1 3 7 3.18 3.72 
0803 7 1 1 9 0.67 0.52 
08031 1 0 1 2 2.37 3.69 
08042 1 3 0 4 7.14 
-
1101* 24 8 15 47 2.35 (1.32-4.20) 0.005 2.39 (1.25-4.60) 0.015 0.006 
1102 1 0 0 1 
- -
1103 2 0 0 2 
- -
1104 13 2 2 17 0.72 0.56 
1201 7 0 3 10 1.01 1.59 
1202 1 0 1 2 2.37 3.69 
1301 65 13 6 84 0.67 (0.40-1.13) 0.32 (0.14-0.74) 0.004 0.03 
1302 28. 5 7 40 1.01 0.92 
1303 2 0 2 4 2.37 3.71 
1304 2 0 2 4 2.37 3.71 
* eINf vs controls O.R:--Z.28, p=0.06 
DRBI Controls CIN I CIN III Total Odds ratio (95 % C.I.) Trend 
'p' 
CIN P CINIII p 
1305 5 0 0 5 
- -
1401 27 4 8 39 1.05 1.09 
1402 2 2 0 4 2.37 
-
1403 1 0 0 1 -
-1404 4 0 0 4 - -
1406 3 0 0 6 2.38 3.72 
1407 3 0 0 3 -
-1501 75 9 17 101 0.8 0.82 
1502 17 3 7 27 1.40 1.53 
1601 12 0 4 16 0.79 1.23 
1602 3 0 3 6 2.38 3.72 
070110702 90 7 16 113 0.58 (0.36-0.92) 0.02 0.63 (0.36-1.09) 0.1 0.05 
0901 37 3 8 48 0.69 0.79 
1001 20 0 3 23 0.35 0.55 
Total n=832 n=126 n=226 n=1184 
DRB3 
0101 139 25 30 194 0.92 0.76 
0201 16 2 3 21 0.73 0.69 
0202 96 16 33 145 1.24 1.31 
0301 27 5 5 37 0.87 0.67 
Null 554 78 151 
DRB4 
DR53 200 27 57 284 0.99 1.07 
Null 632 99 169 
DRB5 
0101 46 4 5 55 0.45 (0.22-0.91) 0.03 0.39(0.16-0.96) 0.04 0.03 0102 15 2 7 24 1.43 1.74 
0201/2 35 5 18 58 1.59 1.97(1.10-3.53) 0.03 0.03 Null 736 115 196 
Total n=832 n=126 n=226 n=1184 
TABLE 4.2 - CORRELATION BETWEEN INDIVIDUAL DQ ALLELES AND CIN 
DQ Controls CINI CINIII Total Odds Ratio (95% C.I.) Trend 
'p' 
CIN ~ CINIII P 
0201 180 27 46 253 0.95 0.93 
0301* 79 22 51 152 2.49 (1.77-3.52) 0.0001 2.78 (1.89-4.09) 0.0001 0.0001 
0302 86 16 45 147 1.82 (1.28-2.59) 0.001 2.16 (1.45-3.20) 0.0002 0.0002 
0303 20 7 5 32 1.43 0.92 
0304 1 0 0 1 - - - -
0401 17 1 4 22 0.69 0.86 
0402 42 7 2 51 0.49 (0.24-1.01) 0.06 0.17 (0-0.63) 0.004 0.02 
0501 89 9 10 108 0.48 (0.29-0.79) 0.004 0.39 (0.20-0.75) 0.003 0.003 
0502 31 3 8 42 0.83 0.95 
I 0503 1 0 0 1 - - - -
05031 20 1 6 27 0.82 1.11 
05032 11 2 3 16 1.08 1.00 
0504 17 1 2 20 0.41 0.43 
0601 69 12 17 98 0.99 0.90 
0602 31 2 9 42 0.83 1.07 
0603 49 6 4 59 0.47 (0.24-0.92) 0.03 0.29 (0.11-0.78) 0.009 0.02 
0604 72 9 10 91 0.6 (0.36-1.01) 0.06 0.49 (0.25-0.95) 0.04 0.04 
0605 17 1 3 21 0.55 0.64 
0606 0 0 1 1 
- - - -
Total n=832 n=126 n=226 . n=1184 
-_._._----- --
* eIN I vs controls O.R. 2.02, p<O.Ol. 
TABLE 4.3 - CORRELATION BETWEEN SIGNIFICANT INDIVIDUAL DQBl AND DRBI ALLELES 
AND HPV 
DQBl Controls HPV· CIN+ HPV+ CIN+ Total Odds ratio (95% C.I.) 'p' 
HPV +CIN vs Controls 
0301 79 14 59 152 2.77 (1.91-4.01) 0.00001 
I 0302 86 15 46 147 1.85 (1.25-2.72) 0.003 
0402 42 5 4 51 0.29 (0.11-0.79) 0.01 
0501 89 3 16 108 0.54 (0.31-0.94) 0.03 I 
0603 49 3 7 59 0.44 (0.20-0.96) 0.04 
0604 72 6 13 91 0.55 (0.30-1.00) 0.06 i 
I 
DRBI 
0101 71 2 13 86 0.56 (0.31-1.02) 0.06 
0401 53 6 36 95 2.34 (1.50-3.66) 0.0004 
0403 6 3 6 15 3.23 (1.09-9.58) 0.04 
0406 0 0 6 6 (5.05-oc:) 0.0002 
1101 24 7 16 47 2.19 (1.16-4.15) 0.02 
1301 65 8 11 84 0.52 (0.27-0.99) 0.05 
I 
DRB5 
0101 46 3 6 55 0.40 (0.17-0.93) 0.03 
Total n=832 n=90 n=262 n=1184 
-
TABLE 4.4 - CORRELATION BETWEEN DRlDQ HAPLOTYPES AND CIN 
DRlDQ baplo~pe* Controls CIN I CIN III Total Odds ratio (95% C.I.) 
CIN vsControls. 'p' CIN 3 vs Controls 
010110501 66 7 7 80 0.48 (0.27-0.86) 0.02 0.37 (0.17-0.81) 
0103/0301 13 2 6 21 1.47 1.72 
030110201 127 22 38 187 1.14 1.12 
040110301 22 5 15 42 2.22 (1.20-4.08) 0.02 2.62 (1.35-5.08) 
040110302 23 5 13 41 1.90 (1.02-3.53) 0.05 2.15 (1.08-4.26) 
040210302 10 2 1 13 0.71 0.37 
0403/0302 5 3 6 14 4.34 (1.51-12.43) 0.007 4.51 (1.45-14.05) 
0404/0302 21 3 6 30 1.01 1.05 
0406/0302 0 1 3 4 oc (2.48-oc ) 0.008 oc (2.90-oc ) 
0406/0301 0 0 2 2 oc (1.23-oc ) 0.09 oc (1.93-oc ) 
070110201 36 3 5 44 0.51 (0.24-1.10) 0.09 0.50 (0.20-1.25) 
0701/0302t 8 0 8 16 2.40 (0.92-6.21) 0.1 3.78 (1.45-9.84) 
080110402 18 3 1 22 0.52 (0.18-1.48) 0.3 0.20 (0-1.19) 
1101I0301:j: 8 4 9 21 3.95 (1.66-9.37) 0.003 4.27 (1.68-10.85) 
110110603 12 3 2 17 0.98 0.61 
1301!0303§ 9 5 1 15 1.59 0.41 
130110603 19 3 1 23 0.49 (0.17-1.39) 0.25 0.19 (0-1.12) 
130110604 30 3 3 36 0.46 0.36 
130210604 23 5 5 33 1.03 0.80 
1401105031 14 1 4 19 0.84 1.05 
150110601 42 7 10 59 0.95 0.87 
150110602 18 0 6 24 0.78 1.23 
150210601 13 2 5 20 1.28 1.43 
160110502 11 0 4 15 0.86 1.34 
Total n=832 n=126 n=226 n=1184 
* DRlDQ haplotypes where there were 10 or more total alleles or for which a tsignificant association was found. 














TABLE 4.5 - CORRELATION BETWEEN SIGNIFICANT DRlDQ HAPLOTYPES AND HPV 
DRlDQ haplotype Controls HPV-CIN+ HPV+CIN+ Total Odds ratio (95% C.I.) 'p' 
HPV+CIN vs 
Controls 
010110501 66 2 12 80 0.56 (0.30-1.04) 0.07 
040110301 22 1 19 42 2.88 (1.55-5.36) 0.001 
040110302 23 5 13 41 1.84 (0.93-3.64) 0.1 
0403/0302 5 3 6 14 3.88 (1.25-12.06) 0.03 
0406/0302 0 0 4 4 (3.34-oc ) 0.003 
0406/0301 0 0 2 2 (1.66-oc ) 0.06 
070110302 8 0 8 16 3.24 (1.25-8.43) 0.03 
080110301 1 0 3 4 9.63 (1.37-oc ) 0.05 
110110301 8 3 10 21 4.09 (1.64-10.16) 0.004 
Total n=832 n=90 n=262 n=1184 
TABLE 4.6 - CORRELATION BETWEEN SIGNIFICANT DRBlIDQBl HAPLOTYPES AND HPV TYPE 
DRBIIDQBI haplotypes 
040110301 040110302 110110301 070110302 010110501 
HPV type No N O. R. (95%Cn 'p' N O.R. 'p' N O.R. (95% 'p' N O.R. 'p' N O.R. 'p' 
el) 
16 150 10 2.63 (1.2·5.6) 0.02 8 1.98 0.09 8 5.80 (2.2-15) 0.001 5 3.55 (1.22-10.05) 0.04 8 0.65 0.4 
18 18 1 2.17 0.4 1 2.07 0.4 0 0 -: 0 0 
-
1 0.7 1 
31 34 3 3.56 0.07 1 1.07 0.6 2 6.44 (1.3-32) 0.05 0 0 
-
0 0 0.1 
33 18 0 0 
-
1 2.07 0.4 0 0 - 1 6.06 0.2 1 0.7 1 
Multiple 42 5 4.98 (1.9-13) 0.007 2 1.76 0.3 0 0 - 2 5.15 0.08 2 0.58 0.8 
Controls 832 22 1* 23 1* 8 1* 8 1* 66 1* 
(HPV-ve) 
-
* reference category 
O.R. odds ratio, (95% CI) 
CHAPTER 5: POOL SEQUENCING OF NATURALLY PROCESSED 
PEPTIDES BOUND TO HLA·DQBl *0301 AND DQBl *0501; PREDICTION 
OF PEPTIDE MOTIFS FROM HUMAN PAPILLOMAVIRUS TYPE 16 
5.1 INTRODUCTION AND PRINCIPLES 
5.2 ELUfED POOL SEQUENCE DATA FROM PEPTIDES ELUTED FROM lILA 
DQBl*0501 ANDDQBl*0301 
5.3 PREDICTION OF PEPTIDE MOTIFS FOR BINDING FROM Ll, L2, E6 AND 
E7 OF HPV 16 TO HLA DQB 1 *0301 AND DQB 1 *0501 
5.4 PREDICTION OF PEPTIDE MOTIFS FOR BINDING FROM Ll, L2, E6 AND 
E7 OFHPV 16TO HLADRBI*0101 AND 0401 
5.5 SUMMARY AND DISCUSSION 
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5.1 INTRODUCTION 
The pioneering work of Buus et a1311 was the first that detailed the acid extraction of 
naturally processed self peptides bound to MHC molecules. The application and refinement 
of this technique has produced substantial information on HLA-associated peptides. Thus, 
it has been shown that the majority of peptides that associate with HLA class I are 8-10 
residues long, with allotype specific binding motifs containing up to three anchor 
positions169,312. This is consistent with the multiple pockets and the close-ended structure 
of the HLA class I peptide binding groove. However, only a few peptide side-chains are 
actively involved, as the majority of the binding energy is obtained through conserved 
binding sites at the terminal ends of the peptide and extensive hydrogen-bonding networks 
along the peptide backbone313-314. 
To further the understanding of the mechanisms of HLA associated susceptibility to HPV 
induced cervical carcinogenesis, it is reasonable to suppose that susceptibility to HPV 
infection reflects the presence or absence of immunodominant peptide binding motifs. 
Therefore, the identification of the type of peptides bound by the susceptibility and 
protective HLA molecules may contribute to the understanding of HPV induced cervical 
carcinogenesis. Furthermore, knowledge of the motif requirements of peptide binding to 
these molecules may allow the modification of the immune response to the human 
papillomavirus. 
In this study, the haplotype HLADRB 1 *040 I-DQB 1 *030 1 was shown to correlate with 
susceptibility to HPV and CIN while DRB 1 *010 I-DQB 1 *0501 indicated protection. The 
extended 3-locus haplotypes, DQA 1 *030 I-DQB 1 *0301-DRB 1 *0401 and DQA 1 *0301-
DQB 1 *0302-DRB 1*0401 have been found at a frequency of 23.1% in British 
caucasoids287• Similarly, DQAl *OlOl-DQBI *0501-DRBI *0101 occurs at a frequency of 
19.8% in British caucasoids287• Therefore, in the present analysis, the peptide pools eluted 
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from HLA {DQAI*0301IDQB1*030I} and {DQAI*OlOIIDQBI*OSOI} were sequenced 
(Since these significant haplotypes cover more than 20% of the British population). Amino 
acid preferences based on peptide sequence alignment with HPV 16 LI, L2, E6 and E7 are 
discussed. 
5.2 ELUTED POOL SEQUENCE DATA FROM PEPTIDES ELUTED 
FROM HLA DQBl*OSOl AND DQBl*0301 
A representative SDS-PAGE analysis of HLA DQA1*01OI-DQB1*OSOl from the 
JESmOM cell line is shown in fig S.l. The rpHPLC absorption profile for (210nm) for 
eluted peptides from HLA DQA1*0101-DQB1*OSOl and HLA DQA1*0301-DQB1*0301 
are shown in figures 5.2 and 5.3 respectively. The profiles illustrate the heterogeneity of 
the eluted protein material. Pooled fractions from the eluted HLA DQAI*OlOl-
DQB 1 ·OS01 and HLA DQA 1 *030 I-HLA DQB 1 *030 1 were used for further analysis 
(Edman sequencing). Only SO% of the HPLC fractions were used for this pool. 
Tables 5.1 and 5.2 show the pool sequencing data for HLA DQA1*0101-DQB1*OSOl and 
HLA DQAl*0301-DQBI*0301. Norvaline (nv) was used as solvent to dissolve PTH 
amino acid and to verify the injection. Norleucine was used as standard. For interpretation 
of the data, the amount of increase of yield of PTH-amino acid at each cycle was 
considered more significant than the actual number itself. Two levels of arbitrary 
significance were employed. Values at least 50% higher as compared with either of the 
three previous cycles are considered highly significant (similar to the evaluation in Falk et 
aI 169). Signals with high absolute values and either a small increase as compared to the 
previous cycle, or a decrease lower than the expected lag for the residue are considered 
likely to be presented in a proportion of peptides in the mixture. These significant residues 
are underlined. In this way, pool sequence data for DQBl*0501 and DQBI*0301 ligands 
were obtained. 
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Fig 5.1: 12% SDS-PAGE Analysis of HLA DQAl*OJOJ -DQBl*050J obtained from the JESTHOM cell 
line. Lane 1: DR- J (control); Lane 2: DQB1*0501 from JESTHOM; Lane 3: DR1; Lane 4: DQBJ*0501; 
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Fig 5.3: HLADQB 1 ·0301 peptide pools were separated by r-HPLC. Each HPLC chromatogram represents the peptide repertoire as detected by UV absorbance at 21 Onm 
Amino acid residues (in pmol) 
cvcle A D E F G H I K L M N P 0 R S smc T V W Y nl nv 
1 22.18 14.27 6.78 17.36 15.09 2.62 0.00 11.76 6.78 1.94 3.24 1.90 0.00 0.32 26.00 0.02 11.00 6.28 0.00 3.77 4.55 2.53 
1 5.01 6.96 4.14 2.20 10.05 1.69 2.84 4.54 4.59 0.54 1.75 z....u 1.68 4.40 9.25 0.01 3.50 3.03 0.00 2.12 0.22 1.65 
3 2.30 5.63 3.39 1.18 6.70 1.29 2.00 2.63 2.94 0.48 1.63 2.01 1.14 4.10 3.92 0.02 2.00 1.84 0.00 2.02 0.03 1.52 
4 1.67 3.89 3.09 1.02 4.07 0.94 1.57 1.36 2.56 0.27 1.18 1.36 1.60 4.20 1.62 0.03 1.00 1.32 0.00 1.03 0.06 1.40 
5 1.74 3.05 2.21 0.80 2.77 0.68 1.48 0.66 2.22 0.27 u.a 0.98 1.37 ~ 1.40 0.01 ~ 1.17 0.00 0.84 0.06 1.35 
6 L.8..6 2.92 2.03 0.98 2.42 0.61 l.2l 0.67 Ul 2.ll 1.06 J....Ql 1.20 ·4.25 1.20 0.03 1.03 1.07 0.00 0.97 4.08 1.34 
7 1.69 1.92 1.36 1.00 1.65 0.44 0.00 2..ll 1.34 0.28 1.01 0.99 0.79 3.15 0.99 0.01 0.76 0.85 0.00 0.90 0.32 1.23 
8 2.ll 1.83 1.19 0.93 l..ll 0.41 0.00 1.79 1.43 0.25 0.75 0.79 0.78 Ul 1.04 0.01 0.86 0.98 0.00 0.84 0.04 1.30 
9 1.36 .2,.M 1.04 0.61 1.34 0.37 0.00 U2 L.8..6 0.20 0.70 0.73 0.74 3.10 0.85 0.02 0.60 0.82 0.00 0.52 0.Q3 1.29 
10 1.17 1.43 0.80 0.44 1.02 0.29 0.00 l.tl 1.03 0.14 0.57 0.55 0.80 2.27 0.62 0.01 0.41 0.60 0.00 0.35 0.05 1.21 
11 .1...ll 1.21 0.71 0.38 1.11 0.23 0.00 0.00 0.69 0.10 0.50 0.49 0.59 2.08 0.67 0.01 0.41 0.52 0.00 0.32 2.89 1.21 
11 1.29 ~ 0.88 o..u ~ 0.29 0.00 1.86 0.78 0.14 0.50 0.47 0.66 2.37 0.77 0.01 0.46 0.86 0.00 0.37 0.49 1.31 
13 0.81 0.89 0.84 0.28 1.05 0.21 0.00 1.66 0.79 0.12 0.45 0.37 0.55 2.37 0.57 0.01 0.37 0.53 0.00 0.32 0.20 1.23 
14 0.65 0.84 0.58 0.25 0.78 0.16 ll..ll 0.06 0.50 0.07 0.43 0.33 0.42 l..l.5. 0.42 0.01 0.24 0.45 0.00 0.25 0.37 1.19 
15 0.64 0.70 0.47 0.27 0.77 0.20 0.00 1.05 0.58 0.04 0.36 0.33 0.43 3....l6 0.43 0.01 0.32 0.56 . 0.00 M2 0.00 1.25 
16 0.69 0.62 0.41 0.26 0.78 0.17 0.00 1.06 0.46 0.11 0.28 0.32 0.44 2.42 0.41 0.01 0.26 0.41 0.00 Q.11 1.78 1.28 
17 0.58 0.56 0.39 ~ 0.80 0.23 0.48 0.11 0.46 0.11 0.27 0.27 0.38 1.97 0.40 0.02 0.35 0.39 0.00 0.45 0.54 1.27 
18 0.59 0.46 0.33 0.25 0.73 0.16 0.00 0.96 0.45 0.09 0.27 0.25 0.36 1.67 0.38 0.01 0.53 0.36 0.00 0.30 0.00 1.27 
19 0.54 0.47 0.28 0.22 0.62 0.12 0.56 0.05 0.41 0.07 0.25 0.23 0.33 1.50 0.35 0.01 0.14 0.35 0.00 0.43 0.00 1.26 
Table 5.1: Sequencing of DQBl*0501 ligands. The pools were sequenced by Edman degradation. The numbers indicate pmols of individual amino acids residues detected at each 
cycle. SMC = S-metbyl cysteine; nl = norleucine (standard); nv = norvaline. 
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Amino acid residues (in pmol) 
cycle A D E F G H I K L M N P 0 R S sme:' T V W Y nl nv 
1 24.48 14.63 8.55 6.78 18.71 2.97 8.92 18.00 6.40 1.SS 4.59 2.25 3.93 10.77 30.89 0.37 14.10 7.02 0.00 3.93 8.47 3.39 
2 6.23 7.93 4.75 2.56 10.39 2.48 4.03 6.99 2.82 0.81 2.89 6.31 2.41 5.60 10.90 0.17 4.39 3.34 0.00 1.76 0.08 1.79 
3 5.32 6.78 4.46 1.91 6.42 1.93 2.02 4.91 1.85 1.09 0.00 2.82 1.65 4.32 4.95 0.07 1.76 1.99 0.00 1.22 0.00 1.S2 
4 5.70 7.36 ~ 0.67 4.86 1.40 1.06 3.51 1.39 0.92 0.00 1.70 1.61 4.62 2.06 0.05 1.40 1.S9 0.00 0.84 0.04 1.38 
5 5.68 4.04 4.88 0.87 4.13 1.28 0.77 3.26 1.17 0.55 0.00 1.33 1.35 MQ 1.63 0.08 Ul 1.42 0.00 0.73 0.04 1.35 
6 BM 2.18 3.94 0.55 3.79 0.84 0.70 2.01 0.98 0.44 0.97 1.37 1.46 4.62 1.45 0.04 1.02 1.86 0.00 0.55 6.41 1.34 
7 Ul 1.38 2.17 2.U !..2..Q 0.69 2...2...1 1.88 0.97 0.30 0.80 1.09 L.tl 4.19 1.43 0.03 0.84 .l...B2 0.00 U1 0.26 1.37 
8 7.43 1.00 1.25 0.46 3.23 0.00 0.49 1.27 1.13 0.26 0.79 Ll1 1.43 4.52 1.30 0.02 0.93 1.79 0.00 0.52 0.05 1.31 
9 7.46 0.82 0.93 0.30 1.78 0.00 .l...Q.Q 1.38 1.14 0.20 0.78 L.lQ 1.02 ~ l.SS 0.02 0.72 l..U 0.00 0.40 0.00 1.30 
10 5.65 0.70 0.87 0.29 1.70 0.00 0.54 0.99 0.89 0.24 0.77 1.48 0.99 4.15 1.22 0.05 l..ll U.6 0.00 0.28 0.05 1.30 
11 5.14 0.58 0.70 0.24 1.83 0.50 0.95 0.23 0.55 0.23 0.67 1.45 0.90 3.15 1.04 0.02 0.61 1.47 0.00 0.26 5.38 1.30 
12 3.31 0.27 0.59 0.15 1.67 0.00 0.47 0.27 0.59 0.18 0.33 1.54 0.81 3.01 0.98 0.01 0.44 1.01 0.00 0.23 0.34 1.25 
13 2.41 0.61 0.61 0.17 1.77 0.00 0.29 0.42 0.59 0.13 0.56 0.93 0.79 2.47 0.70 0.01 0.45 0.63 0.00 0.16 0.08 1.29 
14 1.40 0.54 0.52 0.19 1.16 0.79 0.26 0.46 0.51 0.06 0.49 0.95 0.52 2.11 0.66 0.01 0.23 0.42 0.00 0.13 0.05 1.29 
IS 0.95 0.21 0.39 0.17 0.88 0.00 0.00 0.00 0.52 0.08 0.27 0.68 0.58 1.54 0.58 0.Q3 0.27 0.36 0.00 0.10 0.04 1.28 
16 0.65 0.27 0.32 0.15 0.83 0.00 0.12 0.00 0.30 0.07 0.41 0.5 I 0.47 1.27 0.47 0.01 0.25 0.26 0.00 0.12 2.42 1.26 
17 0.50 0.20 0.27 0.08 0.68 0.00 0.00 0.00 0.29 0.1 S 0.29 0.40 0.42 0.93 0.37 0.01 0.22 0.24 0.00 0.13 0.21 1.30 
Table 5.2: Sequencing of DQB 1 *0301 ligands. The pools were sequenced by Edman degradation. The numbers indicate pmols of individual amino acids residues detected at each 
cycle. SMC = S-metbyl cysteine; nl = norleucine (standard); nv = norvaline. 
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Based on the above pool sequence data, the peptide ligand for HLA 







X - (Pro) - X - (GIn) - (Arg) - (Phe) - X 






- Ala -Leu - X 
8 9 10 
(Gly) Val (Thr) 
Ala - Val - X - Arg - Tyr - Tyr - (His) - Thr 
II 12 13 14 15 16 17 
This sequence shows that proline gives an outstanding signal at position 2. This most likely 
reflects the consequence of processing and not of MHC-binding requirements. In support 
of this notion is the absence of the influence of Pro residues in peptide binding 
studies268,31S. This Pro residue might protect the epitope from degradation by 
exopeptidases some of which, like aminopeptidase N, are hindered by prolines. 
Based on the crystal structure of HLA-DRI, the peptide binding groove usually anchors a 
stretch of pep tides which in most cases is nine amino acids long (PI to P9). The number of 
amino acids between the amino terminus and P I differs considerably between different 
ligands (0-10). Sequencing studies of pools of class II ligands that have had those peptides 
with a high copy number removed have indicated that the distance from the amino terminus 
to PI is 3+/- 1 amino acids for the majority of peptides267. There have been only one 
previously reported motif for HLA-DQI (DQAI*OI0lIDQBI*050l)293 and one for HLA 
DQ7 (DQAI *05011DQB I *0301)267. The latter report suggested that proline gives an 
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outstanding signal at position 2. The DQ7 motif was shown to have three anchors focused 
at positions 5, 9, and 11. The first and the last are dominated by aromatic residues, 
whereas the middle one is mainly aliphatic and only four intermittent polar clusters were 
found. 
The DQB 1 *050 1 motif is characterized by AsnJ Arg (amidic amino acid and amino acid with 
basic or positively charged side chain) at PI (absolute position 5), suggesting that a small 
or polar amino acid is preferred at this position. The central amino-acids are mainly 
aliphatic/aromatic. P5 (absolute position 9) is the focus of a hydrophobic cluster with a 
small contribution by small polar residues. There is another cluster of aromatic residues 
towards the C- terminus. 
Based on the above pool sequence data, the peptide ligand for HLA-
DQAl *0301IDQBl*0301 is as follows: 
(Ser) 
(Pro) 
(Gly) (Gin) (Gly) (Leu) (lie) 
(Ser) (Arg) (Val) Ala (Pro) (Val) 
Sequence: X- Pro- X- Glu - Thr - Ala- Tyr- X- X 
CYCLE# : 1 2 3 4 5 6 7 8 9 
(Val) (lie) (Pro) 
Sequence: Thr - X X - X -HIS 
CYCLE# 10 11 12 13 14 
This sequence also shows that proline gives an outstanding signal at position 2. This is 
similar to the sequence of HLA DQB 1 *050 1 and most likely reflects the consequence of 
processing and not of MHC-binding requirements. 
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In this study, the pool sequencing data beyond Pro at position 2 shows that the 
DQB 1 *0301 motif is characterized by Thr! Arg (small polar amino acid and amino acid with 
positively charged side chain) at PI (absolute position 5), suggesting that a small or polar 
amino acid is preferred at this position. The central amino-acids are mainly 
aliphatic/aromatic. P5 (absolute position 9) is the focus of an aliphatic cluster with a small 
contribution by small polar residues. Proline gives a signal again at absolute position 12 
which is towards the C-terminus. This suggests trimming of the peptide also by 
carboxypeptidases which are also hindered by proline. 
5.3 PREDICTION OF PEPTIDE MOTIFS FOR BINDING FROM E6, E7, 
Ll AND L2 of HPV 16 to lILA DQB1·0301, AND DQB1·0501 
On the basis of the peptide sequence data above, the E6, E7, LI and L2 proteins of HPV 
16 were examined to identify sequences which are likely to bind to HLA DQB 1 *0301 and 
DQB 1 *0501. The examination was performed systematically in an overlapping fashion for 
13-mer peptides. 
The motif analysis of the HPV 16- E7 protein (98 amino acids) shows that a total of 26 
peptides possess at least one preferred residue at PI or P5 for binding to lILA 
DQBI *0301. However, since most HLA molecules require two to three anchors in a 
peptide for optimal binding, further analysis revealed that two of these peptides (7.7%) 
possess the preferred amino acid residues at both PI and P5. These are E,68·80: 
CVQSTHVDIRTLE; and E,82.94: LLMGTLGIVCPIC (Table 5.3). By contrast, a 
total of28 peptides derived from HPV 16-E7 posses at least one preferred residue at PI or 
P5 for binding to HLA DQB 1 *050 I and one of these (3.6%), E,73·85: 
HVDIRTLEDLLMG, possess the preferred residues at PI and P5 (Table 5.4). 
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In the analysis of HPV 16-E6 (1S8 amino acids), a total of 43 peptides possess at least one 
preferred residue at PI or PS for binding to HLA DQB 1 *0301. Of these, four peptides 
(9.3%) possess the preferred residues at both PI and PS. These are E625-37: 
ELQTTIHDIILEC; E651-63:DFAERDLCIVYRD; 
CIVYRDGNPYA VC; and E6127-140: DKKQRFHNIRGRW (Table S.5). In the 
case of HLA DQB 1 *050 1, a total of 46 peptides from HPV 16 E6 are probably capable of 
binding and four of these (8.7%) possess the preferred residues at PI and PS (Table 5.6). 
In the analysis of the L 1 protein of HPV 16 (531 amino acids), a total of 166 peptides 
posses at least one preferred residue at PI or P5 for binding to HLA DQBl *0301. Of 
these, 14 peptides (8.4%) possess the preferred residues at both PI and P5 (Table 5.7). 
The comparable predicted motifs for HLA DQB 1 *0501 show that a total of 128 peptides 
that are probably capable of binding to HPV 16 LI derived peptides with 11 peptides 
(8.6%) possessing the preferred residues at PI and PS. These peptides are listed in table 
5.8. 
Motif analysis of the HPV 16 L2 protein (473 amino acids) for binding to HLA 
DQB 1 *0301 revealed that a total of 216 peptides posses at least one preferred residue at PI 
or PS. Of these, 22 peptides (10.2%) possess the preferred residues at both PI and P4. 
These peptides are listed in table 5.9. Comparative analysis of binding to HLA 
DQB 1 *0501 reveal a total of 119 peptides with at least one preferred residue, and 7 of 
these (6.0%) possess the preferred residues at PI and PS (Table S.lO). 
The finding that there are no significant differences in the number of HPV 16 derived 
peptides that are probably capable of binding the HLA DQB 1 *OSOI molecule compared 
with HLA DQB 1 *0301 supports the notion that the protective effect of the former on HPV 
associated disease relates more to peptide binding affinity. In this way, the HLA 
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DQB 1 *050 I-HPV peptide complex may lead to the generation of a more effective immune 
response. 
Table S.3: The predicted peptide motifs from HPV 16·E7 to 
HLADQBl*0301. 
HPV 16 E7 Peptide Sequence (DQB1*0301) 
68-80 CVQSTHVDIRTLE 
82-94 LLMGTLGNCPIC 
Table S.4: The predicted peptide motifs from HPV 16·E7 to 
HLADQBl*OSOl. 
HPV 16 E7 Peptide Sequence (DQB1*OSOI) 
73-85 HVDIRTLEDLLMG 
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Table 5.5: The predicted peptide motifs from HPV 16·E6 to 
HLADQBl *0301. 





Table 5.6: The predicted peptide motifs from HPV 16·E6 to 
HLADQB1*0501. 






Table 5.7: The predicted peptide motifs from HPV 16·Ll to 
HLADQBl*0301. 
HPV 16 Ll Peptide Sequence (DQBl*0301) 
32-44 PSEA TVYLPPVPV 
46-58 KVVSIDEYV ARTN 











507-519 TLGKRKA TPTTSS 
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Table 5.8: The predicted peptide motifs from HPV 16·Ll to 
HLADQB1*0501 













Table 5.9: The predicted peptide motifs from HPV 16-L2 to 
HLADQBl*0301. 













247-259 TKLITYDNPA YEG 










Table 5.10: The predicted peptide motifs from HPV 16·L2 to 
HLADQB1 *0501 






359-371 TSINNGL YDIY AD 
454-466 MLRKRRKRLPYFF 
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5.4 PREDICTION OF PEPTIDE MOTIFS FOR BINDING FROM Ll, L2, 
E6 and E7 of HPV 16 to HLA DRBI *0101 AND DRBI *0401 
The requirements for peptide binding to several lllA. OR alleles have been defined by the 
analysis of peptide analogs and have been shown to be remarkably simple168,170,268 315-
318. Other than the peptide backbone, only a single hydrophobic amino acid side chain 
appears to be critical. This was initially demonstrated in an analysis of monosubstituted 
analogues of an influenza hemaglutinin peptide to bind ORB 1 *0101 168,317. Of the twelve 
residues examined, only substitutions for a tyrosine near the amino terminus dramatically 
reduced binding. The importance of this single side chain was established unequivocally by 
demonstrating that a peptide of equal length as the natural hemaglutinin sequence, but with 
all amino acids other than the tyrosine and a single lysine replaced with alanine, bound both 
ORBI*0101 and ORB 1 *0401 better than the natural peptide. The ability of simplified 
analogues to bind as well, if not better than, the parent T cell determinants suggest that the 
other amino acids in the peptide ligand either made minor contributions, were neutral, or 
were deleterious to binding. 
More extensive quantitative studies using simplified polyalanine peptides have 
demonstrated for binding to both ORB 1 *0101 and ORB 1 *0401 that: 
i The optimal position for the hydrophobic amino acid in the context of a thirteen amino-
acid peptide was the third position (P3). 
ii The structural requirements at P3 were quite tolerant, with aromatic being superior to 
aliphatic side chains for binding to ORB 1 *0101 and ORB 1 *0401 
iii An analog with tyrosine at P3 bound with an ICso value three orders of magnitude lower 
than a peptide with alanine at this position, and more than five orders of magnitude lower 
than peptides containing polar amino acids at this position317• 
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The minimal requirements for binding shared by eight DR alleles suggested that the 
important hydrophobic side chain interacted with a subsite composed principally of 
conserved residues318. An appropriate site was the relatively deep hydrophobic pocket in 
the region of residues 24a, 26a, 54a of the a-chain and 86B of the B-chain. The only 
polymorphic amino acid present in this subsite was 86B which is either a glycine or valine 
in the DR proteins. The side chains in the peptides that appeared to be responsible for allele 
specificity were determined by correlating their common structural features with 
complementary polymorphic residues in the binding site. The importance of the peptide 
side chains was tested by incorporating them into a poly alanine backbone and was 
confinned by the ability of these residues to transfer allele specificity to these simplified 
analogues. Although polymorphic contacts affect peptide affinity, the majority of the free 
energy of binding in all cases arose from interactions with the peptide backbone and the 
single hydrophobic amino acid at the third position. These constraints appear to orient all 
peptides in a similar location, forcing them to adopt a closely related confonnation in the 
binding site. The corresponding side chain in each peptide contacted the same pocket in the 
binding site, regardless of the allele. This apparent similarity allows for the analysis of any 
DR allele by extrapolation from the DRB 1 *0101 crystal structure. 
The data from the analysis of monosubstituted polyalanine peptides binding to a set of DR 
alleles indicated that the free energy of binding can be viewed as a simple sum of the 
interactions of the peptide side chains and backbone with distinct regions of the binding 
site318-319. Interactions of more than a single peptide side chain with a particular subsite of 
the binding cleft is unlikely because of the extended confonnation the peptide adopts in the 
binding site. Thus, the free energy of binding can be represented as a simple polynomial 
with separate terms for backbone interactions and the side chains. Therefore, the apparent 
affinity of any sequence of common length should be predictable based on the rules of 
binding and data on the relative effects of the natural amino acids at each position. 
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A suitable database for this prediction has been constructed (Rothbard, J; Stanford 
University, USA, personal communication) and was used in this thesis to predict HPV 
peptide motifs for DRBl*0101 and DRB1*0401. The program is simple, written using 
Microsoft Excel and is able to parse any open reading frame into 13 amino acid peptides 
and calculate their affinity for DRB 1 *0401 and DRB 1 *0101. 
In designing the database, the contributions of the individual side chains of a peptide from 
influenza hemaglutinin and tetanus toxin were measured by assaying analogs of 
MY AAAKAAAAAA containing the corresponding amino acid at each position. This 
polyalanine peptide was chosen because alanine can be viewed as having a neutral side 
chain due to lack of size and charge. Consequently, any substitution could be viewed as 
advantageous, neutral or deleterious depending on its effect as compared to the parent 
peptide. Assuming that the tyrosine and the peptide backbone oriented all peptides 
equivalently, any differences in the ICso value was due to the effect of the added amino 
acid. Multiplying each of the ratios for each analogue together resulted in a composite ratio, 
that when multiplied by the ICso value of the parent peptide (14.7nM) resulted in a 
predicted ICso value that was very close to experimentally determined value for both 
peptides. A thorough study of prediction has been done using the ratios derived from all 
possible monosubstituted analogues at the central eleven positions of a simplified 
peptide320. Prediction data from myelin basic protein, human serum albumin show that the 
predicted affinity in all cases, was within a factor of four of the experimentally derived 
value320 Rothbard I, personal communication). This degree of error is comparable to that 
observed for the binding assays. 
The peptide motifs of HPV 16 and their ICso based on the approach described above are 
attached as appendix II. The motifs with ICso less than 20nM are listed as follows: Tables 
5.11 and 5.12 show the motifs derived from LI; Tables 5.13 and 5.14 show the motifs 
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derived from L2; Tables 5.15 and 5.16 the motifs derived from E7; and Tables 5.17 and 
5.18 the motifs derived from E6. 
Table S.I1: The predicted binding affinity of peptides derived from HPV 
16·Ll to DRBl*OlOl. The first nine peptides are shown. 
DPV 16 ·Ll Peptide Sequence ICso DRBl*OlOl (nM) 
58-70 NIYYHAGTSRLLA 1.50 
3-15 V1FIYIL VITCYE 1.85 
398-410 LQFIFQLCKI1LT 2.85 
414-426 MTYIHSMNSTILE 3.25 
442-454 DTYRFVfQAIACQ 4.42 
300-312 DL YIKGSGST ANL 5.05 
317-327 SNYFPTPSGSMVT 6.40 
59-71 IYYHAGTSRLLAV 7.25 
159-171 SAYAANAGVDNRE 22.50 
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Table 5.12: The predicted binding affinity of pep tides derived from HPV 
16-LI to DRBI *0401. The first five pep tides are shown. 
HPV 16 -Ll Peptide Sequence ICso DRBI *0401 (nM) 
442-454 DTYRFVfQAIACQ 1.15 
492-504 RKFLLQAGLKAKP 3.00 
94-106 LQYRVFRIHLPDP 4.30 
3-15 VTFIYIL VITCYE 10.50 
124-136 L VW ACVGVEVGRG 21.00 
Table 5.13: The predicted binding affinity of peptides derived from HPV 
16-L2 to DRBI *0101. The first nine peptides are shown. 
HPV 16 -L2 Peptide Sequence ICso DRBI *0101 (nM) 
240-252 P AFVTfPTKLITY 2.70 
444-456 GDFYLHPSYYMLR 3.35 
52-64 GVFFGGLGIGTGS 7.20 
301-313 IRYSRIGNKQTLR 11.50 
200-212 TFIVSTNPNTVTS 13.00 
445-457 DFYLHPSYYMLRK 13.00 
70-82 TGYIPLGTRPPT A 14.00 
418-430 INITDQAPSLIPI 19.00 
161-173 PTFTDPSVLQPPT 32.00 
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Table 5.14: The predicted binding affinity of pep tides derived from HPV 
16-L2 to DRBI *0401. The first four peptides are shown. 
HPV 16 -L2 Peptide Sequence ICso DRB1*0401 (nM) 
46-58 LQYGSMGVFFGGL 9.80 
266-278 L YFSSNDNSINIA 11.00 
391-403 SGYIPANTTIPFG 12.00 
444-456 GDFYLHPSYYMLR 20.20 
Table 5.15: The predicted binding affinity of pep tides derived from HPV 
16-E7 to DRBI *0101. The first four peptides are shown. 
HPV 16 -E7 Peptide Selluence ICso DRB1*0101 (nM) 
81-93 DLLMGTLGNCPI 45.20 
80-92 EDLLMGTLGIVCP 230.00 
52-64 YNIVTFCCKCDST 300.00 
55-67 VTFCCKCDSTLRL 1120.00 
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Table 5.16: The predicted binding affinity of pep tides derived from DPV 
16-E7 to DRB1"'0401. The first four pep tides are shown. 
DPV 16 -E7 Peptide Sequence ICso DRBl"'0401 (nM) 
21-33 DLYCYEQLNDSSE 105.00 
9-21 . HEYMIDLQPEITD 210.00 
84-96 MGTLGIVCPICSQ 230.00 
63-75 STLRLCVQSTHVD 452.00 
Table 5.17: The predicted binding affinity of peptides derived from DPV 
16-E6 to DRB1"'OlOl. The first five pep tides are shown. 
HPV 16 ·E6 Peptide Sequence ICso DRB1"'OlOI (nM) 
59-71 IVYRDGNPYAVCD 4.00 
33-45 Ill..ECVYCKQQLL 12.00 
142-154 RCMSCCRSSRTRR 12.50 
75-87 KFYSKISEYRHYC 18.20 
84-96 RHYCYSLYGTTLE 34.50 
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Table 5.18: The predicted binding affinity of peptides derived from HPV 
16·E6 to DRBI *0401. The first four pep tides are shown. 
HPV 16 ·E6 Peptide Sequence ICso DRBI *0401 (nM) 
59-71 IVYRDGNPYAVCD 24.00 
52-64 FAFRDLCNYRDG 35.00 
75-87 KFYSKISEYRHYC 83.00 
86-98 YCYSLYGTfLEQQ 120.00 
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5.5 SUMMARY AND DISCUSSION 
In this chapter, data obtained from immunoaffinity purification and sequencing of peptides 
bound to the susceptibility and protective HLA DQ alleles were used to predict peptide 
motifs from HPV 16. There are two limitations of this data. Firstly, sequencing of the 
individual peptide peaks obtained after rpHPLC would have provided additional 
information on both sequence match and protein source of the peptides. These peptides 
could then be aligned with the motif derived from the pool sequence to derive anchor 
residues with certainty. Indeed, an attempt was made to obtain this data using electrosplay 
ionization mass spectrometry (LC-ESI-MSIMS) but proper identification could not be made 
using the parameters described by Dongre et al (1997) because of insufficient samples 
(Data not shown). Secondly, in order to confirm the motif derived from pool sequencing, 
binding studies on synthetic variants of the eluted peptides could be performed. 
Nevertheless, the results suggest that many more peptide motifs are capable of binding to 
HLA DQB 1 *0501 than DQB 1 *0301. This may partly explain the mechanisms of the 
association of these alleles to HPV related cervical carcinogenesis (see also chapter 6). 
For HLA DQ molecules, information on ligand specificity has only recently been available. 
Single-substitution experiments defined a simple motif for DQA 1 *030 IIDQB 1 *0301 that 
was quite different from the motifs recognized by DR molecules290• Its prominent feature 
is the requirement of two small and/or hydrophobic residues spaced at relative positions i+2 
and i+4. However, because these features can basically be found in almost every natural 
peptide frame, this motif is not suitable for predicting HLA-DQ ligands. Simple motifs 
have also been described for the autoimmune disease-linked HLA 
DQA1*0501IDQB1*0201291 ,296,321 and DQAl *0301IDQBI *0302295,322. As for 
DQAl *0301IDQB 1 *0302, these motifs were different from the ones recognized by DR 
molecules. For example, no prominent position 1 anchors were found, as indicated by Ala-
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substitution experiments. Both motifs consisted mainly of inhibitory residues, with the 
exception of a negatively charged anchor at residue at position 9. 
The tendency of HLA DQ ligands to be less dependent on the interaction of peptide side 
chains with the class II cleft than HLA DR ligands has recently been confinned by the 
determination of a quantitative matrix-based motif for DQAl*050lIDQBl*0301323• This 
motif revealed the ability of DQA 1 *050 IIDQB 1 *0301 molecules to bind peptide structures 
without the involvement of large peptide side chains. Based on this finding, it was possible 
to modify DR-selected peptide repertoires such that they loose the binding capacity for 
HLA DR molecules and bind exclusively to the DQAl *050l1DQB 1 *0301, thus 
demonstrating, at least in part, a complementary function of HLA DR and DQ isotypes in 
antigen presentation323• These differential binding capabilities between HLA DR and HLA 
DQ may maximize the diversity of peptide repertoires available for T cell recognition. This 
may result in an additive positive or negative effect on the immune response depending on 
an individual's HLA class II haplotype. 
Published data for the HLA DRB1*0101 and 0401 alleles were also used for motif 
prediction from HPV 16. Although a threshold of 20nM was arbitrarily chosen in this 
study to define peptides that bind with high affinity, it has been determined that an affinity 
threshold of 500nM determines the capacity of a peptide to elicit a CfL response in a series 
of HLA-A2 motif peptides evaluated in transgenic mice and in vitro recall responses in 
patients with acute hepatitis infection324• There is currently no available infonnation on the 
affinity threshold for HLA class II. Nevertheless, in most cases, ranking of peptides 
according to binding affinity for a particular HLA allele seems to correlate with their 
immunogenic potential. 
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The results include information on the binding affinity of the peptides (ICso) and show a 
number of interesting features. For the HPV 16 LI protein, ORBI*0101 is capable of 
binding twice as many peptides with high affinity (ICSO<20) than ORB 1 *0401 (Tables 
5.11 and 5.12). Even when these HLA molecules bind to the same set of peptides, the 
binding affinity to ORB 1*01 0 I is several orders of magnitude higher than for 
ORBI*0401. For example, HPVI6 L158.70: NIYYHAGTSRLLA binds ORBI*0101 
with an ICso of 1.5. The corresponding ICso for ORBI*0401 is 105 (almost lOO-fold 
difference). 
HLA ORB I *0101 is also capable of binding twice as many L2 peptides with high affinity 
(ICS0<20) than DRB1*0401 (Tables 5.13 and 5.14). The peptide L2240·252: 
PAFVTTPTKLITY that binds with the highest affinity to ORB1*0101 (ICsO=2.70), 
binds to ORB I *0401 with an ICso of 4900, a difference of over 4,OOO-fold. 
None of the HPVI6 E7 derived peptides is capable of binding to either HLA ORB I *0101 
or HLA ORB I *0401 with high affinity (i.e ICsO<20) (Tables 5.15 and 5.16). 
Nevertheless, the peptide that binds best to ORBI*OlOl, E,81·93: 
DLLMGTLGIVCPI (ICsO=45.20) does so at two orders of magnitude better than the 
peptide with the highest binding affinity to ORB 1 *0401 (E721·33: 
DLYCYEQLNDSSE; ICso=105.00). In addition, the ICso for E781-93 with respect 
to ORB 1 *0401 is 710, an almost 20-fold difference. 
Four HPV 16 E6 derived peptides are capable of binding with high affinity (ICs0<20) to 
lILA DRB1*0101 compared with none for lILA DRBI*0401. Peptide E659·71: 
IVYRDGNPY A vcn binds to ORB 1 *0101 with an ICso of 4.00. The corresponding 
ICso using the same peptide for ORB 1 *040 1 is 24.00, a six fold difference in binding 
affinity. 
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In conclusion, there are significant differences in both the number and binding affinity of 
HPV derived peptides to the susceptibility and protective HLA DQ and DR alleles. Since 
peptide binding to lILA molecules is an important step in the generation of effective 
immune response, these differences would likely account for the observations of HLA 
associations with HPV induced cervical carcinogenesis. In addition, lILA molecules 
influence the choice between Th 1 and Th2 response from CD4+ cells. A Th 1 response is 
required to provide an adequate response to intracellular pathogens such as viruses. If a 
particular HPV -derived peptide is presented in the context of a susceptibility allele, it could 
induce a Th2 response, and disease could progress or persist. Since CD4+ T lymphocytes 
playa central role in the complex immune network that leads to antigen-specific reactivity, 
future studies (discussed in chapter 6) should be directed at identifying HLA class II 
specific immunodominant epitopes from HPV that may be useful for the prevention and 
treatment of CIN and cervical cancer. 
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6.1 : SUMMARY 
The primary objective of this project was to examine the association between HLA-DQ and 
-DR alleles, the human papillomavirus and premalignant disease of the uterine cervix. This 
was accomplished by HPV and lILA DNA typing. The latter consisted of three phases. 
The first phase involved the development of a novel polymerase chain reaction-restriction 
fragment length polymorphism (artificial restriction fragment length polymorphism) for 
HLA DQB 1 *03 typing308. The results show a significant association between CIN and 
DQB 1*03 that is only slightly stronger for CIN III than CIN I. Homozygosity at the 
DQB 1*03 locus, was significantly associated with CIN and was more strongly related than 
heterozygosity, a result not reported so far in any previous studies. A significant 
association with HPV positive CIN and DQB 1*03 was found for all HPV types tested 
(16,18,31,33) and homozygosity at the DQB 1*03 locus was strongly associated with HPV 
positive CIN. 
The second phase consisted of polymerase chain reaction with sequence specific primers 
for lILA DQB 1 *03. The DQB 1 *0301 allele was shown to be most strongly associated 
with eIN and HPV, but 0302 was also positively related308• 
The third phase of HLA DNA typing involved polymerase chain reaction followed by 
sequence specific oligonucleotide hybridization with digoxigenin labeled probes using the 
11 th Histocompatibility Protocol with some modifications. This enabled the identification 
of susceptibility and protective lILA DQ-DR haplotypes in relation to human 
papillomavirus and premalignant disease of the cervix. The haplotype HLADRB 1 *0401-
DQB 1 *030 1 was shown to correlate with susceptibility to HPV and eIN while 
DRB 1 *0101-DQB 1 *0501 indicated protection325• 
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In an attempt to further understand HPV antigen processing events, the final phase of the 
project consisted of immunoaffinity purification of the susceptibility and protective lILA 
DQ molecules and sequencing of the naturally processed peptide sequences bound to these 
lILA molecules. The data obtained was used for motif prediction of HPV 16 E6, E7, Ll 
and L2 sequences that are probably capable of binding to these lILA molecules. Motif 
prediction as well as the binding affinity of predicted peptide motifs for lILA ORB 1 *0401 
and ORB 1 *0101, the DR alleles associated with susceptibility and protection respectively, 
was accomplished using published data on the naturally processed peptide sequences 
bound to these molecules. The data revealed significant differences in both the number and 
binding affinity of the HPV 16 derived peptides to the protective and susceptibility lILA 
molecules. 
6.2: DISCUSSION 
During the course of this project, a number of studies were published on the association 
between HLA class II and premalignant and malignant disease of the cervix. The purpose 
of this section is to discuss these studies including their merits and limitations. The results 
from these studies have been inconsistent, probably for the following reasons: 
i. Differences in sample size. 
ii. Difficulties in obtaining representative control groups. 
iii. Methodological differences in HLA typing (obviated by peR-based methods in more 
recent studies). 
iv. Lack of infonnation on HPV status of patients and controls in many studies. 
In a report from Norway, Helland and co-workers326-327 using polymerase chain reaction 
and a DNA hybridization technique, found that 67% of 213 patients with squamous cell 
carcinoma of the cervix carried the DQB I gene encoding HLA DQB 1 ·03 compared with 
51% of 118 controls ( RR=2.0, p<0.OO2 ). However, the report provided no infonnation 
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on the HPV status of the patients and controls. Another report328 on a population of 66 
Mrican American women with cervical cancer using a PCR based technique showed an 
increased risk with HLA DQBl*03 compared with 214 controls (RR 2.3, p= 0.004) and 
the risk was highest for lILA DQBl*0303 (RR 2.7, p= 0.017). Apple et al. 306 
examined a Hispanic population of 98 women with cervical cancer and 220 controls. 
Although no association between cervical carcinoma and HLA DQB 1 *03 alone was found, 
an increased risk of cervical cancer was found with the DRB 1 *0407 -DQB 1 *0302 
haplotype (OR 2.19, p=0.030). The highest risk in the study was with the lILA 
DRB 1 * 150 I-DQB I *0602 haplotype ( OR 2.87, p=0.005 ) and this increase was greater 
for HPV 16 positive cases relative to controls (OR 4.78, .95%CI 1.90-11.83; p=0.OOO07). 
The authors suggested that based on the co-occurrence of HPV 16 and DRB I * 1501-
DQB I *0602, the combined relative risk was 75. In addition, protective haplotypes were 
identified, all in the DR 13 group. These were DRB 1 * 130 I-DQB 1 *0603, DRB 1*1302-
DQBI *0604 and DRBI *1303-DQBI *0301. The DRB 1 * I 302-DQB I *0604 among HPV 
16 positive cases was found to be strong enough to be significant independently 
(p=0.048). Although the control population in the study had normal cervical smears, the 
study suffers from the drawback that the HPV status of the control group was not 
examined. It is well recognized that between 5 -50% of women with normal cervical 
cytology may have HPV infection, and of these up to 50% may harbour high risk or 
oncogenic HPV infection8S• 
Nawa et al329 examined the HLA DQBl frequency in 23 Japanese patients (age 23-35 
years) with invasive squamous cell carcinoma of the cervix using a PCR-RFLP technique. 
Twenty patients (87%) carried a DQB 1 gene encoding the HLA-DQB 1 *03 alleles, 
compared with 49.4% Japanese control subjects in the International Histocompatibility 
Workshop panel (p=0.0003). However, the correlation between DQB 1 *03 alleles and 
HPV infection was not statistically significant. The limitations of the study include the 
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small sample size, typing only for HPV 16 and 18, and the use of a control group that may 
not necessarily be comparable. By contrast, Amar et al330 investigated HLA class n in a 
population of 30 Jewish patients with invasive squamous cell carcinoma of the cervix and 
compared with 400 local healthy controls. The results showed no significant association of 
any of the HLA DQ alleles with cancer. 
A total of three other reports were published in 1996. Sastre-Garau et al331 performed 
PCR-SSO reverse dot blot for HLA DRB 1 typing and PCR-SSO for HLA DQ typing in a 
population of 126 French women with invasive squamous carcinoma of the cervix. 
Controls were 165 randomly selected individuals previously typed for HLA DR and OQ. 
The results showed a decreased frequency of the ORB 1 * 1301/02 alleles in patients (11 %) 
compared with controls (29%) (p=O.OOO4, OR=0.33) and the decrease was limited to HPV 
positive tumors. The haplotype DRB 1* 1301l02-DQA1*0103-DQB 1*0601 was also lower 
in patients (2%) than in controls (9%) (p=O.OOI, OR=0.25) and the decrease was again 
limited to the HPV positive tumours. Although the study used PCR-based strategies for 
lILA and HPV typing, the major drawback is the limited information on the control group, 
as they may not necessarily be comparable. 
In a Swedish study by Allen et al332, 150 patients with invasive squamous cell carcinoma 
of the cervix were examined using PCR-based Ill.A and HPV typing. The results were 
compared with data from a general Swedish population and showed the DRB 1 *0401-
OQB 1 *0302 haplotype to be positively associated with disease (p=O.05). 
In contrast to the results of the above studies, Glew et al333 reported no significant 
differences in HLA class II antigen frequencies in a group of 58 patients with squamous 
cell carcinoma of the cervix from Northwestern England. Further, the study showed no 
significant differences in the HLA antigen frequencies of patients with HPV 16 positive or 
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negative tumours. There were also no differences in antigen frequencies in relation to stage 
of disease. The control population in the study were 857 organ donors (347 males and 510 
females) from the same geographical area. The relatively small patient group in the study 
may reflect a type -1 statistical error rather than the true biologic pattern of disease. 
Furthermore, the patient and control population are not necessarily comparable as the HPV 
status of the control group was not known. In a more recent report from Northwestern 
England334 an HPV 16 oncogene variant leading to an amino acid change from arginine to 
glycine at position 10 from the E6 consensus start codon was identified in 32% ( 7 out of 
22 ) of lILA B7 - positive patients. The altered sequence was not found in lILA B7 -
negative individuals. Although the substitution could have a profound effect on the 
interaction of the epitope to HLA B7, binding studies showed that the variant peptide binds 
to lILA B7 in a similar manner to its wild type equivalent. However, computer modeling 
suggests that the alteration may affect the amino acid residues which are exposed for 
interaction with the T cell receptor. This raises the possibility that both the lILA type 
and/or presence of mutations in specific T cell epitopes of HPV oncoproteins act in concert 
to determine the risk of developing cervical carcinoma or progressing from low grade SIL 
to cancer. 
As cervical intraepitheliaJ neoplasia occurs at a stage prior to the development of cancer and 
is about 50 times as common, any HLA association identified will be important in 
establishing the role of immunological factors in the progression to invasive cervical 
cancer. Indeed it has been estimated that 20 - 30 % of CIN III progress to SCC in 5 - 10 
years 11. To date, five studies have specifically addressed this question. In a Belgian 
population, Vandenvelde et al303 using an lILA DQB 1 *03 allele-specific oligonucleotide 
(ASO) primed fast PCR technique, found a significant difference between normal women 
(174/323=0.539) and CIN I (18124=0.750, p=0.045) and CIN II patients (16/21=0.762, 
p=0.046) but not CIN III (15126=0.577, p=0.707). The data from the study suggest a 
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greater risk of high risk HPV associated dysplastic transformation of the normal cervix in 
DQB1*03 positive women (RR=2.647, p=0.022), but not a higher risk of malignant 
transformation (RR=I.168, p=0.707). This conclusion is slightly different from the results 
of another study by David et al335 from northwestern England which showed a higher risk 
of both dysplastic change as well as malignant transformation in lILA DQB 1 *03 positive 
women. Using the peR-SSO technique, the DQB 1 *03 frequency in 50 patients with CIN 
compared with 49 age-matched controls without abnormal cervical cytology were 40% in 
CIN m, 22% in CIN 1/11, 26% in cytology negative controls, and 21% in a local panel of 
blood donors (RR=2.5 for CIN III, p= 0.017). In another report by Apple et a1309, the 
frequency of distribution of lILA DR-DQ haplotypes among 128 Hispanic women with 
HPV 16 positive severe dysplasia was significantly different from a control population of 
220 women, whereas severe dysplasia containing HPV types other than HPV 16 did not 
reveal any significant differences. The study also showed that the DR-DQ haplotypes 
previously found306 to be associated with HPV 16 positive cervical carcinomas were also 
associated with HPV 16 positive severe dysplasia/CIS. 
In a Swedish study, Sanjeevi et al336 examined a population of 74 women with CIN and 
164 controls using PCR-SSO for HLA DQ typing, low resolution PCR-SSP for lILA DR 
typing, and serological typing for HPV 16 and 6. The results showed increased risk of 
CIN in patients with DQB 1 *0602 compared with controls (OR 2.23, p<O.O 1), and the 
association was stronger for HPV 16 seropositive patients (OR 3.37, P<0.05). In addition, 
DRB1*15 was associated with disease (OR 2.20; p<O.OI), stronger for HPV 16 
seropositive patients (OR 5.82, p<0.05). The DQAl *0501-DQB 1 *0301 was also found to 
be increased among HPV seronegative patients. The study suffers significant drawbacks 
because cervical cytology (not biopsy) was used to diagnose CIN in the majority of cases 
and only 2 HPV types were tested serologically. Furthermore, serum antibodies against 
HPV 16 are absent in a significant proportion of patients with CIN and cancer232, 
167 
Finally, Helland et al337, in a Norwegian population-based case-control study examined 91 
patients with histologically verified eIN grade II-III and 213 control subjects. The control 
population were randomly selected through the Central Population Register, and were 
without eIN at study entry. HPV typing was performed using PCR with general nested 
primers, followed by type specific primers for HPV 6, 11, 16, 18, 31, 33 and X. lILA 
DQAl and DQB 1 typing was performed using PCR-SSO. There were no differences in 
frequencies of the individual alleles when the cases were compared with controls. 
However, the haplotype DQA 1 *0 102-DQB 1 *0602 was increased in HPV positive cases 
(OR 3.2; p = 0.02) and this association was stronger for HPV 16 positive cases (OR 1 0.1, 
P = 0.01). It is unlikely that the discordance between th~ Norwegian and Swedish studies 
is due to genetic heterogeneity in liLA frequencies. and may reflect differences in HPV 
detection methodologies. 
In the present study t the patients and control groups have been well characterized. The 
diagnosis of eIN was made by histological examination of material from women with 
abnormal pap smears. The control population were drawn from women attending the same 
clinics and had negative cytology. Furthermore. the latter population were further 
characterized to be negative for HPV 16, 18, 31 and 33. Thus the study comprises 
important subsets for analysis namely: 
(i) HPY negative and eIN negative (controls). 
(ii) lIPY negative. eIN positive 
(iii) HPY positive, CIN positive. 
Analysis was performed for trend as well as for direct correlation. lILA DQB 1 *0301 and 
0302 correlated significantly with increased risk for both CIN and HPV positive CIN. 
DQB 1 ·0301 had the most significant association (O.R. 2.49; p<O.OOOO I). The DR alleles 
that correlated significantly with increased risk of eIN were the DR4 group (O.R. 1.76, 
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p<O.OOI) principally DRBI *0401 (O.R. 1.99, p=0.002); DRBI *0403 (O.R. 3.61; 
P=0.02) and DRBI*0406 (O.R. 3.74-@; p=0.0007). In addition, DRBI*llOl also 
correlated with increased susceptibility to eIN (O.R. 2.31, p=0.004). These alleles were 
also found to correlate significantly with eIN3 and HPV positive eIN. 
DRB 1 *0 101 and DRB I * 1301 were significantly associated with protection (O.R. 0.48 and 
0.67 respectively) for both HPV infection and CIN. The most significant DQBI allele 
associated with protection from HPV and eIN was DQB 1 *0501 (O.R. 0.48, P<0.005). 
Homozygosity at only the DQB 1 *0301 locus conferred an increased risk (O.R. 4.39, 
p<0.002). 
In addition, the two locus haplotypes DRBl*0401-DQBI*0301 (O.R.2.22,p<0.0l), 
DRB I *0401-DQB 1 *0302 (O.R. 1.90, p<0.05), DRB 1 *0403-DQB I *0302 (O.R. 4.34, 
p<O.OI) and DRB 1 * llOl-DQB 1 *0301 (O.R. 3.95, p<0.OO3) were significantly associated 
with HPV and eIN and indicated susceptibility. The haplotype which significantly 
correlated with protection from HPV positive CIN was DRB1*0101-DQBI*0501 (O.R. 
0.48, p<O.Ol). The significant protective and susceptibility alleles were analysed to 
examine for associations with individual HPV types. HPV 16 was present in 75 (57%) of 
cases, HPV 18 in 9 (7%), HPV31 in 17 (13%), HPV 33 in 9 (7%), and multiple HPV 
types were detected in 21(16%}. The best correlation was with HPV 16 and the susceptible 
haplotypes were DRB1*0401-DQB1*0301 (O.R. 2.63, p<0.02) and DRB1*1l01-
DQBI*0301 (O.R 5.80, p<O.OOI). There was a weak positive correlation with 
DRB1*1101-DQB1*0301 and HPV 31 (O.R. 6.44, p<0.05). The haplotype which 
conferred a protective effect did not show any significant correlation with any of the HPV 
types. 
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Of interest, the studies in which HLA class I frequencies were determined by serological 
typing in cervical cancer and controls showed an increase in HLA B 12 and HLA B7333.255 
while there was a negative association with HLA B35. HLA B 12 is known to be in linkage 
disequilibrium with DRB1*0401-DQB1*0301286 suggesting that the observed increase in 
HLA B 12 may be due to linkage disequilibrium rather than an independent effect. The 
negative association with HLA B35 may likewise be due linkage disequilibrium with 
DRBI *OlOl-DQBl *0501286, which was found to be important in the present study. 
The natural history of CIN has shown that the majority of low grade lesions regress 
spontaneously. The plurality of HPV types associated with low grade lesions is greater 
than that observed in high grade lesions or in invasive cancer, suggesting the existence of 
HPV-type specific regression mechanisms. Taken together, the evidence from this and 
other studies indicate that genetic factors are involved in the control of HPV -induced 
tumors. Although a familial trend has not been reported in cervical cancer, a familial 
aggregation has been reported in about 10% of cases of epidermodysplasia verruciformis, a 
disease characterized by a high susceptibility to cutaneous HPV338. The study of 
immunogenetic mechanisms controlling the regression or the development of genital 
neoplasia should shed light on mechanisms involved in the progression or regression of 
HPV -associated tumors. 
6.3 MECHANISMS OF HLA CLASS II ASSOCIATION \VITH HPV AND 
CIN 
The significance of lILA association with cervical cancer is supported by data on the 
analysis of HLA class I and II using restriction fragment length polymorphisms in New 
Zealand rabbits infected with Shope cotton-tail rabbit papillomavirus, which showed a 
strong linkage between wart regressions and DR locus, and an increased risk of malignant 
transformation with the DQ locus305• A number of diseases have been associated with the 
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DQB 1 *03 group of alleles. These include autoimmune disorders as well as malignancies. 
The fo~er group include the lupus-anticoagulant response339, vitilig0340, ocular cicatricial 
phemphigoid341, and the herpes-associated form of erythema multiforme342. Malignant 
diseases associated with HLA DQB 1 *030 1 include malignant melanoma261 , adult T-cell 
leukemia, T -cell lymphoma, human T -cell leukemia virus type 1 carrier state343 and gastric 
adenocarcinoma344. 
There are at least three possible ways by which the association between DQB 1 *03 and 
HPV positive disease may be explained. Firstly, these women may present peptide antigen 
to CD4+ T cells ineffectively; secondly there may be clonal deletion of antigen specific T 
cell during thymic maturation may occur; or thirdly there may be active suppression of 
immune response to HPV in DQB 1 *03 positive women. Indeed, there is a high level of 
expression of HLA DQ in the thymic cortex345 and a role for negative selection for HPV 
specific T cell clones would fit predisposition to HPV positive eIN by the DQB 1 *03 
alleles. 
The other possible mechanism is based on observations of HLA associated immunological 
low responsiveness to antigens such as streptococcal cell wa1l346, schistosoma347, 
mycobaterium leprae348, tetanus toxoid349 and hepatitis surface antigen350 either after 
natural exposure or after vaccination. Despite the controversy regarding the function of 
suppressor T cells, there is evidence to suggest that HLA DQ maybe the preferred 
restriction element for immunological suppression mediated by CD8+ T suppressor 
cells351-352. It is possible that women who are positive for the DQB 1 *03 phenotype 
maybe unable to mount an effective cytotoxic T cell response against HPV infection. This 
is particularly important as it has been shown that HPV16 E7 is a target for cytotoxic T 
cells and to mediate tumour rejection307. 
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There are several lines of evidence that cloned T suppressor (Ts) cells express conventional 
a. and B genes353-354. These clones respond to peptides presented in the context of MHC 
class I or II molecules. There are a number of ways by which this class of T cells can 
suppress immune responses in an antigen-specific manner. The first mechanism involves 
soluble antigen specific factors. These factors are comprised, at least in part, of some form 
ofTCR 0.- andlor B chains355. A second mechanism of suppression is cytotoxicity, which 
requires specific recognition of antigen-MHC complexes and is achieved by specific (cell 
mediated) or non-specific (cytokine-mediated) means. For example, it has been shown that 
CD8+ T cells can kill a CD4+ T cell line that mediates experimental autoimmune 
encephalomyelitis and neutralize their ability to mediate disease in vivo356, and a Ts clone 
that kills T helper (Th) cells has been described357. Specific suppression could be achieved 
by killing T cells bearing cIonally distributed TCRs (via recognition of TCR-peptide-MHC 
complexes). 
In the case of HLA DR associations with HPV infection this may be due to polymorphisms 
in the second exon of the molecule. For example , position 86 of the p chain is dimorphic 
and the amino acids glycine (Gly) and valine (Val) are found at this position. The functional 
significance of the GlyNal dimorphism at this position has been explained by the resolution 
of the tertiary structure of HLA DRB 1 *0101. p86 contributes to the formation of the 
'hydrophobic' pocket and its substitution by valine restricts the size of the peptide side 
chain which can bind to HLA DRB 1 *0101 and therefore the peptide which can bind to the 
T cell receptor. A possible explanation for the protective effect of HLA DRB 1 *0101 in this 
study is that an immunodominant HPV epitope might contain a large hydrophobic side 
chain (Trp, Tyr, Phe, Leu, lIeu) as a major anchor in the p86 Gly pocket and this epitope 
binds with high affinity to DRB 1 *0101. 
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6.4 POLYMORPHIC STRUCTURAL FEATURES OF HLA-DQ 
MOLECULES ASSOCIATED WITH SUSCEPTIBILITY OR RESISTANCE 
TO HPV ASSOCIATED CIN 
An attractive hypothesis for the molecular basis of the association between HLA DQ and 
HPV associated CIN may be based on the results of motif analysis in chapter 5: HPV 
epitopes bind with higher affinity to the resistant than to susceptible DQ molecules, leading 
to a more effective elimination of the virus. Although this hypothesis is not contrary to 
current immunological paradigms, very little is known about the function of DQ molecules. 
They are only constitutively present on a subfraction of antigen-presenting cells, and at 
much lower density than DR molecules358. However, their expression on APCs can be 
induced by gamma interferon359, and infectious agents such as Epstein Barr Virus360 and 
Human Papillomavirus361. It has been postulated that DQ molecules exercise epistatic 
action over DR molecules362 and that they are the mediators of immunosuppression351. 
In order to examine this hypothesis of differential binding to susceptibility and protective 
alleles, a model of the structure of lILA DQ molecules based on the HLA DRI structure 
can be inferred363. This model suggests that they possess the mould of a class II 
histocompatibility molecule with an antigen-binding groove in the alp 1 domain that is 
bounded by a "floor" of eight p-sheets and two "walls" of antiparaJlel a-helices. There is 
an a2p2 domain that contains the homodimerisation region, the CD4-binding area and the 
Arg-Gly-Asp loop. This domain and the alp 1 domain dimerise in some alleles with their 
counterparts in an identical DQ molecule forming a h<?modimer of aB heterodimers. 
The polar residues lining the antigen binding groove of DRl and participating in hydrogen 
bonding with antigenic peptide are located in exactly the same positions in modeled 
molecules164-165, with nearly identical orientations348. Within the binding groove are five 
pockets which can trap specific residues of antigenic peptides. The first pocket of ~ 
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molecules (formed by aIO, 27, 34, 35, 46 and P85, 86, 89 and 90) is either amphiphilic or 
hydrophilic, as judged from the amino acids that line-up this formation. The hydrophilic 
variant of this pocket appears shallower, because of the presence of bulky residues in P85, 
86 and 89 (Leu, Glu and Thr instead of Val, Ala, and Gly respectively for the amphiphilic 
variant). The character of the first pocket is also modified by residue a34 (GIu or GIn). 
Thus, the HLA DQB 1 *0501, which is protective for HPV associated CIN in this study has 
valine, alanine and glycine in the ~85, 86 and 89 positions respectively and is therefore 
amphiphilic. By contrast, the susceptibility alleles HLA DQBl *0301,0302 and 0303 have 
leucine, glutamate and threonine in the same positions and are therefore hydrophilic. 
The second lILA DQ pocket appears to be the most prominent or anchoring pocket. This is 
probably due to the presence of small residues in position a9 and p 13 of DQ molecules in 
contrast to the bulky glutamine or phenylalanine respectively in DR!. There is extensive 
polymorphism in the four residues from the PI helix of this pocket (70, 71, 74 and 78). In 
the case of lILA DQB I *050 I, which correlates with resistance to HPV associated CIN, 
these residues consist of glycine, alanine, serine and valine respectively. All the DQB I *03 
susceptibility alleles have arginine, threonine, glutamate and valine in these positions and 
the size of these residues may restrict peptide binding to an immunodominant HPV epitope. 
The presence of aspartate in p57 which is part of the fifth pocket is a major determinant of 
peptide affinity318. This residue consists of valine in HLA DQB 1 *0501. HLA-
DQB 1 *0302 and DQB 1 *0303 differ only in Ala to Asp polymorphism at codon 57, 
whereas DQBl *0301 encodes Asp 57 and three additional polymorphisms at positions 13, 
26, and 45. The aspartic acid residue on DQBl *0301 and 0303 likely interacts with an 
arginine at residue 79 of the DQAl chain to form a salt bridge by analogy with a similar 
structure of HLA-DRI165. Although an influence of this potential salt bridge has been 
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suggested322,364, it does not appear to significantly influence the HLA-DQ3 association 
with HPV infection and CIN since all three alleles result in increased risk of disease. 
There are important differences in the ~49-56 dimerisation patch164 of all the HPV 
associated susceptible DQ molecules when compared with the patch of the DQB 1 *0501 
resistant molecule. In the DR molecule, there is a monomorphic dimerisation patch, with 
dimerisation probably promoted after T cell receptor binding164, by symmetrical salt 
bridges between ~52Glu of one heterodimer and ~55Arg of the opposite heterodimer. By 
contrast DQ alleles are polymorphic in this region leading to ~9-56 sequences that may be 
very hydrophobic, amphiphilic or hydrophilic. The alleles DQB 1 *0301, 0302 and 0303 
have a hydrophilic patch. On the other hand, the protective DQBl *0501 allele is 
amphiphilic. It contains an arginine at position 55, and glutamine in position 53 and proline 
at position 56, right opposite each other at the first turn of the ~1 helix. The relative ease of 
homodimerisation by the protective DQBl *0501 molecule means that in case any cognate 
T-ceII clones exist in the periphery, their activation upon recognition of this protective IQ 
molecule complexed with an HPV peptide would be easy. By contrast, susceptible IQ 
molecules will form homodimers with more difficulty leading to less effective activation of 
cognate T-cell clones. In the case of the a2~2 homodimerisation domain, it involves a large 
surface area of the DQ molecule and the dimerisation is stabilized by multiple interactions 
involving charged and hydrophobic residues164,363. There appears to be no difference 
between susceptible and protective DQ molecules in this domain. 
The CD4 binding area is formed by the homodimerisation of DQ molecules (~2 of one IQ 
heterodimer to a2 of another DQ heterodimer), and has been shown in DR to be composed 
of the sequence P134-148 and several residues on the alpha chain apposed to this 
sequence. Of the residues shown to be critical for CD4 binding to HLA DRP, by site 
directed mutagenesis (P137Glu, 142Val, 143Val)365, all remain invariant in the DQB 
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alleles suggesting that this region of the DQ molecule is unlikely to be important in 
determining susceptibility or resistance to HPV. 
The Arg-Gly-Asp loop on 8167-169, present in the protective allele, HLA DQB 1 *0501, is 
absent in HLA DQB 1 *030 1 where p 167 is histidine. The exact function of this RGD loop 
in DQ molecules is unknown but probably functions in cell adhesion as in other integral 
membrane proteins and proteins of the extracellular matrix involved in such function366-
367, and may be important in the DQ restricted T-cell clone activation. 
A scheme where the three structural features of the DQ molecules segregate in the two 
phenotypes of susceptible and protective HLA-DQB alleles that confer susceptibility or 
protection to HPV -associated CIN is shown in table 6.1. The difference in the 
physicochemical properties of the antigen-binding groove of susceptibility and protective 
DQ alleles would translate into different affinities for an "immunodominant" epitope in 
HPV. Such differences would certainly playa role both in the ontogenesis of the immune 
system and in the mounting of a specific DQ restricted immune response in the mature 
organism. Indeed, the human embryonic thymus is very rich in DQ molecules that probably 
function as restriction elements368. Therefore, the CD4+ T-cell clones recognizing the 
combination of susceptible DQ molecules with its bound peptide epitope would be 
eliminated. In the periphery, the susceptible DQ molecules expressed under proper 
stimulation on antigen presenting cells could bind to HPV derived peptide(s) and present 
such complexes to cognate CD4+ T cells. The ensuing immune reaction may be insufficient 
for viral clearance. 
The dominant effect of the protective DQ molecule in the periphery could be exercised in 
the same manner. The differences in the physicochemical character of the antigen-binding 
groove assures preferential peptide binding. The difficulty of dimerization by the 
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susceptibility molecules ensures that even though the peptide has been trapped, the 
activation of cognate T-cell clones that might have escaped elimination in the thymus would 
be very difficult. 
It is to be noted that in offering an explanation for the involvement of HLA DQ molecules 
in the susceptibility to HPV -associated CIN based on HLA structural features, account is 
not taken of the polymorphisms of DQ molecules in the intracellular amino acid sequences 
that participate in signal transduction369, or the possible differences in the level of 
expression of various DQ alleles. Also, a number of regulatory sequences have significant 
effects on DQB genes370 and their possible role in the HPV induced cervical carcinogenesis 
is unknown. 
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Domain Features Character DQBl*03 DQBl*OSOl 
(Susceptible) (Protective) 
(Xl~l Antigen binding groove Polymorphic 
First residue binding pocket Dimorphic, hydrophilic, 
amphiphilic Hydrophilic Amphiphilic 
Residue at ~57 Polymorphic 0301 Asp, 0302 Valine 
Ala, 0303 Asp 
1349-55 dimerisation patch Polymorphic, very hydrophilic, Amphiphilic 
amphiphilic hydrophilic 
(X2~2 CD4 binding region No discernible 
differences 
~167-169 RGD loop Probably involved in cell Absent in 0301 Present 
adhesion I 
Table 6.1: Summary of the structural features of HLA DQB 1 *03 and HLA DQB 1 *0501. 
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6.5 CLINICAL IMPLICATIONS 
DEVELOPMENT 
HLA TYPING AND VACCINE 
This study raises the question as to whether women infected with HPV will benefit from 
HLA typing to predict disease susceptibility andlor severity. At the present, there is no data 
to suggest that information on HLA type will alter current clinical practice. However, the 
information would be useful in a research setting in screening programmes, evaluation of 
treatment outcome ( surgery, radiation therapy, and chemotherapy), on-going vaccination 
trials as well in the design of novel immunomodulatory strategies for the prevention and 
treatment of HPV associated cervical cancer. 
Screening with the Papanicolaou smear remains the best available method of reducing the 
incidence and mortality of invasive cervical cancer. There are large numbers of women with 
Papanicolaou smears showing squamous intraepithelial lesions (SIL) each year. Only a 
minority of these women will progress to invasive cancer, and it would be advantageous to 
develop predictive markers to identify those women. The need for predictive markers is 
even more important in the category of patients with atypical squamous cells of 
undetermined significance (ASCUS), atypical glandular cells of undetermined significance 
(AGUS) and low-grade SIL (LGSIL), lesions that are usually managed expectantly. 
However, Cox et aI371 , Wright et a1372 and Kinney et al373 reported that 6.9%, 6.1 % and 
7.3% of women with ASCUS cytology, respectively harboured histologic high-grade SIL 
(HGSIL). Attempts to improve the triage of these women with HPV typing assays have 
yielded conflicting results. The addition of HLA class II typing may allow "low-risk" 
women (with ASCUS, AGUS, LGSIL or HGSIL) to avoid costly and potentially morbid 
diagnostic and therapeutic procedures. Further, women in the different categories could be 
followed longitudinally over several years to determine the effects of HLA type on the 
natural history of disease. 
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Another major clinical impact of this study is likely to be in the area of vaccine design for 
HPV associated CIN and cervical cancer. The rationale for the use of HPV epitopic 
determinants as prophylactic and therapeutic cancer vaccines is supported by the following: 
i. In a recent study utilizing the sorting signal of the lysosomal-associated membrane 
protein-l (LAMP-I) to reroute HPV 16-E7 into the MHC class II processing pathway, 
there was enhanced presentation to CD4+ cells, greater E7 specific lymphoproliferative 
activity, antibody titres, and CTL activity374. 
ii.Using the LAMP-l / HPV E-7 chimera expressed in a recombinant vaccinia virus, Lin et 
al375 showed that 80% of vaccinated mice remained tumour free 3 months after injection 
compared to progressive tumour growth in all wild type E7 injected mice. Further, 
vaccination cured mice with small established tumours, whereas the wild type E7 vaccinia 
showed no effect on established tumour. 
iii. It has been recognized that in the case of other tumours, especially human melanoma, 
systemic administration of melanoma-associated antigens (MAA) derived peptides can elicit 
anti-tumor CTL activity in_viv0376-377. 
As an increasing number of HPV 16 and 18 epitopes are reported, the practical question to 
be raised is which, given limited resources, should be given priority for clinical trials. The 
identification within the context of a specific HLA restriction element of the 
immunorelevant antigen among the repertoire of several possible HPV peptide molecules 
may allow a more focused selection of the most appropriate target antigen for vaccination. 
The HPV peptide epitopes identified in this study (chapter 5) as probably being capable of 
binding with high affinity to both susceptibility and protective alleles may be utilized in in-
vitro and in-vivo vaccine design experiments using the LAMP-l sorting signal to route the 
peptides into the HLA class II pathway. 
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The processing of endogenous HPV proteins for class II restricted presentation is of 
considerable practical interest because it allows direct recognition of HPV infected cells by 
CD4+ cells. Although CD4+CD8- T cells are often referred to as belonging to the 
helper/inducer subset, this population is heterogeneous in terms of their effector functions 
such as lymphokine production and secretion or cytolysis. In humans, CD4+ cytotoxic T 
cells have been described as an effector population in a variety of viral infections including 
EBV378, hepatitis B 379 and herpes simplex380. Furthermore, CD4+ T cells have been 
shown to be critical in generating immune responses against several solid malignancies in 
murine381-382 and human systems 383-384. Given that an appropriate peptide epitope in 
association with HLA molecules might be expressed on the surface of infected cells, lysis 
of these cells by CD4+ cytotoxic T cells is likely to be an important mechanism for the 
protection against persistent HPV infection. 
The advantages of peptide vaccines include stability, ease of preparation, transportation, 
and injection; and they do not pose the biological risks that may occur with the use of intact 
proteins. The potential disadvantages include the requirement for knowledge of the epitopic 
determinant for each HLA allele, the potential limitation of the targeting of only one 
restriction element among several expressed by a given tumour, and dependence for 
immunogenicity on the stability of the peptideIHLA complex385. Although the use of 
peptide mixtures that will bind to several class I alleles may overcome some of these 
problems, the immunogenicity of these mixtures will need to be determined. Since MHC 
class II peptide binding exhibit allele specificity as well as promiscuity, knowledge from 
studies of class II association with HPV infection should lay the framework for the 
development of "promiscuous" immunogenic peptides that would be presented via the class 
II pathway. 
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Vaccination trials in mice and rats have clearly demonstrated the feasibility of inducing 
immunity that can protect against the growth of HPV 16 containing tumours. A number of 
immunization approaches have been used with varying degrees of success. It was shown 
that immunization of C3H1HeN mice with syngeneic fibroblasts transfected with HPV 16 
E7 gene conferred protection against E7 transfected syngeneic tumour cells307. Similarly, 
immunization of mice with HPV 16 gene transfected fibroblasts induced regression of 
transplanted tumours expressing E6386• Populations of CfL isolated from the spleens of 
mice which rejected the tumour challenge were shown to specifically lyse E6 expressing 
target cells in vitro. Meneguzzi et al387 used recombinant vaccinia virus expressing E6 or 
E7 to immunize rats which were then challenged with cells co-transformed with HPV 16 
and Ras. The study showed tumour development to be delayed or prevented in immunized 
rats. Vaccines based on recombinant live virus have the advantage of physiologic antigen 
delivery and is not HLA haplotype dependent since different HLA alleles will select 
different peptides from the naturally processed peptide pool. The major disadvantage is 
safety concern but this may be obviated by designing vaccines with non transforming 
mutant variants without compromising the immunogenicity of the parent protein. 
In another approach, synthetic peptides corresponding to residues 49-57 of the E7 protein 
were used to immunize C57BU6 mice and they showed complete or partial protection 
against tumour formation by transformed cells containing HPV 16 and Ras388. The 
immunogenicity of HPV 16 E6 and E7 proteins were analyzed extensively by Kast et a1389• 
A set of 240 nonamer peptides derived from E6 and E7 were synthesized and tested for 
binding to several of the most common HLA-A alleles. From these studies, a number of 
high affinity binding peptides were determined and the immunogenicity of these peptides 
was tested in vivo by immunization of HLA-A2.1 + transgenic mice and in vitro by 
stimulation of CTLs from normal HLA-A2.1 + human peripheral blood lymphocytes 390. 
Four high-affinity binding peptides were immunogenic in the transgenic mice and three of 
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these peptides were also immunogenic to crLs from normal donors. Human HLA-2.I-
restricted CfL clones specific for these peptides were able to recognize and lyse peptide-
pulsed targets as well as HLA-A2.1+ cervical carcinoma cell line CaSki that expresses the 
HPV-16 E6 and E7 genes. These results suggest that these peptides are naturally processed 
T cell epitopes of HPV -16 and may act as cervical carcinoma tumour antigens. 
There are at least six human papillomavirus vaccine trials that have been initiated worldwide 
in the past 12 months. Although the growing number of HPV vaccine trials has raised 
hopes for the future of vaccine therapy in cervical cancer, differences among the trials make 
the details of that future still far from clear. All of the trials are small phase I or phase IIII 
studies, and are all testing vaccines against HPV 16 and 18. There is however an array of 
different vaccine formulations and a variety of patients, as seen in the following summary 
of the studies: 
1. National Cancer Institute (NCI) phase I trial of HPV 16 E7 lipopeptide vaccine for 
recurrent or refractory cervical cancer. In this study, a vaccine consisting of a lipidated 
HPV E7 peptide epitope (Cytel Corporation, San Diego) linked to a nonspecific helper 
peptide (PADRE) is used in HLA-2 and HPV 16-positive patients with recurrent or 
refractory cancer. 
2. NCI phase II pilot study of HPV 16 E6 and E7 peptide vaccines for advanced or 
recurrent cervical cancer. The trial involves the use of antigen-presenting cells pulsed with 
synthetic peptide corresponding to the tumour's HPV 16 E6 or E7. 
3. Multicenter European trial using a vaccine as an adjunct to surgery and radiation therapy 
in women with early stage invasive disease. 
4. Two HPV vaccine trials, one at the University of Wales in Cardiff and the other at the 
Norris Cancer Center of the University of Southern California, Los Angeles - will give 
HPV vaccines to women with high grade preinvasive lesions (CIN2/3). 
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In the future, the development of a prophylactic or therapeutic vaccine for cervical cancer 
may offer an attractive and cost-effective immunologic approach to reduce the need for 
expensive screening and surveillance prevention programs and substantially decrease the 
worldwide morbidity from this disease. 
6.6 CONCLUSIONS 
Genetic variation at the HLA loci accounts for differences in immune recognition between 
individuals and similarly underlies differences in disease susceptibility to HPV associated 
CIN. One of the important functional consequences of this genetic variation is the 
generation of distinct patterns of peptide recognition and antigen presentation. 
Understanding the structural basis for these functional properties of specific HLA 
molecules is helping to unravel the peptide-binding properties that are inherent to each 
distinct allele. In studying HLA class II genes with HPV associated CIN, these peptide-
specific interactions presumably form the basis for genetically regulated events in immune 
activation and disease. 
There is compelling evidence to suggest that the lILA class II type is important in 
determining the risk of HPV infection and progression to CIN and cancer. Taken together, 
the most consistent finding in several studies is the increased risk of HPV infection, CIN 
and cancer in individuals with lILA DQB 1 *03. A number of other HLA class II al1eles 
have been shown to correlate with susceptibility or protection in different populations. It is 
possible that differences in results are either due to variations in methodologies employed in 
the different studies or different patterns of linkage disequilibria with the disease 
susceptibility gene in different populations. Difficulties of single mechanisms to· explain 
HLA association with HPV and cervical cancer is to be expected, since the development of 
cancer is a complex process influenced by many factors, environmental and genetic. 
Nevertheless, all these studies should add a new insight into the development of 
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immunomodulatory strategies for the prevention and treatment of cervical cancer. Several 
vaccination approaches against HPV infection are currently being evaluated and it is 
expected that further refinements in vaccine design and delivery will be made based on 
rapidly emerging information on the role of lILA class II in HPV infection. 
6.7 FUTURE STUDIES 
6.7.1 liLA ASSOCIATION STUDIES 
While ethnic variations in HLA haplotype frequencies may explain the differences between 
the Mexican-American and African-American patient cohorts on the one hand, and the 
European patient cohorts on the other, the heterogeneity on HLA frequencies among the 
North European populations is hardly sufficient to explain the observed differences in 
association reported for English, German, Norwegian and Swedish patients. The 
differences may really be due to statistical error or heterogeneity in an as yet undetermined 
genetic or environmental fashion, including the HPV genome. The former possibility can 
be addressed by replicating the analysis in an unrelated set of patients. 
The possible susceptibility and protective haplotypes identified in this study need to be 
confirmed in a larger sample size especially if relations to specific HPV types are to be 
determined. Additional studies on patients with invasive cervical cancer are also needed to 
determine the contribution of lILA class II alleles in progression to invasive cancer. A 
complete lILA class I typing of cases with eIN will allow the identification of the complete 
haplotype and also determine the contribution of individual alleles towards susceptibility 
and protection. 
6.7.2 ASSOCIATION WITH HLA RELATED GENES AND P53 
Differences in the distribution of HLA class II genes observed after a comparison of 
patients and controls may suggest that the immune response to HPV may be determined, at 
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least in part, by specific class II alleles. However, these differences could be related to a 
linkage disequilibrium with other MHC-related genes such as T AP-I, the TNFa gene 
promoter, or antigen processing regulator genes. Furthermore, recently, it was shown that 
patients with HPV associated tumors have an overrepresentation of homozygous arginine-
72p53 compared with the normal population391 . This finding will need to be confirmed in 
larger populations and in different geographic regions to determine the combined roles of 
lILA and p53 polymorphisms on HPV associated cervical carcinogenesis. 
6.7.3 IMMUNODOMINANCE AND ANTIGEN PRESENTATION 
The ability of the immune system to direct T-cell responses against a select number of 
peptides is termed immunodominance392• Epitopes that trigger potent T-cell activation and 
proliferation are classified as immunodominant. By contrast, epitopes that are poor 
activators of cellular immune response are termed subdominant, whereas those peptides 
that fail to elicit any response are cryptic. These terms indicate that there may be a 
discrepancy between the number of peptides within an antigenic protein that could be 
predicted to potentially bind to a particular lILA molecule and the number of epitopes 
actually recognized in a CTL response to that protein. The. molecular events that control 
immunodominance appear to be complex with both APC and T cells regulating the process. 
Since the binding affinity of naturally processed peptides for class II proteins plays a 
significant role in influencing the heirachy of epitopes displayed to T cells392, in-vitro 
studies of the binding affinity of predicted motifs of L 1, L2, E6 and E7 may be used to 
select a library of peptides for evaluation of CTLs from normal human peripheral blood 
lymphocytes. In addition, the peptides could be tested in vivo by immunization of HLA 
DQ and DR transgenic mice. 
186 
6.7.4 VACCINATION TRIALS 
The expression of HPV E6 and E7 genes is constitutive in cervical tumors and required for 
the maintenance of the transformed state. Because of their continued expression in tumor 
cells, the E6 and E7 proteins are promising targets for immune intervention. 
Immunodominant epitopes from E6 and E7 identified as above (6.7.3) could be used in 
clinical trials for the treatment of HPV associated cervical cancer. On the other hand, 
immunodominant epitopes from LI and L2 could be used in the clinical trials for prevention 
and treatment ofHPV associated CIN. In this way, HPV vaccine design will be based on a 
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2 MP,OO' CIN, 331 0303/060' 03011'30' 030110202 0 _. 0 __ . __ o1. _ _. ~__ 003031130,.. _. ;0~0-'/030': 030'11301lB3-030' _ 0601l0301lB3'0202 
3 MP,oa CIN' 3,H 020110302 030110404 '0'0' 0R53 0 .J!j 0 02011030' lf302/0404 10201l030IlB3'O'O' 0302/o604/B4'0,0, 21 
4 MP1122 CIN3 18H 0303/0503' 13011'40' '0'0' a 0 _._ ~(~= =-. -_._ 0103031130' _. ~ 0_50_H!UO'030311301lB3'0,O' . _~._ 050311'301183'0'0' 
5 MP1138 CIN' N_tlve 020110603 03011'30' '0'0' a 0 0 0 02011030' 06031130' 0201lo301lB3'O'O' 060311301lB3'0,0, 
'MP1152 CIN, N_,lve 02011060' 03011'50' '020' a -0'0' ---.~ -.-.-.... 0 02011030' ·=~_Q.!1150' 0201l0301lB3'020' 080'11501185'0'0' 
-----
7 MP117' CIN, 33H 02011020' 03011030' '0'0' a 0 02011030' 02011030' 02011030' 02011030' 020110301183-0'0' 0201l0301lB3'0'0' 
I MP'22' CIN, '81 040110602 00011'502 0 DR53 '0'0' O' 000011000'" 060211502" 040110401184'0'0'2 060211502/B5'0'01 
• MP'230 CIN3 '6H 030110601 '5011'20' '0202 0 '020112 0 ~.- -. 0 06011'50'" --~~1I'20' 0601l'501lB5"020' 21 030111201lB3'0202 
'0 MP'236 CIN3 16H 02011050' 03011OR,0 '0'01 0 0 0 0020110301 050111001 0201l0301lB3'0101 05011100110 
II MPI237 ClNI II6I.a'H:pH 030UD605 04011OR7.0 0R53 0 0, _ 0 03~,10001 0605/0701(2l' __ 0301l0401l84'Q101[2l 0605/0701(2l/B4'0101(2' 
030110801" 03011080110 03011010110 
0302/0401 0601l1501lB5'0201 2 0302/0401184'0101 2 
0302/0404 020110301183'0202 0302/0404104'0101 (2L 
I 5 010201/030, 010211 502" 060211502/85'0102 
II 01010311101" 030110401 0301l0401lB4'010112 
17 MP1460 lCttn 181 020110804 030 111302 '010' 0 oT 06041'302 020110301183'010' 080411302/83'0'0" 
...1.1 MP1480 CIN3 31H 02011010, 03011,50' '0101 a 020112 0 08011150'" 0201l0301lB3'0'01 0801l,501lB5'020, 2 • 
,. MP'S05 CIN' N_tive 020110402 01011030' '0'0' a 0 01 00402/010'" 02011030' 0402/080110 020110301183'0'0' 
~ MP1621 CIN3 N_'lve 020110801 030111501 '0'0' 0 '020112 J!.).. 01020110301 06011150'" 0201l030IlB3'0'0' 0601l,501lB5'0201 
~, MPue 'C1N3 ,6H 030110303 0'031OR8 0 0 0 0, -.--.-- ~O'03" ~303/080'" 030110103/0 0303/080110' 
...ll MPm ~- 'SH 3,H 33H 020110302 030110402 '0202 0R53 --IQ--::--I---___ ._ ..::..0~._.·.::.:~:::010201l0301-.-~~-cii.t~.-02. ~_~ 0201l03I?'i,B3-;;)202--- 0302/0402IB4'0'0' 
~3 MP200 \C1N3 'ISH 3,H '030110302 040110404 DR53 J!L.. ~ 0' 0103011000' 10302/0404 . 0301l040IlB4'0,0' 2 0302/0404lB4'0,0,2 
24 MP20' _d. ,ClNI '31H 1020110302 o404IOR7 '0 0R53 _+L~::- . ..1 ___ . .. - -- Cit--- -_ 0\0302/0404 . ·.-:-t~20Jl9!9il2L_J2iiij04~~-:'!.7~!L _ 0202/070'2 /B4'010' 
25 MP230 _ ~ ~_ 03011060' 0'071OR7 10 .. _ .•. _~~ ____ +'1 ______ -4 __ .. _.. 0: .. lhQ~_0..!!0407~ _ OIO-'/()~!9-'j~)' __ 10301l0~07/BO"0~~1 060110701 2 /B4'0'0' 
~ ~247 iC1N3 116Hl0302/0503, 04011140' '0'0' '0 '0" l 0 O~/O'O' 0503111401 -f0302/0001l0' 0503111401lB3'010, 
Li7 "'P2S3- -. \CIN' _=.~ ~01l0301 11011110' ...:llQL_..;i __ ~~':_~-li- -_.-.::-.... --+i!Q.T~~o·, :11O.!!O.~Q': _ ~ ~01l0301--.' +,':,0"9i01-:~~~ iIOl/i301i83;020f~ __ 1101l0301lB3'0202 
~~~5 ~ ~'i.. 10302/030, 040311303 i'0202 iOR53 .J!I. -t 0' 00302/0403 .030111303 10302/0403/BO"010, 2 030111303/83'0202 ~~!'262-'- :ClNI -- -· . ..lli..._'i.. '0303/0604 13011130' '01011030' 10R53'-~._~'._JL_:. ::--..::.. 0303/1jo':,-.: :~:0~(14'-;3Jl) __ = ·.10303/lln-:.= .-:J.i!.60.i'301·::,-=,=--=- 0303/!i~l.{!1L'~~ 060.11301lB3·0101 
30 MP306 jCIN' 133H '020110501 0~7/0'0' 10 10R53-.. ~ __ ._-=== ___ ......J!i __ .. _.91020110701(~L _to_5~ti.CV.!!1 u_ 020ILQIQ!i~ /84'010' 2 050110'0110 
3' MP320C1N3 161 02011030' 030ll040'-l.:.Q!.l!.!0R53 ___ 10 _.. ~ __ . ____ .. _. (1, __ _ ___ ._Oi0201l0~' _._ .. ..J!!3~0-'!~0..!. . _ 0201l0.30IlB1:010' _ 0301l040IlB"0'01 2 
32 MP352. ~ __ -2!.!lI!!!!"I '03011020' ,030110'02 _~.1QL _ .--l2-~--.--K _ _ .... ____ _ Q:_ . .«!'0201.!93.9~'_ .. _.L0301l040~" _ '~/03_0'"H".l!.!.9.L __ ~~01l0402/B"0101(2) 
33 ... P4Q, 'ClNI 13,H '030110402 '01011080' [0 -1.9__ 40 .. __ -:::103011080' ____ '040_210_1.!!.L. 030110~.!!.L·':'. 'O~~~/.l!.I..l!.I" 0301l080,lO ~402/0101l0 ~ MP44e _~ ~ ---102011060' '03011'502 "010' . iO'0'02 t of 0020'/030' 106011'502 020110301183'0'0' -l9~1502/85'0'02 . ~~e::-'_-=-~.=~ 3,H -. 1030110501 040110802 ·020~_-' ~--. :"~~.~'_-::- ~ -:-~:. 'oj '. !I'Oi~"o,o, J0501/0SQ2: . m ~~ ~o.~iiBO·010Iin:.:::-:-_.~0102/B3·0202~_: = .. 
31 ~ _. ICINI _ .. f::uve 05011060' "50110'03 10 --1.Q ____ .. 1·02QII2 .-J. u • ____ u ___ 0,.. . OtQ60.!i~0'" __ . '059110lJl~ .. _ ~!'!'!~..!{!I5"020..!ill_. 1050110103/0 ~ MPS67 CIN, N liv. 03011060' '5011040' 0 =f.R53 NO 112 ' . 01 0~60'/150'" 1030110.01 0_6.l!!l15_0Wil£020U2) 0301l040IlBO'0'01 ___ ._. _ . __ ~~.!~- .. CIN3 ~- il6H -.-- 02011020' 0301l030~-r.-O~- -- 0 _:::-.-~:+~':'- .=~ --roi.l!il~.l!.!-:-:~ 1020110301 _ROll03"-, .~.rg2_oi-,-o~0,_' ~~_~}_O.illl~~-:02 - - 0201l0301lB3"0202 .•. ____ ._ ._ 
38 ... PSM CIN, 1&H 0302/0201 030110'03 "0'0' 0R53 ----tlL----~ ____.l!j • ~ _0 020110301 ._. _. f!'~30.:!./0~~ _ .. _, 020ll030IlB3'01'" 0302/0003/BO'0'0' 2 
00 MP621 CIN3 "6H '020110301 0'0610301 0 OR53 _.--19...._ __ _ __ ._ .. ___ I!.l _____ . __ ._010301111.008 ___ lIl.~.Y!l}.«!L.. 0301l040611!4'0101(2) 02011030110' 
., MP63 CIN3 ISH ISH 030110302 ORi/0103 a 0R53. 0 ____ ' __ 0\ ._ _. _ .. _~~0302/91.!U.:""' .. ~H!/Q.1Q'!.:· _ 0302/080IlB.·Ol0..!ill....... --t,,0~3"'0_.!!1I"!0c:',,0~3/'}0'::-_____ . __ _ 
... P633 CIN3 '6H 030110801 '30110803' '0202 'a 0 O[ 003011'30'" .).Q!ll"0103'· 0301/1301183'0202 060110803110 
43 MP652 ClNI I6H 0303/0303 OR71ORI a DR53 0 0303/07=r'(2L 030:i/Ci.oa.l!l: ~~=-=: .030~'-'-=fo':: 10_~!1i1080'_.;_; __ ._ 0303/0701 2 184'010' 2l 0303/080118~'0'01(2) 
U MP688 CIN3 ,eH 030110303 0,031OR8 0R53 0 . 0 _ _ .. _____ 01030110'.9.1:: O~l!O@.O-'·: 030110103/0 0303/080llB4'O'OI(2l 
4S MP706 CIN' 33H 020110302 030110'06 '0'0' 0R53 0 a _. _____ . 0102011030' 0302/040e: ___ ~t/0301/81"0'0' 0302/0006184'0'01(2 
.. MP742 ClNI 18H 03011050' 0'0110402 a 0R53 a -L-.-- 0050110'0' 1030110402" 05011010110 030110402/B4'010' 2' 
41 MP743 CIN3 N_'i.. 020110302 0'0410301 "0'01 0R53 a 01. 010302/0404 02011030, 0302/0404lB4"0,0, 2 0201l030IlB3'0,01 
41 MP752 CIN3 N_U.. 0302/0602 040410101 '020110202 0R53 0 oC-- - --- 0 103021040.-- 0602/080'" 0302/0~04/B"0'01(2l 0602/0101/83'020" 
u "'P765 CIN, [N_li.. 0502/0604, 5011' 302 '030' 0 '0201/2 01 --- - 0 105021150' 06041'302 05021150I/B5'020, (2l 060411302/B3'030, ---
MP810 ClNI N IIv. 050110'01 0503211401183'0'0, 05011010110 
CIN' '33H 020110301 020110301183"010' 020110301183"010' 
I~""' ____ 13,H___ 0301111 04 0301lll0llB3'0202 030111104/83'0202 
L.u1.MP8n 1clIQ_ \tIL 331 \0302/0802 ~li50'/QR7 ~ -10 ~ -IOR53-- ~~1'020i/2 0\ 0101021150' \0302/070'12l·· _ ~_10602/'5Q!'-B5'0201(2l 10302/070' (2l1B4'0'01 (2 
54 1101_5 - ----- - 060311301 0601l,50IlB5'0,0, 
55 "'_8 0301/1104 0201103911B3"0202 
U1MP885 1C1N3 II6H 1020110302 10301l040~ 1'0'01 IOR53 10 01 Oi0201/030' 10302/0404 1020110301183'0'01 [0302/0404184'0,01(2 
57 NTl06 1c1N3 TI6H 030110601 040111502 0 iOR53 '0'02 01 0i0301/0401 06011,50 0301l0401lB4"O'O' 2 0601l,502/B5'010--
51 NT11, CIN3 31l 020110602 030111501 '010' 0 '020112 a 01020110301 08021150' 020110301183'0'0, _ 08021150IlB5'020, 
JNI 3,l33 030110402 04011'301 '010' DR53 a _~_. _ 0,0301l0~0' 04021130'_' ___ . 030110001184'0'0' 2 0'0211301183'0'0' ___ _ 
~ 'N_llve 0302/0201 040110301 "0101 OR53 a ~~ OJ QlQ192/040, 02011030' 0302/040IlBO'0'0,2 020110301183'0'01 _____ ~ __ . 
m ICINJ JISH IIl33H 0302/030, 040110401 a OR53 .. __ a -.--==t- ~--=- .. '=':QL~. -'Q'0301l~1!.1 ~ 030~/1!.'.l!i;~=-: __ 0301l1!~Q:'i~~Ol.!!.!HL__ 0302/0.06lB4·0'0' 2 
NT1I7 ___ .~ :31H '02011030' 030111304 '0202 a _ ~~_. ___ '. __ . ____ .. _ 9.; _. _ Qj()1()1I03Q! .. 0_~01i.!.3..l!.~': ." 02011030!!B1:!!202 __ 0301l'304/B3"0202 
NT'28_ .. _ IClNI _ jl6l ____ .. 0201/020, 040110301 "0202 ~._. ~ .. IO .. _.~ i 02 D.tL04.0J 192011030' J~I!.'.!9~40'· 1020.110.30' 020J!0401180·()LQ.!(2J_ 020110301183'0202 
.. NT'28 lCINJ '8t1 _____ 10301!0602 '50110802 '0202 !.Q20112 -;= O· 0'06021150' '030110802" 10602115Ql/65"0201(21 030110802/83'0202' 
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ClNOQ.OR.3 
2 4 II 10 II -12- 13 ,. 
--
15 NT12~ CIN3 '31H 1030110302 10 .. 01/0406 iO ;OR53 0 ___ ~_ _~_. _______ OI0301'.Q!0.1~-_=.~~Q219 .. 06· j0301/0~~i-B"~O'O' 2 10302/0,,06/8".0101(2) 
" NT131 ClNl 16h18131h33h0201/0301 04~IOR7 0 IOR53 0 ' oj 0:030110000' ---J-~01l0701 2 0301/0000/84'0101 2 020110701 2/80'0101 2 
17 NT133 ClNl llH 33H 0302/0302 ~011OR7 0 'OR53 0 0302/0001-- -iO.302/07·01(21 . i0302/0'-~' 0302/0701 2 ., 0302/000118,'0101 2 0302/0701 2/8,'0101 2 I. NT137 ClIO 16H 030110201 030110001 0 OR53 0 0 0020110301 030110401 0201/030110' 03011040118.·0101 2 
Ie NT143 CIN3 llH 311 0301105032 140110103 ·0202 0 0 .----"-7 -. - --- 0 05032/1401 030110103" 05032/1401183"0202 030110103/0 
70 NT,.. CINl N_U". 10201/0301 I I 01/0301 '0202 10 0 01 Ql0301l" 01 020110301 030111101183'0202 020110301183'0202 
"71lNT11O ICINl IN__ 1020110302 10001/0301 1'0101 IOR53 10 01 01030110.01 1020110301 10302/040118"0101(21 1020110301183·0101 
i2]NTI61 ----lclNl II8H 10302/0002 11303/0803 1'0202 10 10 01 0:0302/1303' 10.0210803' 1030211303/83'0202 10002/0803/0 
mNT28 --lClNl !Ill 33H 1050110502 1010111501 10 10 1'020112 01 01050110101 1050211501 105011010110 1050211501185'020112 
74 INT211 1C1N3 111131L33H ]000210502 -1 160110801 10 10 1·020112 o! 010502/1801 10002/0801" 10502/1601185'0201(21 10002/010110 
175 060211501 020110301183'0101 060211501185'0201121 
71 030110401 ,030111101 030111 I 01 03011000118.'0101 (21 030111101183'0202 
77 NT38 ICINl "IL IlL 020110603 130110301 '0101 10 0 0' 0'0603/1301 1020110301 060311301183'0101 020110301183'0101 
71 Nr.1 ClNl I8H 0600/0605 1302/0101 ·0301 0 0 ~ 0060./1302 0605/0101' 0604/1302/83'0301 0605/0101/0 
171 NT02 'C1N3 16H 0302/0302 ,.0111008 '0101 '0 0 0302/"06 ~92/1401 0302/1406' '0302/140,' 030211'06/83'0101 030211.06/83·0101 
10 NT" CINl llH 31H 030110501 010111201 '0202 0 0 0' Oi0501l0101 ---.l!l301l1201 050110101/0 03011120110202 
I I NT07 CINl llH 31L 0302/0302 0007/0407 0 OR53 0 030210'07 -~i02IO.-c;r- 10302/0«;7 ~2/0'07 0302/0007/8.·~~ 0302/0'07/80'0101l~_h___ 
12 NT53 'CINl 'Il. 3'H 000110601 040111501 0 'OR53 020112 ----i:==---=~ uoL--=--=_=-=-_-=-O'o'01l0'i--;:·~-=~0_6QillJi_Ql" 0001'--O'-O"8~0101(2J 080111501185·020121 -
13 NTS8 CINl Ill. 3'H '030110301 000110008 0 'OR53 ,0 ___ .1030110401 _. _iO_3_0_1I9'!1.~ _ .. _1030110008'._ }0301l0001 030110008184·0'0' 21 030110001180·01012 
.. NTSI ClN, Noaa... 0803/0600 "0111302 ·0202/0301 0 0. _ _ -l. __ ____ C!I _ .. ____ 0060311101" __ 1060411302 0803jl101l83·0202 _ 060.11302/83·0301 
15 NT62 ICINl 16H 030110601 0.0711501 0 ~R53 '0101 ~ ,~ . QT0301i0007 -'0&0111501" 030110007/80·010121' 060111501185·0101 
II NT64C1Nl llH'IH 060110801 150111502 '0 10 ·020112 '060i11S0;- . __ 101011'-502 - -~501'" 1060111502 0601l1501l8S'02012 060111502/85'0201 21 
_l.7 NT67 CINl '16H 06041050' 140111302 '030110101:0 ._~_----+. __ . ___ ._ .. q,_ .. ____ ._0:05041140.1-_.. 060411302 050.1,.01/83·0101 060011302/83·0301 
II NT71 CIN3 31H 0201/0601 030111101 '0202 0 0 ' . 0: . 01020110301 ---+9-60111101' 020110301183·0202 060111101183·0202 
'-'-I NT72 CINl III 31H 0302/0601 0401llS02 0 'OR53 ·0102 ' ~-.- O:'-===- 010302/0001 1080111502 0302/0001180·01012 060111502/85'0102 
---
10 NT73 ,ClNl _~ 000110502 1&02/0000 '0 ~ 1020112: . ___ ~ .. ___ . __ ~2l1&0.~~ __ --l.Q00..!{goOO· 05021160~i!!5·0201 2 0'011000418"0101(2 
..!.l.~.!. ICINl _ .... L!.~ '0302/0201 OR71OR7 l!!.-._.~~_~ __ ._~_30210701J~1 _ ~02Q!!Q!!1.ll~ 10302/0701m~02~1I0701 10302/07.Q!Rj/U·01012 0201107012/80'010H2} 
Ii" NT711 ICINl u_ • ',ISH. 0302/0302 0.031OR7 10 'OR53 iO _.-- _-1ll302/0.0 .. 3 _ .. _._ ~~01£.Q7J!.!(!L.~~0 .•. .oL. ___ ..!1.I'~0~701 2 •• 0302/0003/80·0101 21 0302/0701 2/80·0101 2 ----
~~T.!'L __ IClNl._ -l.'.!.~_ 0302/0601 j1501/0001-!9..-____ ._~~_._._-i ___ . __ . __ .9~ _. __ . h. __ ~_~O'-- _ _ j0302/0001 ___ ,g.~.g.g'~O!!85·0'01 0302/0.0118.·01012 
U NU3 ICINl. _ ~_ 0302/0602 '1502/0.03 '0 _ IOR53 i·Ol02 ____ . __ . _. -0.;-. _ ....... " .... _010602~I~I1.~. ._._103J1~.1.!!'03 0602115~2/85'!l'02 0302/0003/8,'0101 
f-!.!. ~~ __ ~.!N3 ........ 1.'.!L ... __ 1020110602 0301/1S01 .. +,~' 0.'-. _ .. _._10 __ .. --.p.!C!1-.-- .t .___ _. 0, .._ .. __ . Q'0?9YQ301.. j0602j!5.l)'--__ ,Q?91!.03.Q1'.~.3":QJ.l)!" _. 060211501185'0101 
II NnO __ .. _2!!i_._ -t0301l0301 120110001 ~'0101 iOR53 0 030111201 '03.0110'01. j!f301111201 '030110.01 0301/1201183·0101 03011000118'·0101(2) 
17 Nn6 'CINl _.~ .1000110600 010311301 '0301 10 --=-=F-'-i -- ""-"oi""'-- ---.- "-0000110"-03; ---1o'60.i1301 1000110103/0 1060'11301183'0301 
----
II WIO ClNI ~,,,,. '0201/0301 0301108002 '01010 ~ "--1 ._-. -=~'':'~ =~L·. _.~ ~-=~_ ~~._ 0 0201/030'- - --.19.3:.01108002 020110301183·0101 0301101002/0 
t-:':!:~. CINl f1!!:!-. 0503110604,OR71ORII 0 :OR53 _ 0 __ ... _~. __ .. _ .. _ .O,060'~79'!W.· _. iOS!1.3..!{CJ.!.0~:. 0604l0!lli21/~~_:.C!1~L 05031/01101180'010121 __ 
100 Wl02 CINl 31L 05032/0600 180211301 '0101 -ro=- '0'02 +:: __ -._-.. ..!!l. _._. _____ OF3ill.!l~:_._. 1'060011301" 0503211602/85·0102 060'11301183'0101 . ____ . __ 
101 WIO. ClNI NoaaU.. ·020110602 030Z/OR!! ·0101 IOR53 0 ' ___ .. _. __ ..!!l .. _____ ~0'!!Q~11.2':'. __ 0.6.l)~/01l11.!..:' ___ ~~02/~~__ 0602/01101184'0101(21. _ 
10; Wl1 CIN1 31H '0301/0302 '0103/0002 0 OR53 0 0 01030110103·' 030210002 030110103/0 0302/0002180'0101 2 
103 Will ClNl II 000110501 000110101 0 OR53 0 ~:::-=-. ___ ~~OJ/0001':--=-=:1i!~HOI01 00o.~000!.1l_0:0l01(2) 05011010110 __ ----
10' WII2 CIN3 16H 030110301 1 '0"'202 ·0202 0 0 030111101 _---!030!l!1~~~ ___ ~01l1202·· 030111101183'0202 030111202/83'0202 
05 W12 ClNl 16 0301/050. 040111401 '0202. OR53 0 0' 0'030110001 050.11.01" 030110'01/84·01012 05041,.01183'0202 
106 WI20 CINl 16H 030110301 0'0110.0. 0 OR53 0 030110001 ~1/000' 030110001 030110004' 030110'0118'·01012 03011000418,'0101 2 
U.7 WI21 CINJ N_Uve 0502/05031 140111601 ·0202 0 020112 . or 0105031/1401 050211101 OS031/1401l83'0202 050211601185'0201 2 
-08 W125 CINl NoaaU.. 0201l92_0t ..!Jl301l0301 '0101 0 __ 0 1020110301 .1020110301020110301 020110301 020110301183'0101 1020110301/83'0101 
iOtlW12' --TClNJ IN_II.. 10302/0302 1110111101 1'0101 10 10 1030211101 1030211101 1030211101 1030211101 1030211101183'0101 1030211101183'0101 
11otW132 IClNI I Noaa... 10303/0101 1150111301 1'0101 10 1'020112 0' 01060111501" 10303/1301 106011150118S·020l(2) 1030311301183'0101 
",IW1,. ICINl I16H 1020110301 10.011OR7 10 IOR53 10 01 01030110001 1020110701(21 103011000118.·0101121 1020110701(21/80'0101(2 
121W13S ICINl I16H 1020110301 10'Ol1OR7 -[0 lo~-Io 01 of 030110'01 1020110701(2) 10301/0.0118 •• 0101(2) 1020110701(2)/84'0101(2 
I I 31W137 ICINl 116H 1030110301 10103/0.01 10 IOR53 10 10301/0103 1030110001 1030110103·' 1030110001 1030110103/0 1030110.01180'010112 
050211 601 0302/0.03/8.·0101 2 0502/160118S'0201(2 
060.11302 05011010110 060011302183'0101 
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.. IMP1461 1020110603 II301lDR7 1'0101 10R53 10 10 10 10201l0701ill 1060311301 1020110701(2)/84.0101(2) 1060311301183"0101 
nIMPI462 10303/0501 1010111301 1'0101 10 10 10 10 1050110101 1030311301 105011010110 1030311301183·0101 
UlMPI465 1030210603 1130110401 1'0202 IOR53 10 10 10 10302/0401 1080311301 10302/0401/84'0101(2) 1080311301183'0202 
UlMP1466 10301105031 1140111201 1'0202 10 10 10 10 1030111201 10503111401 1030111201183'0202 10503111401183'0202 
50lMP1467 1020110303 IOR71OR7 10 IOR53 10 10201l070~303/070l(21 10201l0701(2} 10303/0701(2\ 102011070112\184·0101(2) 10303/0701(2\184'0101(2 
5 I I.4P1468 10302/0301 0404l0~04 0 10R53 0 10302/0404 10301l0~04 030210404 1030110404' 0302/0404/84.0101(2) 030110404/84"010112 
52 MP1469 1050110501 OlOllDR7 0 10R53 0 050110101 050110701 2 050110101 050110701 2· 05011010110 050110701(2)/84·0101(2) 
_.u I.4PI47 -- .1030110501 0101/0103 0 10 0 0 __ ~~1!L. 030l/0103"~: __ ~501/!!1~_~;!QI/Ol03/0 050110101/0 I 
~~1470 1020110201 0301l0R7 '0101 '_"¥ 0 ______ 10201l0~01. _lQ?01l070.1(~L_~1Q.!._ .. _JP20110701(2), 020110301183·0101 02011070~84'OI01(~ 
55 MP1471 0301/0301 0103/0401 0 OR53 10 0301lQ.1Jl.L ..JQ301.tQ.~9J.. 0301/0103" 1030110401 ._~01l0103/0 0301l0401l84'010lli!)_ _ 
5& I.4P1472 ._ 020110603 030111301 ·0202 0 '0 __ .li:'"' __ ~ ____ . --...020110301. i9!ll~ 0.2!l..!!0301lB3"0202. 060311301183"0202 ._. 
57 MP1473 0402/0604 130110801 ·0202 _. __ .JI!.. ___ .-1L.._ .. -K- _ 10. __ .'_ --lJ;, 0402/0801"':. i!,.0~Q411;!'Ql'.'-=- ~~.l!0801l0 ___ 060~/I301l83'0202 
Sf MP1474 050110605 010111302 ·0201 lo-_Jo " To ____ 10 ___ '050110101 1060511302· 05011010110 0605/1302/83·0201 
P8ge I 
Control OO·OR.3 
i 2 3 4 I 7 I I 10 11 12 
59 MP1475 _. 10402/0501 0801/0R7 0 1DR53 IOU m_-.-.}.L __ _ _ T~ _._.:..:~ - '0402/·0S(W· 1050"/0701T2j~ 04021080110 0501/0701C21/B4·010H21 
10 MP1478 0501/0604 010111301 ·0101 0 0 '0 L 050110101 0604/1301·· 0501;010110 0604/1301/83·0101 
11 MPI48 0302/0302 11011OR7 ·0202 DR53 ___ ~-=-__ .~02/1·10i ':"- ~~02/0701{21 0302/1101. ,0302/0701{n 030211101/83·0202 0302/0701 2/B4·0101 2 
12 MP149 020110301 0301/0401 ·0101 _ DR53 0 ---iQ... ____ .. _ _~._.__ 020110301 .1030110401 0201/0301/83·0101 030110401184·0101 
13 MP14g6 0402/05031 0803/1401 ·0202 .-rl1---- O ____ ~ _. ____ ... . .J9_____ 0402/0803·· 'IOS03111401 0402/0803/0 0503111401183·0202 
84 MP1497 0402/0104 130110801 ·0101 0 0 JJ!.......... 10 0402/0801 0604/1301 0402/0801/0 0604/1301/83·0101 
15 MP1498 020110801 1S01l0301 ·0101 0 ·0101 10 ----. 10--- 0201/0301 +.060111 SOl 020110301183·0101 060111501185·0101 
II MP1499 0201/0201 030110301 ·0101 0 0 _ 10201!QIQ l .~ .JQ.201/030!. 020110301 .. ~_-_·10201/0301 020110301183·0101 0201/0301/83·0101 
87 MP15 0301l0S01 010110401 ,0 0R53 0 0 ~ 0301/0401 ~1I010l 0301/0401l84·0101{2) 050110101 
II MPISO 0201/0603 1103/0301 ·010110202 10 0 .. -~ --.-. - '0 ·----·----~-,/030, . -- 0601/1 103· 020110301183·0101 060111103/83·0202 
.1 MP1S00 0201/0201 030110301 ·0101 0 '0 - ,020110301-'~20110301 020110301 020110301 020110301/83·0101 020110301183·0101 
70 MP1S03 0401/0S01 0101/0401 0 i0R53 0 0 10 OS01/0101 0401/0401·· 050110101/0 040110401184·0101L2l 
71 MP1S04 0201/0101 030111 SOl ·0101 0 ·0101 0 ----- -ro- 020110301 080111501·· 0201/0301183·0101 060111501/85·0101 
72 MPISOI _ 030110302 0404/0404 0 DR53 ~_ 0301/0404 r30~/.Q.~04_-=-- 0101/0404"_ .. 0~02/0404 030110404/84·0101 0302/0404/84·0101 --, 
73 MP1507 050110104 010111302 ·0301 0 0 0 ~ ________ ~1I0101 ___ 0604/1302 0~01l0101/0 0604/1302/83·0301 
74 MP1S09 0301/0303 1201/1201 ·0201 0 0 030111201 JQ.~91L!..~1 ___ . ~!?_<!L __ 0303/1201· 0301/1201183·0201 0303/1201183·0201 
75 MP151 0501/0601 010111502 0 0 ·0102 0 :0 0501/0101 0601/1502 0501/010110 0601/1502/85·0102 1 
71 MP152 0302/0201 040110301 ·0101 - DR53 0 0 '-rO-"---'--' -~301"'- 0302/0401 020110301183·0101 0302/0401/84·0101 
77 MP153 050110604 0101/1302 ·0301 '0 0 0 L---- 050110101 -l0104/1302 0501/010110 10604/1302/83.0301 
71 MP154 1050110104 010110302 ·0101 10 0 0 10 .--- 050110101 10604/0302· OS01/0101100604/0302/83·0101 
71!MP15S 10201/0601 1030111301 1·0301 10 10 10 10 1020110301 1060111301· 1020110301183·0301 1060111301183·0301 
101MP156 10303/0S02 11S01/DR7-~ ~0R53 1·0101 10 :0 IOS02/1 SO'-~0303/0-i01(2f-:-IoS0211501l85"Q.1_0_1 _---.l030~/0701{2)/B4·0101 
.,IMPI57 1020110301 1030111202 1·0101 10 10 10 10 1020110301 1030111202·· 1020110301183·0101 10301/1202/83·0101 
121MPI56 10302/0S04 10404/1404 1·0101 10R53 10 10 :0 1030210404 10504/1404·· 10302/0404/84·0101 10504/1404183·0101 
...l.UMP1S9 1050110604 1010111302 1·0101 10 10 10 io IOS01l0101 1060411302 IOS01/0101l0 1060411302/83·0101 
UlMP1591 10302/0201 IOR9IOR10 10 1DR53 10 10 10 10302/0901· !0201/1001· 10302/0901184·0101 102011100110 
15 IMP1592 10201/0302 10404/0301 1·0101 IOR53 10 10 10 1020110301 10302/0404 10201/0301/83·0101 10302/0404/84·0101 
U !MP1593 10302/0302 10404/0802 10 1DR53 10 10302/0404 1030210802 1030210404 1030210802 10302/0404184·0101 103021080210 
I71MP15g6 1030110301 10401/0404!0 1DR53 10 1030110401 10301/0404 1030110401 10301/0404·· 10301/0401/84·0101 1030110404184·0101 
II MP1S94 020110301 030111201 ·0101 0 0 0 To 1020110301 030111201 020110301183·0101 030111201183·0101 
It MP1598 020110601 0 0 0 0 0 _.lQ.. 0 0 0 0 
.0 MP1599 050110604 010111301 ·0101 0 0 0 -. -TO .- 050110101 - 0804/1301·· OS01l0101l0 060411301183·0101 I 
., MP11 0301/0402 120110801 ·0101 0 0 0 .. -. 10 030111201 040210801·· 030111201/83·0101 04021080110 ~ 
t2 MP160 - 060110603 DR71OR10 0 IOR53 0 ~--.-- .. -. 10 - -- 0601/070.ll!l - 060311001· 0601/0701{2)184·0101 0603/100110 --
U MPI600 050110604 0101/0404 0 OR53 -----=1t r------ -10- - -.- 0501/0101 -- 10604/0404· 05011010110 060410404/84·0101{2j 
t4 MP1601 '0604/0604 1301l0R7 ·0301 OR53 ':=r-. __ .-__ 10'041..!~i- -:- -702.~,!Q.l~L.Q!Q.4/131)'!::' __ ~ 0604/0701(2)· 060411301183·0301 060410701(2)184·0101{2) 
IS MP1602 0201/0601 0301/0R7 ·0101 OR53 _ _ 0 _____ 19-.. __ _ _lo. _____ 0~.Q.!{!l701(2) J!l_60110301· 0201/0701(2)184·0101{2j 060110301183·0101 
II MP1604 040110402040110801 10 IOR53 0 To __ lQ. ___ 04021080r.:.._ '040110401" 040.21080110 0401/0401/84·0101(2) 
t7 MP1606 020110201 030110R7 ·.Q!QL __ .. _IOR~. _-+g.. _ ._. _ . ~lIQ~91. iO~01l0791J~J_ . OAQ.!~o.3cu... ]!l:2.Q!!.0701(~_~2.QlI030!/83·0101 020110701{2jI84·0101{2j 
II MP1607 OS01l0604 010111302 ·0201 tO~- 0 .. J!!.......... . 10 050110101 1.060411302 05011010110 060411302183·0201 
" MP1608 - 06031060S 1301l0R7 ·0202 ro----- 10 ~- ----- -. 10 --- ~603I1io, . -.l0B05/0701{2j· 060311301183·0202 OB05107011WB4·0101(2) 
100 MP161 060110601 1S01l1501 0 10 ·0101 -. 10601l1501.-==.fu01/150·;_-~601l1501"·-10601l1S01" 060111S0118S·0101 0601l1S01/BS·010l 
101 MP163 0501/0601 1S01/0101 '0 ----jg. :020112 0 ill m'10'01 .1960111501" OS01l0101l0 0601/1501185·020121 
102 MP1633 020110201 0301lDR10 ·0101 ,0'- _ 10 . 020110'301 --~10.1!t!!..1001---·~201l0301 _.:_·.·l0201l1 001· 020110301183·0101 02011100110 
103 MP1634 050210S031 "01/1401 ·0101 _~_ _ 020112 0 ___ . ..j.9 _. ___ ~!..!..~ __ !OS03111401 OS0211101185·0201 2 05031/1401183·0101 
104 MP1635 050110604 010111301 ·0101 10 10 0 '0 OS0110101 +0604/1301·· 05011010110 0604/1301183·0101 
105 MP1636 ------ 0302/0601 0404/1S01 OOR53·0101 0 - .. ---- . ··tii - . - 030210404 -- 0601l1S01" 0302/0404184·0101 0601/1501185·0101 
101 MP1637 020110201 030110301 ·0101 100 1:/0301 "1020110301 -- 020110301 - '020110301 020110301183·0101 020110301183·0101 
107 MP164 020110303 OR71OR7 0 OR53 0 0201/0701(21-~' 1020'-/0701(2) 0201107012 0201107012 02W07Oi2!S.·01012 ------
108 MP16S 060110603 1501/1301 ·0202 0 ·0101 0 0 0601/1501... '060311301 060111501/85·0101 
109 MP166 0501/0604 010111301 ·0101 0 ___ 0 0 __ . __ .L___ OS0110101 0604/1301·· OS01l010110 0604/1301183-010,-__ 
110 MP167. 0601/0601 IS01l1S01 0 0 ·0101 060111501 _ 0601l1S0L 0601/1501·· _ -1960111501.. 0601l1S01185·0101 0601l1S01l8S·0101 
11 I MP168 0502/0S032 150111401 ·0202 0 ·0101 0 0 OS0211501 S03211401 0502/1501185·0101 OS032/1401lB3·0202 
112 MP169 0501l0S04 0101/1401 ·0202 0 0 0 0 -- 1050110101 0504/1401" 05011010110 0504/1401/83·0202 
113 MP17 0201/0303 0301l0R7 ·0101 0R53 0 0 '--'IO~= 020110301 0303107012 020110301183·0101 0303107012/84·0101(2·---1 
114 MP170 0201/0603 0301/1301 ·0101 0 0 0 ____ .)Q.. ___ ._ 020110301 0603/1301 0201/0301183·0101 0603/1301183·0101 
115 MP171 0301/0601 1104/1305 ·0202 0 0 0 . __ ~_ __ 0301/1104 060111305· 030111104183·0202 060111305/83·0202 
111 MPln 020110601 ...'J)30111501 ·010L_ .. ~ ·0101!0 10 0201[9301 060111S0r· 110301163·0101 060111501/85·0101 
Page 2 
Control OO-OR.3 
2 4 • 7 • , 10 11 12 
117 MPH3 0201/0504 DR9IDR7 0 DR53 '0 0 _ L~. 0201l0701!21. 10504/0901" 0201/0701(21/B4"0101 0504/0901/B4"0101(2-)-
111 MPH4 0301/0S04 1401/0401 ·0101 DR53 0 0 t 0301/0401 0504/1401"· 0301l0401lB4·0101(21. 0504/1401/B3·0101 
1111 MPHS 020110601 IS01l0302 ·0101 0 0201/2 0 _~ .. - O. __ 020110302· -- 0601l1S01"· 0201/0302/B3"0101 0601/1S01/BS·0201(2) 
120 MPH6 OS01l0604 0101/0801 0 0 0 0 0 OS01/0101 0604/0801 OS01l0101l0 0604/080110 
121 MPln 0301/0402 DR7IDR10 0 DR53 0 0 _~ !l___ 0301/0701 2·· 0402/1001· 0301l0701(2l/B4"0101{21 0402/100110 
122 MP178 020110601 0301l1S01 ·0101 0 ·0101 0 0 020110301 0601l1S01"· 020110301/83"0101 0601/1S01/BS·Ol01 
1 3 MPI79 OS04l0601 IS01/DR10 0 0 0201/2 0 0 - 0601/1501 0504/1001· 0601/1501/BS·0201(2) OS04/1001/0 
124 MP11 0302/0201 0401/DR7 0 DR53 0 0 -~....l~ -- 0201/0701(21.._: 0302/0401 0201/0701(2)/B4"0101{2) 0302/0401lB4·0101 2) 
125 MPI80 0201/0604 030111302 ·0101 0 0 0 10 020110301 0604/1302 020110301/83"0101 0604/1302/B3·0101 
12. MP181 0302/0501 0101lDR7 0 DR53 0 0 10 10501/0101 --- 0302/07012·· 050110101/0 0302/0701 (2)/B4"01 01 (21 
127 MPI82 020110601 1502/0301 ·0202 0 ·0101 0 -10- 1020110301 - 0601l1S02 0201l0301lB3·0202 _ 0601l1S02/BS·Ol01 
121 UP1S3 0 0302/0407/B4·0101 2 0601l1S01/BS·Ol0l 
129 MP1S4 0 030111101/B3"0202 0201l0301lB3·0202 
130 UP185 0 020110302/B3·0101 0601/1S02/BS·Ol02 
1311UP188 10302/0302 1040110402 10 1DR53 10 . 10302/0401 ____ 10302/0!Q.2 __ J03Q~'-0_40L _ jg192/0402 ----.l9:t02l9401lB4.o1 01 (2) 10302/0402/B4·0101ru 
1321UP117 1020110601 10301/1S01 1·0101 10 1·0101 10 10 10201/0301 10801/1S01·· 10201/0301lB3·0101 10601l1S01lBS·Ol0l 
1 UIUPI88 10402/0803 11S01l1S01 10 10 1020112 10402/1 SOl 10603/1501 10402/1S01· j0603/1 SOl· 10402l1S01/BS"0202(2L_ 10603/1S01lBS·0201(21 
luluP189 IOS031/0S04 10404/oRl0 10 1DR53 10 10 10 IOSO_41J001' IOS03110404"-----10S04/1001/0 IOS03110404/E!4"0IQlli1. 
13slMPlll 10302/0201 10301/0401 1·0101 1DR53 10 _ 10 10 ___ 10201/0301 _ m02/()40L ___ ----.l2.2J11l0301lB3·0101 10302/0401lB4'0101ru 
lulUP111Q 10601/0603 11S01l1301 1·0101 10 1·0101 10 10 1060111501·· 10803/1301 10601/1S01/BS·Ol01 10603/1301/B3'0101 
13711AP2 1030110603 1010311101 1·0202 10 10 10 10 1030110103 10803/1101 10301/0103/0 10603/1101/B3·0202 
131IUP21 IOS03210602 11401l1S01 1"0101 10 1·0101 10 10 1060211S01 IOS03211401 1060211S01lBS·Ol0l IOS03211401lB3·0101 
1311 UP202 060110604 1501/1301 ·0101 0 1·0101 0 10 0601/1501·· 10604/1301" 0601/1501lBS"0101 0604/1301/B3·0101 
UO UP203 030110302 110110401 "0201 DR53 0 - 0 ____ JJ!__ 0302/0401 030111101 030210401/B4·0101(2) 030111101lB3"0201 
Ul UP207 0303/0601 oR911S01 0 DR53 ·0101 0 ____ 10_ __ _ 0303/0901·" 0601l1S01·· 0303/0901/B4"0101(2) 060111S01lBS"0101 
142 UP208 040110604 01011oR7 0 DR53 '0 0 . _____ lQ..____ 040110701(2)· '060410101' 0401l0701lB4"0101(21 06041010110 
U3 UP2Q9 10301/0S04 140110103 "0202 0 0 0 :0 '0301/0103·" 050411401·· 0301/0103/0 050411401/B3·0202 
1 U UP210 030210601 1501/0404 0 OR53 "0101 0 - -. :0-- .-- 0302/0404 -- 1060111501" 0302"404/84"0101 [21. 030210404IB4·0101l~ 
US MP211 050110601 IS0111502 0 0 "0101/010_2I0801l1~Q..! __ :-: -:-j~Oi.0~_~1502___ 0601/1501"· _ -.~01/1502 0801l1501lB5·0101 0801115021B5·0102 
146 MP212 0503/0604 0302/1407 "0101 0 ___ 0 _____ 0 ____ ,CL. _ ___ ___ 0603/0302· ..)Q.!.04114 07· 060310302/B3·0101 060411'07/B3·0101 
U7 MP22 050110501 010110101;0 0 0 OS0110l01. j0501l0101 050110101 rugl/0101 0501/010110 OS01/010110 
1" MP23 _ 020110302 030110401 ;"0101_ DI!.!!;!__ _ !O~-=-_--==JO __ -~-~ _-. LO - .~= ~-___ 020119~D.!.- - 1o_302~~~_ 0~Ql-'Q.~01lB3·0101 0302/0401IB4·0101(2) 
141 MP234 _______ 030110402 130411304 ·0202 _10: ____ ~ ___ _____ .lQ~9yl.3_04 L040~!~~Q4 ____ 19_3Q..!J~_~Q~:" jq~ll_I~~_ ~Y_~!l~£~3"0202 _ 0402113041B3·0202 
150 MP236 0201/0302 030110402 "0202 1oR53 ___ j 10 ___ . __ ~_ _ _____ 10201!.Q~0.L ___ :Q.30210402 020110301/B3"0202 030210402IB4·010l(2J 
151 MP237 _ 0603/0604 130111302 "0202/0301 0 0 10 . _____ io_ ___ j0603/1301 J!l604/1302 0603/1301/B3·0202 0604/1302/B3·0301 
152 MP236 0402/0S01 080110802 "0101 0 0 ~ '0 _~_02/0801 [9S01l0801· 0402/08011B3"0101 OS01/080110 
153 MP239 020110601 0302/0302 "0101 -- 0 --- --- 0----- 0201/0302- - . 1060 110302 --- -----r0201/0302" --. - ,060110302· 020 I/03021B3"0 1 0 1 060 1I0302/B3·01 0 I 
154 MP24 020110602 0301/1405 "0202 0 0 0 ----- - ---Ii.. ------- '020110301 -- Jg60211406· 020110301lB3"0202 0602/1406IB3·0202 
155 UP240 0501/0601 IS0111S02 0 0 020112 0601l1501---___ -tQ.6g1L!502_ 060111501 _ ':-_4.o601/1S02 0601/15011B5"02012 060111502/B5·02012) 
156 MP241 030210603 040411301 "0101 DR53 10 0 ____ ~C!_____ ___ J0302/0404 _ 0603/1301 030210404IB4·0101(2) 0603113011B3·0101 
157 MP242 0201/0603 03011DR10 "0101 0 0 0 --4!1..- 1020110301 0603/1001· 020l/0301/B3·0101 0603/100110 
151 MP243 0302/0504 0401/1401 ·0101 DR53 0 0 _ jC!.____ 10302/0401 _ ~~/1401" 030210401IB4·0101(2) 0504/1401lB3·0l01 
159 MP244 020110601 IS0110R9 0 DR53 "0101 0 ~ 060111S01 1020110901· 0601/1S01/BS·Ol0l 0201/0901lB4·01012 
160 MP246 030210201 0301/0404 ·0101 DR53 0 0 --~- 0302/0404 - 020110301 0302/0404/B4·0101(2) 0201l0301lB3·0101 
111 MP249 0201/0302 oR7Ill01 ·0202 DR53 0 0 10 1020110701(2) 0302/1101 0201/0701(2)/B4"0101(2 030211101/B3·0202 
112 UP250 OS02/060S 1404/0802 "0202 0 0 0 -10- IOS0211404· - 060S10802- 050211404/B3·0202 060S1080210 
113 MP251 030110302 1104/0403 ·0101 OR53 0 0 F 10301/1104 030210403 030111104/B3·0101 0302/0403/B4·0101 
114 MP2S2 0501/0803 010111301 ·0101 0 _ 0 _ 0 10 IOS01l0101 060311301 05011010110 0603113011B3·0101 
1 eslMP2S4 10302/0401 1040410404 10 [0R53 10 10302/0404 10401/0404 103_02/049~_ _ JG_4JHI0404" ----.l9~0_210404/B4·01..01(2l._ 10401/0404/84·0101(2 
lu1MP256 1020110301 1030110401 .1"0202 10R53 10 10 10 1020110301 1030110401 _--.J.QlQ!LO_301IB3"0202 10301/0401IB4·0101@ 
1I71UP257 1030210S04 1040211401 1·0101 ..1DR~___ [0 10 10 1030210402 1050411411_t .. --.J.g~.o_2!0402/B4"!l.101rn.. 1050411401/B3'0101 
1 III MP258 10301/0504 11101l130S ["0202..10 10 10 10 1030111101 10604/130_5·_~1IJ_tOIlB3·0202 ___ 10504/130SIB3·0202 
lulMP259 10401105032 loRil1S01 10 [0R53 _lO _______ ~ ___ JO _____ [04011.0901' 10503211501"--__ 10401109QlIB4·0101(2~IOS03211501IBS·? 
170 MP26 0 ~. _ 0201103011B3·0101 0302/04081B4·0101 2 
171 MP261 0 10 OS01l0101l0 0604/13021B3·0101 I 1721MP267 0 -l.2- 0201/0301/B3·0201 - ------
173 MP268 0 -- 10 --- 0302/0403/B4·0101(2L __ 
174IMP2G.9... 1030110501 [0101l0401-lo.____ IOR53 10 10 10 10501101 01 ~!!0401 ---.lo.501l01~ ____ lo301/040IlB4·01 01 (2) 
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Control DQ-OR.3 
1 2 3 4 5 6 7 8 II 10 11 12 
175 t.AP270 0501/0604 0103/1302 '0301 0053 0 0 0 050110103 0604/1302 050110103/0 0604/1302183'0301 
176 t.AP271 0402105031 OR7/1401 '0101 DR53 0 O ... __ . _______ fg___ _ 0503111401 0402/07012\' 0503:j1401l83'OI01 040210701[21/84'OI01t~1 
177 t.AP272 020110302 OR7/0404 0 DR53 0 0 0 0201/070112 0302/0404 020110701[2}IB4'OI 01 (2l 030210404184'0101 2\ 
178 t.AP273 0201/0201 030110301 '0101 0 0 . ~1I0301--' 020110301' 020110301 0201/0301 020110301183'0101 020110301183'0101 
1711 t.AP274 0302/0501 0101/0405 0 0053 0 0 --1Q.. 0501/0101 0302/0405 050110101/0 030210405183"0101 
180 t.AP275 0502/0603 0101/1302 "0301 0 0 0 10 0502/0101" 0602/1302' 05021010110 0603/1302183"0301 
181 t.AP278 '020110302 OR7/0407 0 0053 0 0 ___ 10 0201/0701{2) 0302/0407 020110701 2/84'0101 2 030210407184"0101l2} 
182 t.AP279 020110603 030111301 '0202 0 0 0 10 0201/0301 0603/1301 020110301/83'0202 060311301183"0202 
113 t.AP28 0302/0603 OR7/1101 -0202 0053 0 0 --= __ ~ 0302/0701{2L 10603/1101" 030210701(1)/B4"01012 060311101183"0202 
184 t.AP2BO Oe03/0e04 130111301 "0101 0 0 0603/1301 fOe04/1301 0603/1301 '0604/1301"' 0603/1301/B3'0101 060411301183"0101 
185 t.AP281 OeOl/0601 1501/1501 0 0 0201/2 0601l1501~ __ ~ &.~1/1501 0601/1501" 10601/1501" 060;/1501lB5'02012 060111501/85"02012 
186 t.AP288 020110602 150110301 "0101 '0 "0101 0 19 _____ .. 0201/0301 !Oe02/1501 0201l0301lB3'0101 0602/1501/85"0101 
187 t.AP289 0402/0402 080111104 "0202 JO 0 __ ~402/9801__~0402/1 104 0402/0801" __ 0402/1 I 04' 0402/0801/0 0402/11 04/B3"0202 _ 
'188 t.AP29 030110501 0101/0103 0 10 0 To '0 0301/0103" 050110101 030110103/0 05011010110 
In t.AP290 0301/0402 0402/1301 "0202 0053 '0 r ---.1-- 0301/1301 0402/0402" 0301/1301/83'0202 0402/0402/84"0101(21 
no t.AP293 020110603 030111101 '0201 0 0 0 to 020110301 0603/1101" 0201/0301lB3'0201 0603/1101183"0201 
191 t.AP294 0201/0201 030110301 "0101 '0 10 _020110301 10201/0301 0201/0301 0201/0301 020110301183'0101 0201/0301/83"0101 
192 t.AP294 05031/0604 010111302 '0301 0 ___ 0 '0 ___ . ____ +~_._ 0604/1302 0503110101' 0604/1302/B3'0301 05031/010110 
193 t.AP297 020110402 OR10/0BOl "0202 0 0 0 ~ 0201/1001' ~2/0BOI 0201/1001/0 0402/0BOll 
1 t4 t.AP299 0201/0402 OR7/0B03 0 DR53 0 ~---. --- - 10 ----- -. 020110701 2 -10402/0803" 020110701(21/84"0101 040210803/0 
US t.AP3 020110502 150110301 '0101 0 020112 0 --.'0.---- 020110301 050211501 020110301183'0101 0502/1501185'0101(21. 
196 t.APJO 0402/0605 080111401 '0101 0 0 0 ____ ._ -l!L ___ ._ 040210801" jQ605/1401' 0402/080110 060S/1401l83"0101 
197 t.AP300 0402/0201 OR711201 '0202 0053 0 0 10 0201/0701(2) '0402/1201' 020110701 2/B4'OI01.(2 0402/1201lB3'0202 
198 t.AP32 0301/0601 0404/1501 0 DR53 '0101 0 '0 030110404" '0601/1501" 030110404/84'0101 0801/1501185'0101 
199 t.AP34 0201/0201 0301/0301 '0202 0 0 020110301 '020110301 020110301 0201/0301 020110301/83'0202 0201/0301183'0202 
200 t.AP340 05032/0504 OR7/1404 '0201 0053 0 0 10 OS032/1404" 0504/0701 2' 05032/1404/83'0201 050410701lZ1/B4'OI0Illi. 
201 t.AP341 020110301 030111101 '0101 0 0 0 .JQ.--. 020110301 0301/1101 0201/0301183'0101 030111101/83'0101 
202 t.AP342 030110303 1303/0R7 '0101 DR53 0 0 iO 030111303 0303/0701(2} 0301/1303/B3'0101 0303/0701 2/84"0101 2\ 
203 t.AP343 0302/0303 0402/0R9 0 DR53 0 0 ,0 0302/0402 0303/0901" 0302/0402/B4'0101 0303/0901/84'0101 2 
204 t.AP344 0502/0601 1501/0301 '0202 0 0201/2 0 0 0601/1501" 0502/0301' 0601/1501185'0201 2 0502/0301/B3"0202 
205 t.AP345 0201/0301 1103/0301 '0101 0 0 0 0 020110301 030111103 0201/0301lB3'0101 0301/1103/B3'0101 
206 t.AP346 0201/0201 0301/0301 "0202 0 0 0201/0301 0201/0301 020110301 020110301 0201/0301/83'0202 020110301183'0202 
207 t.AP347 0201/0302 0404/0301 '0201 DR53 0 0 0 020110301 0302/0404 0201l0301/B3'0201 0302/0404/84'0101 
208 t.AP35 0803/0604 1301/1302 '0201 0 0 0 0 0603/1301 0604/1302 0603/1301/83'0201 0604/1302/83"0201 
209 t.AP350 0201/0201 OR10/0301 "0101 0 0 0 0 020111001' 0201/0301 02011100110 020110301183'0101 
210 t.AP355 0301/0801 1102/1S02 "0301 0 '0102 0 0 0301/1102 0601/1502 0301/1102/84'0301 060111502/B5'0102 
211 t.AP358 020110201 OR7/0301 '0101 0053 0 10201l0701!2L _l-Q1.Q.l/0301_ 0201/0701!21 \020110301 0201107012\/B4'0101 0201l0301lB3'0101 __ 
2 I 2 t.AP357 0301/0301 0301/0801 '0101 0 0 030110801 10301/0301 030110801" 0301/0301' 0301/0801/0 0301/0301/83"0101 
213 t.AP358 '0602/0401 040111302 "0301 DR53 '0 ~ ___ 'h_- . .10 .. ____ .. ___ 0401/0401" __ .)9.!i02/1302" 0401/0401/B4'OI01 0602/1302/83'0301 
214 t.AP359 0301/0602 040111501 0 0053 '"0101!0 :0 030110401 ~602/1S01 030110401/84'0101 0602/1501l8S'0101 
215 t.AP38 050110502 010111101 '0101 --~-- ,0 '1---" .--- ;0'- --- 050110101 --".10502/1101' 05011010110 0502/1101/83'0101 ---
216 t.AP360 0201/0201 OR7/0301 '0101 _ IOR53 ___ ~_~n 0201/07..Q..l.l2)_·:. :O~OJl0301" 0201/070un. __ J9~01/0301 0201l0701(2}/B4"0101 020110301184'0101 
217 t.AP381 0402/0801 OR7/0302 '0202 0 ._.___ 0 _ 0 ___ ". __ . ,0 ___ ._ 0402/0701(2)'1960110302' 0402/0701(21/B4'0101 060110302/83'0202 
218 t.AP362 0201/0502 0301/1S01 "0101 0 -0201/2 ,0 '0 0201/0301 IOS02/1601 020110301183'0101 0502/1601l8S-0201{2L 
219 t.AP383 050110504 0101/1401 '0201 0 - 0 ,0 ---'--'10 --.. -" 050110101 '0504/1401" 050110101/0 0504/1401/83'0201 
220 t.AP364 _ 0201/0301 0401/0301 '0101 OR53 -- 0 0 .~:.::~~- .. ~ 'J~-:"-=__ '020110301- 1.030110401 0201/0301183'0101 030110401184'0101 
221 t.AP366 0504/0602 OR71OR10 0 ,DR53 0 0 :0 10504/0701' 10602/1001' 0504/0701/B4'0101 06021100110 
222 t.AP37 0201/0603 OR9/1501 0 - ._~_ - 0201/2 0 .----~: .. _J9.=__.~=-~_ 0201l1S01' . i0603/0901' 0201/1501/85'02012\ 0603/0901/84'0101 
223 t.AP372 0604/0605 1302/0401 "0301 0053 0 0 ]0 . ,0604/1302 '0605/0401' 0604/1302/83'0301 0605/0401/84'0101 
224 t.AP373 -----. 060110604 150111302 "0301 --~ --- 020112 0 ---... - '0' -_. ---'0601/150'-;;" JO-S04l1302 0601/1501185'0201 2\ 0604/1302/83"0301 
225 t.AP374 __ . - 030110302 040110404 0 OR53 0 0 ____ ._:.::: ..... "-l~_ .. _--=-~- __ 1030,,0401 -:. _.)91.02/0404 0301l0401lB4'0101 0302/0404/84"0101 
226 t.AP375 0504/0602 150110302 "0101 0 0201/2 0 . ___ ._ ICL- __ _ 10602/1501 _ '0504/0302' 0602/1501/B5'0201(2\ 050410302/83'0101 
227 t.AP376 0201/0602 030111501 '0202 0 '0101 0 19 020110301 10602/1501 0201103011B3'0202 060211501/85'0101 
228 t.AP378 - 0402/0501 010110401 0 OR53 0 0 -. - -,0-'" - -- 0501/0101 ,0402/0401' 05011010110 0402/0401/84'0101(2) 
229 t.AP379 0201/0201 0301/0301 '0202 0 0 020110301'=:- ~_!Qi~i0301_ -- 0201/0301 __ ~i'0201/0301 0201l0301/B3'0202 0201/0301183'0202 
230 t.AP38 0402/0503 080111401 "0101 0 0 0 W 0402/0801" 0503/1401 0402/0801/0 0503/1401/83'0101 
231 t.AP380 0602/0603 130111501 '0202 0 .- '0101 0 ----... ,0 - .--- - ~50-1-' 10603/1301 0602/1501/B5'0101 060311301/83'0202 
232 t.AP381 0201/0201 0301/0301 "0101 0 10 0201l0301------!0201/0301 -- !0201/Jl.301~-·· :0~JjJl;lJ2L . _&.~QlIQ301/B3'01.2.L.._. 0201/0301183'0101 
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233 IAP382 _ 0201/0501 DR9/0301 i'0101 iDRS3 -.l9 10 - 10 1020110301 _.lO~Q!/0901· 020110301163'0101 050110901164'0101 
234 IAP383 0503110604 150111302 "03010 $O_lli_=:I~-_-:""::' =19:".:.= ~ :- 0503111501;'_~1302 050311150110201 2 060411302/63'0301 
235 IAP384 __ 050110605 DR9/0101:0 1DRS3 ~O --ro--- 10 050110101 0605/0901' 05011010110 0605/0901164'0101 
236 IAP3811 0301/0604 DR7/0407 10DR53 "---0 -- -. ---ro-- -.--- ----li.:---- 030110407 0604t0~ 030ilo~;o--,- 060410701/64'0101 2 
'" ",M' '''''".. "'"'''' .,," , ~~ ~--r --:.~-. ::> : :~-: ___ "" "'" """ ",.. """ '"'' " .. ,"" m,·"" 238 IAP389 0201/0501 DR9/0102 0 DRS3 0 10 0 050110102 020110901' 050110102/0 020110901164'0101 
239 IAP39 -- 020110601 150110301 '0202 10 ~~~:~=---- --:f::: .::::.... """'" ~: -""",,,,.. ""'"'''",.,''' "'"'''''".,''' 
240 IAP391 __ 0602/0603 150111301 '0101 0 '0101 10 0 0602/1501 060311301 060211501165'0101 060311301163'0101 
241 IoIP392 _ 020110602 150110301 '0101 0 020112--- 0---- ---.--- 0-'- .- -- 020110301 060211501 020110301163'0101 060211501/65'02012 
242101P393 0302/0303 0402/0402 0 DRS3 0 0302/0402 .~~ 0303/0402 ~_ 0302/0m-_1030=!j0402' 0302/0402/B4'0101 2 0303/0402/64'01012 
243 IAP394 0301/0302 0103/0410 0 'DR53 '020112 0 0 030110103" 0302/0410" 030110103/0 0302/0410/B4'0101 2 
244 IoIP395 020110602 DR711501 0 DR53 1'0101 0 _ ---10----=._ 0201107012L 060211501 0201107012/64'0101 060211501l6S'0101 
2U IoIP41 _ 0302/0302 040110401 '0 DR53 10 0302/0401 0302/0401 0302/0401 J302/0401 0302/040IlB4'0101 2 0302/0401164'0101 2 
2" IoIP426 0602/0602 150111502 0 -0 '020112 060211501 n~~lli..!lL- 060211 ~0-1--'Thr211501" 060211501l65'0201ill-- 060211502/B5'0201 2 
247 IoIP427 020110201 030110301 '0202 10 0 020110301 020110301 ---+0201l03~__ 020110301 020110301183'0202 020110301163'0202 
248 IAP428 040110502 DR1011501 0 10 10201/2 0 --fg..- 050211 SOl ,040111001' 050211501165'0201(2) 04011100110 --I 
241 IoIP429 0201101101 150110301 '0101 0 '0101 ~ ____ ._ • __ ~ ___ ._.___ 0201l0~~ 0i9111501" 020110301163'0101 0601l1S01l6S'0101 
250lolP'l 030110801 120111501 '0202 0 '0101 10 ~ 030111201 060111501" 0301112011(13'0202 0601l1501l6S'0101 
251 IAP430 0501l0S01 0101/0101 0 0 0 OS01l0101- ---- 05011010"'-- 05011010;--' 050110101 osii1I0101io 05011010110 -
252 lAP'll 020110402 080110301 '0202 0 0 0 -- 0----- 020110301 0402/0801" 0201l0~202- 0402/080110 
253 MP'l2 OS032/0603 140111104 '0202 0 0 0 -- 0 -------- 0503211401 060311104" OS03211401l83'0202 080311104163'0202 
254 IAP433 0802/0603 1101lDR7 '0202 DR53 0 0 0 -- 060311 101" 0602/0701121' 080311101163'0202 0602/07'Q1LW64'0101 
25SIMP434 1050210602 1150111601 10 -10---- 1'020112 10 10 1050211601 1060211501 - -- IOS0211601l8S'0201l21 10602/1501165'020112 
256IIAP'l5 1020110601 IDR7I1406 1'0301 1DR53 -- 10 - - --10 10 ~0201l0701(2)-nI0601l1406' __ L0201lQ.7Q1(zl/64·0101 1060111406/83'0301 
2571MP438 1050110501 10101lDR7 10-1DR53--- 10 1050110101 1050110701(2) 105011010'_ 10501l0701(2~ 105011010110 1050110701121/64'010112 
12UIIolP44 1020110402 IDR9/0301 1'0202 10 10 10 10 1020110301 10402/0901' 1020110301163'0202 10402/0901164'010112 
259IMP44Q \020110304 \0402/0301 \'0101 1DR53 10 10 10 1020110301 10304/0402' 1020110301183'0101---10304/0402/64'0101(21 
26 01 IoIP'" 10503110604 \130211401 1'01011"0301 10 10 10 10 IOS03111401 1060411302 10503111401/83'0101 \060411302/63'0301 
261 MP442 '050110604 010111301 '0202 '0 0 0 -- '0 ---- 050110101 1060411301" 050110101/0 0604/1301163'0202 
282 lAP'" 0302/0302 0402/0410 0 DR53 0 0302/0402 0302/0410 0302/0402 0302/0410" 0302/0402/64'0101(2) 0302/0410/64'0101(2) 
263 IAP445 0501l0S01 DR7/0102 0 DR53 0 050110102 n_.n ,050110701(2L OS01l0102 - 050!!:0701 2' 050110102/0 050110701(2)/84'0101(2) 
264 IoIP4S 060110601 DR7I1S01 0 DR53 020112 ~1150L. ~~Q'!!9791~0~01l1S01"_._ 0801/0701(21' 0601l150IlBS'0201(2) 060110701(2)/64'0101(21 
265 MP46 0301/0603 040111302 '0301 DR53 _-12-_ t= 0 0301/0401 060311302' 030110401184'0101 060311302/63'0301 
266 IAP47 ---- -- 0401/0502 010111602 0 0 1'020112 -.~---~~-_~ - t- ~. _= ~ --.- -~0211802 --_ JQ~!I0101' OS0211802/85·020~l2J. 04011010110 
287 IoIP475 0201/0302 DR7/0401 0 DR53 0 0 0 020110701(2) 10302/0401 020110701184'0101 2 0302/040118,'0101 21 
~ IAP478 ____ .___ 05032/0601, 1501lDR7 ° . DR53 _ ".Q_!.Q.1. _____ •. [0. _ ~~'-=--_.:. -_ ~-_ -~_'==- .~' ___ ~~cu.:~_ -tmS03211701 2' 08o.HJSOllBS..:.Q.l0l OS032/0701lB4'0101 ~ 
261 IAP4n 050110604 010111402 '0301 ~ ==to 10 10 050110101 0804/1402' OS01l0101l0 0804/1402/63'0301 
270 IAP'7' _. _____ . _ 0302/0402 08011080'2 '0101 _'_ 0 _==+.Q. ~-=.:.-_ 10-: __ :~ '. 10_= . __ .:.- 0302/08041"-- 0402i0801' 0302/08042/0 _ 0402/080110 
271 MP46 030110301 0103/DR10 0 ~ ;0 1030110103 [030111001 030110103" 030111001' 030110103/0 03011100110 
272 MP460 .~__ 0803/060' I 10111302 ·030110202_J.Q._ --=:-=-f-~--- ----.J _ ---. -:-':'_.' 19_ -:_~'.~ _-- .-. ~-;-,;ol;; _. LOM.4!!l_02 __ ~l1 I 01/B3'0202 060411302/63'0301 __ 
273 MP461 030110302 040110404 0 IDR53 0 0 '0 1030110401 [Q302/0404 0301/0401184'0101(2) 0302/0404164'0101(2) 
274 IAP482 -----.-. 0502/0604 160111301 '0101 ___ ~ ____ . ·0201lL.+0 ___ .·_· __ :-·· .-~-_ -.= ____ =_'OS02I1e~<!.!_.~. 1060411301" 050211601lBS'0201(2) 060411301163'0101 
275 MP463 020110303 130110301 '0202 iO ___ 10 '0 ~O 020110301 1030311301 020110301183'0202 030311301183'0202 
278 IAP48' 020110601 1S01l0301 '0202 --r---i0101 --. -~-==--_- '_'&.._ -.. --~ ... 0-iO'1l030'- _19.601l1s01" 020110301183'0202 060111S01l6S'0101 
277 IAP486 0602/0603 DR71DR9 0 ~ ,0 .-1=----------- -111-- ______ .10602/0701(2)" i0803/0901' 0802/070112/6,'0101 21 0803/0901164'0101 
278 IoIP487 0501l080S 010110301 '0202 '0 0 0 0 050110101 \060S/0301' OS01l0101l0 060S/0301l63'0202 
278 MP488__ 0503110602 "01lDR7 '0101 DR53 _ 10 -~-.L-=--=~=--.. !t=.~-~~--. -~11401 .::-:= 0602/0701(2 OS0311,.01lB3·0101 0602/07012/64'0101(2 
210 IAP489 030110601 040111502 0 DR53 '0102 0 __ ~ 1060111S02 030110401 0601l1S02/BS'0102 030110401164'0101 
211 IoIP49 - 1020110601 0301/DR9 '0202 DR53 0 0 _~:.-:..:JJL='::--=--=-~- 020110301 -_:-=- 060110901' 020110301183'0202 080110901164'0101 
--
212 IAP491 ___ 0402/05032 DR7/0803 0 DR53 ~ 0 _. 0 ____ 0'02/0803". _._ OS032/0701(2' 0402/0803/0 OS032/0701 2/84'0101(2 
283 MP492 0201/0201 DR7/DR7 0 DR53 0 020110701 2 ~01l0701(21 020110701 2 020110701 2 020110701 2/64'0101 2 020110701 2/84'0101(21 
214 IAP493 OS01l0504 DR9I010l ° DR53 0 0 0 050110101 05041090,. 05011010110 050410901184'0101 
285 IAP494 0302/0302 DR7/0401 ° DR53 0 0302/0401 _. 0302/0701tU" 0302/0'01-~_ 0302/0701(21 0302!0701(2)/B"0101 0302/0401l64'0101ill 
286 IAP495 0402/0605 080111301 '0202 0 0 0 0 0402/0801" 060S11301' 0402/080110 080511301183'0202 
287IAP496 0302/0302 040""01 '0202 DR53 O' 0302/0'04'- -~030ii;'01- 0302/0404 030211101 0302/0404184'0101 030211101163'0202 
288 IAP497 -. 0605/0605 130110'04 '0101 DR53 0 _ .. ' __ ~.1301 _ . 060iti4i. _ 060511301' ._:-- 060S/0404' 060S11301l83'0101 060S/0404lB"01012 __ 
289 IAP'98 0302/0303 040411301 '0101 DR53 0 0 0 0302/0404 030311301 0302/0404184-010112 030311301183"0101 
290 IAP499 - 050410801 ..u.2.411~Qz.... '0202 0 ,'0102 '--:2::=...., --=-:-: to .- -_ -=- 0~J)_1LH_o2__ ,0504/110" _ID"1502/BS'0102 _____ 050411 104lB3'0202 
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~'..!f==---.--- __ i'0302/0302 . __ -k... __ ~0302/.0~Q! 0302/0401lB4'0101 0302/0402/B4'OI0Il~L 
0401/0402 0 _~. '_'" . ___ . 0401/0401/B4'OI01 0402/0803/0 
050210604 0 0502/1601lB5'0201 2 0604/1301/B3'0101 
10201/0201 0201l0301lB3'0202 0201l0301lB3'0202 
295IMPS02 10303/0303 IOR9/0R9 10 iOR53 10 - !0303/0901 10303/0901 10303/0901" i0303/0901" 10303/0901lB4'0101(2) 10303/0901lB4'0101(2) 
296IMPS03 10201/0604 IOR7/1301 1'0201 10 io 10 io 10201/0701(2\ 10604/1301" 1020110701(2)/84"0-'-01(2) 10604/1301183'0201 
2171MPSOO 10402/0501 IOR7/0101 10 10R53 10 10 10 1050110101 10402/0701(2)' 105011010110 __ lCl40~LQ.701(2)/84'OI01(21 
2t1IMP52 10201/0604 IOR911301 1'0202 10R53 10 10 10 10604/1301" 10201/0901' 10604/1301183'0202 10201/0901184'0101(2) 
2nIMP~ 10603/0604 I 1104/1301 1'0202 10 10 10 10 10603/1104" 10604/1301" 10603/1104/83'0202 10604/1301183'0202 
3001MPS5 10302/0603 10402/1101 1'0202 10R53 10 10 10 10603/1101" 10302/0402 10603/1101183'0202 10302l1402/8~'()1Q1{21. 
3011MPse 10501/0604 IOR911301 1'0202 10R53 10 10 10 10604/1301" 10501/0901' 10604/1301/83'0202 10501/0901/84'0101(2) 
3021MP57 10301/0504 10103/1404 1'0202 10 10 10 10 1030110103" 10504/1104" 1030110103/0 10504/1404/83'0202 
3031MPse 10201/0201 IOR7/0301 1'0202 10R53 10 1020110301 10201l0701(2) 1020110301 10201l0701(2) 10201l0301lB3'0202 10201l0701(2)/B4'OI01C2 
3041MP59 10302/05031 1040111401 1'0101 IOR53 10 10 10 10302/0401 105032/1401 __ 10302/0401/84'010~ 105032/1401/83'0101 
30slMPS 1020110601 11407/0301 1'0202 10 10 10 10 10201/0301 10601/1407' 10201/0301183'0202 10601/1407/83'0202 
306 MP60 '0301/0502 1301111101 1'0202 lo 020112 10 10 030111301 10502/1601 0301/1301/83'0202 0502/1601l85'020ml 
307 MP61 0201/0301 030111101 '0101 10 0 0 0 020110301 1030111101 0201/0301/83'0101 0301/1101183'0101 I 
301 MP1S2 0502/0604 160111301 '0101 10 '0102 0 -. 0 0502/11501 -..l0604/1301" 0502/11101185'0102 0604/1301183'0101 
301 MPISS 0201/0201 OR9/0301 '0101 ~ 0 020110301 .-__ 020110901 0201/0301 ---='020110901' 020110301183'0101 020110901/84'0101[21. 
310 MP611 ,0301/0402 130110801 '0101 10 0 0 0 1030111301 1040210801" 030111301183'0101 0402/080110 
311 MPlS7 10201/0501 010110301 '0202 10 10 to 10 10201/0301 10501/0101 020110301/83'0202 10501/010110 
[312 MP687 0501/0502 010111501 0 ._---!L. ___ j0201/2 ! _ _ .. .JlL._. __ . 0501/0101 .J0502/1501 050110101/0 10502/1501/8S'020'-T21. 
L313 MP68i '0501101103 OR7/0102 0 10R53 10 0 10 0501/0102 .jo603/0701(2)' 050110102/0 0603/07012/84'01012 
314 MP69 0302/0602 0401108031 0 .JQFI53 ___ +'!-- 0 -- -- ""!O--- -- 0302/0401 _. 10602/08031' 030210401/84'0101(2) 0602/0803110 
315 MP691 ______ • __ 020110201 DR7IDR7 0 __ ~53-~~=-' 1020;29i0112) ro~oli~--:O'-iij-=--0201l07Qllii- J0201/0701(21 020110'701[2\/84'0101(2) 0201/07012/84'01012 
31. MP692 .. 0604/0605 OR711301 '0101 ~53 __ 10 0 ___ •. _ __ _LCl. ___ ~4/1301" . 10605/0701 2' 060411301/83'0101 0605/0701(2)/84'OI01(2l. 
317 MP693 020110502 1601/0301 '0202 ,0 '020112 0- __ .. _ l.Q. ____ 10201l0~.QJ _ _ .~502/11101 020110301183'0202 0502/11101l8S'0201[2.1-----1 
318 MP695 020110604 030111301 '0202 '0 0 0 '0 1020110301 10604/1301" 020110301183'0202 060411301183'0202 
319 MPII97 --- 020110602 0301/1501 '0202 ~-- ,'0101 0 .~-=-":-~10____ 1020110301 .~-+0602/1501 020110301183'0202 060211501/8S'0101 
.ll..Q MP698 0302/0603 040111101 '0202 0R53 0 0 _____ 10____ 0302/0401 _ i0603/1 101" 0302/0401/84'0101 0603/1101183'0202 
321 MPII99 050110604 010111301 '0101 0 0 0 To 050110101 !060411301" 050110101/0 0604/1301183'0101 
:tl.2 MP7 0502/01103 0302/1303 '0202 0 0 0 0 0502/0302' 0603/1303' 0502/0302/83'0202 0603/1303/83'0202 
323 MP70 020110201 0408/0301 '0101 0R53 0 020110408 1020110301 020110408' .)0201/0301 0201/0408/84'0101 2 020110301183'0101 
324 MP701 030110301 1104/1305 '0101 0 0 030111104 1030111305 -1030111104 --:10301/1305 0301/1104183'0101 0301/1305/83'0101 
325 MP702 0501/0501 DR7/0101 0 OR53 0 050110101 0501/0701~ 050110101 _ '0501/0701(2)' 05011010110 0501/07012/84'0101l2L 
326 MP703 0302/0302 DR710801 0 OR53 0 0302/0701121. 030210801 0302/0701 2\': '0302/0801' 0302/0701(2)/84'0101(~ 0302/080110 
327 MP704 020110605 OR9/0301 '0202 0R53 0 0 0 0201/0301 0605/0901' 020110301183'0202 0605/0901184'0101 21 
328 MP753 020110601 0301/1502 '0101 0 '0102 0 O' 0201/0301 .-. 060111502 0201/0301183'0101 060111502/85'0102 
329 MP7~ 0602/0604 OR9/1501 0 0R53 '0101 0 0" 0602/1501 - 0604/0901' 0602/1501/85'0101 0804/0901/84'0101 2) 
330 MP7se 040110502 OR7/1501 0 0R53 0201/2 0 0 040111 SOl' ~Q.21'1]01(2)' 040111501/85'0201(2) 0502l0701(2)/84'0101(2 
3311MP758 1020110302 1030110401 1'0101 10R53 10 10 10 10201/0301 10302/0401 10201/0301183'0101 10302l0401l84'OI01{2 
332IMP760 10501/0805 1010111301 1'0201 10 10 10 10 1050110101 10605/1301 1050111010/0 10805/1301/83'0201 
3331MP762 10603/0604 IOR9/1301 1'0101 10R53 10 10 10 10603/1301 10604/0901' 10603/1301183'0101 10604/0e01l84'0101 
334IMP763 10201/0601 1030111501 1'0101 10 1'0101 10 10 i0201/0301 1080111501" 1020110301/83'0101 10601/1501/85'0101 
33SIMP766 1020110602 IOR9/0301 1'0101 10R53 10 10 10 1020110301 10602/0901' 1020110301/83'0101 10602/0901/84'0101 
336 MP767 0302/0402/e4'0101 0201/0301/83'0101 
337 MP768 0402/0701(2)/84'0101C2) 0503110302/83'0202 
lll.!IMP77o \030110301 """lO4 0 110 1 0310 --~OR53---lo ----1030110401- 10301/0103 10301/0401 10301/0103" 10301/0401/84'OI01(2) 1030110103/0 
3u1MP771 1020110502 10301111102 1'0101 10 1'0201/2 10 10 1020110301 10502/1602" 10201/0301/83'0101 10502/11102/85'0201(21 
3401MP772 1030210401 IOR7/0401 10 10R53 10 10 10 10302/0401 1040110401" . .J1)302/0401l8~'OI01(21 _J04jl1l0401/84'0101(2) 
341 MP773 0201/0604 ORS/0301 '0101 OR53 0 0 10 10201/0301.0604/0901' 020110301/83'0101 0804/0901184'0101 
342 MP774 0201/0302 DR7/0301 '0202 0R53 0 0 10------· 1020110301 -.- 0302/0701(2)" 0201/0301/83'0202 0302/0701(2)/84'0101 
U3 MP775 05031/0601 150111401 '0101 0 '0101 0 --~-W·-·-"---- 1060111501;' -.-. 0503111401 080111501/85'0101 0503111401183'0101 
U4.t.lP777 050110501 DR9/0101 0 . OR53 ,Q._. __ ._~!./01C!1 __ i.5l!1~_c!~- __ 10501/0101 __ . 05 .. 0110901' 05011010110 . 0501/0901184'01012 
345 t.lP778 _ 020110301 0301/0401 '0101 OR53 ____ ~ .. - __ .. S--. ...... . 0 __ ._ _ _'1020110301 _. 03.Q..l{l)401 0201/0301183'0101 0301/0401/84'0101 
346 MP780 1040210501 0 0 0 0 0 0 0 ·0 0 0 I l!!1I~____ 0201/0302 OR7/040e 0 _._ ~a .. _ .. _. LO._. _._._. __ L._m_ .. ~ - 0.' -_.- .~1I07c!'llil. rci!.0~~08': __ 020110701/84':Q.19.L __ _ 0302/0408/84'0101(2) _ 
rJ4iIt.lP782 1030310303 .1301/1301 -0101 10 10 1030311301 ___ .l030311301 ~30311301 1030311301 ·-~;3011E13'OI01 . .0303/1301lB3'0101 
Plge6 
Control DO-DR.3 
2 3 4 5 • 7 • • 10 11 12 3U MP79 0201/0302/83"0202 030110401184·0101 
350 MP799 0201/0301183·0101 0604/1407/83·0101 
3511MP11 10502/0603 IOR10/1101 1·0202 10 10 10 10 IOS0211001· 10603/1101·· IOS0211001l0 1060311101lB3·0202 
3521MP60 10201/0601 1030111501 1·0101 10 10 10 10 1020110301 1060111501·· 1020110301/83·0101 10601115011· 
3531MPBOO 1040110402 IOR7/0401 10 10R53 10 10 10 1040110401 10402/0701U}"- 10401l040IlB4"0101(2) 10402/0701(2)/B4·0101(2 
354 MP601 10 020110701184·0101 060211502/85·0102 
355 MPI02 00 05011010110 0401l0701(2)/B4·0101~L 
356 MPI03 0302/0302 OR10/0404 0 0R53 0 0302/0404 10302/1001 10302/0404 _ 1030211001· 0302/0404/84·0101{21 03021100110 
357 IAPI04 0502/05031 160111401 ·0101 0 0 0 0 050211601 0503111401 0502116011· OS03111401183·0101 
3S1IAPB05 020110301 OR7/0103 0 OR53 0 -~- =-=-~-To-:---- 020110701 030110103·· 0201l070t(21/84·0101(2) 030110103/0 
35t IAPBce OS01l0604 OR7/0101 ·0101 0 0 0 fa OS01l0101 0604/0701(2)· 05011010110 0604/0701121/0 
310 MPB07 020110301 OR7/0408 10 0R53 0 0 .=--=-~-:-:_ .. ~____ 020110701121 _ 030110408 0201l0701(2)/84·0101{2) 0301l0408/84·0101{2t 
3S1 IAPB08 02011060' 030'1150' ·0101 0 ·010' 0 10 020110301 060111501·· 020110301183·0101 06011'501185·010' 
312 IAPB09 02011020' 030110301 ·0202 0 0 020110301- -- - -fo201Io301- - 02011030'-- 020110301 020110301183·0202 020110301/83·0202 
3I3IAPSI OS04/0803 110411305 03011020' 0 0 0 -_. 10 060311104·· OS041130S· 060311104183"0201 OS0411305/83·030'._ 
384 MPll' 040110603 11011040, ·0202_ OR53 O·-r- ~_ --~F"':--=--~::--=-~401·':-_~-JO!0311~_0401l0 .• 01l84·0101 060311101183·0202 
365 IAP812 020110302 OR7/0401 0 OR53 0 0 0 _ 0201l0701(2) 0302/0401 020110701-(2 /B4·0101 21 0302/040IlB4·0101 2 
368 IAP813 0302/0302 0402/0403 0 ~~ ___ .l9-____ ._ 0302iQ~Qr· ~=kj02/a.03_-=~~IO~O~0402 __ .-:~1!O2/0403 0302/0402/84"0101 0302/0403/84·0101(2) I 
317 MPS" 050110604 010211302 ·0301 --10 --10 10 -f!!- 10501l0102~0411302 0501/0102/0 060411302/B3·030' I 
368 MPI15 0201/0603 130110301 ·02020 10----%= - - - _____ -- ,0 - -- -·---To-201l0301 - -. 106031130' 020110301183·0202 060311301183·0202 
369 MPB1S 0402/050, 010110801 0 0 10 io =t 105011010110402/080'.. OS01l0101l0 0402/080110 
370 MPS17 020110604 03011130, ·010, 0 0 10 --- 0 ----020110301 06041130'" 020110301183·0101 060411301183·0'01 
37, MP818 020110604 OR7/0301 ·0201 0 0 0 __ -=_ O_---.:-~~~ 1020110301 0604l0701{21· 020110301183"020' 0604l0701(2)/B4·0101.!n 
372 MP81. 020110604 03011'302 ·010110301 0 0 - .0 ~ 020110301 1080411302 020110301183·010, 060411302/83·0301 
3731AP82 __ . 05032/060, 01021150' 0 0 1020112 ~ ______ ___ lo-==~~_ -_____ J9601l150..L:" __ 05032/0102· 0601l1501l85·0201(2) 05032/0102/0 
374 MP820 OS01l0S031 OR1011403 ·030' 0 _ _0 _______ ~ __ . ________ --l1l.~031i.!~~ __ ,050"1001 OS03111403/83·0301 OS01l1001l0 
~ IAP821 ___ 0302/0303 040111301 0 10R53 10 jO ______ . )Q_. ____ . ____ l0302/0~ _____ ._ ~30311301 ~2/04Q.!LB4·0101(2) 030311301183· • __ 
375IAP822 . 030110201 OR9/0301 ·0101 jOR53 ___ 10 10 _____ . ____ +0_ __ _ ______ )Q3_01l0901:. ... fQ~0-'-'031l.L.._._ 0}Q.1I0.?01lB4·0101-(l!) 020110301183·0101 ___ ._ 
377IAP821 0303/0S01 0 '0 ,0 .0 "'0" . __ '0 '0 0 0 0 
378 MP823 020110604 OR71OR7 0 OR53 0 _10201l0701i~~._~_04l0701l~~- fQiO;/07IU.tn:: 060410701 2\· 020110701 2\/84·0101 2 060410701184·0101 2\ 
379 MP824 0603/0604 COR711301 ·0101 OR53 0 0 0 1060311301 060410701 2\· 060311301183·0101 0604l0701(2)/B4·0101(2) 
380 MP825 030110301 0103/0401 0 OR53 0 030110103 030110401 030110103·· 03011040, 030110103/0 030110401184·0101(21 
38, IAP828 0501l0S02 OR7/1601 0 0R53 ·020112 0 0 050211601 0501l0701(2)· 050211601l8S·0201(2) OS01l0701lB4·0'01(2L 
382 MP827 030110301 ORII11104 ·010' 0R53 0 030110901 0301l110i 1030110901· 030111'04 0301l0901l84·0'01{21 030111104/83·0'01 
383IMP83 10301/0603 1110110403 1·0202 10R53 10 10 10 1030110403·· 10603/,,01·· 10301l0403/84·0'OH2) 1060311101183·0202 
384 IAP84 0201l.Q701lB4·0'01 2 0303/'30IlB3·0101 
385 MPes _ 0601l1S01l~'·92o.1 t2l 0~9SI1S0J18S·0201 (2L 
386IMP86 1020110201 1030110301 1·0202 10 10 1020110301 1020110301 1020110301 1020110301 10201/0301lB3·0202 10201l0301/B3·0202 
3171 MP87 10502/0603 1160211 I 04 1·0202 10 1·020112 10 10 1050211602·· 1060311104·· _10S9211602@.S·02.Q1L2l. 1060311104/83·0202 
3uIMP88 10602/0604 1150111401 1·0101 10 10 10 10 10602/'501 1060411401· 1060211S01l8S· 1060411401183·0101 
3891 MP89 1020110501 IOR10/0101 10 10 10 10 10 1050110101 1020111001· 105011010110 102011100110 
39o\1AP9 080411301lB3·0201 060411302/B3·0202 
39' MPIIO 0301l110IlB3·0202 0302/0701(2)/B4·010t{2 
392 MP91 0603/0604 0302/1302 ·0101 0 0 0 __ . __ ---10-_._ 10603/0302·. 060411302 0603/0302/B3·0101 060411302/83·0101 
393 MP92 0502/0602 OR10l1S01 0 0 ·0101 0 _____ . ..)9 _______ JOS02/1S01 060211001· 05_02/150IlB5·0101 06021100110 
394 IAP93 020110301 OR7/0401 0 OR53 0 0 ~ 020110701121 030110401 02011070112/84·0101 2 030110401184·010' 2 I 
395 MP934 OS01l0S01 OR7/0102 0 OR53 0 OS01l0102_. __ ·_-!!l.5Q.'i!l.!Q.!L2l: 1050110102._ 05011070112\· 050110102/0 OSOl/0701 2/84·0101 2) I 
396 IAP935 0302/0302 0401/080' 0 OR53 10 0302/0401 10302/0801 030210401 0302/080'· 0302/0401184·0'01 0302/080110 
3t7 MP936 - 0503110603 OR7/140' ·0202 0R53 0 -~-~_~~ . ..-::=---.:--- ~~401 .. ~ 0603/0701{21· 0503111401183·0202 0603/0701{21/84·0101(2) 
318 IAP937 _____ 050110604 010211302 ·0301 __ _ 0 ____ ~ ___ ._ ~__ _ ~ __ . ________ 0501/0_~~____ ~0_411302 _.l!..5Jl1J.9.!Q..2/_O_ 060411302/B3·030' 
399 MP938 _.M 0402/0402 080111302 ·0301 --::- ~: _____ .~ _ .. _____ -10402/08..9.1. 1040211}..Q.2 ____ ~80'" _ 040211302· 0402/080110 040211302/83·0301 
400 IAP939 __ 1020110601 10408/0301 1·0101 OR53 -lIl.--_- _-1L.. _.__ fL . ___ . _____ 02_0..1J030_'-... ___ l!>~_"0408· 020110301183·0101 __ 060110408/84·0101(2) __ _ 
401 IAP!14 0302/0303 040411301 1·0101 OR53 - __ J~ __ _ -lL______ . .10 ________ .. _jQ.302/0404 _ !03~~~_ ~0_404l84·0101 03031130IlB3·0101_. ~~940 _ 0501l0S0' 0101101 01 '0=~"-:"" __ -f.g-__ . _____ loSOIl9.1Ql_ !.Q.s.9..!.l.QI91 ____ j9S.l!..1l..!P_IU.___ jQIO 110 1 01 OS01l0101l0 05011010110 
403 MP94.L ______ . _._ 0603/0604 "01l1301~~Q!Q.!___ 0 ____ -ill.- _____ ~------ jO__ _ __ -l060311.1J!1.":._ ~0~Q..4J1301·· _ 060311101183·010, 060411301183·0101 ~~2 ___ .. _ _ .. _. 060S/060S OR7/0301 __ ·Jl~~L ___ ~~53 .--to-- _._. 0'!'Q5_/0_701(2) _ 10605/0301 ;06~S-'.07_0'--_(2) • .!()6.1~5/o3cu.:._-=-~~~/0_7j11l!!.~·.Q..!Q.!~.L 0605/0301183"0202 _ 
.!Q.! MP943 __________ .. ~S02 OR9/0410 __ ~ __ . __ ~_. _ 0__ 0 _ _ ___ (0_ ,0401jJl_41Jl· . __ jOJ02l0901· 04011041 0/84·01 0' (2) 0502/0901lB4·0101(2) 















0402/0S031 080311401 "0101 O:=l'-=-'~-'--- --JQ- .-
0501/0502 oR9/0101 0 DR53 0 0 --f.Q 1050110101 0502/0901" OS01l0101l0 0502/0901l1i4-0101 2 
0201/0601 030111502 "0202 __ -1L_. ____ ".9-'_01 ___ 0 _ -:: ~.--~ .jQ _ .__ 020110301_ ._ 060111502 020110301/63"0202 0601/1502/6S'0102 
020110201 030110301 '0101 '0 0 0 10 020110301 !0201/0301 0201/0301/B3"0101 0201/0301/B3'0101 
0302/05032 1501/1402 '0101 -- 0 .- - '0101 0 -- .-- --10---- -- 030211501' 05032/1402 030211501165'0101 05032/1402/63'0101 
;;:.N 040210602 oR7/1502 0 DR53 '0102 0 -ro- 0602/1502" 10402/0701' 060211502/65"0102 0402/0701/64"0101 
";:.~; 0602/0201 1501loR7 0 DR53 ~0101 0. __ ~_ -~ .£=-=---= 020110701(2) 1060211501 020110701(2)/64"010HU 0602/1501/65"0101 
;;:.~~ '050110604 oR7IDR7 '0 DR53 _ 0 _ _ 10501l070! ____ --+Q!04l07..Q..1_ 0~01l0701(2)" ,0604/0701(2)' 050110701/64"010112 0604107012/64'0101 2 
0502/0603 130111601 "0101 '0 "020112 --ro- 10. 0502/1601 .10603/1301 050211601/65"020112 0603/1301163"0101 
0201/0602 oR711502 0 -=--tBRs;---- '0102 '-'-10--- ~_=.~ :::]Q_-.-,,:,,~--=---':~- 0201/0701[2LjQ.602/1502" 02011070112 IB4'0101 2) 0602/1502/B5"0102 -
0402/05031 oR9/1'01 '0201 'OR53 0 0 10 0503111401 10402/0901' 050311401163'0201 0402/0901/64"0101(2) 






;;::;~u 0201/0604 0301/1302 '030110202 0 0 0 ~-::_~.____ 0201/0301 060411302 0201/0301/63'0202 060411302163"0301 
:,;;::;:; 0603/0604 1101/1301 '0202 0 0 0 __ 0 0603/1101" 060411301" 0603/1101/1l3"0202 060411301163"0202 
0501/0601 DRt/Ol01 0 DR53 0 ° .- 0-- 0501/0101 060110901' 05011010110 0601/0901/64"0101 
0201/0501 0301/0101 "0202 ° 0 ° --0' 0201/0301 0501/0101 0201/0301163"0202 0501/010110 
422 
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APPENDIX III: FULL MOTIF PREDICTION FROM IIPV 16 E6, E7, Ll 
AND L2 FOR BINDING TO lILA DRB1*OlOI AND DRBl*0401 
E6-DRB10101 
IC50 DRB1·0101(nm) 
59 71 I V Y R 0 G N P Y A V C 0 4 
33 45 I I L E C V Y C K Q Q L L 12 
142 154 R C M S C C R S S R T R R 12.5 
75 87 K F Y S K I S E Y R H Y C 18.2 
84 96 R H Y C Y S L Y G T T L E 34.5 
130 142 Q R F H N I R G R W T G R 56.2 
106 118 L L I R C I N C Q K P L C 170 
101 113 K P L C 0 L L I R C I N C 185 
93 105 T T L E Q Q Y N K P L C 0 265 
133 145 H N I R G R W T G R C M S 362 
109 . 121 R C I N C Q K P L C P E E 365 
36 48 E C V Y C K Q a L L R R E 415 
74 86 L K F Y S K I S E Y R H Y 440 
50 62 Y 0 F A F R 0 L C I V Y R 520 
37 49 C V Y C K Q Q L L R R E V 622 
105 117 0 L L I R C I N C a K p L 770 
52 64 F A F R 0 L C 1 V Y R 0 G 825 
81 93 S E Y R H Y C Y S L Y G T 880 
88 100 Y S L Y G T T L E a a Y N 1300 
31 43 H 0 1 I L E C V Y C K a a 1900 
58 70 C I V Y R 0 G N P y' A V C 2600 
28 40 T T I H 0 1 I L E C V Y C 3200 
48 60 E V Y 0 F A F R 0 L C I V 3350 
57 69 L C 1 V Y R 0 G N P Y A V 4000 
24 36 T E L a T T 1 H 0 1 I L E 4600 
80 921 S E Y R H Y C Y S L Y G 5900 
47 59 R E V Y 0 F A F R 0 L C I 6120 
-
97 109 Q Q Y N K P L C 0 L L I R 6500 
32 44 0 I I L E C V Y C K a Q L 7000 
127 139 0 K K Q R F H N 1 R G R W 7350 
65 . 77N P Y A V C 0 K C L K F Y 10200 
72 84 K C L K F Y S K I S E Y R 11000 
78 90 S K 1 S E Y R H Y C Y S L 11000 
137 149 G R W T G R C M S C C R S 12000 
43 55 a L L R R E V Y 0 F A F R 29200 
67 79 Y A V C 0 K C L K F Y S K 35000 
71 830 K C L K F Y S K I S E Y 37000 
6 18 T A M F a 0 p Q E R P R K 39500 
140 152 T G R C M S C C R S S R T 45000 
104 116 C 0 L L I R C I N C a K p 60000 
139 151 W T G R C M S C C R S S R 65200 
86 98 Y C Y S L Y G T T L E a 0 74500 
7 19 A M F 0 0 p a E R P R K L 84200 
128 140 K K a ,R F H N I R G R W T 110000 
89 101 S L Y G T T L E Q Q Y N K 155000 
55 67 R 0 L C I V Y R 0 G N P Y 162000 
115 127 K P L C P E E K a R H L 0 170000 
103 115 L C 0 L L I R C I N C a K 180000 
136 148 R G R W T G R C M S C C R 182000 
42 540 0 L L R R E V Y 0 F A F 200000 
77 89 Y S K I S E Y R H Y C Y S 230000 
145 157 S C C R S S R T R R E T a 245000 
83 95 Y R H Y C Y S L Y G T T L 265000 
124 136 R H L 0 K K a R F H N I R 272000 
87 99 C Y S L Y G T T L E a 0 y 305000 
17 29 R K L P a L C T E L a T T 390000 
49 61 V Y 0 F A F R 0 L C I V Y 415000 
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E6-0RB10101 
107 119 L IRe INC Q K P L C P 422000 
35 47 LEe V Y C K Q Q L L R R 430000 
53 65 A FRO Lei V Y R 0 G N 475000 
39 51 Y C K Q Q L L R REV Y 0 480000 
98 110 Q Y N K P Leo L L IRe 530000 
125 137 H L 0 K K Q R F H N I R G 580000 
30 42 I HOI I LEe V Y C K Q 612000 
82 94 E Y R H Y C Y SLY G T T 650000 
143 155 eMS C C R S S R T R R E 770000 
56 68 0 Lei V Y R 0 GNP Y A 805000 
1----.. -1 __ .....:.1-'13..=.:M'-----t'-'H:..-+Q=---t'-'-K_t'-R_'__--t-'-T_--r:-A M F Q 0 P Q 1000000 
2 14 H Q K R TAM F Q 0 P Q E 1000000 
3 15 Q K R TAM F Q 0 P Q E R 1000000 
4 16 K R TAM F Q 0 P Q E R P 1000000 
5 17 R TAM F Q 0 P Q E R P R 1000000 
8 20 M F Q 0 P Q E R P R K L P 1000000 
9 21 F Q 0 P Q E R P R K L P Q 1000000 
10 22 Q 0 P Q E R P R K L P Q L 1000000 
11 230 P Q E R P R K L P Q L C 1000000 
12 24 P Q E R P R K L P Q LeT 1000000 
13 25 Q E R P R K L P Q LeT E 1000000 
14 26 E R P R K L P Q LeT E L 1000000 
15 27 R P R K L P Q LeT E L Q 1000000 
16 28 P R K L P Q LeT E L Q T 1000000 
18 30 K L P Q LeT E L Q TTl 1000000 
19, 31 L P Q LeT E L Q T IT I H 1000000 
1--___ --'2=-.00 .. __ 32 P Q LeT E L Q T T I H r9-- _______ .--o.:1OO=00'-=00=_-I 
21 i 33 Q LeT E L Q TTl H 10 'I 1000000 1----='-'-+--=:j~=-___1-=---t=--t-'--_+'~-t.:::-_+=-- ~- ·-'---j-'---+'--'---F--+'---f-·--------
221 34 LeT E L Q T IT I HOI 11 1000000 -----~~~~~~~-+~-~'--~-~~~_r-~___1~_+~·~--+~___1~-------~~4 
231_.=:.35'+'-c __ -t-'-T_+E=---+L=----+=Qo.-+'-T __ +T~_ll_-t'_IH-'--_t=_o-+'_I-+1 IL 1000000 
-=-___ -251 37 E L Q TTl H '0 I I LEe 1000000 
1 ___ ----=261 38 L Q TTl HOI I LEe V 1000000 
27 39 Q TTl HOI I LEe V Y 1000000 
29: 41 T I HOI I LEe V Y C K 1000000 
34 46 I LEe V Y C K Q Q L L R 1000000 
38 50 V Y C K Q Q L L R REV Y 1000000 
40 52 C K Q Q L L R REV Y 0 F 1000000 
41 53 K Q Q L L R R IE. V YO. F A 1000000 
1-___ ...:.44+_......;::5-"-16 L=---+L=---+-R~_rR'"---t=E-+V-'---+Y=--· .. -t .OIF A F -'R 0 1000000 
45 57 L R REV Y 0 F+ I;A.!-...-4!-F_+R~~D~+L~-+------_1.:..::oooc::..::..:0'-=00_=_t 
46 58 R REV Y 0 F A IF R 0 L C 1000000 
51 63 0 F A FRO Lei V Y R 0 1000000 
54 66 FRO Lei V Y R 0 GNP 1000000 
60 72 V Y R 0 GNP Y A V C 0 K 1000000 
61 73 Y R 0 GNP Y A V C 0 K C 1000000 ~---~-.....:..=:.f~___1~-t=-~=--+-'--~-~-
~----=:62=t-.--'-7...:..4~R'---t='0_-t=G--f:::'N-+P-:-_r:_Y-_+_'_A. V C 0 K C L 1000000 
63 75 0 GNP Y A V C 0 K eLK 1000000 
64 76 GNP Y A V C 0 K eLK F 1000000 
66 78 PYA V C 0 K eLK F Y S 1000000 
68 80 A V C 0 K eLK F Y SKI 1000000 
1-__ ~6~91-_8~1~V!.--f!C~-f!'=0_-f::!K_rC~fL -t:K:- F Y SKI S 1000000 
70 82 C 0 K eLK F Y SKI S E 1000000 
73 85 eLK F Y SKI S E Y R H 1000000 
76 88 F Y SKI S E Y R H Y C Y 1000000 
1-___ .!.:.79~-==9-:'11 ~K:-+I :_-+S'=--t~E-t:Y:-+R'--tH Y C Y SLY 1000000 
1 ____ ~85~~9~7r.H~~Y:_-+C=--t=Y-~S~~L-~Y __ ~--.~T~-~T~~L-~E~-+~Q_-~-_--.~1OO~00~00, 
1 ____ .5!:.90~~1~0~2pL'----t-::Y--+G::::--t.!...T_~T"--__+=L:__+=_E Q Q Y N K P _. _____ .--o.:1oo~0::..:0:..::.00_=_t 
91 103 Y G TTL E Q Q Y N K P L 1000000 
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92 104 G T T L E a a y N K P L C 1000000 
94 106 T L E a a y N K P L C 0 L 1000000 
95 107 L E a a y N K P L C 0 L L 1000000 _. 
96 108 E a a y N K P L C 0 L L I 1000000 
99 111 Y N K P L C 0 L L I R C I 1000000 
100 112 N K P L C 0 L L I R C I N 1000000 
102 114 P L C 0 L L I R C I N C Q 1000000 
108 120 I R C I N C a K p L C P E 1000000 
110 122 C I N C a K P L C P E E K 1000000 
111 123 I N C a K p L C P E E K Q 1000000 
112 124 N C a K P L C P E E K a R 1000000 
113 125 C a K p L C P E E K a R H 1000000 
114 126 Q K P L C P E E K a R H L 1000000 
116 128 P L C P E E K a R H L 0 K 1000000 
117 129 L C P E E K a R H L 0 K K 1000000 
-
118 130 C P E E K a R H L 0 K K Q 1000000 
-
119 131 P E E K a R H L 0 K K a R 1000000 
.. -~ . 
120 132 E E K Q R H L 0 K K Q R F 1000000 
121 133 E K Q R H L 0 K K a R F H 1000000 
.. 
122 134 K a R H L 0 K K a R F H N 1000000 
123 135 Q R H L 0 K K a R F H N I 1000000 
126 138 L 0 K K a R F H N I R G R 1000000 
129 141 K a R F H N I R G R W T G 1000000 
... 
131 143 R F H N I R G R W T G R C 1000000 
132 144 F H N I R G R W T G R C M 1000000 
-
134 146 N I R G R W T G R C M S C 1000000 
135 147 I R G R W T G R C M 5 C C _____ .. ____ _ 100QQQQ 
138 150 R W T G R C M S C C R S 5 1000000 
- _._- "--
141 153 G R C M S C C R S S R T R 1000000 
--.~ ._--- --
144 156 M S C C R 5 S R T R R E T 1000000 
--------




59 71 I V V R 0 G N P V A V C 0 24 
52 64 F A F R 0 L C I V V R 0 G 35 
75 87 K F V S K I S E V R H V C 83 
86 98 V C V S L V G T· T L E a a 120 
31 43 H 0 I I L E C V V C K a a 135 
58 70 C I V V R 0 G N P V A V C 250 
81 93 S E V R H V C V S L V G T 265 
106 118 L L I R C I N C Q K P L C 290 
43 55 a L L R R E V V 0 F A F R 360 
142 154 R C M S C C R S S R T R R 370 
133 145 H N I R G R W T G R C M S 425 
109 121 R C I N C a K p L C P E E 532 
139 151 W T G R C M S C C R S S R 620 
32 44 0 I I L E C V V C K a a L 660 
28 40 T T I H 0 I I L E C V V C 732 
88 100 V S L V G T T L E a a V N 862 
105 117 0 L L I R C I N C a K P L 930 
137 149 G R W T G R C M S C C R S 1550 
37 49 C V V C K a Q L L R R E V 1600 
78 90 S K I S E V R H V C V S L 2200 
74 86 L K F V S K I S E V R H V 2500 
50 62 V 0 F A F R 0 L C I V V R 2720 
27 39 a T T I H 0 I I L E C V V 3400 
48 60 E V V 0 F A F R 0 L C I V 5300 
82 94 E V R H V C V S L V G T T 6700 
77 89 V S K I S E V R H V C V S .~ 130 142 a R F H N I R G R W T G R 
65 77 N P V A V C 0 K C L K F V 10500 
84 96 R H V C V S L V G T T L E 10500 
91 103 V G T T L E a a V N K P L 11000 
103 115 L C 0 L L I R C I N C a K 12000 
24 36 T E L a T T I H 0 I I L E 17500 
104 116 C 0 L L I R C I N C a K P 20000 
57 69 L C I V V R 0 G N P V A V 20200 
30 42 I H 0 I I L E C V V C K a 27000 
33 451 I L E C V V C K a Q L L 28000 
47 59 R E V V 0 F A F R 0 L C I 45200 
72 84 K C L K F V S K I S E V R 48000 
100 112 N K P L C 0 L L I R C I N 51500 
20 32 P a L c T E L a T T I H 0 54000 
92 104 G T T L E a a V N K P L C 60000 
83 95 V R H V C V S L V G T T L 64500 
6 18 T A M F a 0 P a E R P R K 67000 
42 54 a a L L R R E V V 0 F A F 68500 
26 38 L- a T T I H 0 I I L E C V 75000 
97 109 a a V N K P L C 0 L L I R 79000 
93 105 T T l E a a y N K P L C D 81200 
36 48 E C V Y C K a a L L R R E 82000 
136 148 R G R W T G R C M S C C R 95200 
87 99 C V S L V G T T L E a a V 98000 
Page 1 
E6-DRB10401 
138 150 R W T G R C M S C C R S S 110000 
80 921 S E Y R H Y C Y S L Y G 115000 
89 101 S L Y G T T L E Q Q Y N K 120000 
127 139 0 K K Q R F H N I R G R W 130000 
4 16 K R T A M F Q 0 P Q E R P 175000 
66 78 P Y A V C 0 K C L K F Y S 180000 
135 147 1 R G R W T G R C M S C C 225000 
18 30 K L P Q L C T E L Q T T 1 320000 
16 28 P R K L P Q L C T E L Q T 390000 
55 67 R 0 L C I V Y R 0 G N P Y 402000 
85 97 H Y C Y S L Y G T T L E Q 472000 
71 83 0 K C L K F Y S K 1 S E Y 550000 
90 102 L Y G T T L E Q Q Y N K P 615000 
95 107 L E Q Q Y N K P L C 0 L L 760000 
101 113 K P L C 0 L L 1 R C I N C 780000 
108 1201 R C I N C Q K P L C P E 785000 
54 66 F R 0 L C I V Y R 0 G N P 915000 
1 13 M H Q K R T A M F Q D P Q 1000000 
2 14 H Q K R T A M F Q 0 P Q E 1000000 
3 15 Q K R T A M F Q 0 P Q E R 1000000 
5 17 R T A M F Q 0 P Q E R P R 1000000 
7 19 A M F Q 0 P Q E R P R K L 1000000 
8 20 M F Q 0 P Q E R P R K L P 1000000 
9 21 F Q 0 P Q E R P R K L P Q 1000000 
10 22 Q 0 P Q E R P R K L P Q L 1000000 
11 23 D P Q E R P R K L P Q L C 1000000 
12 24 P Q E R P R K L P Q L C T 1000000 
13 25 Q E R P R K L P Q L C T E 1000000 
14 26 E R P R K L P Q L C T E L 1000000 
15 27 R P R K L P Q L C T E L Q 1000000 
17 29 R K L P Q l C T E l Q T T 1000000 
--
19 31 L P Q L C T E L Q T T 1 H 1000000 
21 33 Q L C T E L Q T T 1 H 0 1 1000000 
22 34L C T E L Q T T I H 0 1 1 1000000 
23 35 C T E L Q T T 1 H D 1 1 L 1000000 
25 37 E L Q T T 1 H 0 1 1 L E C 1000000 
29 41 T I H 0 I 1 L E C V Y C K 1000000 
34 461 L E C V Y C K Q Q L L R 1000000 
35 47 L E C V Y C K Q Q L L R R 1000000 
38 50 V Y C K Q Q L L R R E V Y 1000000 
39 51 Y C K Q Q L L R R E V Y 0 1000000 
40 52 C K Q Q L L R R E V Y D F 1000000 
41 53 K Q Q L L R R E V Y 0 F A 1000000 
44 56 L L R R E V Y D F A F R 0 1000000 
45 57 L R R E V Y 0 F A F R 0 L 1000000 
46 58 R R E V Y 0 F A F R 0 L C 1000000 
49 61 V Y 0 F A F R 0 L C 1 V Y 1000000 
51 63 0 F A F R 0 L C I V Y R 0 1000000 
53 65 A F R D L C I V Y R 0 G N 1000000 
56 68 0 L C 1 V Y R 0 G N P Y A 1000000 
60 72 V Y R 0 G N P Y A V C D K 1000000 
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61 73 Y R 0 G N P Y A V C 0 K C 1000000 
62 74 R 0 G N P Y A V C 0 K C L 1000000 
63 75 0 G N P Y A V C 0 K C L K 1000000 
64 76 G N P Y A V C 0 K C L K F 1000000 
67 79 Y A V C 0 K C L K F Y S K 1000000 
68 80 A V C 0 K C L K F Y S K I 1000000 
69 81 V C 0 K C L K F Y S K I S 1000000 
70 82 C 0 K C L K F Y S K I S E 1000000 
73 85 C L K F Y S K I S E Y R H 1000000 
76 88 F Y S K I S E Y R H Y C Y 1000000 
79 91 K I S E Y R H Y C Y S L Y 1000000 
94 106 T L E Q Q Y N K P L C 0 L 1000000 
96 108 E Q Q Y N K P L C 0 L L I 1000000 
98 110 Q Y N K P L C 0 L L I R C 1000000 
99 111 Y N K P L C 0 L L I R C I 1000000 
102 114 P L C 0 L L I R C I N C Q 1000000 
107 119 L I R C I N C Q K P L C P 1000000 
110 122 C I N C Q K P L C P E E K 1000000 
111 123 I N C Q K P L C P E E K Q 1000000 
112 124 N C Q K P L C P E E K Q R 1000000 
113 125 C Q K P L C P E E K Q R H 1000000 
114 126 Q K P L C P E E K Q R H L 1000000 
115 127 K P L C P E E K a R H L 0 1000000 
116 128 P L C P E E K a R H L 0 K 1000000 
117 129 , C P E E K Q R H L 0 K K 1000000 .... 
118 130 C P E E K Q R H L 0 K K Q 1000000 
119 131 P E E K a R H L 0 K K Q R 1000000 
120 132 E E K Q R H L 0 K K a R F 1000000 
121 133 E K a R H L 0 K K a R F H 1000000 
122 134 K Q R H L 0 K K a R F H N 1000000 
123 135 a R H L 0 K K Q R F H N I 1000000 
124 136 R H L 0 K K Q R F H N I R 1000000 
125 137 H L 0 K K Q R F H N I R G 1000000 
126 138 L 0 K K Q R F H N I R G R 1000000 
128 140 K K Q R F H N I R G R W T 1000000 
129 141 K Q R F H N I R G R W T G 1000000 
131 143 R F H N I R G R W T G R C 1000000 
132 144 F H N I R G R W T G R C M 1000000 
134 146 N I R G R W T G R C M S C 1000000 
140 152 T G R C M S C C R S S R T 1000000 
141 153 G R C M S C C R S S R T R 1000000 
143 155 C M S C C R S S R T R R E 1000000 
144 156 M S C C R S S R T R R E T 1000000 
145 157 S C C R S S R T R R E T Q 1000000 
146 158 C C R S S R T R R E T Q L 1000000 
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IC50 ORB1 *01 01JnM) 
81 93 0 L L M G T L G I V C P I 45.2 
80 92 E 0 L L M G T L G I V C P 230 
52 64 Y N I V T F C C K C 0 S T 300 
55 67 V T F C C K C 0 S T L R L 1120 
10 22 E Y M L 0 L a p E T T 0 L 1600 
77 89 R T L E 0 L L M G T L G I 1800 
74 86 V 0 I R T L E 0 L L M G T 2200 
21 33 0 L Y C Y E a L N 0 S S E 4550 
63 75 S T L R L C V Q S T H V 0 5600 
50 62 A H Y N I V T F C C K C 0 8020 
67 79 L C V Q S T H V 0 I R T L 8950 
36 48 0 E I 0 G P A G a A E P 0 9420 
65 77 L R L C V a s T H V 0 I R 11000 
20 32 T 0 L Y C Y E a L N 0 S S 13000 
79 91 L E 0 L L M G T L G I V C 18500 
9 21 H E Y M L 0 L a p E T T 0 25000 
85 97 G T L G I V C P I C S a K 28200 
23 35 Y C Y E Q L N 0 S S E E E 28500 
46 58 E P 0 R A H Y N I V T F C 33500 
35 47 E 0 E I 0 G P A G Q A E P 47500 
83 95 L M G T L G I V C P I C S 51000 
82 94 L L M G T L G I V C P I C 56500 
53 65 N I V T F C C K C 0 S T L 60000 
.-
17 29 P E T T 0 L Y C Y E a L N 64500 
62 74 0 S T L R L C V a s T H V 67500 
57 69 F C C K C 0 S T L R. L C V 97500 
13 25 L 0 L Q P E T T 0 L Y C Y 140000 
51 63 H Y N I V T F C C K C 0 S 315000 
59 71 C K C 0 S T L R L C V Q S 405000 
84 96 M G T L G I V C P I C S Q 410000 
.-
6 18 P T L H E Y M L 0 L a P E 435000 
58 70 C C K C 0 S T L R L C V a 572000 
72 84 T H V 0 I R T L E 0 L L M 670000 
69 81 V a s T H V 0 I R T L E 0 720000 
60 72 K C 0 S T L R L C V a s T 815000 
61 73 C 0 S T L R L C V a s T H 850000 
1 13 M H G 0 T P T L H E Y M L 1000000 
2 14 H G 0 T P T L H E Y M L 0 1000000 
3 15 G D T P T L H E Y M L 0 L 1000000 
4 16 0 T P T L H E Y M L 0 L a 1000000 
5 17 T P T L H E Y M L 0 L a p 1000000 
7 19 T L H E Y M L 0 L a p E T 1000000 
8 20 L H E Y M L 0 L a P E T T 1000000 
11 23 y. M L 0 L a P E T T 0 L Y 1000000 
12 24 M L 0 L a P E T T 0 L Y C 1000000 
14 26 0 L a P E T T 0 L Y C Y E 1000000 
15 27 L a P E T T 0 L Y C Y E a 1000000 
16 28 Q P E T T 0 L Y C Y E a L 1000000 
18 30 E T T 0 L Y C Y E Q L N 0 1000000 
19 31 T T 0 L Y C Y E Q L N 0 S 1000000 
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22 34 L Y C Y E Q L N 0 S S E E 1000000 
24 36 C Y E Q L N 0 S S E E E 0 1000000 
25 37 Y E Q L N 0 S S E E E 0 E 1000000 
26 38 E Q L N 0 S S E E E 0 E I 1000000 
27 39 Q L N 0 S S E E E 0 E I 0 1000000 
28 40 L N 0 S S E E E 0 E I 0 G 1000000 
29 41 N 0 S S E E E 0 E I 0 G P 1000000 
30 42 0 S S E E E 0 E I 0 G P A 1000000 
31 43 S S E E E 0 E I 0 G P A G 1000000 
32 44 S E E E 0 E I 0 G P A G Q 1000000 
33 45 E E E 0 E I 0 G P A G Q A 1000000 
34 46 E E 0 E I 0 G P A G Q A E 1000000 
37 49 E I 0 G P A G Q A E P 0 R 1000000 
38 50 I 0 G P A G Q A E P 0 R A 1000000 
39 51 0 G P A G Q A E P 0 R A H 1000000 
40 52 G P A G Q A E P 0 R A H Y 1000000 
41 53 P A G Q A E P 0 R A H Y N 1000000 
42 54 A G Q A E P 0 R A H Y N I 1000000 
43 55 G Q A E P 0 R A H Y N I V 1000000 
44 56 Q A E P 0 R A H Y N I V T 1000000 
45 57 A E P 0 R A H Y N I V T F 1000000 
47 59 P 0 R A H Y N I V T F C C 1000000 
48 60 0 R A H Y N I V T F C C K 1000000 
49 61 R A H Y N I V T F C C K C 1000000 
54 66 I V T F C C K C 0 S T L R 1000000 
56 68 T F C C K C 0 S T L R L C 1000000 
64 76 T L R L C V Q S T H V 0 I 1000000 
66 78 R L C V Q S T H V 0 I R T 1000000 
68 80 C V Q S T H V 0 I R T L E 1000000 
70 82 Q S T H V 0 I R T L E 0 L 1000000 
71 83 S T H V 0 I R T L E 0 L L 1000000 
73 85 H V 0 I R T L E 0 L L M G 1000000 
75 87 0 I R T L E 0 L L M G T L 1000000 
76 88 I R T L E 0 L L M G T L G 1000000 
78 90 T L E 0 L L M G T L G I V 1000000 
-
86 98 T L G I V C P I C S Q K P 1000000 
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IC50 ORBl ·0401 (nM) 
21 33 0 L Y C Y E Q L N 0 S S E 105 
9 21 H E Y M L 0 L Q P E T T 0 210 
84 96 M G T L G I V C P I C S a 230 
63 75 S T L R L C V Q S T H V 0 452 
81 93 0 L L M G T L G I V C P I 710 
85 97 G T L G I V C P I C S Q K 920 
53 65 N I V T F C C K C 0 S T L 1700 
80 92 E 0 L L M G T L G I V C P 1800 
50 62 A H Y N I V T F C C K C 0 2600 
74 86 V 0 I R T L E 0 L L M G T 2650 
67 79 L C V Q S T H V 0 I R T L 3700 
17 29 P E T T 0 L Y C Y E Q L N 4750 
82 94 L L M G T L G I V C P I C 5120 
65 77 L R L C V Q S T H V 0 I R 5600 
20 32 T 0 L Y C Y E a L N 0 S S 6720 
48 60 0 R A H Y N I V T F C C K . 7120 
13 25 L 0 L a p E T T 0 L Y C Y 7300 
10 22 E Y M L 0 L Q P E T .T 0 L 9320 
6 18 P T L H E Y M L 0 L Q P E 9700 
54 66 I V T F C C K C 0 S T L R 11500 
52 64 Y N I V T F C C K C 0 S T 16500 
51 63 H Y N I V T F C C K C 0 S 30000 
83 95 L M G T L G I V C P I C S 53000 
57 69 F C C K C 0 S T L R L C V 60000 
55 67 V T F C C K C 0 S T L R L 62500 
75 87 0 I R T L E 0 L L M G T L 68000 
49 61 R A H Y N I V T F C C K C 76200 
5 17 T P T L H E Y M L 0 L a p 96500 
79 91 L E 0 L L M G T L G I V C 110000 
46 58 E P 0 R A H Y N I V T F C 122000 
64 76 T L R L C V Q S T H V 0 I 132000 
76 88 I R T L E 0 L L M G T L G 145000 
86 98 T L G I V C P I C S Q K P 202000 
77 89 R T L E 0 L L M G T L G I 260000 
18 30 E T T 0 L Y C Y E Q L N 0 535000 
62 74 0 S T L R L C V Q S T H V 580000 
26 38 E Q L N 0 S S E E E 0 E I 590000 
60 72 K C 0 S T L R L C V Q S T 695000 
71 83 S T H V 0 I R T L E 0 L L 870000 
24 36 C Y E Q L N 0 S S E E E D 952000 
1 13 M H G 0 T P T L H E Y M L 1000000 
2 14 H G 0 T P T L H E Y M L 0 1000000 
3 15 G 0 T P T L H E Y M L 0 L 1000000 
4 16 0 T P T L H E Y M L 0 L Q 1000000 
7 19 T L H E Y M l 0 l Q P E T 1000000 
8 20 L H E Y M L 0 l Q P E T T 1000000 
11 23 Y M l 0 l Q P E T T 0 L Y 1000000 
12 24 M l 0 L Q P E T T D l Y C 1000000 
14 26 D L a p E T T 0 L Y C Y E 1000000 
15 27 L a p E T T 0 L Y C Y E Q 1000000 
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16 28 Q P E T T 0 L Y C Y E a L 1000000 
19 31 T T 0 L Y C Y E Q L N 0 5 1000000 
22 34 L Y C Y E a L N 0 S S E E 1000000 
23 35 Y C Y E a L N 0 5 S E E E 1000000 
25 37 Y E a L N 0 S S E E E 0 E 1000000 
27 39 a L N 0 5 S E E E 0 E I 0 1000000 
28 40 L N 0 S S E E E 0 E I 0 G 1000000 
29 41 N 0 S S E E E 0 E I 0 G P 1000000 
30 42 0 S 5 E E E 0 E I 0 G P A 1000000 
31 43 5 S E E E 0 E I 0 G P A G 1000000 
32 44 S E E E 0 E I 0 G P A G a 1000000 
33 45 E E E 0 E I 0 G P A G Q A 1000000 
34 46 E E 0 E I 0 G P A G Q A E 1000000 
35 47 E 0 E I 0 G P A G Q A E P 1000000 
36 48 0 E I 0 G P A G Q A E P 0 1000000 
37 49 E I 0 G P A G Q A E P 0 R 1000000 
38 50 I 0 G P A G Q A E P 0 R A 1000000 
39 51 0 G P A G Q A E P 0 R A H 1000000 
40 52 G P A G Q A E P 0 R A H Y 1000000 
41 53 P A G Q A E P 0 R A H Y N 1000000 
42 54 A G Q A E P 0 R A H Y N I 1000000 
43 55 G Q A E P 0 R A H Y N I V 1000000 
44 56 a A E P 0 R A H Y N I V T 1000000 
45 57 A E P 0 R A H Y N I V T F 1000000 
47 59 P 0 R A H Y N I V T F C C 1000000 
56 68 T F C C K C 0 S T L R L C 1000000 
58 70 C C K C 0 S T L R L C v a 1000000 
59 71 C K C 0 S T L R L C V Q S 1000000 
61 73 C 0 S T L R L C V Q S T H 1000000 
66 78 R L C v a s T H V 0 I R T 1000000 
68 80 C V Q S T H V 0 I R T L E 1000000 
69 81 V Q S T H V 0 I R T L E 0 1000000 
70 82 Q S T H V 0 I R T L E 0 L 1000000 
72 84 T H V 0 I R T L E 0 L L M 1000000 
73 85 H V 0 I R T L E 0 L L M G 1000000 
78 90 T L E 0 L L M G T L G I V 1000000 
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IG50 DRB1*0101 (nM) 
58 70 N 1 Y Y H A G T S R L L A 1.5 
3 15 V T F 1 Y I L V 1 T C Y E 1.85 
398 410 L Q F 1 F Q L C K 1 T L T 2.85 
414 426 M T Y 1 H S M N S T 1 L E 3.25 
442 454 0 T Y R F V T Q A 1 A C Q 4.42 
300 312 0 L Y I K G S G S T A N L 5.05 
315 327 S N Y F P T P S G S M V T 6.4 
59 71 1 Y Y H A G T S R L L A V 7.25 
159 171 S A Y A A N A G V 0 N R E 22.5 
21 33 H H 1 F F Q M S L W L P S 28.5 
124 136 L V W A C V G V E V G R G 28.5 
234 246 M 0 F T T L Q A N K S E V 33 
5 17 F I Y I L V I T C Y E N 0 36 
468 480 K K Y T F W E V N L K E K 36 
273 285 F F Y L R R E Q M F V R H 54 
280 292 Q M F V R H L F N R A G T 57 
67 79 R L L A V G H P Y F P I K 65.5 
1 13 M Q V T F 1 Y I L V 1 T C 67.5 
281 293 M F V R H L F N R A G T V 84 
94 106 L Q Y R V F R I H L P 0 P 86 
175 187 M 0 Y K Q T Q L C L I G C 89.5 
22 34 H 1 F F Q M S L W L P S E 90.2 
45 57 S K V V S T 0 E Y V A R T 92 
366 378 T N M S L C A A I S T S E 93 
114 126 T S F Y N P 0 T Q R L V W 96.5 
212 224 P P L E L I N T V 1 Q 0 G 110 
337 349 Y W L Q R A Q G H N N G I 115 
504 516 P K F T L G K R K A T P T 115 
123 135 R L V W A C V G V E V G R 120 
52 64 E Y V A R T N I Y Y H A G 122 
335 347 K P Y W L Q R A Q G H N N 130 
84 96 N K 1 L V P K V S G L Q Y 150 
492 504 R K F L L Q A G L K A K P 150 
76 88 F P 1 K K P N N N K 1 L V 152 
405 417 C K 1 T L T A 0 V M T Y 1 152 
6 181 Y 1 L V 1 T C Y E N 0 V 160 
85 97 K 1 L V P K V S G L Q Y R 165 
150 162 N K L 0 0 T E N A S A Y A 190 
285 297 H L F N R A G T V G E N V 195 
23 351 F F Q M S L W L P S E A 200 
115 127 S F Y N P 0 T Q R L V W A 205 
412 424 0 V M T Y I H S M N S T 1 240 
51 63 0 E Y V A R T N 1 Y Y H A 260 
129 141 V G V E V G R G Q P L G V 265 
12 24 T C Y E N 0 V N V H H 1 F 432 
9 21 L V 1 T C Y E N 0 V N V H 505 
248 260 L 0 1 C T S I C K Y P 0 Y 540 
394 406 E E Y 0 L Q F 1 F Q L C K 540 
271 283 S L F F Y L R R E Q M F V 550 
445 457 R F V T Q A I A C Q K H T 570 
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270 282 0 S l F F Y L R R E Q M F 582 
299 311 0 0 L Y I K G S G S T A N 630 
36 48 T V Y L P P V P V S K V V 680 
347 359 N G I C W G N Q L F V T V 700 
182 194 l C L I G C K P P I G E H 835 
411 423 A 0 V M T Y I H S M N S T 845 
27 39 M S L W l P S E A T V Y l 860 
430 442 F G l Q P P P G G T l E 0 860 
173 185 I S M 0 Y K Q T a l c L I 912 
224 236 G 0 M V H T G F G A M 0 F 1720 
89 101 P K V S G L Q Y R V F R I 1900 
258 270 P 0 Y l K M V S E P Y G 0 1950 
423 435 T I L E 0 W N F G l a p p 2250 
237 249 T T L Q A N K S E V P l 0 2500 
336 348 P Y W l a R A a G H N N G 2620 
225 237 0 M V H T G F G A M 0 F T 2650 
399 411 a F I F a L c K I T l T A 2800 
353 365 N Q l F V T V V 0 T T R S 2950 
331 343 a I F N K P Y W l Q R A a 3050 
193 205 E H W G K G S P C T N V A 3250 
310 322 A N L A S S N Y F P T P S 3300 
180 192 T Q l C l I G C K P P I G 3600 
444 456 Y R F V T Q A I A C Q K H 3700 
330 342 A a I F N K P Y W L Q R A 3720 
357 369 V T V V 0 T T R S T N M S 3750 
18 30 V N V H H I F F Q M S L W 3800 
246 258 V P l 0 I C T S I C K Y P 4150 
323 335 G S M V T S 0 A a I F N K 4200 
426 438 E 0 W N F G l Q P P P G G 4350 
219 231 T V I Q 0 G 0 M V H T G F 4550 
202 214 T N V A V N P G 0 C P P L 4750 
141 153 V G I S G H P L l N K L 0 5020 
379 391 T T Y K N T N F K E Y L R 5050 
122 134 a R L V W A C V G V E V G 5320 
8 20 I L V I T C Y E N 0 V N V 5400 
25 37 F a M s l W l P S E A T V 5450 
88 100 V P K V S G l Q Y R V F R 5500 
231 243 F G A M 0 F T T l a A N K 5750 
396 408 Y 0 l Q F I F Q L C K I T 5900 
329 341 0 A a I F N K P Y W l a R 5950 
252 264 T S I C K Y P 0 Y l K M V 6250 
16 28 N 0 V N V H H I F F a M s 6600 
131 143 V E V G R G Q P l G V G I 7220 
261 273 L K M V S E P Y G 0 S L F 7220 
364 376 R S T N M S L C A A I S T 7600 
92 104 S G l a Y R V F R I H L P 7920 
470 482 Y T F W E V N l K E K F S 8150 
165 177 A G V 0 N R E C I S M 0 Y 8320 
483 495 A 0 l 0 a F p l G R K F l 8600 
138 150 P l G V G I S G H P l L N 9950 
365 377 S T N M S L C A A I S T S 11000 
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97 109 R V F R I H L P 0 P N K F 12500 
349 361 I C W G N Q L F V T V V 0 12500 
303 315 I K G S G S T A N L A S S 13000 
384 396 T N F K E Y L R H G E E Y 13000 
479 491 E K F S A 0 L 0 Q F P L G 13000 
493 505 K F L L a A G L K A K P K 13000 
137 149 a p L G V G I S G H P L L 14500 
400 412 F I F Q L C K· I T L T A 0 15200 
465 477 0 P L K K Y T F W E V N L 15200 
441 453 E 0 T Y R F V T a A I A C 16000 
73 85 H P Y F P I K K P N N N K 17000 
127 139 A C V G V E V G R G a p L 17000 
155 167 T E N A S A Y A A N A G V 17200 
388 400 E Y L R H G E E Y 0 L Q F 19200 
34 46 E A T V Y L P P v P v S K 19500 
387 399 K E Y L R H G E E Y 0 L a 21000 
438 450 G T L E 0 T Y R F V T Q A 21000 
156 168 E N A S A Y A A N A G V 0 21500 
171 183 E C I S M 0 Y K a T a L c 21500 
153 165 0 0 T E N A S A Y A A N A 23200 
232 244 G A M 0 F T T L a A N K S 23500 
13 25 C Y E N 0 V N V H H I F F 24000 
278 290 R E a M F V R H L F N R A 24000 
306 318 S G S T A N L A S S N Y F 25200 
410 422 T A 0 V M T Y I H S M N S 25200 
513 525 A T P T T S S T S T T A K 25500 
56 68 R T N I Y Y H A G T S R L 26500 
272 284 L F F Y L R R E Q M F V R 26500 
408 420 T L T A 0 V M T Y I H S M 27500 
126 138 W A C V G V E V G R G Q P 31500 
259 271 0 Y L K M V S E P Y G 0 S 32000 
317 329 Y F P T P S G S M V T S 0 33500 
373 385 A I S T S E T T Y K N T N 36000 
497 509 Q A G L K A K P K F T L G 39000 
47 59 V V S T 0 E Y V A R T N I 39500 
415 427 T Y I H S M N S T I L E 0 40200 
77 89 P I K K P N N N K I L V P 41200 
86 98 I L V P K V S G L a y R V 45000 
214 226 L E L I N T V I Q 0 G 0 M 45000 
324 336 S M V T S 0 A a I F N K P 46000 
2 14 Q V T F I Y I L V I T C Y 47000 
316 328 N Y F P T P S G S M V T S 47200 
475 487 V N L K E K F S A 0 L 0 a 48200 
309 321 T A N L A S S N Y F P T P 51000 
176 188 0 Y K a T a L c L I G C K 54500 
401 413 I F Q L C K I T L T A 0 V 54500 
443 455 T Y R F V T Q A I A C a K 55500 
50 62 T 0 E Y V A R T N I Y Y H 56000 
301 313 L Y I K G S G S T A N L A 58000 
63 75 A G T S R L L A V G H P Y 58500 
283 295 V R H L F N R A G T V G E 65000 
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37 49 V Y L P P V P V S K V V S 66000 
204 216 V A V N P G 0 C P P L E L 66000 
276 288 L R R E Q M F V R H L F N 66000 
29 41 L W L P S E A T V Y L P P 67200 
502 514 A K P K F T L G K R K A T 70500 
352 364 G N Q L F V T V V 0 T T R 71000 
107 119 N K F G F P 0 T S F Y N P 72000 
179 191 Q T Q L C L I G C K P P I 74000 
327 339 T S 0 A Q I F N K P Y W L 74000 
488 500 F P L G R K F L L Q A G L 74500 
222 234 Q 0 G 0 M V H T G F G A M 76000 
196 208 G K G S P C T N V A V N P 79000 
494 506 F L L Q A G L K A K P K F 82000 
91 103 V S G L Q Y R V F R I H L 86000 
322 334 S G S M V T S 0 A Q I F N 89200 
35 47 A T V Y L P P V P V S K V 92500 
40 52 P P V P V S K V V S T 0 E 93500 
82 94 N N N K I L V P K V S G L 99000 
422 434 S T I L E 0 W N F G L Q P 100000 
19 31 N V H H I F F Q M S L W L 102000 
355 367 L F V T V V 0 T T R S T N 102000 
471 483 T F W E V N L K E K F S A 102000 
360 372 V 0 T T R S T N M S L C A 110000 
218 230 N T V I Q 0 G 0 M V H T G 112000 
340 352 Q R A Q G H N N G I C W G 112000 
266 278 E P Y G 0 S L F F Y L R R 115000 
223 235 0 G 0 M V H T G F G A M 0 120000 
7 19 Y I L V I T C Y E N 0 V N 125000 
199 211 S P C T N V A V N P G D C 130000 
358 370 T V V 0 T T R S T N M S L 130000 
362 374 T T R S T N M S L C A A I 130000 
428 440 W N F G L Q P P P G G T L 130000 
215 227 E L I N T V I Q D· G 0 M V 132000 
57 69 T N I Y Y H A G T S R L L 140000 
198 210 G S P C T N V A V N P G 0 142000 
183 195 C L I G C K P P I G E H W 145000 
60 72 y' Y H A G T S R L L A V G 150000 
262 274 K M V S E P Y G 0 S L F F 152000 
429 441 N F G L Q P P P G G T L E 155000 
157 169 N A S A Y A A N A G V 0 N 162000 
64 76 G T S R L L A V G H P Y F 165000 
498 510 A G L K A K P K F T 'L G K 165000 
140 152 G V G I S G H P L L N K L 170000 
152 164 L 0 0 T E N A S A Y A A N 170000 
370 382 L C A A I S T S E T T Y K 172000 
28 40 5 L W L P 5 E A T V Y L P 180000 
343 355 Q G H N N G I C W G N Q L 182000 
118 130 N P 0 T Q R L V W A C V G 200000 
314 326 S S N Y F P T P S G S M V 200000 
381 393 Y K N T N F K E Y L R H G 202000 
369 381 S L C A A I S T S E T T Y 205000 
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65 77 T 5 R L L A V G H P Y F P 210000 
189 201 P P I . G E H W G K G S P C 210000 
93 105 G l Q Y R V F R I H l P 0 220000 
121 133 T Q R l V W A C V G V E V 220000 
359 371 V V 0 T T R S T N M S l C 225000 
346 358 N N G I C W G N Q l F V T 232000 
33 45 S E A T V Y l P P V P V S 235000 
53 65 Y V A R T N I Y Y H A G T 240000 
170 182 R E C I S M 0 Y K Q T Q l 240000 
397 409 0 l Q F I F Q l C K I T l 240000 
447 459 V T Q A I A C Q K H T P P 242000 
286 298 l F N R A G T V G E N V P 245000 
46 58 K V V S T 0 E Y V A R T N 250000 
255 267 C K Y P 0 Y l K M V S E P 250000 
120 132 0 T Q R l V W A C V G V E 252000 
30 42 W l P S E A T V Y l P P V 260000 
117 129 Y N P 0 T Q R l V W A C V 270000 
424 436 I l E 0 W N F G l Q P P P 270000 
403 415 Q l C K I T l T A 0 V M T 275000 
404 416 l C K I T l T A 0 V M T Y 335000 
48 60 V S T 0 E Y V A R T N I Y 340000 
274 286 F Y l R R E Q M F V R H l 380000 
495 507 l l Q A G l K A K P K F T 380000 
260 272 Y l K M V S E P Y G 0 S Il 382000 
339 351 l Q R A Q G H N N G I C W 385000 
511 523 R K A T P T T 5 5 T S T T 390000 
287 299 F N R A G T V G E N V P 0 392000 
356 368 F V T V V 0 T T R S T N M 400000 
158 170 A S A Y A A N A G V 0 N R 402000 
54 66 V A R T N I Y Y H A G T 5 415000 
269 281 G 0 S l F F Y l R R E Q M 430000 
240 252 Q A N K S E V P l 0 I C T 440000 
20 32 V H H I F F Q M S l W l P 442000 
267 279 P Y G 0 S l F F Y l R R E 455000 
99 111 F R I H l P 0 P N K F G F 462000 
81 93 P N N N K I l V P K V S G 485000 
62 74 H A G T S R L L A V G H P 500000 
393 405 G E E Y 0 l Q F I F Q l C 512000 
109 121 F G F P 0 T 5 F Y N P 0 T 555000 
307 319 G S T A N l A S S N Y F P 555000 
154 166 0 T E N A S A Y A A N A G 562000 
416 428 Y I H S M N S T I L E 0 W 572000 
66 78 S R L L A V G H P Y F P I 575000 
134 146 G R G Q P L G V G I S G H 575000 
418 430 H S M N S T I l E 0 W N F 580000 
334 346 N K P Y W l Q R A Q G H N 605000 
4B4 496 0 l 0 Q F P L G R K F L L 605000 
100 112 R I H L P 0 P N K F G F P 625000 
446 458 F V T Q A I A C Q K H T P 635000 
247 259 P L 0 I C T S I C K Y P 0 660000 
201 213 C T N V A V N P G 0 C P P 670000 
Page 5 
L1-DRB10101 
449 461 Q A I A C a K H T P P A P 710000 
344 356 G H N N G I C W G N a L F 752000 
31 43 L P S E A T V Y L P P v P 770000 
111 123 F P 0 T S F Y N P 0 T a R 770000 
348 360 G I C W G N Q L F V T V V 770000 
105 117 0 P N K F G F P 0 T S F Y 775000 
112 124 P 0 T S F Y N P 0 T Q R L 782000 
367 379 N M S L C A A I S T S E T 782000 
83 95 N N K I L V P K V S G L Q 602000 
220 232 V I a 0 G 0 M V H T G F G 810000 
321 333 P S G S M V T S 0 A a I F 810000 
439 451 T L E 0 T Y R F V T a A I 842000 
489 501 P L G R K F L L a A G L K 905000 
282 294 F V R H L F N R A G T V G 915000 
354 366 a L F V T V V 0 T T R S T 980000 
26 38 a M s L W L P S E A T V Y 995000 
4 16 T F I Y I L V I T C Y E N 1000000 
10 22 V I T C Y E N 0 V N V H H 1000000 
11 23 I T C Y E N 0 V N V H H I 1000000 
14 26 Y E N 0 V N V H H I F F Q 1000000 
15 27 E N 0 V N V H H I F F Q M 1000000 
17 29 0 V N V H H I F F Q M S L 1000000 
24 36 F F a M s L W L P S E A T 1000000 
32 44 P S E A T V Y L P P v P V 1000000 
38 50 Y L P P v P v S K V V S T 1000000 
39 51 L P P v P v S K V V S T 0 1000000 
41 53 P V P V S K V V S T 0 E Y 1000000 
42 54 V P V S K V V S T 0 E Y V 1000000 
43 55 P V S K V V S T 0 E Y V A 1000000 
44 56 V S K V V S T 0 E Y V A R 1000000 
49 61 S T 0 E Y V A R T N I Y Y 1000000 
55 67 A R T N I Y Y H A G T S R 1000000 
61 73 Y H A G T S R L L A V G H 1000000 
68 80 L L A V G H P Y F P I K K 1000000 
69 81 L A V G H P Y F P I K K P 1000000 
70 62 A V G H P Y F P I K K P N 1000000 
71 83 V G H P Y F P I K K P N N 1000000 
72 84 G H P Y F P I K K P N N N 1000000 
74 86 P Y F P I K K P N N N K I 1000000 
75 87 Y F P I K K P N N N K I L 1000000 
78 90 I K K P N N N K I L V P K 1000000 
79 91 K K P N N N K I L V P K V 1000000 
80 92 K P N N N K I L V P K V S 1000000 
87 99 L V P K V S G L Q Y R V F 1000000 
90 102 K V S G L Q Y R V F R I H 1000000 
95 107 Q Y R V F R I H L P 0 P N 1000000 
96 106 Y R V F R I H L P 0 P N K 1000000 
98 110 V F R I H L P 0 P N K F G 1000000 
101 113 I H L P 0 P N K F G F P 0 1000000 
102 114 H L P 0 P N K F G F P 0 T 1000000 
103 115 L P 0 P N K F G F P 0 T S 1000000 
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104 116 P 0 P N K F G F P 0 T S F 1000000 
106 118 P N K F G F P 0 T S F Y N 1000000 
108 120 K F G F P 0 T S F Y N P 0 1000000 
110 122 G F P 0 T S F Y N P 0 T a 1000000 
113 125 0 T S F Y N P 0 T a R l V 1000000 
116 128 F Y N P 0 T a R l V W A C 1000000 
119 131 P 0 T a R l V W A C V G V 1000000 
125 137 V W A C V G V E V G R G a 1000000 
128 140 C V G V E V G R G a P l G 1000000 
130 142 G V E V G R G a p l G V G 1000000 
132 144 E V G R G a p l G V G I S 1000000 
133 145 V G R G a p l G V G I S G 1000000 
135 147 R G a p l G V G I S G H P 1000000 
136 148 G a P l G V G I S G H P l 1000000 
139 151 l G V G I S G H P l l N K 1000000 
142 154 G I S G H P l l N K l 0 0 1000000 
143 155 I S G H P l L N K L 0 0 T 1000000 
144 156 S G H P L L N K L 0 0 T E 1000000 
145 157 G H P L L N K l 0 0 T E N 1000000 
146 158 H P L L N K L 0 0 T E N A 1000000 
147 159 P l l N K L 0 0 T E N A S 1000000 
148 160 L L N K L 0 0 T E N A S A 1000000 
149 161 L N K L 0 0 T E N A S A Y 1000000 
151 163 K L 0 0 T E N A S A Y A A 1000000 
160 172 A Y A A N A G V 0 N R E C 1000000 
161 173 Y A A N A G V 0 N R E C I 1000000 
162 174 A A N A G V 0 N R E C I S 1000000 
163 175 A N A G V 0 N R E C I S M 1000000 
164 176 N A G V 0 N R E C I S M 0 1000000 
166 178 G V 0 N R E C I S M 0 Y K 1000000 
167 179 V 0 N R E C I S M 0 Y K a 1000000 
168 180 0 N R E C I S M 0 Y K Q T 1000000 
169 181 N R E C I S M 0 Y K Q T a 1000000 
172 184 C I S M 0 Y K Q T Q L C L 1000000 
174 186 S M 0 Y K Q T Q L C L I G 1000000 
177 189 Y K a T a L c L I G C K P 1000000 
178 190 K a T a L c L I G C K P P 1000000 
181 193 a L c L I G C K P P I G E 1000000 
184 196 L I G C K P P I G E H W G 1000000 
185 197 I G C K P P I G E H W G K 1000000 
186 198 G C K P P I G E H W G K G 1000000 
187 199 C K P P I G E H W G K G S 1000000 
188 200 K P P I G E H W G K G S P 1000000 
190 202 P I G E H W G K G S P C T 1000000 
191 203 I G E H W G K G S P C T N 1000000 
192 204 G E H W G K G S P C T N V 1000000 
194 206 H W G K G S P C T N V A V 1000000 
195 207 W G K G S P C T N, V A V N 1000000 
197 209 K G S P C T N V A V N P G 1000000 
200 212 P C T N V A V N P G 0 C P 1000000 
203 215 N V A V N P G D C P P L E 1000000 
Page 7 
L1-DRB10101 
205 217 A V N P G D C P P L E L I 1000000 
206 218 V N P G 0 C P P L E L I N 1000000 
207 219 N P G D C P P L E L I N T 1000000 
208 220 P G 0 C P P L E L I N T V 1000000 
209 221 G 0 C P P L E L I N T V I 1000000 
210 222 0 C P P L E L I N T V I Q 1000000 
211 223 C P P L E L I N T V I Q 0 1000000 
213 225 P L E L I N T V I Q 0 G 0 1000000 
216 228 L I N T V I Q 0 G 0 M V H 1000000 
217 229 I N T V I Q 0 G 0 M V H T 1000000 
221 233 I Q 0 G 0 M V H T G F G A 1000000 
226 238 M V H T G F G A M 0 F T T 1000000 
227 239 V H T G F G A M 0 F T T L 1000000 
228 240 H T G F G A M 0 F T T L Q 1000000 
229 241 T G F G A M 0 F T T L Q A 1000000 
230 242 G F G A M 0 F T T L Q A N 1000000 
233 245 A M 0 F T T L Q A N K S E 1000000 
235 247 0 F T T L Q A N K S E V P 1000000 
236 248 F T T L Q A N K S E V P L 1000000 
238 250 T L Q A N K S E V P L 0 I 1000000 
239 251 L Q A N K S E V P L 0 I C 1000000 
241 253 A N K S E V P L 0 I C T S 1000000 
242 254 N K S E V P L 0 I C T S I 1000000 
243 255 K S E V P L 0 I C T S I C 1000000 
244 256 S E V P L 0 I C T S I C K 1000000 
245 257 E V P L 0 I C T S I C K Y 1000000 
249 261 0 I C T S I C K Y P 0 Y L 1000000 
250 262 I C T S I C K Y P 0 Y L K 1000000 
251 263 C T S I C K Y P 0 Y L K M 1000000 
253 265 S I C K Y P 0 Y L K M V S 1000000 
254 266 I C K Y P 0 Y L K M V S E 1000000 
256 268 K Y P 0 Y L K M V S E P Y 1000000 
257 269 Y P 0 Y L K M V S E P Y G 1000000 
263 275 M V S E P Y G 0 S L F F Y 1000000 
264 276 V S E P Y G 0 S L F F Y L 1000000 
265 277 S E P Y G 0 S L F F Y L R 1000000 
268 280 Y G 0 S L F F Y L R R E Q 1000000 
275 287 Y L R R E Q M F V R H L F 1000000 
277 289 R R E Q M F V R H L F N R 1000000 
279 291 E Q M F V R H L F N R A G 1000000 
284 296 R H L F N R A G T V G E N 1000000 
288 300 N R A G T V G E N V P 0 0 1000000 
289 301 R A G T V G E N V P 0 0 L 1000000 
290 302 A G T V G E N V P 0 0 L Y 1000000 
291 303 G T V G E N V P 0 0 L Y I 1000000 
292 304 T V G E N V P 0 0 L Y I K 1000000 
293 305 V G E N V P 0 0 L Y I K G 1000000 
294 306 G E N V P 0 0 L Y I K G S 1000000 
295 307 E N V P 0 0 L Y I K G S G 1000000 
296 308 N V P 0 0 L Y I K G S G S 1000000 
297 309 V P 0 0 L Y I K G S G S T 1000000 
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298 310 P 0 0 L Y I K G S G S T A 1000000 
302 314 Y I K G S G S T A N L A S 1000000 
304 316 K G S G S T A N L A S S N 1000000 
305 317 G S G S T A N L A S S N Y 1000000 
308 320 S T A N L A S S N Y F P T 1000000 
311 323 N L A S S N Y F P T P S G 1000000 
312 324 L A S S N Y F P T P S G S 1000000 
313 325 A S S N Y F P T P S G S M 1000000 
318 330 F P T P S G S M V T S 0 A 1000000 
319 331 P T P S G S M V T S 0 A Q 1000000 
320 332 T P S G S M V T S 0 A Q I 1000000 
325 337 M V T S 0 A Q I F N K P Y 1000000 
326 338 V T S 0 A Q I F N K P Y W 1000000 
328 340 S 0 A Q I F N K P Y W L Q 1000000 
332 344 I F N K P Y W L Q R A Q G 1000000 
333 345 F N K P Y W L Q R A Q G H 1000000 
338 350 W L Q R A Q G H N N G I C 1000000 
341 353 R A Q G H N N G I C W G N 1000000 
342 354 A Q G H N N G I C W G N Q 1000000 
345 357 H N N G I C W G N Q L F V 1000000 
350 362 C W G N Q L F V T V V 0 T 1000000 
351 363 W G N Q L F V T V V 0 T T 1000000 
361 373 0 T T R S T N M S L C A A 1000000 
363 375 T R S T N M S L C A A I S 1000000 
368 380 M S L C A A I S T S E T T 1000000 
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371 383 C A A I S T S E T T Y K N 1000000 
372 384 A A I S T S E T T Y K N T 1000000 
374 386 I S T S E T T Y K N T N F 1000000 
375 387 S T S E T T Y K N T N F K 1000000 
376 388 T S E T T Y K N T N F K E 1000000 
377 389 S E T T Y K N T N F K E Y 1000000 
378 390 E T T Y K N T N F K E Y L 1000000 
380 392 T Y K N T N F K E Y L R H 1000000 
382 394 K N T N F K E Y L R H G E 1000000 
383 395 N T N F K E Y L R H G E E 1000000 
385 397 N F K E Y L R H G E E Y 0 1000000 
386 398 F K E Y L R H G E E Y 0 L 1000000 
389 401 Y L R H G E E Y 0 L Q F I 1000000 
390 402 L R H G E E Y 0 L Q F I F 1000000 
391 403 R H G E E Y 0 L Q F I F Q 1000000 
392 404 H G E E Y 0 L Q F I F Q L 1000000 
395 407 E Y 0 L Q F I F Q L C K I 1000000 
402 414 F Q L C K I T L T A 0 V M 1000000 
406 418 K I T L T A 0 V M T Y I H 1000000 
407 419 I T L T A 0 V M T Y I H S 1000000 I 
409 421 L T A 0 V M T Y I H S M N 1000000 
413 425 V M T Y I H S M N S T I L 1000000 
417 429 I H S M N S T I L E 0 W N 1000000 
419 431 S M N S T I L E 0 W N F G 1000000 
420 432 M N S T I L E 0 W N F G L 1000000 
421 433 N S T I L E 0 W N F G L Q 1000000 
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425 437 L E D W N F G L Q P P P G 1000000 
427 439 D W N F G L Q P P P G G T 1000000 
431 443 G L Q P P P G G T L E D T 1000000 
432 444 L Q P P P G G T L E D T Y 1000000 
433 445 Q P P P G G T L E D T Y R 1000000 
434 446 P P P G G T L E D T Y R F 1000000 
435 447 P P G G T L E D T Y R F V 1000000 
436 448 P G G T L E D T Y R F V T 1000000 
437 449 G G T L E D T Y R F V T Q 1000000 
440 452 L E D T Y R F V T Q A I A 1000000 
448 460 T Q A I A C Q K H T P P A 1000000 
450 462 A I A C Q K H T P P A P K 1000000 
451 463 I A C Q K H T P P A P K E 1000000 
452 464 A C Q K H T P P A P K E 0 1000000 
453 465 C Q K H T P P A P K E D D 1000000 
454 466 Q K H T P P A P K E D D P 1000000 
455 467 K H T P P A P K E D D P L 1000000 
456 468 H T P P A P K E D D P L K 1000000 
457 469 T P P A P K E D D P L K K 1000000 
458 470 P P A P K E 0 D P L K K Y 1000000 
459 471 P A P K E D 0 P L K K Y T 1000000 
460 472 A P K E D D P L K K Y T F 1000000 
461 473 P K E D D P L K K Y T F W 1000000 
462 474 K E D D P L K K Y T F W E 1000000 
463 475 E D D P L K K Y T F W E V 1000000 
464i 476 0 D P L K K Y T F W E V N 1000000 
466 478 P L K K Y T F W E V N L K 1000000 
467 479 L K K Y T F W E V N L K E 1000000 
469 481 K Y T F W E V N L K E K F 1000000 
472 484 F W E V N L K E K F S A D 1000000 
473 485 W E V N L K E K F S A D L 1000000 
474 486 E V N L K E K F S A 0 L 0 1000000 
476 488 N L K E K F S A D L 0 Q F 1000000 
477 489 L K E K F S A D L D Q F P 1000000 
478 490 K E K F S A 0 L D Q F P L 1000000 
480 492 K F S A 0 L D Q F P L G R 1000000 
481 493 F S A 0 L D Q F P L G R K 1000000 
482 494 S A D L 0 Q F P L G R K F 1000000 
485 497 L 0 Q F P L G R K F L L Q 1000000 
486 498 D Q F P L G R K F L L Q A 1000000 
487 499 Q F P L G R K F L L Q A G 1000000 
490 502 L G R K F L L Q A G L K A 1000000 
491 503 G R K F L L Q A G L K A K 1000000 
496 508 L Q A G L K A K P K F T L 1000000 
499 511 G L K A K P K F T L G K R 1000000 
500 512 L K A K P K F T L G K R K 1000000 
501 513 K A K P K F T L G K R K A 1000000 
503 515 K P K F T L G K R K A T P 1000000 
505 517 K F T L G K R K A T P T T 1000000 
506 518 F T L G K R K A T P T T S 1000000 
507 519 T L G K· R K A T P T T S S 1000000 
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508 520 L· G K R K A T P T T S S T 1000000 
509 521 G K R K A T P T T S S T S 1000000 
510 522 K R K A T P T T S S T S T 1000000 
512 524 K A T P T T S S T S T T A 1000000 
514 526 T P T T S S T S T T A K R 1000000 
515 527 P T T S S T S T T A K R K 1000000 
516 528 T T S S T S T T A K R K K 1000000 
517 529 T S S T S T T A K R K K R 1000000 
518 530 S S T S T T A K R K K R K 1000000 
519 531 S T S T T A K R K K R K L 1000000 
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IC50 DRB1*0401 (nM) 
442 454 0 T Y R F V T a A I A C a 1.15 
492 504 R K F L L a A G l K A K P 3 
94 106 L- a y R V F R I H L P 0 P 4.3 
3 15 V T F I Y I L V I T C Y E 10.5 
124 136 L V W A C V G V E V G R G 21 
412 424 0 V M T Y I H S M N S T I 27.5 
5 17 F I Y I L V I T C Y E N D 28.2 
159 171 S A Y A A N A G V 0 N R E 31.5 
444 456 Y R F V T a A I A C a K H 40 
6 18 I Y I L V I T C Y E N 0 V 71.5 
23 35 I F F a M s L W L P S E A 88.2 
394 406 E E Y D L a F I F a L c K 92 
400 412 F I F a L c K I T L T A D 96.5 
28 40 S L W L P S E A T V Y L P 102 
58 70 N I Y Y H A G T S R L L A 105 
97 109 R V F R I H L P 0 P N K F 105 
9 21 L V I T C Y E N 0 V N V H 110 
414 426 M T Y I H S M N S T I L E 110 
415 427 T Y I H S M N S T I L E D 120 
301 313 L Y I K G S G S T A N L A 135 
45 57 S K V V S T 0 E Y V A R T 145 
1 13 M a v T F I Y I L V I T C 162 
21 33 H H I F F a M s L W L P S 165 
25 37 F a M s L W L P S E A T V 200 
422 434 S T I L E D W N F G L a p 242 
281 293 M F V R H L F N R A G T V 245 
182 194 L C L I G C K P P I G E H 265 
428 440 W N F G L a p p P G G T L 280 
51 63 D E Y V A R T N I Y Y H A 310 
234 246 M 0 F T T L a A N K S E V 310 
237 249 T T L a A N K S E V P L 0 310 
259 271 0 Y L K M V S E P Y G 0 S 322 
398 410 L a F I F a L c K I T L T 322 
355 367 L F V T V V 0 T T R S T N 330 
258 270 P 0 Y L K M V S E P Y G 0 342 
449 461 a A I A C a K H T P P A P 352 
300 312 0 l Y I K G S G S T A N l 425 
4 16 T F I Y I L V I T C Y E N 430 
261 273 L K M V S E P Y G 0 S L F 445 
324 336 S M V T S 0 A a I F N K P 505 
22 34 H I F F a M s L W L P S E 540 
52 64 E Y V A R T N I Y Y H A G 550 
426 438 E 0 W N F G L a p p P G G 612 
123 135 R l V W A C V G V E V G R 650 
366 378 T N M S l C A A I S T S E 710 
280 292 a M F V R H l F N R A G T 732 
468 480 K K Y T F W E V N L K E K 745 
372 384 A A I S T S E T T Y K N T 815 
115 127 S F Y N P 0 T a R L V W A 835 
405 417 C K I T L T A 0 V M T Y I 880 
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59 71 I Y Y H A G T S R L L A V 922 
271 283 S L F F Y L R R E Q M F V 1050 
273 285 F F Y L R R E Q M F V R H 1420 
337 349 Y W L Q R A Q G H N N G I 1420 
16 28 N 0 V N V H H I F F Q M S 1450 
141 153 V G I S G H P L L N K L 0 1500 
335 347 K P Y W L Q R A Q G H N N 1500 
175 187 M 0 Y K Q T Q L C L I G C 1700 
421 433 N S T I L E 0 W N F G L Q 1850 
388 400 E Y L R H G E E Y 0 L Q F 1900 
150 162 N K L 0 0 T E N A S A Y A 2300 
57 69 T N I Y Y H A G T S R L L 2500 
53 65 Y V A R T N I Y Y H A G T 2650 
347 359 N G I C W G N Q L F V T V 2700 
67 79 R L L A V G H P Y F P I K 2720 
315 327 S N Y F P T P S G S M V T 2800 
361 373 0 T T R S T N M S L C A A 3200 
407 419 I T L T A 0 V M T Y I H S 3320 
204 216 V A V N P G 0 C P P L E, L 3400 
218 230 N T V I Q 0 G 0 M V H T G 3520 
445 457 R F V T Q A I A C Q K H T 3600 
12 24 T C Y E N 0 V N V H H I F 3700 
96 108 Y R V F R I H L P 0 P N K 3850 
46 58 K V V S T 0 E Y V A R T N 4020 
285 297 H L F N R A G T V G E N V 4020 
202 214 T N V A V N P G 0 C P P L 4100 
8 20 I L V I T C Y E N 0 V N V 4250 
418 430 H 5 M N S T I L E 0 W N F 4300 
2 14 Q V T F I Y I L V I T C Y 4350 
229 241 T G F G A M 0 F T T L Q A 4350 
66 78 S R L L A V G H P Y F P I 4500 
362 374 T T R S T N M S L C A A I 4700 
291 303 G T V G E N V P 0 0 L Y I 4720 
219 231 T V I Q 0 G 0 M V H T G F 4820 
274 286 F Y L R R E Q M F V R H L 4820 
139 151 L G V G I S G H P L L N K 5000 
479 491 E K F S A 0 L 0 Q F P L G 5150 
387 399 K E Y L R H G E E Y 0 L Q 5900 
310 322 A N L A S S N Y F P T P S 6020 
408 420 T L T A 0 V M T Y I H S M 6200 
120 132 0 T Q R L V W A C V G V E 7220 
225 237 0 M V H T G F G A M 0 F T 7300 
35 47 A T V Y L P P V P V S K V 7450 
214 226 L E L I N T V I Q 0 G 0 M 7900 
73 85 H P Y F P I K K P N N N K 7950 
164 176 N A G V 0 N R E C I S M 0 8120 
354 366 Q L F V T V V 0 T T R S T 8700 
329 341 0 A Q I F N K P Y W L Q R 8800 
231 243 F G A M 0 F T T L Q A N K 9200 
309 321 T A N L A 5 S N Y F P T P 9550 
353 365 N Q L F V T V V 0 T T R S 9950 
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342 354 A Q G H N N G I C W G N Q 11000 
138 150 P L G V G I 5 G H P L L N 11200 
336 348 P Y W L Q R A Q G H N N G 11200 
303 315 I K G 5 G 5 T A N L A 5 5 12000 
378 390 E T T Y K N T N F K E Y l 12500 
411 423 A 0 V M T Y I H 5 M N 5 T 13200 
180 192 T Q l C l I G C K P P I G 13500 
399 411 Q F I F Q L C K I T l T A 13500 
245 257 E V P L 0 I C T 5 I C K Y 14000 
358 370 T V V 0 T T R 5 T N M 5 L 14500 
155 167 T E N A 5 A Y A A N A G V 15500 
365 377 5 T N M 5 L C A A I 5 T 5 16200 
122 134 Q R L V W A C V G V E V G 16500 
64 76 G T 5 R L L A V G H P Y F 17000 
179 191 Q T Q L C L I G C K P P I 17000 
427 439 0 W N F G L Q P P P G G T 18000 
396 408 Y 0 l Q F I F Q L C K I T 18200 
84 96 N K I l V P K V 5 G l Q y 19000 
470 482 Y T F W E V N l K E K F. 5 19500 
357 369 V T V V 0 T T R 5 T N M 5 20000 
65 77 T 5 R L L A V G H P Y F P 22200 
290 302 A G T V G E N V P 0 0 L Y 22200 
373 385 A I 5 T 5 E T T Y K N T N 23500 
323 335 G 5 M V T 5 0 A Q I F N K 24000 
279 291 E Q M F V R H l F N R A G 24500 
85 97 K I L V P K V 5 G l Q y R 26000 
368 380 M 5 L C A A I 5 T 5 E T T 26500 
108 120 K F G F P 0 T 5 F Y N P 0 28000 
34 46 E A T V Y L P P V P V 5 K 29200 
248 260 l 0 I C T 5 I C K Y P 0 Y 30000 
132 144 E V G R G Q P l G V G I 5 31000 
246 258 V P l 0 I C T 5 I C K Y P 31000 
232 244 G A M 0 F T T L Q A N K 5 33200 
215 227 E l I N T V I Q 0 G 0 M V 34000 
514 526 T P T T 5 5 T 5 T T A K R 34500 
230 242 G F G A M 0 F T T l Q A N 36000 
340 352 Q R A Q G H N N G I C W G 37000 
18 30 V N V H H I F F Q M 5 L W 39500 
29 41 L W L P 5 E A T V Y L P P 40500 
212 224 P P L E L I N T V I Q 0 G 40500 
351 363 W G N Q L F V T V V 0 T T 40500 
364 376 R 5 T N M 5 L C A A I 5 T 40500 
178 190 K Q T Q L C L I G C K P P 42200 
193 205 E H W G K G 5 P C T N V A 43000 
443 455 T Y R F V T Q A I A C Q K 43000 
307 319 G 5 T A N L A S 5 N Y F P 44000 
515 527 P T T 5 5 T S T T A K R K 45500 
140 152 G V G I 5 G H P L L N K L 49500 
379 391 T T Y K N T N F K E Y L R 53200 
107 119 N K F G F P 0 T 5 F Y N P 53500 
196 208 G K G 5 P C T N V A V N P 55200 
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469 481 K Y T F W E V N L K E K F 57500 
55 67 A R T N I Y Y H A G T S R 58000 
152 164 L 0 0 T E N A S A Y A A N 58200 
126 138 W A C V G V E V G R G Q P 59200 
252 264 T S I C K Y P 0 Y L K M V 59500 
171 183 E C I S M 0 Y K Q T Q L C 60500 
63 75 A G T S R L L A V G H P Y 61200 
217 229 I N T V I Q 0 G D M V H T 62000 
147 159 p L L N K L D 0 T E N A S 62200 
266 278 E P Y G 0 S L F F Y L R R 63500 
224 236 G D M V H T G F G A M D F 64000 
331 343 Q I F N K P Y W L Q R A Q 65000 
284 296 R H L F N R A G T V G E N 66000 
134 146 G R G Q P L G V G I S G H 66500 
137 149 Q P L G V G I S G H P L L 67500 
446 458 F V T Q A I A C Q K H T P 68200 
504 516 P K F T L G K R K A T P T 69000 
436 448 P G G T L E 0 T Y R F V T 71000 
148 160 L L N K L 0 D T E N A S' A 73000 
42 54 V P V S K V V S T 0 E Y V 74200 
36 48 T V Y L P P V P V S K V V 74500 
176 188 D Y K Q T Q L C L I G C K 76500 
384 396 T N F K E Y L R H G E E Y 78200 
410 422 T A 0 V M T Y I H S M N S 83500 , 
4021 414 F Q L C K I T L T A D V M 91000 
--
240 252 Q A N K S E V P L 0 I C T 93200 
270 282 D S L F F Y L R R E Q M F 97500 
131 143 V E V G R G Q P L G V G I 98000 
360 372 V D T T R S T N M S L C A 98000 
223 235 0 G 0 M V H T G F G A M D 100000 
494 506 F L L Q A G L K A K P K F 102000 
89 101 p K V S G L Q Y R V F R I 105000 
129 141 V G V E V G R G Q p L G V 105000 
173 185 I S M 0 Y K Q T Q L C L I 112000 
201 213 C T N V A V N P G 0 C P P 112000 
313 325 A S S N Y F P T P S G S M 112000 
213 225 p L E l I N T V I Q D G D 115000 
306 318 S G S T A N L A S S N Y F 115000 
332 344 I F N K P Y W L Q R A Q G 125000 
56 68 R T N I Y Y H A G T S R L 130000 
111 123 F P D T S F Y N P 0 T Q R 130000, 
367 379 N M S L C A A I S T S E T 132000 
250 262 I C T S I C K Y P D Y L K 135000 
11 23 I T C Y E N 0 V N V H H I 140000 
79 91 K K p. N N N K I L V P K V 140000 
325 337 M V T S 0 A Q I F N K P Y 140000 
475 487 V N L K E K F S A 0 l 0 Q 140000 
127 139 A C V G V E V G R G Q p L 145000 
19 31 N V H H I F F Q M S L W L 150000 
54 66 V A R T N I Y Y H A G T S 150000 
304 316 K G S G S T A N L A S S N 150000 
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438 450 G T L E D T Y R F V T Q A 150000 
471 483 T F W E V N L K E K F 5 A 150000 
194 206 H W G K G S P C T N V A V 160000 
345 357 H N N G I C W G N a L F V 160000 
247 259 P l 0 I C T 5 I C K Y P D 170000 
489 501 P l G R K F l l Q A G L K 170000 
321 333 P 5 G 5 M V T 5 D A a I F 172000 
493 505 K F L L Q A G L K A K P K 175000 
283 295 V R H L F N R A G T V G E 180000 
27 39 M S L W L P S E A T V Y L 190000 
7 19 Y I L V I T C Y E N D V N 192000 
200 212 P C T N V A V N P G D C P 195000 
356 368 F V T V V 0 T T R 5 T N M 195000 
136 148 G Q P L G V G I 5 G H P L 200000 
198 210 G S P C T N V A V N P G D 200000 
338 350 W L a R A a G H N N G I C 205000 
363 375 T R S T N M S L C A A I S 205000 
397 409 0 l a F I F a l c K I T l 220000 
490 502 L G R K F l L a A G l K. A 225000 
114 126 T 5 F Y N P 0 T a R L V W 230000 
317 329 Y F P T P S G S M V T 5 0 230000 
191 203 I G E H W G K G 5 P C T N 235000 
352 364 G N a L F V T V V D T T R 235000 
465 477 D P L K K Y T F W E V N L 250000 ------.---"~ 
13 25 C Y E N D V N V H H I F F i 252000 
----
312 324 l A S S N Y F P T P 5 G S i 255000 
272 284 L F F Y L R R E a M F V R I 260000 
156 168 E N A S A Y A A N A G V D 262000 
305 317 G S G S T A N L A S S N Y 262000 
349 361 I C W G N a L F V T V V D 265000 
-516 528 T T 5 5 T S T T A K R K K , 272000 
-
473 485 W E V N L K E K F 5 A 0 L 275000 
47 59 V V 5 T D E Y V A R T N I 282000 
348 360 G I C W G N a l F V T V V 282000 
406 418 K I T L T A D V M T Y I H 290000 
437 449 G G T L E 0 T Y R F V T a 290000 
413 425 V M T Y I H 5 M N 5 T I L 305000 
255 267 C K Y P D Y L K M V 5 E P 315000 
62 74 H A G T 5 R L l A V G H P 330000 
320 332 T P 5 G 5 M V T 5 0 A Q I 330000 
506 518 F T L G K R K A T P T T 5 34009~ 
298 310 P D D L Y I K G S G 5 T A 342000 
401 413 I F Q l C K I T L T A D V 352000 
119 131 P 0 T Q R L V W A C V G V 355000 
299 311 0 0 L Y I K G 5 G S T A N 360000 
286 298 L F N R A G T V G E N V P 365000 
99 111 F R I H L P 0 P N K F G F 380000 
268 280 Y G 0 S L F F Y L R R E a 380000 
308 3205 T A N L A S 5 N Y F P T 380000 
153 165 0 D T E N A S A Y A A N A 382000 
330 342 A a I F N K P Y W L a R A 390000 
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243 255 K S E V P L 0 I C T S I C 392000 
350 362 C W G N a L F V T V V 0 T 395000 
222 234 a 0 G 0 M V H T G F G A M 400000 
508 520 L G K R K A T P T T S S T 415000 
262 274 K M V S E P Y G 0 S L F F 430000 
416 428 Y I H S M N S T I L E 0 W 440000 
404 416 L C K I T L T A 0 V M T Y 450000 
189 201 P P I G E H W G K G S P C 455000 
92 104 S G L a y R V F R I H L P 475000 
226 238 M V H T G F G A M 0 F T T 480000 
32 44 P S E A T V Y L P P v P V 490000 
109 121 F G F P 0 T S F Y N P 0 T 492000 
441 453 E 0 T Y R F V T a A I A C 492000 
488 500 F P L G R K F L L a A G L 510000 
403 415 Q L C K I T L T A 0 V M T 515000 
467 479 L K K Y T F W E V N L K E 515000 
482 494 S A 0 L 0 a F p L G R K F 525000 
177 189 Y K a T· a L c L I G C K P 560000 
511 523 R K A T P T T S S T S T. T 560000 
50 62 T 0 E Y V A R T N I Y Y H 572000 
10 22 V I T C Y E N 0 V N V H H 575000 
509 521 G K R K A T P T T S S T S 610000 
167 179 V 0 N R E C I S M 0 Y K a 630000 
294 306 G E N V P 0 0 L Y I K G S 642000 
149 161 L N K L 0 0 T E N A S A Y 650000 
409 421 L T A 0 V M T Y I H S M N 650000 
477 489 L K E K F S A 0 L 0 a F p 665000 
76 88 F P I K K P N N N K I L V 700000 
486 498 0 a F p L G R K F L L a A 710000 
82 94 N N N K I L V P K V S G L 720000 
451 463 I A C a K H T P P A P K E 722000 
112 124 P 0 T S F Y N P 0 T a R L 730000 
157 169 N A S A Y A A N A G V 0 N 730000 
311 323 N L A S S N Y F P T P S G 730000 
70 82 A V G H P Y F P I K K P N 735000 
91 103 V S G L a y R V F R I H L 745000 
220 232 V I Q 0 G 0 M V H T G F G 765000 
265 277 S E P Y G 0 S L F F Y L R 765000 
30 42 W L P S E A T V Y L P P V 785000 
20 32 V H H I F F a M s L W L P 795000 
r-1M 166 0 T E N A S A Y A A N A G 795000 369 381 S L C A A I S T S E T T Y 840000 
383 395 N T N F K E Y L R H G E E 882000 
480 492 K F S A 0 L 0 Q F P L G R 895000 
343 355 a G H N N G I C W G N a L 900000 
113 125 0 T S F Y N P 0 T a R L V 920000 
121 133 T Q R L V W A C V G V E V 922000 
341 353 R A a G H N N G I C W G N 925000 
174 186 S M 0 Y K a T Q L C L I G 945000 
491 503 G R K F L L a A G L K A K 960000 
17 29 0 V N V H H I F F a M S L 985000 
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33 45 S E A T V Y L P P V P V S 985000 
165 177 A G V 0 N R E C I S M 0 Y 985000 
14 26 Y E N 0 V N V H H I F F Q 1000000 
15 27 E N 0 V N V H H I F F Q M 1000000 
24 36 F F Q M S L W L P S E A T 1000000 
26 38 Q M S L W L P S E A T V Y 1000000 
31 43 L P S E A T V Y L P P V P 1000000 
37 49 V Y L P P V P V S K V V S 1000000 
38 50 Y L P P V P V S K V V S T 1000000 
39 51 L P P V P V S K V V S T 0 1000000 
40 52 P P V P V S K V V S T 0 E 1000000 
41 53 P V P V S K V V S T 0 E Y 1000000 
43 55 P V S K V V S T 0 E Y V A 1000000 
44 56 V S K V V S T 0 E Y V A R 1000000 
48 60 V S T 0 E Y V A R T N I Y 1000000 
-
49 61 S T 0 E Y V A R T N I Y Y 1000000 
60 72 Y Y H A G T S R L L A V G 1000000 
61 73 Y H A G T S R L L A V G H 1000000 
68 80 L L A V G H P Y F P I K. K 1000000 
69 81 L A V G H P Y F P I K K P 1000000 
71 83 V G H P Y F P I K K P N N 1000000 
72 84 G H P Y F P I K K P N N N 1000000 
74 86 P Y F P I K K P N N N K I 1000000 
- -
75 87 Y F P I K K P N N N K I L 1000000 
--nr- 89 -P I K' K P N N N K I L V P I 1000000 -- .,-78i 90 I K K P N N N K I L V P K 1000000 
80' 92 K P N N N K I L V P K V S 1000000 
81 93 P N N N K I L V P K V S G 1000000 
83 95 N N K I L V P K V S G L Q 1000000 
86 98 I L V P K V S G L Q Y R V 1000000 
87 99 L V P K V S G L a y R V F 1000000 
88 100 V P K V S G L Q Y R V F R 1000000 
90 102 K V S G L Q Y R V F R I H 1000000 
93 105 G L Q Y R V F R I H L P 0 1000000 
95 107 Q Y R V F R I H L P 0 P N 1000000 
98 110 V F R I H L P 0 P N K F G 1000000 
100 112 R I H L P 0 P N K F G F P 1000000 
101 113 I H L P 0 P N K F G F P 0 1000000 
102 114 H L P 0 P N K F G F P 0 T 1000000 
103 115 L P D P N K F G F P 0 T S 1000000 
104 116 P 0 P N K F G F P 0 T S F 1000000 
105 117 0 P N K F G F P D T S F Y 1000000 
106 118 P N K F G F P 0 T S F Y N 1000000 
110 122 G F P 0 T S F Y N P 0 T a 1000000 
116 128 F Y N P 0 T Q R L V W A C 1000000 
117 129 Y N P 0 T Q R L V W A C V 1000000 
118 130 N P 0 T Q R L V W A C V G 1000000 
125 137 V W A C V G V E V G R G Q 1000000 
128 140 C V G V E V G R G Q P L G 1000000 
130 142 G V E V G R G a p L G V G 1000000 
133 145 V G R G Q P L G V G I S G 1000000 
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135 147 R G a p L G V G I S G H P 1000000 
142 154 G I S G H P L L N K L 0 0 1000000 
143 155 I S G H P L L N K L D D T 1000000 
144 156 S G H P L L N K L 0 D T E 1000000 
145 157 G H P L L N K L 0 0 T E N 1000000 
146 158 H P L L N K L 0 0 T E N A 1000000 
151 163 K L 0 0 T E N A S A Y A A 1000000 
158 170 A S A Y A A N A G V D N R 1000000 
160 172 A Y A A N A G V 0 N R E C 1000000 
161 173 Y A A N A G V D N R E C I 1000000 
162 174 A A N A G V D N R E C I S 1000000 
163 175 A N A G V 0 N R E C I S M 1000000 
166 178 G V 0 N R E C I S M D Y K 1000000 
168 180 D N R E C I S M 0 Y K a T 1000000 
169 181 N R E C I S M D Y K Q T Q 1000000 
170 182 R E C I S M D Y K Q T Q L 1000000 
172 184 C I S M 0 Y K Q T Q L C L 1000000 
181 193 Q L C L I G C K P P I G E 1000000 
183 195 C L I G C K P P I G E H. W 1000000 
184 196 L I G C K P P I G E H W G 1000000 
185 197 I G C K P P I G E H W G K 1000000 
186 198 G C K P P I G E H W G K G 1000000 
187 199 C K P P I G E H W G K G S 1000000 
188 200 K P P I G E H W G K G S P 1000000 
190 202 P I G E H W G K G S P C T 1000000 
192 204 G E H W G K G S P C T N V 1000000 
195 207 W G K G S P C T N V A V N 1000000 
197 209 K G S P C T N V A V N P G 1000000 
199 211 S P C T N V A V N P G 0 C 1000000 
203 215 N V A V N P G D C P P L E 1000000 
----
205 217 A V N P G 0 C P P L E L I 1000000 
206 218 V N P G 0 C P P L E L I N 1000000 
207 219 N P G 0 C P P L E L I N T 1000000 
208 220 P G D C P P L E L I N T V 1000000 
209 221 G D C P P L E L I N T V I 1000000 
210 222 0 C P P L E L I N T V I Q 1000000 
211 223 C P P L E L I N T V I Q 0 1000000 
216 228 L I N T V I Q D G 0 M V H 1000000 
221 233 I Q D G 0 M V H T G F G A 1000000 
227 239 V H T G F G A M D F T T L 1000000 
228 240 H T G F G A M D F T T L Q 1000000 
233 245 A M D F T T L Q A N K S E 1000000 
235 247 0 F T T L a A N K S E V P 1000000 
236 248 F T T L a A N K S E V P L 1000000 
238 250 T L a A N K S E V P L D I 1000000 
239 251 L Q A N K S E V P L 0 I C 1000000 
241 253 A N K S E V P L 0 I C T S 1000000 
242 254 N K S E V P L D I C T S I 1000000 
244 256 S E V P L 0 I C T S I C K 1000000 
249 261 0 I C T S I C K Y P 0 Y L 1000000 
251 263 C T S I C K Y P 0 Y L K M 1000000 
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253 265 S I C K Y P D Y L K M V S 1000000 
254 266 I C K Y P 0 Y L K M V S E 1000000 
256 268 K Y P 0 Y L K M V S E P Y 1000000 
257 269 Y P 0 Y L K M V S E P Y G 1000000 
260 272 Y L K M V S E P Y G D S L 1000000 
263 275 M V S E P Y G 0 S L F F Y 1000000 
264 276 V S E P Y G D S L F F Y L 1000000 
267 279 P Y G 0 S L F F Y L R R E 1000000 
269 281 G D S L F F Y L R R E Q M 1000000 
275 287 Y L R R E Q M F V R H L F 1000000 
276 288 L R R E Q M F V R H L F N 1000000 
277 289 R R E Q M F V R H L F N R 1000000 
278 290 R E Q M F V R H L F N R A 1000000 
282 294 F V R H L F N R A G T V G 1000000 
287 299 F N R A G T V G E N V P D 1000000 
288 300 N R A G T V G E N V P 0 0 1000000 
289 301 R A G T V G E N V P D 0 L 1000000 
292 304 T V G E N V P 0 D L Y I K 1000000 
293 305 V G E N V P D 0 L Y I K G 1000000 
295 307 E N V P D D L Y I K G S G 1000000 
296 308 N V P 0 D L Y I K G S G S 1000000 
297 309 V P 0 0 L Y I K G S G S T 1000000 
302 314 Y I K G S G S T A N L A S 1000000 
314 326 S S N Y F P T P S G S M V 1000000 
-
316 328 N Y F P T P S G S M V T S 1000000 
-
- -
318 330 F P iT P S G S M V T S D A 1000000 
319 331 P T P S G S M V T S 0 A Q 1000000 
-
322 334 S G S M V T S 0 A Q I F N 1000000 
-
326 338 V T S 0 A Q I F N K P Y W 1000000 
327 339 T S 0 A Q I F N K P Y W L 1000000 
328 340 S D 'A Q I F N K P Y W L Q 1000000 
333 345 F N K P Y W L Q R A Q G H 1000000 
334 346 N K P Y W L Q R A Q G H N 1000000 
339 351 L R R A Q G H N N G I C W 1000000 
344 356 G H N N G I C W G N Q L F 1000000 
-
346 358 N N G I C W G N Q L F V T 1000000 
359 371 V V 0 T T R 5 T N M S L C 1000000 
370 382 L C A A I S T S E T T Y K 1000000 
371 383 C A A I S T S E T T Y K N 1000000 
374 386 I S T S E T T Y K N T N F 1000000 
375 387 S T S E T T Y K N T N F K 1000000 
I 
376 388 T S E T T Y K N T N F K E 1000000 
377 389 S E T T Y K N T N F K E Y 1000000 
380 392 T Y K N T N F K E Y L R H 1000000 
381 393 Y K N T N F K E Y L R H G 1000000 
-
382 394 K N T N F K E Y L R H G E 1000000 
385 397 N F K E Y L R H G E E Y D 1000000 
386 398 F K E Y L R H G E E Y 0 L 1000000 
389 401 Y L R H G E E Y D L Q F I 1000000 
390 402 L R H G E E Y 0 L Q F I F 1000000 
391 403 R H G E E Y D L Q F I F Q 1000000 
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392 404 H G E E Y 0 L a F I F Q L 1000000 
393 405 G E E Y 0 L Q F I F Q L C 1000000 
395 407 E Y 0 L Q F I F Q L C K I 1000000 
417 429 I H S M N S T I L E 0 W N 1000000 
419 431 S M N S T I L E 0 W N F G 1000000 
420 432 M N S T I L E 0 W N F G L 1000000 
423 435 T I L E 0 W N F G L Q P P 1000000 
424 436 I L E 0 W N F G L a p p p 1000000 
425 437 L E 0 W N F G L Q p p P G 1000000 
429 441 N F G L Q P P P G G T L E 1000000 
430 442 F G L a p p p G G T L E 0 1000000 
431 443 G L a p p P G G T L E 0 T 1000000 
432 444 L Q P P P G G T L E 0 T Y 1000000 
433 445 Q p p P G G T L E 0 T Y R 1000000 
434 446 P P P G G T L E D T Y R F 1000000 
435 447 P P G G T L E 0 T Y R F V 1000000 
439 451 T L E D T Y R F V T a A I 1000000 
440 452 L E D T Y R F V T a A I A 1000000 
447 459 V T a A I A C Q K H T P. P 1000000 
448 460 T Q A I A C Q K H T P P A 1000000 
450 462 A I A C Q K H T P P A P K 1000000 
452 464 A C a K H T P P A P K E D 1000000 
453 465 C a K H T P P A P K IE D D 1000000 
454 466 a K H T P P A P K E D D P 1000000 
.-
455 467 K H T P P A P K E D jD P L 1000000 
-
456 468 H T P P A P K E D 0 !p L K 1000000 
457 469 T P P A P K E 0 0 P L K K 1000000 
458 470 P P A P K E D 0 P L K K Y 1000000 
459 471 P A P K E D D P L K K Y T 1000000 
460 472 A P K E D 0 P L K K Y T F 1000000 
.. -
461 473 P K E 0 0 P L K K Y T F W 1000000 
462 474 K E 0 0 P L K K .y T F W E 1000000 
463 475 E 0 0 P L K K Y T F W E V 1000000 
464 476 0 0 P L K K Y T F W E V N 1000000 
466 478 P L K K Y T F W E V N L K 1000000 
472 484 F W E V N L K E K F S A 0 1000000 
474 486 E V N L K E K F S A 0 L 0 1000000 
476 488 N L K E K F S A 0 L 0 Q F 1000000 
478 490 K E K F S A 0 L D Q F P L 1000000 
481 493 F S A 0 L 0 Q F P L G R K 1000000 
.~. 495 A D L 0 Q F P L G R K F L 1000000 
484 496 0 L D a F p L G R K F L L 1000000 
485 497 L 0 a F P L G R K F L L a 1000000 
487 499 Q F P L G R K F L L a A G 1000000 
495 507 L L a A G L K A K P K F T 1000000 
496 508 L Q A G L K A K P K F T L 1000000 
497 509 Q A G L K A K P K F T L G 1000000 
498 510 A G L K A K P K F T L G K 1000000 
499 511 G L K A K P K F T L G K R 1000000 
500 512 L K A K P K F T L G K R K 1000000 
501 513 K A K P K F T L G K R K A 1000000 
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502 514 A K P K F T L G K R K A T 1000000 
503 515 K P K F T L G K R K A T P 1000000 
505 517 K F T L G K R K A T P T T 1000000 
507 519 T L G K R K A T P T T S S 1000000 
510 522 K R K A T P T T S S T S T 1000000 
512 524 K A T P T T S S T S T T A 1000000 
513 525 A T P T T S S T S T T A K 1000000 
517 529 T S S T S T T A K R K K R 1000000 
518 530 S S T S T T A K R K K R K 1000000 




240 252 P A F V T T P T K L I T Y 2.7 
444 456 G 0 F Y L H P S Y Y M L R 3.35 
52 64 G V F F G G L G I G T G S 7.2 
301 313 I R Y S R I G N K Q T L R 11.5 
200 212 T F I V S T N P N T V T S 13 
445 457 0 F Y L H P S Y Y M l R K 13 
70 82 T G Y I P L G T R P P T A 14 
418 430 I N I T 0 Q A P S l I P I 19 
161 173 P T F T 0 P S V L Q P P T 32 
144 156 A I L 0 I N N T V T T V T 34 
150 162 N T V T T V T T H N N P T 40 
285 297 0 I V A L H R P A l T S R 40 
199 211 0 T F I V S T N P N T V T 44 
196 208 I P M 0 T F I V S T N P N 61.5 
208 220 N T V T S S T P I P G S R 63 
17 29 Q l Y K T C K Q A G T C P 68 
388 400 T S L S G Y I P A N T T I 69 
112 124 T S F I 0 A G A P T S V P 70.5 
347 359 S T Y T T T S H A A S P T 79.5 
450 462 P S Y Y M L R K R R K R L 102 
43 55 E Q I L Q Y G S M G V F F 135 
325 337 H Y Y Y 0 L S T I 0 P A E 135 
281 293 P 0 F L 0 I V A L H R P A 140 
265 277 T L Y F S S N 0 N S I N I 142 
266 278 L Y F S S N 0 N S I N I A 160 
428 440 I P I V P G S P Q Y T I I 190 
292 304 P A L T S R R T G I R Y S 210 
425 437 P S L I P I V P G S P Q Y 222 
282 294 o F L o I V A L H R P A L 275 
84 96 0 T L A P V R P P L T V 0 305 
404 416 G A Y N I P l V S G P 0 I 432 
255 267 P A Y E G I 0 V 0 N T L Y 462 
51 63 M G V F F G G L G I G T G 550 
310 322 Q T L R T R S G K S I G A 600 
241 253 A F V T T P T K L I T Y 0 650 
408 420 I P L V S G P 0 I P I N I 725 
233 245 Q Q V K V V 0 P A F V T T 955 
181 193 F T L S S S T I S T H N Y 1100 
400 412 I P F G G A Y N I P L V S 1100 
49 61 G S M G V F F G G L G I G 1150 
398 410 T T I P F G G A Y N I P L 1400 
103 115 P S I V S L V E E T S F I 1700 
235 247 V K V V 0 P A F V T T P T 1900 
226 238 G L Y S R T T Q Q V K V V 2050 
167 179S V L Q P P T P A E T G G 2250 
391 403 S G Y I P A N T T I P F G 2300 
452 464 y. Y M L R K R R K R L P Y 2500 
339 351 I E l Q T I T P S T Y T T 2620 
385 397 V P S T S L S G Y I P A N 2800 
67 79 G G R T G Y I P L G T R P 3100 
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91 103 P P l T V 0 P V G P S 0 P 3300 
220 232 R P V A R l G l Y S R T T 3600 
34 46 P K V E G K T I A E Q I L 3650 
53 65 V F F G G l G I G T G S G 3720 
248 260 K L I T Y 0 N P A Y E G I 4050 
225 237 l G l Y S R T T Q Q V K V 4100 
264 276 N T l Y F S S N 0 N S I N 4200 
50 62 S M G V F F G G l G I G T 4550 
31 43 0 I I P K V E G K T I A E 4950 
416 428 I P I N I T 0 Q A P S L I 5000 
451 463 S Y Y M L R K R R K R L P 5600 
326 338 Y Y Y 0 l S T I 0 P A E E 6300 
39 51 K T I A E Q I L Q Y G S M 6700 
87 99 A P V R P P L T V 0 P V G 6850 
364 376 G l Y 0 I Y A 0 0 F I T 0 7300 
127 139 P P 0 V S G F S I T T S T 7400 
258 270 E G I 0 V 0 N T L Y F S S 7500 
299 311 T G I R Y S R I G N K Q T 7650 
435 447 P Q Y T I I A 0 A G 0 F Y 7750 
322 334 A K V H Y Y Y 0 L S T I 0 7800 
30 42 P 0 I I P K V E G K T I A 8000 
426 438 S L I P I V P G S P Q Y T 8900 
63 75 G S G T G G R T G Y I P L 9450 
315 327 R S G K S I G A K V H Y Y 10200 
346 358 P S T Y T T T S H A A S P 10200 
93 105 L T V 0 P V G P S 0 P S I 11000 
250 262 I T Y 0 N P A Y E G I 0 V 11000 
304 316 S R I G N K Q T L R T R S 11000 
331 343 S T I 0 P A E E I E L Q T 13500 
186 198 S T I S T H N Y E E I P M 14000 
179 191 G H F T L S S S T I S T H 14200 
222 234 V A R l G L Y S R T T Q Q 15500 
438 450 T I I A 0 A G 0 F Y L H P 15500 
349 361 Y T T T S H A A S P T S I 16000 
44 56 Q I L Q Y G S M G V F F G 18000 
147 159 0 I N N T V T T V T T H N 18000 
247 259 T K L I T Y 0 N P A Y E G 18200 
284 296 L 0 I V A L H R P A l T S 19000 
180 192 H F T L S S S T I S T H N 21000 
374 386 I T 0 T S T T P V P S V P 21000 
437 449 Y T I I A 0 A G 0 F Y L H 21200 
153 165 T T V T T H N N P T F T 0 22200 
46 58 L Q Y G S M G V F F G G L 23000 
372 384 0 F I T 0 T S T T P V P S 24000 
397 409 N T T I P F G G A Y N I P 25000 
317 329 G K S I G A K V H Y Y Y 0 25200 
429 441 P I V P G S p Q Y T I I A 25500 
61 73 G T G S G T G G R T G Y I 26200 
56 68 G G L G I G T G S G T G G 28000 
211 223 T S S T P I P G S R P V A 29500 
228 240 Y S R T T Q Q V K V V 0 P 32000 
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453 465 Y M L R K R R K R L P Y F 33000 
352 364 T S H A A S P T S I N N G 37200 
283 295 F L 0 I V A L H R P A L T 38500 
152 164 V T T V T T H N N P T F T 39000 
178 190 G G H F T L S S S T I S T 39000 
195 207 E I P M 0 T F I V S T N P 40000 
143 155 P A I L 0 I N N T V T T V 42000 
409 421 P L V S G P 0 I P I N I T 43000 
57 69 G L G I G T G S G T G G R 44500 
384 396 S V P S T S l S G Y I P A 45000 
82 94 A T 0 T L A P V R P P L T 46000 
3 15 H K R S A K R T K R A S A 46500 
359 371 T S I N N G l Y 0 I Y A 0 47200 
345 357 T P S T Y T T T S H A A S 50500 
214 226 T P I P G S R P V A R l G 51500 
166 178 P S V L Q P P T P A E T G 53200 
328 340 Y 0 L S T I 0 P A E E I E 58000 
118 130 G A P T S V P S I P P 0 V 65200 
201 213 F , V S T N P N T V T S S 65500 
402 414 F G G A Y N I P l V S G P 67000 
159 171 N N P T F T 0 P S V l Q P 69500 
172 184 P T P A E T G G H F T l S 71000 
37 49 E G K T I A E Q I L Q Y G 73200 
136 148 T T S T 0 T T P A I L 0 I 74000 
--
114 126 F I 0 A G A P T S V P S I 75000 
113 125 S F I 0 A G A P T S V P S 76000 
377 389 T S T T P V P S V P S T S 76200 
286 298 I ·V A l H R P A l T S R R 78500 
81 93 T A T 0 T l A P V R P P l 80000 
78 90 R P P T A T 0 T l A P V R 86000 
216 228 I P G S R P V A R L G L Y 88500 
96 108 0 P V G P S 0 P S I V S L 95000 
300 312 G I R Y S R I G N K Q T L 96000 
249 261 L I T Y 0 N P A Y E G I 0 96200 
107 119 S l V E E T S F I 0 A G A 102000 
356 368 A S P T S I N N G l Y 0 I 110000 
7 19 A K R T K R A S A T Q l Y 112000 
294 306l T S R R T G I R Y S R I 112000 
106 118 V S l V E E T S F I 0 A G 115000 
268 280 F S S N 0 N S I N I A P 0 122000 
382 394 V P S V P S T S l S G Y II 122000 
419 431 N I T 0 Q A P S l I P I V 122000 
16 28 T Q L Y K T C K Q A G T C 125000 
244 256 T T P T K L I T Y 0 N P A 125000 
18 30 l Y K T C K Q A G T C p P 130000 
353 365 S H A A S P T S I N N G L 130000 
109 121 V E E T S F I 0 A G A P T 140000 
395 407 P A N T T I P F G G A Y N 140000 
341 353 L Q T I T P S T Y T T T S 142000 
42 54 A E Q I L Q Y G S M G V F 145000 
202 214 , V S T N P N T V T S S T 145000 
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461 473 R L P Y F F S 0 v S L A A 145000 
55 67 F G G L G I G T G S G T G 150000 
15 27 A T Q L Y K T C K Q A G T 155000 
40 52 T I A E Q I L Q Y G S M G 160000 
177 189 T G G H F T L S S S T I S 162000 
198 210 M 0 T F I V S T N P N T V 165000 
336 348 A E E I E L Q T I T P S T 180000 
48 60 Y G S M G V F F G G L G I 200000 
371 383 0 0 F I T 0 T S T T P V P 202000 
170 182 Q P P T P A E T G G H F T 205000 
431 443 V P G S P Q Y T I I A 0 A 205000 
99 111 G P S 0 P S I V S L V E E 210000 
263 275 0 N T L Y F S S N 0 N S I 210000 
260 272 I 0 V 0 N T L Y F S S N 0 215000 
38 50 G K T I A E Q I L Q y G S 220000 
338 350 E I E L Q T I T P S T Y T 222000 
90 102 R P P L T V 0 P V G P S 0 235000 
396 408 A N T T I P F G G A Y N I 235000 
146 158 L 0 I N N T V T T V T T H· 240000 
227 239 L Y S R T T Q Q V K V V 0 250000 
358 370 P T S I N N G L Y 0 I Y A 260000 
191 203 H N Y E E I P M 0 T F I V 270000 
342 354 Q T I T P S T Y T T T S H 270000 
141 153 T T P A I L 0 I N N T V T 272000 
14 26 S A T Q L Y K T C K Q A G 280000 
399 411 T I P F G G A Y N I P L V 282000 
423 435 Q A P S L I P I V P G S P 290000 
259 271 G I 0 V 0 N T L Y F S S N 292000 
105 117 I V S L V E E T S F I 0 A 305000 
102 114 0 P S I V S L V E E T S F 310000 
205 217 T N P N T V T S S T P I P 315000 
131 143 S G F S I T T S T 0 T. T P 320000 
379 391 T T P V P S V P S T S L S 325000 
59 71 G I G T G S G T G G R T G 330000 
219 231 S R P V A R L G L Y S R T 330000 
296 308 S R R T G I R Y S R I G N 330000 
279 291 P 0 P 0 F L 0 I V A L H R 345000 
420 432 I T 0 Q A P S L I P I V P 345000 
348 360 T Y T T T S H A A S P T S 355000 
110 122 E E T S F I 0 A G A P T S 370000 
41 53 I A E Q I L a y G S M G V 375000 
207 219 P N T V T S S T P I P G S 375000 
72 84 Y I P L G T R P P T A T 0 390000 
414 426 P 0 I P I N I T 0 Q A P S 390000 
376 388 0 T S T T P V P S V P S T 392000 
446 458 F Y L H P S Y Y M L R K R 392000 
280 292 0 P 0 F L 0 I V A L H R P 395000 
160 172 N P T F T 0 P S V L Q P P 410000 
185 197 S S T I S T H N Y E E I P 410000 
324 336 V H Y Y Y 0 L S T I 0 P A 412000 
363 375 N G L Y 0 I Y A 0 0 F I T 432000 
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6 16 5 A K R T K R A 5 A T Q L 455000 
269 261 5 5 N D N 5 I N I A P D P 465000 
132 144 G F 5 I T T 5 T 0 T T P A 475000 
142 154 T P A I L D I N N T V T T 475000 
236 246 K V V D P A F V T T P T K 480000 
403 415 G G A Y N I P L V 5 G P D 480000 
183 195 L 5 5 5 T I 5 T H N Y E E 485000 
381 393 P V P 5 V P 5 T 5 L 5 G Y 492000 
111 123 E T 5 F I 0 A G A P T 5 V 510000 
45 57 I L Q Y G 5 M G V F F G G 542000 
433 445 G 5 P Q Y T I I A 0 A G D 545000 
246 258 P T K L I T Y D N P A Y E 562000 
11 23 K R A 5 A T Q L Y K T C K 570000 
128 140 P D V 5 G F 5 I T T 5 T D 585000 
217 229 P G 5 R P V A R L G L Y 5 635000 
267 279 Y F 5 5 N D N 5 I N I A P 642000 
121 133 T 5 V P 5 I P P D V 5 G F 655000 
96 110 V G P 5 0 P 5 I V 5 L V E 670000 
193 205 Y E E I P M D T F I V 5 T 710000 
230 242 R T T Q Q V K V V 0 P A F 710000 
354 366 H A A 5 P T 5 I N N G L Y 820000 
370 382 A 0 0 F I T D T 5 T T P V 842000 
406 418 Y N I P L V 5 G P 0 I P I 855000 
392 404 G Y I P A N T T I P F G G 870000 
367 379 D I Y A 0 D F I T 0 T 5 T 910000 
138 150 5 T D T T P A I L 0 I N N 930000 
307 319 G N K Q T L R T R 5 G K S 965000 
190 202 T H N Y E E I P M 0 T F I 985000 
1 13 M R H K R 5 A K R T K R A 1000000 
2 14 R H K R 5 A K R T K R A 5 1000000 
4 16 K R 5 A K R T K R A 5 A T 1000000 
5 17 R 5 A K R T K R A 5 A T Q 1000000 
8 20 K R T K R A 5 A T Q L Y K 1000000 
9 21 R T K R A 5 A T Q L Y K T 1000000 
10 22 T K R A 5 A T Q L Y K T C 1000000 
12 24 R A 5 A T Q L Y K T C K Q 1000000 
13 25 A 5 A T Q L Y K T C K Q A 1000000 
19 31 Y K T C K Q A G T C P P D 1000000 
20 32 K T C K Q A G T C P P D I 1000000 
21 33 T C K Q A G T C P P D I I 1000000 
22 34 C K Q A G T C P P D I I P 1000000 
23 35 K Q A G T C P P 0 I I P K 1000000 
24 36 Q A G T C P P D I I P K V 1000000 
25 37 A G T C P P D I I P K V E 1000000 
26 38 G T C P P D I I P K V E G 1000000 
27 39 T C P P 0 I I P K V E G K 1000000 
28 40 C P P 0 I I P K V E G K T 1000000 
29 41 P P 0 I 1 P K V E G K T I 1000000 
32 441 1 P K V E G K T 1 A E Q 1000000 
33 451 P K V E G K T 1 A E Q 1 1000000 
35 47 K V E G K T I A E Q 1 L Q 1000000 
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36 48 V E G K T 1 A E a 1 L a y 1000000 
47 59 a y G S M G V F F G G l G 1000000 
54 66 F F G G L G 1 G T G S G T 1000000 
58 70 l G 1 G T G S G T G G R T 1000000 
60 721 G T G S G T G G R T G Y 1000000 
62 74 T G S G T G G R T G Y 1 P 1000000 
64 76 S G T G G R T G Y 1 P l G 1000000 
65 77 G T G G R T G Y I P l G T 1000000 
66 78 T G G R T G Y 1 P l G T R 1000000 
68 80 G R T G Y I P l G T R P P 1000000 
69 81 R T G Y I P l G T R P P T 1000000 
71 83 G Y I P l G T R P P T A T 1000000 
73 85 I P l G T R P P T A T 0 T 1000000 
74 86 P l G T R P P T A T 0 T l 1000000 
75 87 l G T R P P T A T 0 T l A 1000000 
76 88 G T R P P T A T 0 T l A P 1000000 
77 89 T R P P T A T 0 T l A P V 1000000 
79 91 P P T A T 0 T l A P V R P 1000000 
80 92 P T A T 0 T l A P V R P P 1000000 
83 95 T 0 T l A P V R P P l T V 1000000 
85 97 T l A P V R P P L T V 0 P 1000000 
86 98 l A P V R P P L T V 0 P V 1000000 
88 100 P V R P P L T V 0 P V G P 1000000 
89 101 V R P P l T V 0 P V G P S 1000000 
92 104 P L T V 0 P V G P S 0 P S 1000000 
94 106 T V 0 P V G P S 0 P S I V 1000000 
95 107 V 0 P V G P S 0 P S I V 5 1000000 
97 109 P V G P 5 0 P 5 1 V S L V 1000000 
100 112 P S 0 P S I V S L V E E T 1000000 
101 113 S 0 P S I V S L V E E T S 1000000 
104 116 S I V S L V E E T S F I 0 1000000 
108 120 L V E E T S F I 0 A G A P 1000000 
115 127 I 0 A G A P T S V P S I P 1000000 
116 128 0 A G A P T S V P S I P P 1000000 
117 129 A G A P T S V P S I P P 0 1000000 
119 131 A P T S V P S I P P 0 v S 1000000 
120 132 P T S V P S I P P 0 v S G 1000000 
122 134 S V P S I P P 0 v S G F S 1000000 
123 135 V P S I P P 0 v S G F S I 1000000 
124 136 P S I P P 0 v S G F S I T 1000000 
125 137 S I P P 0 v 5 G F S I T T 1000000 
126 138 I P P 0 v S G F S I T T S 1000000 
129 141 0 V S G F S I T T S T 0 T 1000000 
130 142 V S G F S I T T S T 0 T T 1000000 
133 145 F S I T T S T 0 T T P A I 1000000 
134 146 S I T T S T 0 T T P A I L 1000000 
135 147 I T T S T 0 T T P A I L 0 1000000 
137 149 T S T 0 T T P A I l 0 I N 1000000 
139 151 T 0 T T P A I l 0 I N N T 1000000 
140 152 0 T T P A I l 0 I N N T V 1000000 
145 157 I l 0 I N N T V T T V T T 1000000 
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148 160 I N N T V T T V T T H N N 1000000 
149 161 N N T V T T V T T H N N P 1000000 
151 163 T V T T V T T H N N P T F 1000000 
154 166 T V T T H N N P T F T 0 P 1000000 
155 167 V T T H N N P T F T 0 P S 1000000 
156 168 T T H N N P T F T 0 P S V 1000000 
157 169 T H N N P T F T 0 P S V L 1000000 
158 170 H N N P T F T 0 P S V L a 1000000 
162 174 T F T 0 P S V L a p p T P 1000000 
163 175 F T 0 P S V L a p p T P A 1000000 
164 176 T 0 P S V L Q P P T P A E 1000000 
165 177 0 P 5 V L Q P P T P A E T 1000000 
168 180 V l Q P P T P A E T G G H 1000000 
169 181 L Q P P T P A E T G G H F 1000000 
171 183 P P T P A E T G G H F T L 1000000 
173 185 T P A E T G G H F T l 5 S 1000000 
174 186 P A E T G G H F T L 5 S S 1000000 
175 167 A E T G G H F T L S S S T 1000000 
176 188 E T G G H F T L S S S T I 1000000 
182 194 T L 5 5 S T I S T H N Y E 1000000 
184 196 5 S S T I 5 T H N Y E E I 1000000 
187 199 T I 5 T H N Y E E , P M 0 1000000 
188 200 I 5 T H N Y E E I P M 0 T 1000000 
189 201 S T H N Y E E I P M 0 T F 1000000 
192 204 N Y E E I P M 0 T F I V 5 1000000 
194 206 E E I P M 0 T F I V S T N 1000000 
197 209 P M 0 T F , V S T N P N T 1000000 
203 215 V 5 T N P N T V T 5 S T P 1000000 
204 216 5 T N P N T V T S 5 T P I 1000000 
206 218 N P N T V T 5 S T P I P G 1000000 
209 221 T V T S 5 T P I P G 5 R P 1000000 
210 222 V T S 5 T P I P G S R P V 1000000 
212 224 S S T P I P G S R P V A R 1000000 
213 225 S T P I P G S R P V A R l 1000000 
215 227 P I P G S R P V A R L G L 1000000 
218 230 G 5 R P V A R L G L Y 5 R 1000000 
221 233 P V A R L G L Y S R T T a 1000000 
223 235 A R L G L Y S R T T a a v 1000000 
224 236 R L G l Y 5 R T T Q a V K 1000000 
229 241 5 R T T a Q V K V V 0 P A 1000000 
231 243 T T Q a V K V V 0 P A F V 1000000 
232 244 T Q Q V K V V 0 P A F V T 1000000 
234 246 Q V K V V 0 P A F V T T P 1000000 
237 249 V V 0 P A F V T T P T K L 1000000 
238 250 V 0 P A F V T T P T K L I 1000000 
239 251 0 P A F V T T P T K L I T 1000000 
242 254 F V T T P T K L I T Y 0 N 1000000 
243 255 V T T P T K l I T Y 0 N P 1000000 
245 257 T P T K L I T Y 0 N P A Y 1000000 
251 263 T Y 0 N P A Y E G I 0 V 0 1000000 
252 264 Y 0 N P A Y E G I 0 V 0 N 1000000 
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253 265 0 N P A Y E G I 0 V 0 N T 1000000 
254 266 N P A Y E G I 0 V 0 N T l 1000000 
256 268 A Y E G I 0 V 0 N T L Y F 1000000 
257 269 Y E G I 0 V 0 N T L Y F S 1000000 
261 273 0 V 0 N T l Y F S S N 0 N 1000000 
262 274 V 0 N T L Y F S S N 0 N S 1000000 
270 282 S N 0 N S I N I A P 0 P 0 1000000 
271 283 N 0 N S I N I A P 0 P 0 F 1000000 
272 284 0 N 5 I N I A P 0 P 0 F l 1000000 
273 285 N S I N I A P 0 P 0 F L 0 1000000 
274 286 S I N I A P 0 P 0 F L 0 I 1000000 
275 287 I N I A P 0 P 0 F L 0 I V 1000000 
276 286 N I A P 0 P 0 F L 0 I V A 1000000 
277 269 I A P 0 P 0 F L 0 I V A L 1000000 
278 290 A P 0 P 0 F L 0 I V A L H 1000000 
287 299 V A L H R P A L T S R R T 1000000 
268 300 A L H R P A L T S R R T G 1000000 
289 301 L H R P A L T S R R T G I 1000000 
290 302 H R P A L T S R R T G I R 1000000 
291 303 R P A L T S R R T G I R Y 1000000 
293 305 A L T 5 R R T G I R Y S R 1000000 
295 307 T 5 R R T G I R Y S R I G 1000000 
297 309 R R T G I R Y S R I G N K 1000000 
298 310 R T G I R Y S R I G N K a 1000000 
302 314 R Y S R I G N K Q T L R T 1000000 
303 315 Y S R I G N K Q T L R T R 1000000 
305 317 R I G N K a T L R T R 5 G 1000000 
306 318 I G N K Q T L R T R S G K 1000000 
308 320 N K a T L R T R 5 G K S I 1000000 
309 321 K a T L R T R S G K S I G 1000000 
311 323 T L R T R S G K 5 I G A K 1000000 
312 324 L R T R S G K S I G A K V 1000000 
313 325 R T R 5 G K S I G A K V H 1000000 
314 326 T R S G K S , G A K V H Y 1000000 
316 328 S G K S , G A K V H Y Y Y 1000000 
318 330 K S I G A K V H Y Y Y 0 L 1000000 
319 331 S I G A K V H Y Y Y 0 L S 1000000 
320 332 I G A K V H Y Y Y 0 L 5 T 1000000 
321 333 G A K V H Y Y Y 0 L S T I 1000000 
323 335 K V H Y Y Y 0 L S T I 0 P 1000000 
327 339 Y Y 0 L S T , 0 P A E E I 1000000 
329 341 0 L S T I 0 P A E E , E L 1000000 
330 342L 5 T I 0 P A E E I E L Q 1000000 
332 344T I 0 P A E E I E L a T I 1000000 
333 345 I 0 P A E E I E L Q T I T 1000000 
334 346 0 P A E E I E L Q T I T P 1000000 
335 347P A E E I E l a T I T P S 1000000 
337 349E E I E L a T I T P S T Y 1000000 
340 352 E L a T I T P S T Y T T T 1000000 
343 355 T I T P S T Y T T T S H A 1000000 
344 356 I T P S T Y T T T S H A A 1000000 
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350 362 T T T S H A A S P T S I N 1000000 
351 363 T T S H A A S P T S I N N 1000000 
355 367 A A S P T S I N N G L Y 0 1000000 
357 369 S P T S I N N G L Y 0 I Y 1000000 
360 372 S I N N G L Y 0 I Y A 0 0 1000000 
361 373 I N N G L Y 0 I Y A 0 0 F 1000000 
362 374 N N G L Y 0 I Y A 0 0 F I 1000000 
365 377 L Y 0 I Y A 0 0 F I T 0 T 1000000 
366 378 Y 0 I Y A 0 0 F I T 0 T S 1000000 
368 380 I Y A 0 0 F I T 0 T S T T 1000000 
369 381 Y A 0 0 F I T 0 T S T T P 1000000 
373 385 F I T' 0 T S T T P V P S V 1000000 
375 367 T 0 T S T T P V P S V P S 1000000 
378 390 S T T P V P S V P S T S L 1000000 
380 392 T P V P S V P S T S L S G 1000000 
383 395 P S V P S T S L S G Y I P 1000000 
386 398 P S T S L S G Y I P A N T 1000000 
387 399 S T S L S G Y I P A N T T 1000000 
389 401 S L S G Y I P A N T T I P 1000000 
390 402 L S G Y 1 P A N T T I P F 1000000 
393 405 Y I P A N T T 1 P F G G A 1000000 
394 4061 P A N T T I P F G G A Y 1000000 
401 413 P F G G A Y N I P L V S G 1000000 
405 417 A Y N 1 P L V S G P 0 1 P 1000000 
407 419 N 1 P L V S G P 0 I P 1 N 1000000 
410 422 L V S G P 0 I P 1 N I T 0 + 100000Q 411 423 V S G P 0 1 P I N I T 0 Q 1000000 
412 424 S G P 0 I P I N I T 0 Q A 1000000 
413 425 G P 0 I P I N I T 0 Q A P 1000000 
415 427 0 I P I N I T 0 Q A P S L 1000000 
417 429 P I N I T 0 Q A P S L I P 1000000 
421 433 T 0 Q A P S L I P 1 V P G 1000000 
422 434 0 Q A P S L I P I V P G S 1000000 
424 436 A P S L I P I V P G S P Q 1000000 
- --
427 439 L I P I V P G S P Q Y T I 1000000 
-
430 442 I V P G S P Q Y T I I A 0 1000000 
432 444 P G S P Q Y T I I A 0 A G 1000000 
434 446 S P Q Y T I I A 0 A G 0 F 1000000 
436 448 Q Y T 1 I A 0 A G 0 F Y L 1000000 
439 451 I I A 0 A G 0 F Y L H P S 1000000 
440 452 I A 0 A G 0 F Y L H P S Y 1000000 
441 453 A 0 A G 0 F Y L H P S Y Y 1000000 
442 454 0 A G 0 F Y L H P S Y Y M 1000000 
443 455 A G 0 F Y L H P S Y Y M L 1000000 
447 459 Y L H P S Y Y M L R K R R 1000000 
448 460 L H P 5 Y Y M L R K R R K 1000000 
449 461 H P S Y Y M L R K R R K R 1000000 
454 466 M l R K R R K R L P Y F F 1000000 
455 467l R K R R K R l P Y F F 5 1000000 
456 468 R K R R K R L P Y F F S 0 1000000 
457 469 K R R K R L P Y F F S 0 V 1000000 
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458 470 R R K R L P Y F F S 0 v S 1000000 
459 471 R K R L P Y F F S 0 v S L 1000000 
460 472 K R L P Y F F S 0 v S L A 1000000 
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IC50 DRB1*0401 nM) 
46 58 L Q Y G S M G V F F G G L 9.8 
266 278 L Y F S S N 0 N S I N I A 11 
391 403 S G Y I P A N T T I P F G 12 
444 456 G 0 F Y L H P S Y Y M L R 20.2 
179 191 G H F T L S S S T I S T H 23.2 
199 211 0 T F I V S T N P N T V T 26 
325 337 H Y Y Y 0 L S T I 0 P A E 44.5 
208 220 N T V T S S T P I P G S R 62 
131 143 S G F S I T T S T 0 T T P 66.5 
347 359 S T Y T T T S H A A S P T 86 
70 82 T G Y I P L G T R P P T A 91 
17 29 Q L Y K T C K Q A G T C P 112 
112 124 T S F I D A G A P T S V P 120 
143 155 P A I L D I N N T V T T V 122 
43 55 E Q I L a y G S M G V F F 150 
326 338 Y Y Y D L S T I D P A E E 150 
51 63 M G V F F G G L G I G T G 170 
150 162 N T V T T V T T H N N P T 175 
299 311 T G I R Y S R I G N K Q T 192 
281 293 P 0 F L 0 I V A L H R P A 250 
53 65 V F F G G L G I G T G S G 285 
264 276 N T L Y F S S N 0 N S I N 305 
337 349 E E I E L a T I T P S T Y 335 
52 64 G V F F G G L G I G T G S 340 
200 212 T F I V S T N P N T V T S 385 
372 384 0 F I T D T S T T P V P S 420 
388 400 T S L S G Y I P A N T T I 445 
367 379 D I Y A 0 D F I T D T S T 450 
437 449 Y T I I A D A G 0 F Y L H 530 
181 193 F T L S S S T I S T H N Y 580 
233 245 Q Q V K V V 0 P A F V T T 585 
103 115 P S I V S L V E E T S F I 602 
128 140 P 0 v S G F S I T T S T D 655 
201 213 F I V S T N P N T V T S S 912 
49 61 G S M G V F F G G L G I G 940 
39 51 K T I A E a I L a y G S M 1100 
371 383 D 0 F I T 0 T 5 T T P V p 1100 
301 313 I R Y 5 R I G N K a T L R 1200 
247 259 T K L I T Y 0 N P A Y E G 1300 
435 447 P a y T I I A 0 A G D F Y 1400 
324 336 V H Y Y Y D L S T I D P A 1500 
346 358 P S T Y T T T S H A A S p 1650 
400 412 I P F G G A Y N I P L V S 1700 
285 297 D I V A L H R P A L T S R 1800 
265 277 T L Y F S S N D N S I N I 1900 
416 428 I P I N I T 0 a A p S L I 1900 
402 414 F G G A Y N I P L V S G P 1950 
248 260 K L I T Y D N P A Y E G I 2100 
146 158 L D I N N T V T T V T T H 2220 
445 457 D F Y L H P S Y Y M L R K 2300 
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255 267 P A Y E G I 0 V 0 N T L Y 2320 
312 324 L R T R S G K S I G A K V 2850 
425 437 P S L I P I V P G S P a y 3000 
58 70 l G I G T G S G T G G R T 3350 
284 296 L 0 I V A L H R P A l T S 3400 
152 164 V T T V T T H N N P T F T 3620 
14 26 S A T a L y K T C K a A G 3700 
66 78 T G G R T G Y I P L G T R 3700 
397 409 N T T I P F G G A Y N I P 4000 
418 430 I N I T 0 a A p S L I P I 4200 
203 215 V S T N P N T V T S S T P 4800 
240 252 P A F V T T P T K L I T Y 4900 
180 192 H F T L S S S T I S T H N 5000 
161 173 P T F T 0 P S V L a p p T 5220 
292 304 P A l T S R R T G I R Y S 5220 
106 118 V S l V E E T S F I 0 A G 5400 
386 398 P S T S l S G Y I P A N T 5500 
446 458 F Y L H P S Y Y M l R K R 5700 
249 261 l I T Y 0 N P A Y E G I D 5850 
263 275 0 N T L Y F S S N 0 N S I 5920 
153 165 T T V T T H N N P T F T 0 6000 
64 96 0 T l A P V R P P L T V 0 6200 
38 50 G K T I A E a I L a y G S 6400 
207 219 P N T V T S S T P I P G S 6450 
258 270 E G I 0 V 0 N T L Y F S S 6620 
282 294 0 F L 0 I V A l H R P A l 6800 
225 237 L G L Y S R T T a a v K V 7000 
438 450 T I I A 0 A G 0 F Y l H P 7000 
259 271 G I 0 V 0 N T L Y F S S N 7150 
342 354 a T I T P S T Y T T T S H 7420 
134 146 S I T T S T 0 T T P A I L 8000 
55 67 F G G l G I G T G S G T G 8920 
209 221 T V T S S T P I P G S R P 9250 
135 147 I T T S T 0 T T P A I L 0 9300 
349 361 Y T T T S H A A S P T S I 9850 
339 351 I E l a T I T P S T Y T T 9950 
56 68 G G l G I G T G S G T G G 11000 
133 145 F S I T T S T 0 T T P A I 13000 
268 280 F S S N 0 N S I N I A P 0 14000 
322 334 A K V H Y Y Y 0 L S T I 0 15200 
363 375 N G L Y 0 I Y A 0 0 F I T 15200 
8 20 K R T K R A S A T Q L Y K 17200 
144 156 A t L 0 I N N T V T T V T 17500 
154 166 T V T T H N N P T F T 0 P 17500 
186 198 S T I S T H N Y E E I P M 17500 
226 238 G l Y S R T T a a v K V V 17500 
364 376 G L Y 0 I Y A 0 0 F I T 0 18000 
198 210 M 0 T F I V S T N P N T V 18500 
185 197 S S T I S T H N Y E E I P 21500 
91 103 P P L T V 0 P V G P S 0 P 22000 
404 416 G A Y N I P L V S G P 0 I 23200 
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377 389 T S T T P V P S v p S T 5 23500 
414 426 P 0 I P I N I T 0 Q A P 5 24000 
350 362 T T T S H A A 5 P T 5 I N 25500 
149 161 N N T V T T V T T H N N P 26500 
42 54 A E Q I L Q Y G 5 M G V F 27000 
450 462 P S Y Y M L R K R R K R L 28200 
387 399 S T S L S G Y I P A N T T 29000 
331 343 5 T I 0 P A E E I E L Q T 29500 
110 122 E E T 5 F I D A G A P T 5 30000 
309 321 K Q T L R T R S G K S I G 30200 
50 62 S M G V F F G G L G I G T 31000 
151 163 T V T T V T T H N N P T F 39000 
246 258 P T K L I T Y 0 N P A Y E 41000 
317 329 G K S I G A K V H Y Y Y 0 41000 
175 187 A E T G G H F T L 5 5 S T 41500 
44 56 Q I L Q Y G 5 M G V F F G 43000 
236 248 K V V D P A F V T T P T K 43000 
224 236 R L G L Y S R T T Q Q V K 46000 
220 232 R P V A R L G L Y S R T T 47000 
16 28 T Q L Y K T C K Q A G T C 48200 
348 360 T Y T T T 5 H A A 5 P T 5 51500 
273 285 N 5 I N I A P 0 P 0 F L 0 53500 
358 370 P T S I N N G L Y 0 I Y A 59000 
113 125 5 F I 0 A G A P T S V P S 61200 
359 371 T S 1 N N G L Y 0 1 Y A 0 61500 
431 443 V P G S P Q Y T I 1 A 0 A 65000 
460 472 K R L P Y F F S 0 V S L A 65000 
93 105 L T V 0 P V G P S 0 P S 1 66000 
162 194 T L S S S T I S T H N Y E 72500 
423 435 Q A P S L I P I V P G 5 P 73000 
196 2081 P M 0 T F I V S T N P N 74500 
409 421 P L V S G P 0 I P I N I T 77000 
433 445 G S P Q Y T I I A 0 A G 0 78000 
315 327 R S G K S I G A K V H Y Y 79000 
57 69 G L G 1 G T G S G T G G R 87000 
374 366 I T 0 T S T T P V P 5 V P 87200 
428 440 I P I V P G S p Q y T I I 88000 
223 235 A R L G L Y S R T T Q a V 88500 
318 330 K S I G A K V H Y Y Y 0 L 94000 
443 455 A G 0 F Y L H P S Y Y M L 97500 
328 340 Y 0 L S T I 0 P A E E I E 102000 
392 404 G Y I P A N T T I P F G G 102000 
320 332 I G A K V H Y Y Y 0 L S T 110000 
441 453 A 0 A G 0 F Y L H P S Y Y 110000 
373 385 F I T 0 T 5 T T P V P S V 120000 
109 121 V E E T 5 F I 0 A G A P T 125000 
257 269 Y E G I 0 V 0 N T L Y F S 130000 
354 366 H A A S P T S I N N G L Y 130000 
60 721 G T G S G T G G R T G Y 140000 
105 117 I V S L V E E T S F I 0 A 150000 
360 372 S I N N G L Y 0 I Y A 0 0 150000 
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436 448 Q Y T 1 1 A 0 A G 0 F Y L 150000 
64 76 S G T G G R T G Y I P L G 160000 
244 256 T T P T K L I T Y 0 N P A 160000 
271 283 N 0 N S I N 1 A P 0 P 0 F 162000 
167 179 S V L Q P P T P A E T G G 165000 
54 66 F F G G L G 1 G T G S G T 175000 
19 31 Y K T C K Q A G T C P P 0 180000 
176 188 E T G G H F T L S S S T I 180000 
72 84 Y I P L G T R P P T A T 0 190000 
241 253 A F V T T P T K L 1 T Y 0 190000 
96 108 0 P V G P S 0 P S 1 V S L 195000 
393 405 Y 1 P A N T T 1 P F G G A 200000 
230 242 R T T Q Q V K V V 0 P A F 205000 
111 123 E T S F 1 0 A G A P T S V 210000 
124 136 P S 1 P P 0 V S G F S I T 210000 
104 116 S 1 V S L V E E T S F I 0 220000 
357 369 S P T S I N N G L Y 0 1 Y 220000 
37 49 E G K T I A E Q I L Q Y G 222000 
408 420 I P L V S G P 0 I P I N I. 235000 
130 142 V S G F S I T T S T 0 T T 240000 
303 315 Y S R I G N K Q T L R T R 242000 
398 410 T T I P F G G A Y N I P L 245000 
401 413 P F G G A Y N I P L V S G 245000 
193 205 Y E E I P M 0 T F I V S T 260000 
-
245 257 T P T K L I T Y 0 N P A Y 265000 
63 75 G S G T G G R T G Y I IP L 270000 
197 209 P M 0 T F I V S T N P N T 270000 
194 206 E E I P M 0 T F I V S T N 280000 
344 3561 T P S T Y T T T S H A A 292000 
61 73 G T G S G T G G R T G Y I 295000 
321 333 G A K V H Y Y Y 0 L S T I 312000 
379 391 T T P V P S V P S T S L S 320000 
304 316 S R I G N K Q T L R T R S 325000 
385 397 V P S T S L S G Y I P A N 330000 
59 71 G I G T G S G T G G R T G 340000 
345 357 T P S T Y T T T S H A A S 350000 
67 79 G G R T G Y I P L G T R P 360000 
382 394 V P 5 V P 5 T 5 L 5 G Y I 365000 
188 200 I 5 T H N Y E E I P M 0 T 372000 
79 91 P P T A T 0 T L A P V R P 375000 
11 23 K R A 5 A T Q L Y K T C K 382000 
120 132 P T 5 V P 5 1 P P 0 V 5 G 385000 
107 119 S L V E E T 5 F I 0 A G A 400000 
366 378 Y 0 I Y A 0 0 F I T 0 T 5 415000 
189 201 5 T H N Y E E I P M 0 T F 420000 
145 157 I L 0 I N N T V T T V T T 440000 
20 32 K T C K Q A G T C P P 0 I 442000 
183 195 L 5 5 S T I S T H N Y E E 450000 
451 463 S Y Y M L R K R R K R L P 462000 
10 22 T K R A S A T Q L Y K T C 470000 
34 46 P K V E G K T I A E Q I L 490000 
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136 148 T T S T 0 T T P A I L 0 I 490000 
139 151 T 0 T T P A I L 0 I N N T 510000 
118 130 G A P. T S V P S I P P 0 V 545000 
160 172 N P T F T 0 P S V L a p p 545000 
159 171 N N P T F T 0 P S V L Q P 575000 
234 246 Q V K V V 0 P A F V T T P 585000 
81 93 T A T 0 T L A P V R P P L 590000 
177 189 T G G H F T L S S S T I S 590000 
172 184 P T P A E T G G H F T L S 630000 
426 438 S L I P I V P G S P Q Y T 630000 
47 59 Q Y G S M G V F F G G L G 635000 
362 374 N N G L Y 0 I Y A 0 0 F I 640000 
121 133 T S V P S I P P 0 v S G F 650000 
341 353 L Q T I T P S T Y T T T S 665000 
141 153 T T P A I L 0 I N N T V T 685000 
310 322 Q T L R T R S G K S I G A 710000 
406 418 Y N I P L V S G P 0 I P I 730000 
338 350 E I E L a T I T P S T Y T 732000 
280 292 0 P 0 F L 0 I V A L H R P 745000 
294 306 L T S R R T G I R Y S R I 752000 
166 178 P S V L Q P P T P A E T G 770000 
242 254 F V T T P T K L I T Y 0 N 780000 
384 396 S V P S T S L S G Y I P A 795000 
356 368 A S P T S I N N G L Y 0 I 802000 
155 167 V T T H N N P T F T 0 P S 810000 
222 234 V A R L G L Y S R T T Q Q 860000 
75 87 L G T R P P T A T 0 T L A 880000 
440 452 I A 0 A G 0 F Y L H P S Y 910000 
375 387 T 0 T S T T P V P S v p S 922000 
9 21 R T K R A 5 A T Q L Y K T 945000 
417 429 P I N I T 0 Q A P 5 L I P 952000 
190 202 T H N Y E E I P M 0 T F I 982000 
1 13 M R H K R S A K R T K R A 1000000 
2 14 R H K R 5 A K R T K R A 5 1000000 
-
.~ 15 H K R 5 A K R T K R A 5 A 1000000 
4 16 K R 5 A K R T K R A 5 A T 1000000 
5 17 R 5 A K R T K R A S A T a 1000000 
6 18 5 A K R T K R A S A T Q L 1000000 
7 19 A K R T K R A S A T Q L Y 1000000 
12 24 R A S A T Q L Y K T C K Q 1000000 
13 25 A S A T Q L Y K T C K Q A 1000000 
15 27 A T a L y K T C K a A G T 1000000 
18 30 L Y K T C K a A G T C P P 1000000 
21 33 T C K a A G T C p P 0 I I 1000000 
22 34 C K a A G T C P P 0 I I P 1000000 
23 35 K a A G T C p P 0 I I P K 1000000 
24 36 Q A G T C P P 0 I I P K V 1000000 
25 37 A G T C P P 0 I , P K V E 1000000 
26 38 G T C P P 0 I I P K V E G 1000000 
27 39 T C P P 0 I I P K V E G K 1000000 
28 40 C P P 0 I I P K V E G K T 1000000 
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29 41 P P 0 I I P K V E G K T I 1000000 
30 42 P 0 I I P K V E G K T I A 1000000 
31 43 0 I I P K V E G K T I A E 1000000 
32 44 I I P K V E G K T I A E a 1000000 
33 45 I P K V E G K T I A E a I 1000000 
35 47 K V E G K T I A E a I L a 1000000 
36 48 V E G K T I A E a I L a y 1000000 
40 52 T I A E a I L a y G S M G 1000000 
41 53 I A E a I L Q Y G S M G V 1000000 
45 57 I L a y G S M G V F F G G 1000000 
48 60 Y G S M G V F F G G L G I 1000000 
62 74 T G S G T G G R T G Y I P 1000000 
65 77 G T G G R T G Y I P L G T 1000000 
68 80 G R T G Y I P L G T R P P 1000000 
69 81 R T G Y I P L G T R P P T 1000000 
71 83 G Y I P L G T R P P T A T 1000000 
73 85 I P L G T R P P T A T 0 T 1000000 
74 86 P L G T R P P T A T 0 T L 1000000 
76 88 G T R P P T A T 0 T L A 8 1000000 
17 89 T R P P T A T 0 T L A P V 1000000 
78 90 R P P T A T 0 T L A P V R 1000000 
80 92 P T A T 0 T L A P V R P P 1000000 
82 94 A T 0 T L A P V R P P L T 1000000 
83 95 T 0 T L A P V R P P L T V 1000000 
85 97 T L A P V R P P L T V 0 P 1000000 
86 98 L A P V R P P L T V 0 P V 1000000 
87 99 A P V R P P L T V 0 P V G 1000000 
88 100 P V R P P L T V D P V G P 1000000 
89 101 V R P P L T V 0 P V G P S 1000000 
90 102 R P P L T V 0 P V G P S 0 1000000 
92 104 P L T V 0 P V G P S 0 P S 1000000 
94 106 T V 0 P V G P S 0 P S I V 1000000 
95 107 V 0 P V G P S 0 P S I V S 1000000 
97 109 P V G P S 0 P S I V S L V 1000000 
98 110 V G P S 0 P S I V S L V E 1000000 
99 111 G P S 0 P S I V S L V E E 1000000 
100 112 P S 0 P S I V S L V E E T 1000000 
101 113 S 0 P S I V S L V E E T S 1000000 
102 114 0 P S I V S L V E E T S F 1000000 
108 120 L V E E T S F I D A G A P 1000000 
114 126 F I 0 A G A P T S V P S I 1000000 
115 127 I 0 A G A P T S V P S I P 1000000 
116 128 D A G A P T S V P S I P P 1000000 
117 129 A G A P T S V P S I P P 0 1000000 
119 131 A P T S V P S I P P 0 v S 1000000 
122 134 S V P S I P P 0 v S G F S 1000000 
123 135 V P S I P P 0 v S G F S I 1000000 
125 137 S I P P 0 v S G F S I T T 1000000 
126 138 I P P 0 V S G F S I T T S 1000000 
127 139 P P 0 v S G F S I T T S T 1000000 
129 141 0 V S G F S I T T S T 0 T 1000000 
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132 144 G F S I T T S T 0 T T P A 1000000 
137 149 T S T 0 T T P A I L 0 I N 1000000 
138 150 S T 0 T T P A I L 0 I N N 1000000 
140 152 0 T T P A I L 0 I N N T V 1000000 
142 154 T P A I L 0 I N N T V T T 1000000 
147 159 0 I N N T V T T V T T H N 1000000 
148 160 I N N T V T T V T T H N N 1000000 
156 168 T T H N N P T F T 0 P 5 V 1000000 
157 169 T H N N P T F T 0 P S V L 1000000 
158 170 H N N P T F T 0 P S V L Q 1000000 
162 174 T F T 0 P S V L Q P P T P 1000000 
163 175 F T 0 P S V L Q P P T P A 1000000 
164 176 T 0 P S V L a p p T P A E 1000000 
165 177 0 P S V L Q P P T P A E T 1000000 
168 180 V L Q P P T P A E T G G H 1000000 
169 181 L a p p T P A E T G G H F 1000000 
170 182 Q P P T P A E T G G H F T 1000000 
171 183 P P T P A E T G G H F T L 1000000 
173 185 T P A E T G G H F T L S S 1000000 
174 186 P A E T G G H F T L S S S 1000000 
178 190 G G H F T L 5 S 5 T I 5 T 1000000 
184 196 S S S T I S T H N Y E E I 1000000 
187 199 T I 5 T H N Y E E I P M 0 1000000 
191 203 H N Y E E I P M 0 T F I V 1000000 
192 204 N Y E E I P M 0 T F I V S 1000000 
195 207 E I P M 0 T F I V S T N P 1000000 
202 214 I V S T N P N T V T 5 5 T 1000000 
204 216 S T N P N T V T S S T P I 1000000 
205 217 T N P N T V T 5 5 T P I P 1000000 
206 218 N P N T V T S S T P I P G 1000000 
210 222 V T S 5 T P I P G 5 R P V 1000000 
211 223 T 5 5 T P I P G 5 R P V A 1000000 
212 224 S S T P I P G S R P V A R 1000000 
213 225 5 T P I P G S R P V A R L 1000000 
214 226 T P I P G 5 R P V A R L G 1000000 
215 227 P I P G 5 R P V A R L G L 1000000 
216 228 I P G S R P V A R L G L Y 1000000 
217 229 P G S R P V A R L G L Y S 1000000 
218 230 G 5 R P V A R L G L Y S R 1000000 
219 231 S R P V A R L G L Y S R T 1000000 
221 233 P V A R L G L Y S R T T a 1000000 
227 239 L Y S R T T a a V K V V 0 1000000 
228 240 Y S R T T Q Q V K V V 0 P 1000000 
229 241 5 R T T Q a V K V V 0 P A 1000000 
231 243 T T a a V K V V 0 P A F V 1000000 
232 244 T a Q V K V V 0 P A F V T 1000000 
235 247 V K V V 0 P A F V T T P T 1000000 
237 249 V V 0 P A F V T T P T K L 1000000 
238 250 V 0 P A F V T T P T K L I 1000000 
239 251 0 P A F V T T P T K L I T 1000000 
243 255 V T T P T K L I T Y 0 N P 1000000 
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250 262 I T Y 0 N P A Y E G , 0 V 1000000 
251 263 T Y 0 N P A Y E G I 0 V 0 1000000 
252 264 Y 0 N P A Y E G , 0 V 0 N 1000000 
253 265 0 N P A Y E G , 0 V 0 N T 1000000 
254 266 N P A Y E G I 0 V 0 N T L 1000000 
256 268 A Y E G , 0 V 0 N T L Y F 1000000 
260 272 , 0 V 0 N T L Y F S S N D 1000000 
261 273 0 V 0 N T L Y F S S N 0 N 1000000 
262 274 V 0 N T l Y F S S N 0 N S 1000000 
267 279 Y F S S N 0 N S , N I A P 1000000 
269 281 S S N 0 N S I N , A P 0 P 1000000 
270 282 S N 0 N S , N , A P 0 P D 1000000 
272 284 D N S , N , A P D P 0 F L 1000000 
274 286 S , N , A P D P D F l 0 I 1000000 
275 287 , N I A P 0 P 0 F L D , V 1000000 
276 288 N , A P 0 P D F l 0 , V A 1000000 
277 289' A P D P D F l D , V A l 1000000 
278 290 A P 0 P D F L 0 I V A L H 1000000 
279 291 P D P 0 F l 0 I V A l H R 1000000 
283 295 F l 0 , V A L H R P A l T 1000000 
286 298 I V A l H R P A l T S R R 1000000 
287 299 V A l H R P A L T S R R T 1000000 
288 300 A L H R P A L T S R R T G 1000000 
289 301 L H R P A L T S R R T G I 1000000 
290 302 H R P A L T S __ f- R T G , R 1000000 -291 303 R P A L T S R T G I R Y 1000000 
293 305 A l T S R R T G , R Y S R 1000000 
295 307 T S R R T G I R Y S R I G 1000000 
296 308 S R R T G I R Y S R I G N 1000000 
297 309 R R T G , R Y S R , G N K 1000000 
298 310 R T G I R Y S R , G N K Q 1000000 
300 312 G I R Y S R I G N K Q T L 1000000 
302 314 R Y S R , G N K Q T l R T 1000000 
305 317 R I G N K Q T L R T R S G 1000000 
306 318 I G N K Q T l R T R S G K 1000000 
307 319 G N K Q T l R T R S G K S 1000000 
308 320 N K Q T l R T R S G K S I 1000000 
311 323 T L R T R S G K S I G A K 1000000 
313 325 R T R S G K S I G A K V H 1000000 
314 326 T R S G K S , G A K V H Y 1000000 
316 328 S G K S , G A K V H Y Y Y 1000000 
319 331 S , G A K V H Y Y Y 0 L S 1000000 
323 335 K V H Y Y Y 0 L S T I 0 P 1000000 
327 339 Y Y 0 L 5 T I 0 P A E E , 1000000 
329 341 0 L S T I 0 P A E E I E l 1000000 
330 342L S T I 0 P A E E I E L Q 1000000 
332 344T I 0 P A E E , E L Q T I 1000000 
333 345 , 0 P A E E , E l Q T , T 1000000 
334 346 0 P A E E , E L Q T , T P 1000000 
335 347 P A E E , E L Q T , T P S 1000000 
336 348 A E E , E L Q T , T P S T 1000000 
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340 352 E L a T I T P S T Y T T T 1000000 
343 355 T I T P S T Y T T T S H A 1000000 
351 363 T T S H A A S P T S I N N 1000000 
352 364 T S H A A S P T S I N N G 1000000 
353 365 S H A A S P T S I N N G L 1000000 
355 367 A A S P T S I N N G L Y 0 1000000 
361 373 I N N G L Y 0 I Y A 0 0 F 1000000 
365 377 L Y 0 I Y A 0 0 F I T 0 T 1000000 
368 380 I Y A 0 0 F I T 0 T S T T 1000000 
369 381 Y A 0 0 F I T 0 T S T T P 1000000 
370 382 A 0 0 F I T 0 T S T T P V 1000000 
376 388 0 T S T T P V P S v p S T 1000000 
378 390 S T T P V P S v p S T S L 1000000 
380 392 T P V P S v p S T S L S G 1000000 
381 393 P V P S v p S T S L S G Y 1000000 
383 395 P S v p S T S L S G Y I P 1000000 
389 401 S L S G Y I P A N T T I P 1000000 
390 402 L S G Y I P A N T T I P F 1000000 
394 406 I P A N T T I P F G G A Y 1000000 
395 407 P A N T T I P F G G A Y N 1000000 
396 408 A N T T I P F G G A Y N I 1000000 
399 411 T I P F G G A Y N I P L V 1000000 
403 415 G G A Y N I P L V S G P 0 1000000 
405 417 A Y N I P L V S G P 0 I P 1000000 
407 419 N I P L V S G P 0 I P I N 1000000 
410 422 L V S G P 0 I P I N I T D 1000000 
411 423 V S G P 0 I P I N I T 0 a 1000000 
412 424 S G P 0 I P I N I T 0 a A 1000000 
413 425 G P 0 I P I N I T 0 a A P 1000000 
415 427 0 I P I N I T D a A p S L 1000000 
419 431 N I T 0 a A p S L I P I V 1000000 
420 432 I T 0 a A P S L I P I V P 1000000 
421 433 T 0 a A P S L I P I V P G 1000000 
422 434 0 a A P S L I P I V P G S 1000000 
424 436 A P S L I P I V P G S P a 1000000 
427 439 L I P I V P G S P a y T I 1000000 
429 441 P I V P G S P a y T I I A 1000000 
430 442 I V P G S P a y T I I A 0 1000000 
432 444 P G S P a y T I I A 0 A G 1000000 
434 446 S P a y T I I A 0 A G 0 F 1000000 
439 451 I I A 0 A G 0 F Y L H P S 1000000 
442 454 0 A G 0 F Y L H P S Y Y M 1000000 
447 459 Y L H P S Y Y M L R K R R 1000000 
448 460 L H P S Y Y M L R K R R K 1000000 
449 461 H P S Y Y M L R K R R K R 1000000 
452 464 Y Y M L R K R R K R L P Y 1000000 
453 465 Y M L R K R R K R L P Y F 1000000 
454 466 M L R K R R K R L P Y F F 1000000 
455 467 L R K R R K R L P Y F F S 1000000 
456 468 R K R R K R L P Y F F S 0 1000000 
457 469 K R R K R L P Y F F S D V 1000000 
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458 470 R R K R L P Y F F S 0 v S 1000000 
459 471 R K R L P Y F F S 0 v S L 1000000 
461 473 R L P Y F F S 0 v S L A A 1000000 
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